etoposide has been researched along with Lung Neoplasms in 2842 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 439 (15.45) | 18.7374 |
| 1990's | 1051 (36.98) | 18.2507 |
| 2000's | 681 (23.96) | 29.6817 |
| 2010's | 497 (17.49) | 24.3611 |
| 2020's | 174 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Fliri, AF; Kajiji, S; Pollack, VA; Schnur, RC | 1 |
| Chu, DT; Clement, JJ; Klein, LL; McDonald, EJ; Plattner, JJ; Yeung, CM | 1 |
| Feringa, BL; Jansen, JF; Kellogg, RM; Konings, AW; Middel, O; Pras, N; van Oeveren, A; van Uden, W; Woerdenbag, HJ | 1 |
| Fujimoto, K; Kobunai, T; Nomura, M; Shibata, J; Sugimoto, Y; Terada, T; Wierzba, K; Yamada, Y; Yamashita, J; Yamazaki, R | 1 |
| Carmichael, J; Ellis, MJ; Hagan, DJ; Hammonds, TR; Stanslas, J; Stevens, MF; Turner, C; Ward, W | 1 |
| Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z | 1 |
| Chen, JY; Cheng, KF; Ding, J; Meng, LH; Qin, GW; Yu, BW; Zhou, TX | 1 |
| Clardy, J; Wagenaar, MM | 1 |
| Furbacher, TR; Gunatilaka, AA | 1 |
| Tanaka, R; Wada, S | 1 |
| Ashok Kumar, B; Gururaj, S; Lingaiah, BP; Narsaiah, B; Parthasarathy, T; Shireesha, B; Sridhar, B; Yakaiah, T | 1 |
| Chen, SB; Gu, LQ; Huang, SL; Huang, ZH; Huang, ZS; Li, D; Ou, JB; Ou, TM; Shen, LL; Tan, JH; Wu, WB | 1 |
| Benites, J; Ibacache, A; Rodriguez, JA; Theoduloz, C; Valderrama, JA | 1 |
| Basha, MT; Bernhardt, PV; Jansson, PJ; Kalinowski, DS; Lovejoy, DB; Obeidy, P; Prichard, T; Richardson, DR; Seebacher, N; Sharp, DM; Sharpe, PC; Stefani, C | 1 |
| Chang, SM; Chen, TL; Christian, W; Detroja, D; Hwang, MJ; Lee, TC; Lin, YW; Pidugu, HB; Shah, A; Su, TL; Suen, CS; Wu, MH | 1 |
| Bai, X; Chen, H; De Brabander, JK; Kim, J; Liou, J; McFadden, DG; Posner, B; Povedano, JM; Rallabandi, R; Rice, L; Xie, Y; Ye, X | 1 |
| Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G | 1 |
| Fang, Z; He, M; Liu, M; Liu, Q; Peng, J; Wei, Y; Wu, B; Yi, F; Zhang, W | 1 |
| Cao, M; Ding, W; Guo, L; Luo, P; Lyu, Q; Wang, Q; Wei, T; Zhang, J; Zhu, W | 1 |
| Ahn, BC; Cho, BC; Hong, MH; Kim, HR; Lee, S; Lim, SM; Shim, HS | 1 |
| Economidou, SC; Fotopoulos, G; Vrontis, K | 1 |
| Antonini Cappellini, GC; Bria, E; Cappuzzo, F; Carpano, S; Carta, A; D'Argento, E; Fadda, GM; Gelibter, AJ; Giusti, R; Martelli, O; Metro, G; Minuti, G; Nelli, F; Ricciardi, S; Russano, M; Stefani, A | 1 |
| Abdel-Rahman, O; Koski, SL | 1 |
| Al-Salama, ZT | 1 |
| Cheng, H; Kim, SY; Monteiro de Oliveira Novaes, J; Tariq, S | 1 |
| Li, J; Liu, Q; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Blackhall, F; Bratt, S; Brown, S; Chaturvedi, A; Descamps, T; Dive, C; Frese, KK; Galvin, M; Greenhalgh, M; Hossain, ASMM; Humphrey, S; Kerr, A; Lallo, A; Pearce, SP; Pearsall, S; Priest, L; Revill, M; Schenk, MW; Zhou, C | 1 |
| Li, L; Liu, J; Luo, F; Qu, Z; Zhou, Q; Zhu, L | 1 |
| Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inoue, Y; Inui, N; Karayama, M; Nakamura, Y; Suda, T; Suzuki, Y; Watanabe, H; Yasui, H | 1 |
| Hu, Z; Huang, L; Jiang, S; Jin, P; Wang, J; Zhen, H | 1 |
| Dayen, C; Debieuvre, D; Dixmier, A; Falchero, L; Gally, S; Greenwood, W; Pau, D; Sibley-Revelat, A | 1 |
| Ballenberger, M; Harshan, M; Indaram, M; Machnicki, S; Mina, B; Novoselac, AV; Singh, A; Vojnic, M | 1 |
| Chu, J; Fang, J; Jin, N; Li, S; Li, T; Li, X; Li, Y; Liu, X; Sun, L; Xiu, Z; Zhu, G; Zhu, Y | 1 |
| Andrini, E; Ardizzoni, A; Artioli, F; Barbieri, F; Bonetti, A; Brighenti, M; Cinieri, S; Colantonio, I; Ficorella, C; Follador, A; Frassoldati, A; Gelsomino, F; Genova, C; Lamberti, G; Mazzoni, F; Pasello, G; Riccardi, F; Rihawi, K; Tiseo, M; Tognetto, M | 1 |
| Chen, Y; Han, B; Hu, M; Qian, F; Wang, Y; Yang, Z; Zhang, W; Zhang, Y | 1 |
| Brustugun, OT; Engleson, J; Fløtten, Ø; Grønberg, BH; Halvorsen, TO; Hornslien, K; Killingberg, KT; Langer, SW; Madebo, T; Nyman, J; Risum, S; Schytte, T; Tsakonas, G | 1 |
| Barrows, ED; Blackburn, MJ; Liu, SV | 1 |
| Imaoka, S; Sakuma, R; Siswanto, FM; Tamura, A | 1 |
| Kim, JO; Kim, KH; Park, JY; Park, SG; Seo, MD | 1 |
| Bondarenko, I; Chen, Y; Conev, N; Dalvi, TB; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Losonczy, G; Mann, H; Musso, E; Özgüroğlu, M; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Statsenko, G; Trukhin, D; Voitko, O | 1 |
| Hu, Z; Liao, J; Liu, C; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, Y; Zhao, X | 1 |
| Choi, E; Heo, MH; Kim, H; Kim, JY; Park, KU | 1 |
| An, J; Cao, L; Chen, C; Deng, P; Gu, Q; He, B; Hu, C; Jiang, J; Li, M; Qin, L; Yang, H | 1 |
| Cao, L; Chen, G; Cheng, Y; Fan, Y; Fang, Y; Gong, Y; He, Z; Hu, C; Jiang, L; Li, X; Liu, Q; Liu, Y; Lu, K; Min, X; Shi, W; Wang, J; Wang, Q; Wu, J; Xu, F; Xu, X; Yang, R; Yao, W; Yao, Y; Yu, G; Zhang, B; Zhang, X; Zhao, J; Zhao, W; Zhou, C | 1 |
| Kuai, X; Liu, K; Liu, S; Tao, Z; Wang, G; Xia, S; Zhang, H; Zhu, H | 1 |
| Byers, L; Califano, R; Chafin, W; Cho, BC; Faivre-Finn, C; Jabbour, SK; Kato, T; Lai, WV; Rimner, A; Rudin, CM; Yu, J; Yu, L; Zhao, B | 1 |
| Imai, H; Kagamu, H; Kaira, K; Kishikawa, T; Minato, K; Minemura, H; Mouri, A; Nagai, Y; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y; Yamaguchi, O | 1 |
| Fukuizumi, A; Gemma, A; Hirao, M; Matsuda, K; Miyanaga, A; Noro, R; Omori, M; Seike, M; Takano, N | 1 |
| Min, S; Zheng, Q; Zhou, Y | 1 |
| Imai, H; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Minato, K; Minemura, H; Mouri, A; Nagai, Y; Shiihara, J; Shiono, A; Taniguchi, H; Tsuda, T; Wasamoto, S; Yamada, Y; Yamaguchi, O | 1 |
| Bischoff, H; Cardona, A; De Boer, R; de Castro Junior, G; Dziadziuszko, R; Garassino, MC; Hochmair, M; Krzakowski, M; Lam, S; Liu, SV; Losonczy, G; Mansfield, A; Mok, TSK; Morris, S; Reck, M; Smolin, A; Sugawara, S | 1 |
| Koyama, N; Kumazawa, A; Shobatake, R; Takahashi, N | 1 |
| Hara, S; Hata, A; Komatsu, M; Ninomaru, T | 1 |
| Chen, Q; Huang, J; Lin, L; Lv, D; Pan, W; Wu, G; Wu, X; Yan, S | 1 |
| Bal, A; Gupta, N; Gupta, P; Khosla, D; Shastri, M; Singh, N; Srinivasan, R | 1 |
| Chmielewska, I; Grodkiewicz, M; Korbel, MA; Koziel, P; Milanowski, J | 1 |
| Arnold, HU; Friesen, TJ; Garrison, SM; Hiatt, JB; Houghton, AM; Liao, SY; MacPherson, D; Martins, R; Norton, JP; Rienhoff, HY; Sandborg, H; Srivastava, S; Sutherland, KD; Wu, F | 1 |
| Dębczyński, M; Kuklińska, B; Mojsak, D; Mróz, RM | 1 |
| Boku, N; Furuse, J; Hiraoka, N; Honma, Y; Ikeda, M; Kataoka, T; Kato, K; Kitagawa, Y; Machida, N; Mizuno, N; Morizane, C; Nomura, S; Okano, N; Okusaka, T; Ozaka, M; Sato, T; Sekine, S; Taniguchi, H; Terashima, M; Ueno, M; Yamaguchi, K | 1 |
| Imai, H; Kaburagi, T; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Masubuchi, K; Minato, K; Minemura, H; Nagai, Y; Shiihara, J; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y | 1 |
| Fukuhara, M; Matsumura, Y; Mine, H; Muto, S; Okabe, N; Ozaki, Y; Shio, Y; Suzuki, H; Takagi, H; Watanabe, M; Yamaguchi, H | 1 |
| Chen, L; Chen, Y; Deng, P; Dong, Y; Han, B; Kong, T; Liu, D; Qian, F; Yang, H; Zhang, B; Zhang, W; Zhang, Y | 1 |
| Arkania, E; Bai, Y; Chen, J; Cheng, Y; Dvorkin, M; Han, L; Ji, Y; Kang, W; Li, X; Makharadze, T; Melkadze, T; Min, X; Pan, Y; Pan, Z; Shi, J; Sun, H; Viguro, M; Wang, Q; Wang, X; Wen, G; Wu, L; Yang, J; Zhao, Y; Zhu, J | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Huang, JW; Huang, YH; Tseng, JS; Wu, JJ; Yang, TY | 1 |
| Feng, M; Li, Q; Liao, W; Qian, Z; Wen, F; Wu, Q; Yang, Y | 1 |
| Alkassis, S; Austin, A; Azar, I; Chi, J; Chopra, A; Jang, H; Kim, S; Mamdani, H; Mehdi, S; Neu, K; Saha, BK; Yazdanpanah, O | 1 |
| Kang, HS; Kim, JW; Kim, SJ; Kim, SK; Lee, SH; Lim, JU; Shin, AY; Yeo, CD | 1 |
| Li, S; Li, Z; Liu, S; Wang, Z; Zhao, F | 1 |
| Asao, T; Kobayashi, K; Morita, S; Tanaka, T; Watanabe, S | 1 |
| Ando, T; Hanai, K; Kamitani, R; Kashizaki, F; Mizuno, R; Sekido, Y; Tanaka, A | 1 |
| Azuma, K; Ishii, H; Kawashima, Y; Kurata, T; Okamoto, I; Okamoto, M; Shimose, T; Shingu, N; Yoshioka, H | 1 |
| Du, M; Yin, J | 1 |
| Akino, Y; Fujiwara, K; Higashinaka, N; Isohashi, F; Kouno, T; Mabuchi, N; Ogawa, K; Seo, Y; Shiomi, H; Tamenaga, S | 1 |
| Shu, J; Wang, X; Yang, X; Zhao, G | 1 |
| Liu, K; Qin, Q; Zhu, H; Zhu, Y | 1 |
| Gon, Y; Iida, Y; Kenmotsu, H; Ko, R; Kobayashi, H; Kodama, H; Mamesaya, N; Murakami, H; Naito, T; Ono, A; Shimizu, T; Takahashi, T; Wakuda, K | 1 |
| Chen, X; Geng, Y; Hu, Y; Jiang, W; Li, Q; Lu, B; Luo, D; Ma, Z; Ouyang, W; Su, S; Wang, M; Wu, B; Yang, W | 1 |
| Huang, Z; Zhang, Y | 1 |
| Adamo, V; Cantale, O; Castorina, L; Chillari, F; Colarossi, C; Esposito, F; Franchina, T; Giuffrida, D; Puliafito, I; Ricciardi, GRR; Russo, A; Sciacca, D; Vitale, MP | 1 |
| Ozyilkan, O; Sedef, AK; Sumbul, AT; Yildirim, BA | 1 |
| Eom, JS; Jo, EJ; Kim, KU; Kim, MH; Kim, SH; Lee, K; Lee, MK; Mok, J; Park, HK | 1 |
| Gunarić, A; Karan Križanac, D; Kraljević, M; Šekerija Zovko, S; Tomić, K | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Hara, T; Harada, K; Hirata, J; Jimbo, N; Nakano, Y; Okamura, Y; Terakawa, T; Ueki, H | 1 |
| He, Z; Jiang, N; Su, B; Xu, B; Xu, T; Yu, X; Zhang, Y; Zhou, J; Zhu, Y | 1 |
| Che, G; Chen, Y; Gou, H; Huang, Q; Jiang, L; Liao, H; Lu, Y; Zhang, Y; Zhou, N | 1 |
| Kang, K; Lin, G; Lu, Y; Luo, R; Wang, H; Yao, Z | 1 |
| Kimura, T; Kurita, T; Miyoshi, AI; Ueda, Y; Yoshino, K | 1 |
| Chen, M; Han, H; Lin, X; Lv, T; Qiu, G; Song, Y; Xie, J; Xu, K; Ye, J; Zhan, P | 1 |
| Deng, W; Dong, X; Jiang, L; Li, L; Liao, A; Min, Y; Shi, A; Yang, D; Yu, H; Yu, R; Zhao, J | 1 |
| Goto, Y; Hamamoto, R; Horinouchi, H; Imabayashi, T; Kohno, T; Masuda, K; Matsumoto, Y; Motoi, N; Nakagawa, K; Ohe, Y; Okuma, Y; Shinno, Y; Shiraishi, K; Shirasawa, M; Takayanagi, D; Takigami, A; Tsuchida, T; Watanabe, SI; Yamamoto, N; Yoshida, T; Yoshida, Y; Yotsukura, M | 1 |
| Alamgeer, M; Cain, JE; Chen, J; DeVeer, M; Ganju, V; Garama, DJ; Gough, DJ; Guanizo, AC; Inampudi, C; Jakasekara, WSN; Luong, Q; Thakur, N; Watkins, DN | 1 |
| Ni, J; Si, X; Wang, H; Zhang, L; Zhang, X | 1 |
| Deng, X; Hu, CD; Liu, Y; Shen, Q | 1 |
| Chihara, Y; Date, K; Harada, T; Ishida, M; Iwasaku, M; Kanda, H; Kim, YH; Morimoto, K; Shiotsu, S; Takayama, K; Takeda, T; Takemura, Y; Tamiya, N; Tokuda, S; Yamada, T; Yoshimura, A | 1 |
| Artaç, M; Bozcuk, H; Eser, İ; Mutlu, H | 1 |
| Fu, C; Lin, GH; Wang, BC | 1 |
| Adamo, V; Bottari, A; Brogna, A; Cacciola, A; Casablanca, G; Chillari, F; Ferini, G; Ferrantelli, G; Leotta, S; Lillo, S; Minutoli, F; Parisi, S; Pergolizzi, S; Platania, A; Pontoriero, A; Russo, A; Santacaterina, A; Settineri, N | 1 |
| Gu, X; Guan, Y; Hao, Y; Song, Z; Sun, Y; Wang, W; Xiang, J; Yao, Q; Zeng, X | 1 |
| Agarwal, M; Almquist, D; Ernani, V; Langlais, BT; Leventakos, K; Liu, A; Manochakian, R; Yu, NY | 2 |
| Honda, H; Kitamura, Y; Kudo, S; Morikawa, K; Sawai, T; Suzuki, K; Yamada, G; Yokoo, K | 1 |
| Li, Y; Wang, T; Zheng, X | 1 |
| Arriola, E; Cruz-Castellanos, P; Dómine, M; García-Campelo, R; Insa, A; Juan Vidal, O; Morán, T; Reguart, N; Sullivan, I; Zugazagoitia, J | 1 |
| Haasbeek, CJA; Lagerwaard, FJ; Palacios, MA; Schneiders, FL; Senan, S; Slotman, BJ; Tekatli, H | 1 |
| Bullock, TN; Carducci, MA; Gentzler, RD; Hanley, M; Horton, B; Kim, K; Mock, J; Park, KS; Phelps, MA; Piekarz, R; Rhee, JC; Rudek, MA; Rudin, CM; Villaruz, LC | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
| Alimbetov, D; Askarova, S; Begimbetova, D; Davis, T; Kipling, D; Tsoy, A; Umbayev, B | 1 |
| Jiang, X; Tang, X; Wang, X; Yao, H; Zeng, Y | 1 |
| Chen, Y; Feng, J; Guo, R; Han, Z; Jiang, F; Pan, B; Shen, B; Shi, L; Song, H; Wang, L; Wang, Q; Wu, Y; Yang, K; Zhao, W; Zhou, G; Zhou, T; Zhou, W; Zhou, X | 1 |
| Hara, Y; Hashimoto, H; Horita, N; Kaneko, A; Kaneko, T; Kobayashi, N; Kubo, S; Kudo, M; Matsumoto, H; Somekawa, K; Teranishi, S; Watanabe, K | 1 |
| Gerner-Rasmussen, J; Hansen, O; Holm, B; Jeppesen, N; Langer, SW; Mau-Sørensen, M; McCulloch, T; Nielsen, HA; Nyhus, CH; Rytter, C; Wedervang, K | 1 |
| Akram, M; Andreescu, S; Arif, A; Hayat, A; Latif, U; Nawaz, MH; Tariq, A; Zhang, H | 1 |
| Dai, G; Gao, M; Hu, J; Li, L; Ma, J; Wang, Y; Yan, H; Yang, X; Zhang, X; Zhao, Y | 1 |
| Li, K; Lin, A; Lin, W; Luo, P; Qiu, Z; Wang, Q; Wei, T; Zhang, J; Zhu, W | 1 |
| Cheng, PN; Ho, JC; Lam, SK; Xu, S | 1 |
| Álvarez, R; Artal, Á; Camps, C; De Las Peñas, R; de Mon Soto, MÁ; Diz, P; Gómez-Codina, J; Gutiérrez, V; Insa, A; Isla, D; Jurado, JM; Maestu, I; Marsé, R; Martínez-Banaclocha, N; Massuti, B; Morán, T; Mut, P; Ortega, AL; Ponce, S; Provencio, M; Sala, MÁ; Vázquez, MF; Viñolas, N | 1 |
| Capoccetti, F; Castagnoli, H; Fattori, S; Manni, C; Marchesani, F; Rossi, G | 1 |
| Adler, S; Aljumaily, R; Antal, JM; Beck, JT; Boccia, RV; Bulat, I; Chiu, VK; Csoszi, T; Domine Gomez, M; Dragnev, KH; Hamm, JT; Hanna, W; Hart, LL; Hoyer, RJ; Hussein, MA; Lai, AY; Lowczak, A; Maglakelidze, M; Malik, RK; Morris, SR; Nikolinakos, P; Owonikoko, TK; Richards, DA; Roberts, PJ; Rocha Lima, CM; Sawrycki, P; Schuster, SR; Sorrentino, JA; Weiss, JM; Yang, Z | 1 |
| Abrouk, N; Brown, B; Burbano, E; Caroen, S; Carter, CA; Coyle, A; Ferry, L; Larson, C; Oronsky, A; Oronsky, B; Quinn, M; Reid, TR; Scribner, CL; Thilagar, B; Varner, G | 1 |
| Chen, MT; Chen, WL; Li, F; Liu, Y; Qu, CX; Wang, DD; Wang, Y; Yang, SD; You, BG; Zhang, XN; Zhou, YJ | 1 |
| Das, M; Diehn, M; Hellyer, JA; Hoang, NT; Jeong, Y; Neal, JW; Niu, X; Padda, SK; Ramchandran, K; Stehr, H; Wakelee, H | 1 |
| Khalifeh, I; Maroun, CA; Moukarbel, RV; Tfayli, A | 1 |
| Goetze, TO | 1 |
| Adjei, AA; Aubry, MC; Bertino, E; Dakhil, SR; Dy, GK; Lee Hann, C; Mandrekar, SJ; Molina, JR; Nieva, JJ; Sachs, BA; Schenk, EL; Schild, SE; Tan, AD; Wadsworth, TW | 1 |
| Escriu, C; Sallam, M; Wong, H | 1 |
| Abbas, HA; An, T; Chang, L; Chen, H; Chen, R; Chen, W; Dong, Z; Futreal, PA; Glisson, BS; Gong, Y; Guan, Y; Heymach, JV; Hong, L; Kalhor, N; Lee, JJ; Lewis, J; Li, J; Li, Z; Rinsurongkawong, W; Roarty, EB; Roth, JA; Swisher, SG; Wang, J; Wang, Y; Wang, Z; Wistuba, II; Wu, M; Wu, N; Xia, X; Yang, L; Yang, X; Yi, X; Zhang, J; Zhao, J; Zhong, J; Zhu, X; Zhuo, M | 1 |
| Bao, Y; Chen, M; Chen, MY; Chen, PC; Chen, QX; Dong, BQ; Fan, Y; Fang, M; Guo, Y; Hong, W; Hu, X; Jiang, YH; Jin, Y; Kong, Y; Liu, JS; Ma, HL; Mao, WM; Peng, F; Song, ZB; Sun, WY; Tang, HR; Wang, J; Xu, XL; Xu, YJ; Yu, C; Yu, XM; Zhang, L; Zhang, YP; Zhao, Q; Zhou, XM; Zhu, HN; Zhu, L | 1 |
| Cao, P; Gong, Y; Liang, B; Liu, Y; Lu, Y; Luo, C; Wang, J; Wang, Y; Xu, Y; Xue, J; Yan, T; Zhou, L; Zhou, X; Zhou, Y | 1 |
| Baker, J; Dexter, PR; He, J; Hui, SL; Jin, F; Kachroo, S; Shao, C; Zhang, Z | 1 |
| De Petris, L; Fang, F; Lewensohn, R; Pettersson, A; Tendler, S; Viktorsson, K; Zhan, Y | 1 |
| Hao, J; Jing, Y; Wu, W; Xu, Q | 1 |
| Andric, Z; Atagi, S; Califano, R; De Boer, R; Garassino, M; Horn, L; Kabbinavar, F; Karaseva, N; Każarnowicz, A; Lam, S; Lee, JS; Liu, SV; Mansfield, AS; Morris, S; Quach, C; Reck, M; Sánchez, A; Wen, X; Yu, W | 1 |
| Bai, H; Duan, J; Guo, R; Li, J; Sun, J; Wang, J; Wang, Z | 1 |
| Gunturu, KS; Ho, D; Raibagkar, P; Srinivasan, J | 1 |
| Barberi-Heyob, M; Frochot, C; Jouan-Hureaux, V; Lirdprapamongkol, K; Niamsiri, N; Pramual, S; Svasti, J | 1 |
| Althouse, S; Anouti, B; Durm, G; Hanna, N | 1 |
| Huang, M; Jiang, L; Qin, Y; Yu, M; Zhou, L | 1 |
| Eich, HT; Scobioala, S | 1 |
| Aquin, T; Banerji, S; Bucher, O; Dawe, DE; Green, S; Rittberg, R | 1 |
| Bi, N; Chen, D; Chen, M; Feng, Q; He, J; Hui, Z; Jiang, W; Li, J; Liang, J; Liu, L; Lv, C; Lv, J; Shi, A; Wang, J; Wang, L; Wang, W; Wang, X; Wu, S; Xiao, Z; Xu, Y; Yin, W; Zhang, H; Zhang, T; Zhao, L; Zhou, Z | 1 |
| Gao, W; Liu, Z; Lockman, PR; Mohammad, A; Pinti, MV; Saralkar, PA; Shah, N; Sprowls, SA; Tallman, RM; Vickers, SD | 1 |
| Li, J; Lu, M; Peng, Z; Shen, L; Wang, X; Zhang, P; Zhang, X; Zhou, J | 1 |
| Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS | 1 |
| Difilippantonio, S; Huang, SN; James, A; Marzi, L; Pommier, Y; Sun, Y | 1 |
| Andrade, CF; Figueiró, F; Filippi-Chiela, E; Gonzalez, EA; Klamt, F; Nunes, V; Pilar, ES; Solari, JIG | 1 |
| Ahn, J; Baek, JH; Hwang, SG; Kim, EH; Kim, JS; Kim, JY; Lee, CW; Lee, J; Lee, KH; Lee, YJ; Park, JK; Song, JY; Yun, HS | 1 |
| Awad, MM; Cheema, PK; Csőszi, T; Ebiana, V; Gottfried, M; Gümüş, M; Kalemkerian, GP; Kato, T; Kim, HR; Luft, A; Luo, Y; Mazieres, J; Navarro, A; Orlandi, FJ; Peters, S; Pietanza, MC; Rodriguez-Abreu, D; Rudin, CM; Wollner, M; Yang, JC | 1 |
| Gan, GN; Huang, C; Zhang, J | 1 |
| Dowlati, A; Finigan, JH; Foster, DG; Gardner, EE; Kern, JA; Kim, J; Mishra, R; Poirier, JT; Rivard, C; Rudin, CM; Tan, AC; Yu, H | 1 |
| Hirose, K; Kataoka, N; Kunimatsu, Y; Ogura, Y; Sato, I; Sugimoto, T; Tachibana, Y; Takeda, T; Tani, N | 1 |
| Lomma, C; Ransom, D | 1 |
| Azuma, K; Hoshino, T; Ishii, H; Kawahara, A; Matsuo, N; Tokito, T | 1 |
| Akdeniz, N; Alan, Ö; Bilen, E; Ebinç, S; Ercelep, Ö; Işıkdoğan, A; Kaplan, MA; Karhan, O; Küçüköner, M; Laçin, Ş; Sezgin, Y; Teke, F; Urakçı, Z; Yumuk, PF | 1 |
| Abdel-Rahman, O; Karachiwala, H; Morris, D; Tilley, D | 1 |
| Aggarwal, C; Cella, D; Dahlberg, SE; Feliciano, JL; Lash, BW; Leach, JW; Leal, TA; Mohindra, NA; Owonikoko, TK; Ramalingam, SS; Srkalovic, G; Steffen McLouth, LE; Wade, JL; Wagner, LI; Zhao, F | 1 |
| Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D | 1 |
| Arrieta, O; Lara-Mejía, L; Zatarain-Barrón, ZL | 1 |
| Guomin, X; Haifeng, W; Liping, Z; Qi, S; Xiping, W | 1 |
| Chen, Y; Dvorkin, M; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Laud, PJ; Losonczy, G; Özgüroğlu, M; Patel, N; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Shire, N; Statsenko, G; Trukhin, D; Voitko, O | 1 |
| Frampton, JE | 1 |
| Amini, A; Chang, JY; Chetty, IJ; Chun, SG; Donington, J; Edelman, MJ; Higgins, KA; Kestin, LL; Movsas, B; Rodrigues, GB; Rosenzweig, KE; Rybkin, II; Simone, CB; Slotman, BJ; Wolf, A | 1 |
| Carbonnelle, G; Ghysel, V; Lambert, M; Lartigau, E; Lefebvre, G; Marliot, G; Nicot, R; Tresch, E | 1 |
| Cong, X; Gao, F; Liu, Z | 1 |
| Hou, X; Huang, Y; Liu, T; Luo, F; Wang, K; Zhang, L; Zhang, Z; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Cao, Y; Chen, C; Cheng, F; Dong, Q; Fang, J; Gao, J; Ren, H; Wei, H; Wu, Z; Xiong, Z; Xu, L; Yang, J; Zhang, Y; Zhang, Z; Zhou, C | 1 |
| Fouzder, C; Kundu, R; Malick, C; Mukherjee, S; Mukhuty, A | 1 |
| Anevlavis, S; Bouros, D; Froudarakis, ME; Karpathiou, G; Kotsianidis, I; Kouliatsis, G; Mihailidis, V; Nakou, E; Ntolios, P; Tzouvelekis, A | 1 |
| Hiroshima, K; Ikeda, JI; Motoi, N; Nakajima, T; Nakatani, Y; Ota, M; Yoshino, I | 1 |
| Chen, H; Horita, N; Takeshi, K | 1 |
| Baize, N; Chouaid, C; Monnet, I | 1 |
| Caffo, O; Cattrini, C; Merz, V; Messina, C; Messina, M; Salati, M | 1 |
| Alatorre-Alexander, J; Califano, R; Cheng, Y; De Castro Carpeno, J; Deng, Y; Garassino, MC; Horn, L; Lam, S; Leal, T; Lee, JS; Liu, SV; Mansfield, AS; McCleland, M; Mok, T; Nishio, M; Orlandi, F; Phan, S; Reck, M; Reinmuth, N; Scherpereel, A | 1 |
| Ackermann, C; Califano, R; Ortega-Franco, A; Paz-Ares, L | 1 |
| Bu, J; Guo, L; Liang, S; Liu, J; Niu, Y; Wang, Q; Zhang, Z; Zheng, M | 1 |
| Almeida, A; Bartosch, C; Cruz Pires, M; Peixinho, C | 1 |
| Chen, B; Lin, J; Peng, J; Xue, L | 1 |
| Au, KM; Foley, H; Hagan, CT; Medik, Y; Mi, Y; Min, Y; Roche, K; Rodgers, Z; Tian, X; Wagner, K; Wang, AZ; Yang, F; Zhang, M | 1 |
| Cho, YH; Choi, CM; Choi, SY; Jeong, GS; Ji, W; Kim, DS; Lee, JC; Rho, JK | 1 |
| Dolan, ME; Mulford, AJ; Wheeler, HE; Wing, C | 1 |
| Chang, JS; Pan, M | 1 |
| Abdel-Bar, HM; Al-Jamal, KT; Walters, AA; Wang, JT | 1 |
| Goldman, JW; Paz-Ares, L | 1 |
| Horita, N; Katakura, S; Takeshi, K | 1 |
| Chen, TC; Dai, SH; Tsai, WH; Zeng, YH | 1 |
| Li, C; Li, W; Su, Z; Zhang, J; Zhang, X | 1 |
| Xia, D; Xu, X; Yang, W; Zhang, Y | 1 |
| Bogart, JA; Dobelbower, MC; Gao, J; Gaspar, LE; Heymach, JV; Komaki, R; Kuzma, C; Masters, GA; Stinchcombe, TE; Vokes, EE; Wang, X | 1 |
| Chen, J; Qi, W; Zhao, S | 1 |
| Goyal, A; Khurana, AK; Rai, AC; Vangala, A | 1 |
| Bach, BA; Bentsion, D; Byers, LA; de Groot, P; Dunbar, M; Ellis, PM; Fujimoto, J; Gans, S; Gay, CM; Glasgow, J; Groen, HJM; He, L; Kang, K; Owonikoko, TK; Penkov, K; Sehgal, V; Sibille, A; Son, C | 1 |
| Chen, L; Chen, X; Fu, W; Wang, K; Zuyi, W | 1 |
| Chen, L; Chu, C; Fang, J; Guo, J; Guo, S; Huang, X; Huang, Y; Jiang, X; Li, Q; Lin, M; Liu, F; Liu, H; Liu, J; Pang, Q; Qiu, B; Wang, B; Wang, D; Xie, C; Yang, X; Zhu, Z | 1 |
| Burns, TF; Camidge, DR; Chen, C; Dowlati, A; Hann, CL; Koch, MM; Komarnitsky, P; Ludwig, C; Morgensztern, D; Nimeiri, H; Patel, M; Ward, PJ | 1 |
| Li, B; Li, J; Lou, H; Wang, L; Yang, YM | 1 |
| Amri, J; Baazm, M; Karami, H; Shahverdi, M | 1 |
| Ding, D; Hu, H; Huang, J; Li, S; Liao, M; Liu, A; Liu, J; Shi, Y; Tian, X; Zhu, Y | 1 |
| Bianco, A; D'Agnano, V; Della Gravara, L; Matera, MG; Perrotta, F; Rocco, D | 1 |
| Gu, D; Huang, P; Li, M; Lin, S; Luo, S; Rao, X; Wang, C; Weng, X; Xu, X | 1 |
| Bolm, L; Janssen, S; Käsmann, L; Rades, D | 1 |
| Akira, M; Asami, K; Atagi, S; Kawaguchi, T; Morimoto, M; Okishio, K; Omachi, N; Tamiya, A | 1 |
| Barros de Araujo, PL; Bernardes, ES; Cerqueira-Coutinho, C; Dos Santos, SN; Pinto, SR; Ricci-Junior, E; Salvi, R; Santos-Oliveira, R | 1 |
| Barbieri, F; Bertolini, F; Grizzi, G; Lococo, F; Mengoli, MC; Novello, S; Orsi, G; Rossi, G | 1 |
| Chen, W; Gao, S; Gong, X; Liang, Y; Liu, K; Yang, L; Zhang, F | 1 |
| Endo, M; Fujiwara, T; Kawamura, T; Kenmotsu, H; Kobayashi, H; Kotake, M; Mamesaya, N; Mori, K; Murakami, H; Naito, T; Nakashima, K; Omae, K; Omori, S; Ono, A; Taira, T; Takahashi, T; Wakuda, K | 1 |
| Du, Y; Gao, L; Liu, X; Luo, L; Wang, X; Xie, C; Xu, J; Xuan, E; Zhao, Y | 1 |
| Chen, L; Cheng, L; Liang, X; Liu, L; Ma, C; Wu, X; Xiao, L; Xu, Q; Zhang, L | 1 |
| Allinson, K; Candy, N; Carr, O; McMillen, J; Trivedi, R; Young, A | 1 |
| Malkoski, SP; Nolan, K; Patil, T; Tippimanchai, D; Ziemke, M | 1 |
| Besse, B; Dols, MC; Dubey, S; Glisson, B; Jain, R; Jiang, Y; Menon, H; Nackaerts, K; Orlov, S; Paz-Ares, L; Ramlau, R; Schupp, M; Tang, R; Zhang, Y; Zhu, M | 1 |
| Cha, HJ; Go, YH; Hong, SK; Kwon, OS; Kwon, SJ; Oh, E | 1 |
| Bonanno, L; Castiglione, F; Cavanna, L; Costanzo, R; Daniele, G; Di Maio, M; Favaretto, AG; Filipazzi, V; Gallo, C; Gebbia, V; Gridelli, C; Maiello, E; Maione, P; Morabito, A; Perrone, F; Piazza, E; Piccirillo, MC; Rocco, G; Rossi, A; Sandomenico, C | 1 |
| Appel, W; Ashcroft, L; Barlesi, F; Bezjak, A; Bhatnagar, A; Blackhall, F; Cardenal, F; Faivre-Finn, C; Fournel, P; Harden, S; Le Pechoux, C; Lorigan, P; McMenemin, R; Mohammed, N; O'Brien, M; Pantarotto, J; Snee, M; Surmont, V; Van Meerbeeck, JP; Woll, PJ | 1 |
| Bascarevic, S; Ercegovac, M; Jovanovic, D; Kontic, M; Kostic, M; Laban, M; Markovic, J; Moskovljevic, D; Popevic, S; Savic, M; Stojsic, J; Vesovic, R | 1 |
| Aggarwal, C; Berman, AT; Cohen, RB; Evans, TL; Langer, C; Levin, WP; Lin, L; Rengan, R; Rwigema, JM; Simone, CB; Verma, V | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| Cao, CL; Duan, PY; Li, L; Qu, FZ; Sun, B; Wang, G; Zhang, WJ | 1 |
| Delosh, R; Evans, D; Krushkal, J; Laudeman, J; Morris, J; Ogle, C; Parchment, R; Reinhart, R; Rubinstein, L; Selby, M; Silvers, T; Sonkin, D; Teicher, BA | 1 |
| Guo, N; Li, Q; Song, L; Wang, D; Yin, R | 1 |
| Chen, Y; Guo, M; Qin, Y; Qu, D; Wang, L; Zong, B | 1 |
| Akeno, N; Callahan, M; He, D; Kim, RG; Lane, A; Miller, AL; Moulton, JS; Reece, AL; Wikenheiser-Brokamp, KA | 1 |
| Eze, C; Manapov, F | 1 |
| Bai, F; Chen, L; Chen, Y; Xu, Y; Yang, X | 1 |
| Hou, J; Jiang, Y; Song, D; Su, C; Zhao, J | 1 |
| Bi, N; Liang, J; Wang, L | 1 |
| Bang, SM; Chang, H; Kim, JH; Kim, JW; Kim, MJ; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW | 1 |
| Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
| Costa, JC; Grauslund, M; Melchior, LC; Santoni-Rugiu, E; Sørensen, JB; Urbanska, EM | 1 |
| Bado, I; Gustafsson, JÅ; Nikolos, F; Thomas, C | 1 |
| Baker, K; Blackhall, F; Dive, C; Forster, M; Foy, V; Frese, KK; Gomes, F; Lallo, A; Schenk, MW | 1 |
| Celik, B; Demirag, MK; Elmali, M; Gulel, O | 1 |
| Chmielewska, K; Kluska, M; Pietrzak, J; Robaszkiewicz, A; Rygielska, Ż; Tempka, D; Tokarz, P; Virág, L | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ | 1 |
| Dong, Y; Jiang, S; Wang, G | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K | 2 |
| Allan, E; Ayan, A; Barney, CL; Bazan, JG; DiCostanzo, D; Grecula, J; Haglund, KE; Otterson, GA; Scoville, N; Williams, T; Xu-Welliver, M | 1 |
| Balasubramaniam, S; Bates, SE; Bonner, WM; Bryla, C; Figg, WD; Fojo, T; Giaccone, G; Lee, MJ; Peer, CJ; Piekarz, RL; Rajan, A; Redon, CE; Tomita, Y; Trepel, JB | 1 |
| Moeller, M; Schuette, W; Siebolts, U; Wickenhauser, C | 1 |
| Choi, JH; Hahn, S; Heo, DS; Jang, JS; Kang, JH; Kim, BS; Kim, DW; Kim, HG; Kim, HK; Kim, JH; Kim, JS; Kim, SW; Kwon, JH; Lee, KH; Park, K; Ryoo, HM; Shin, SW | 1 |
| Bludau, H; Jordan, R; Kabanov, AV; Keith, A; Min, Y; Sheiko, SS; Sokolsky-Papkov, M; Wan, X; Wang, AZ | 1 |
| Bigda, J; Czetyrbok, K; Filipska, M; Jassem, J; Skrzypski, M; Stasiłojć, G; Stokowy, T; Supernat, A; Żaczek, AJ | 1 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Anderson, JR; Chi, YY; Dix, DB; Dome, JS; Ehrlich, PF; Fernandez, CV; Gastier-Foster, JM; Geller, JI; Gratias, E; Grundy, PE; Kalapurakal, JA; Khanna, G; Malogolowkin, M; Mullen, EA; Paulino, AC; Perlman, EJ; Seibel, NL; Wagner, E | 1 |
| Asanuma, H; Shima, H; Shimada, H; Yamada, Y | 1 |
| Allen, AM; Dudnik, E; Fenig, E; Flex, D; Kramer, MR; Peled, N; Saute, M; Shochat, T; Zer, A | 1 |
| Chouaki, N; Govindan, R; Hossain, AM; Iscoe, N; Koczywas, M; San Antonio, B; Senan, S; Vokes, EE | 1 |
| Berry, E; Hoekstra, AV; Lurain, JR; Maniar, KP; Novak, K; Sobecki-Rausch, J; Winder, A | 1 |
| Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K | 1 |
| Carden, MA; Greenberg, J; McCarty, JM; Perdahl-Wallace, E | 1 |
| Fujimoto, M; Maruyama, H; Okiyama, N; Saito, A; Tanaka, R | 1 |
| Akiba, J; Azuma, K; Hoshino, T; Ishii, H; Masuda, K; Matsuo, N; Naito, Y; Sakazaki, Y; Tokito, T; Tsuneyoshi, S; Yamada, K; Zaizen, Y | 1 |
| Darling, G; Durocher-Allen, LD; Ellis, PM; Goffin, JR; Ramchandar, K; Sun, A; Ung, YC | 2 |
| Abdelfattah, EA; Elgohary, MM; Elzoghby, AO; Fang, JY; Helmy, MW; Mortada, SM; Ragab, DM | 1 |
| Buscemi, G; Chan, SY; Delia, D; Magni, M; Maita, L; Montecucco, A; Peng, L; Zannini, L | 1 |
| Abdel-Rahman, O | 1 |
| Amemiya, K; Hirotsu, Y; Iijima, Y; Kakizaki, Y; Kobayashi, Y; Miyashita, Y; Mochizuki, H; Omata, M; Oyama, T; Tsutsui, T; Uchida, Y | 1 |
| Harada, N; Haruta, N; Higashiura, Y; Hisanaga, H; Nobuhara, I; Sado, T; Watanabe, H; Watanabe, S | 1 |
| Dómine Gómez, M; Fröhling, KP; Huber, RM; Kapp, K; Kollmeier, J; Mauri, C; Navarro, A; Ponce-Aix, S; Riera-Knorrenschild, J; Sadjadian, P; Schmidt, M; Thomas, M; Wiegert, E; Wittig, B; Wolf, M | 1 |
| Pujol, JL; Roch, B | 1 |
| Stanic, K; Vrankar, M | 1 |
| Hayami, Y; Kinoshita, H; Matsuda, T; Yoshida, K; Yoshida, T | 1 |
| Elgohary, MM; Elzoghby, AO; Helmy, MW; Mortada, SM | 1 |
| Ding, B; Havel, L; Hochmair, MJ; Horn, L; Huemer, F; Johnson, ML; Kabbinavar, F; Krzakowski, M; Lam, S; Lin, W; Liu, J; Liu, SV; Lopez-Chavez, A; Losonczy, G; Mansfield, AS; Mok, T; Nishio, M; Reck, M; Sandler, A; Shames, DS; Szczęsna, A | 1 |
| Alhebshi, H; Bakker, E; Demonacos, C; Guazzelli, A; Hussain, M; Krstic-Demonacos, M; Meysami, P; Mutti, L; Schwartz, JM; Tian, K | 1 |
| Anzai, M; Goto, N; Ishizuka, T; Kadowaki, M; Kodawara, T; Morikawa, M; Nakamura, T; Negoro, Y; Suehiro, Y; Tsukamoto, H; Umeda, Y; Watanabe, K; Yamashita, S; Yano, R; Yoshimura, M | 1 |
| Hata, K; Hidaka, T; Iwasaki, Y; Matsuhashi, A; Okuzumi, S; Shimizu, S; Takahashi, H | 1 |
| Gao, Y; Kardos, J; Kim, WY; Major, MB; Mutter-Rottmayer, E; Tamir, TY; Vaziri, C; Weissman, B; Yang, Y | 1 |
| Funaishi, K; Hattori, N; Ishiyama, S; Kawamoto, K; Matsumoto, N; Matsumoto, Y; Ohashi, N; Saito, N; Sakamoto, KI; Taniwaki, M; Yamasaki, M | 1 |
| Barriuso, J; Frizziero, M; Hubner, RA; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Dean, S; Herath, D; Kosmider, S; McCracken, J | 1 |
| Blackhall, F; Faivre-Finn, C; Hatton, M; Locke, I; Mistry, H; Monnet, I; Salem, A | 1 |
| Anai, S; Iwama, E; Nakanishi, Y; Okamoto, I; Otsubo, K; Tanaka, K; Yoneshima, Y | 1 |
| Liu, JZ; Liu, WW; Liu, ZL; Wang, B | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Feng, J; Lin, J; Ye, Q | 1 |
| Hashizume, A; Hiruma, T; Jikuya, R; Kawai, M; Kishida, T; Mizuno, N; Tatenuma, T; Umemoto, S; Yasui, M | 1 |
| Chen, Q; Chen, R; Guo, L; Huang, W; Jia, L; Li, Y; Wu, Y; Zhu, Y | 1 |
| Albert, I; Barlesi, F; Bidoli, P; Cadranel, J; Chung, J; Drews, U; Fritsch, A; Govindan, R; Horn, L; Juhász, E; Kowalski, D; Novello, S; Reck, M; Robinet, G; Wagner, A | 1 |
| Bunn, PA; Pacheco, J | 1 |
| Aksaray, F; Arici, S; Cihan, S; Demir, C; Geredeli, C; Sakin, A; Secmeler, S; Yasar, N | 1 |
| Chen, JN; Feng, T; Li, HM; Lin, DX; Ma, F; Tan, W; Xu, BH; Yang, J; Yin, LL; Yuan, P | 1 |
| Aben, N; Avelar, AT; Berns, A; Cozijnsen, M; de Vries, H; Nagel, R; Proost, N; van de Ven, M; van der Vliet, J; Wessels, LFA | 1 |
| Bai, L; Huang, J; Li, Q; Yang, Y; Zhang, N; Zhou, J; Zhou, K | 1 |
| Binninger, A; Dille, S; Elender, C; Hutzschenreuter, U; Jänicke, M; Marschner, N; Spring, L; Steffens, CC | 1 |
| Ajona, D; Calvo, A; Cirauqui, C; de Aberasturi, AL; de Andrea, C; Exposito, F; Guruceaga, E; Montuenga, LM; Pio, R; Redin, E; Redrado, M; Vicent, S; Villalba, M | 1 |
| Li, Z; Lu, S | 1 |
| Akhtar, T; Mangla, A | 1 |
| Dumas, I; Ferrer, L; Guillem, P; Lattuca-Truc, M; Levra, MG; Moro-Sibilot, D; Pinsolle, J; Ruckly, S; Timsit, JF; Toffart, AC; Villa, J | 1 |
| Gou, J; He, H; Liu, X; Liu, Y; Luo, L; Qi, P; Tang, X; Yin, T; Zhang, Y | 1 |
| Gu, Y; Lin, X; Liu, J; Mai, S; Ouyang, M; Qin, Y; Xie, Z; Zhang, J; Zhou, C | 1 |
| Filipek, A; Jarzab, M; Jurewicz, E; Lipinska, B; Rychlowski, M; Wenta, T; Zurawa-Janicka, D | 1 |
| Bahij, R; Halekoh, U; Hansen, O; Holmskov, K; Jeppesen, SS; Olsen, KE | 1 |
| Pan, YY; Shen, XB; Wang, W; Zhang, YX | 1 |
| Jang, SJ; Jeong, GS; Jung, DJ; Kim, M; Shin, TH; Sung, CO | 1 |
| Akbarzadeh, A; Ardjmand, M; Heydarinasab, A; Zare Kazemabadi, F | 1 |
| Berard, H; Boffa, S; Chouaid, C; Damotte, D; Le Caer, H; Le Treut, J; Lena, H; Monnet, I; Sault, MC; Souquet, PJ; Vergnenegre, A | 1 |
| Masamba, L; Mtonga, P; Mwafulirwa, K; Nyirenda, R | 1 |
| Boutzios, G; Chatzellis, E; Kaltsas, G; Koumarianou, A; Tsavaris, N | 1 |
| Goto, K; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Abu Jawad, J; Eberhardt, W; Freitag, L; Gauler, T; Graupner, B; Pöttgen, C; Stamatis, G; Stuschke, M; Theegarten, D; Welter, S; Wohlschlaeger, J | 1 |
| Jiang, SY; Karam, I; Khaira, M; Lee, CW; Schellenberg, D | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Hasegawa, Y; Kataoka, K; Kimura, T; Kondo, M; Kondoh, Y; Nishiyama, O; Taniguchi, H; Watanabe, N | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Choi, EK; Jo, J; Jo, JS; Jung, SH; Kim, SW; Lee, DH; Lee, JS; Lee, SH; Park, K; Pyo, H; Sohn, HJ; Song, SY; Suh, C; Sun, JM | 1 |
| Abrao, FG; Gross, JL; Naim Younes, R; Rodrigues Pereira, J | 1 |
| Chi, YH; Du, F; Jiang, WC; Song, Y; Sun, YK; Wang, JW; Yang, L; Zhou, AP | 1 |
| Jett, JR; Kalemkerian, GP; Kesler, KA; Schild, SE | 1 |
| Angarita, FA; Meek, E; Rodríguez, JL; Sánchez, JO; Tawil, M; Torregrosa, L | 1 |
| Bai, Y; Guo, L; Liu, H; Peng, J | 1 |
| Al-Hader, AA; Al-Nasrallah, N; Einhorn, LH; Jain, A | 1 |
| Badinloo, M; Esmaeili-Mahani, S | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Ganti, AK; West, WW; Zhen, W | 1 |
| Bakalos, G; Doxani, C; Miligkos, M; Mpoulimari, I; Rodopoulou, P; Zintzaras, E | 1 |
| Bildat, S; Eberhardt, WE; Fischer, B; Gauler, TC; Grunenwald, D; Krbek, T; Le Chevalier, T; Lepechoux, C; Poettgen, C; Rodrigo, Hde L; Seeber, S; Stamatis, G; Stuschke, M; Theegarten, D; Welter, S | 1 |
| Fong, BM; Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
| Alavi, A; Bradley, JD; Cho, KH; DeNittis, A; Duan, F; Gorelick, JJ; Johnson, DW; Kim, SK; Komaki, R; Macapinlac, H; Machtay, M; Munden, R; Neumann, DR; Reddin, JS; Sherwin, N; Siegel, BA; Snyder, BS; Videtic, G; Wilf, LH | 1 |
| Georgoulias, V; Karachaliou, N; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Stathopoulos, E; Trypaki, M | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Argiris, A; Gooding, WE; McLaughlin, B; Schmitz, JC; Siegfried, JM; Socinski, MA; Tarhini, AA; Zahoor, H | 1 |
| Hu, K; Li, L; Liu, H; Ma, M; Wang, H; Wang, M; Xu, Y; Zhang, L; Zhao, J; Zhong, W | 1 |
| Hayashi, T; Ishii, T; Itami, Y; Kobayashi, Y; Minami, T; Nagai, Y; Nozawa, M; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshimura, K | 1 |
| Bai, Y; Chen, Z; Guo, L; Li, Y; Xiao, F; Zeng, X | 1 |
| Bentzen, S; Bialas, M; Nowara, E; Suwinski, R; Tukiendorf, A; Wzietek, I | 1 |
| Albanell, J; Arpí, O; Arriola, E; Arumí-Uría, M; Cañadas, I; Dómine, M; García de Herreros, A; Menéndez, S; Mojal, S; Pijuan, L; Rojo, F; Rovira, A; Salido, M; Taus, Á; Zazo, S | 1 |
| Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV | 1 |
| Harada, M; Hida, T; Imamura, F; Ishikura, S; Kawahara, M; Kubota, K; Matsui, K; Mizusawa, J; Nakagawa, K; Negoro, S; Nishio, M; Okamoto, H; Saijo, N; Sakai, H; Shibata, T; Shinkai, T; Takeda, K; Tamura, T; Yamamoto, N; Yokoyama, A | 1 |
| Fan, D; Hu, Y; Li, S; Xiong, D; Yagüe, E; Yan, C; Yang, M; Zhang, Y; Zhou, Y | 1 |
| Brouwers, EE; Huitema, AD; Kuck, EM; Rozemeijer, R; van Gorp, F; van Rens, MT | 1 |
| Fukuoka, M; Horai, T; Katakami, N; Nakagawa, K; Ohmatsu, H; Okamoto, H; Saijo, N; Sekine, I; Shibuya, M; Yokoyama, A | 1 |
| Choi, WH; Chun, SH; Hong, SH; Jeon, EK; Jung, CK; Kang, JH; Kim, JO; Kim, SJ; Kim, YK; Kim, YS; Lee, J; Yoo, IeR | 1 |
| Beck, JT; Besse, B; Camidge, DR; Dimitrijevic, S; Heist, RS; Johnson, BE; Miller, N; Mulatero, C; Papadmitrakopoulou, VA; Petrovic, K; Pylvaenaeinen, I; Schmid, P; Urva, S | 1 |
| Breitenbücher, F; Ehrenhofer-Murray, AE; Hoffmann, G; Schuler, M | 1 |
| Boutros, PC; Feigen, M; Harris, S; John, T; Lambin, P; Liew, MS; Mitchell, P; Sia, J; Starmans, MH; Tafreshi, A; White, S; Zimet, A | 1 |
| Cai, S; Shi, A; Yu, R; Zhu, G | 1 |
| Dowlati, A; Fu, P; Halmos, B; Ma, P; Mekhail, T; Nickolich, M; Pennell, N; Sharma, N | 1 |
| Li, H; Sun, X; Xie, P; Xing, L; Yu, J; Zhang, X; Zhao, H; Zhu, W | 1 |
| Caprario, LC; Kent, DM; Strauss, GM | 1 |
| Asamura, H; Eba, J; Katayama, H; Kenmotsu, H; Niho, S; Shibata, T; Tamura, T; Tsuboi, M; Watanabe, S; Yamamoto, N | 1 |
| Bover, I; Domine, M; Font, A; Galán, A; Gómez Codina, J; González Billalabeitia, E; Gúrpide, A; Isla, D; Lecumberri, R; López Vivanco, G; Rocha, E; Rosell, R; Vicente, V | 1 |
| Diehn, M; Hanlon, AL; Harris, JP; Le, QT; Loo, BW; Murphy, JD | 1 |
| Bradbury, PA; Ellis, PM; Goss, GD; Laurie, SA; Olivo, M; Powers, J; Seymour, L; Shepherd, FA | 1 |
| Boikos, SA; Brahmer, JR; Ettinger, DS; Forde, PM; Giaccone, G; Hann, CL; Hooker, CM; Illei, PB; Kelly, RJ; Petrini, I; Rudin, CM; Yang, SC | 1 |
| Assavalapsakul, W; Chung, YH; Johnston, RN; Kaewpiboon, C; Koh, SS; Malilas, W; Moon, J; Phuwapraisirisan, P; Surapinit, S; Tip-Pyang, S | 1 |
| Athawale, RB; Gude, RP; Jain, DS; Singh, KK | 1 |
| Connis, N; Cope, L; Dobromilskaya, I; Gallia, GL; Gardner, EE; Hann, CL; Poirier, JT; Rudin, CM | 1 |
| Maggs, FG | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| He, K; Li, Z; Shi, Z; Tian, A; Wu, J; Yang, C; Zhang, Y | 1 |
| Chen, X; Li, W; Ma, KW; Wang, X; Wang, YZ | 1 |
| Buil-Bruna, N; López-Picazo, JM; Martín-Algarra, S; Moreno-Jiménez, M; Ribba, B; Trocóniz, IF | 1 |
| Batus, M; Bonomi, P; Dandekar, VK; Fidler, MJ; Kiel, K; Sher, DJ; Young, J | 1 |
| Yano, S | 1 |
| Kobayashi, S; Nakagawa, K; Nakamatsu, K; Nishimura, Y; Okamoto, I; Okamoto, K; Takeda, K; Takeda, M | 1 |
| Kato, T; Kiuchi, H; Nagahara, A; Nonomura, N; Oshima, J; Tsujimura, A; Uemura, M | 1 |
| Arai, Y; Hayashi, Y; Kakimoto, K; Miyago, N; Nakayama, M; Nishimura, K; Takeda, K; Yamaguchi, Y | 1 |
| Amatulli, M; Balderes, P; Brennan, L; Burtrum, D; Credille, KM; Damoci, CB; DeLigio, JT; Duignan, IJ; Kotanides, H; Lebron, MB; Loizos, N; O'Mahony, M; Paz, K; Persaud, K; Prewett, MC; Schwartz, KD; Starodubtseva, M; Surguladze, D; Zhang, Y | 1 |
| Chen, M; Ni, J; Qi, HW; Xie, HK; Xu, JF; Zhang, J; Zheng, H; Zhou, CC; Zhu, J | 1 |
| Brkic, S; Dedic, S; Jamakosmanovic, S; Osmic, M; Ramic, N; Umihanic, S | 1 |
| Albert, I; Ao-Baslock, A; Berger, MS; Blakely, LJ; Kazarnowicz, A; Kovacs, P; Langer, CJ; Moezi, MM; Pajkos, G; Pathak, AK; Ross, HJ; Schnyder, J; Schreeder, MT; Somfay, A; Zatloukal, P | 1 |
| Chen, Z; Guo, L; Guo, Y; Huang, J; Li, M; Li, X; Luo, L; Zhang, F; Zhu, W | 1 |
| Bacakoglu, F; Cok, G; Erdinc, M; Goker, E; Goksel, O; Goksel, T; Karakus, H; Uslu, R | 1 |
| Asamura, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Tamura, T; Tanaka, A; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Beumer, J; Chen, A; Chen, Z; Christner, SM; Deng, X; Doho, GH; Khuri, FR; Kim, S; Kowalski, J; Li, C; Owonikoko, TK; Ramalingam, SS; Rossi, MR; Sica, GL; Strychor, S; Sun, SY; Switchenko, JM; Yue, P; Zhang, G | 1 |
| Ak, G; Akcay, M; Bayman, E; Etiz, D | 1 |
| Akhurst, T; Cullinane, C; Eu, P; Hicks, RJ; Lewin, J; Mileshkin, L; Rao, A; Waldeck, K; Watkins, DN | 1 |
| Lonial, K; Noyes, AM; Siegel, RD | 1 |
| Benson, C; Blay, JY; Dirksen, U; Gelderblom, H; Judson, I; Juergens, H; Placzke, J; Rasper, M; Rutkowski, P; van den Berg, H; van Maldegem, AM | 1 |
| Ausch, C; Bajna, E; Brenner, S; Buxhofer-Ausch, V; Hamilton, G; Jäger, W; Klameth, L; Reiner, A; Riha, J; Schölm, M; Thalhammer, T | 1 |
| Eba, J; Misumi, Y; Nakamura, K; Ohe, Y; Okamoto, H; Shibata, T; Shimokawa, T; Yamamoto, N | 1 |
| Butts, C; Chu, KP; Chu, Q; Fairchild, A; Gabos, Z; Ghosh, S; Joy, AA; Kim, JO; Nijjar, T; Roa, WH; Robinson, DM; Sangha, R; Scrimger, R; Smylie, M; Yee, D | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Han, J; Ji, JH; Kim, KM; Park, K; Sun, JM | 1 |
| Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY | 1 |
| Arslan, D; Bozcuk, H; Coskun, HS; Goksu, SS; Gunduz, S; Mutlu, H; Ozdogan, M; Savas, B; Tatli, AM; Uysal, M | 1 |
| Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L | 1 |
| Assavalapsakul, W; Chung, YH; Jeong, HG; Johnston, RN; Kaewpiboon, C; Malilas, W; Moon, J; Oh, S; Srisuttee, R | 1 |
| Ahmad, S; Ahmed, M; Al-Badawi, IA; Al-Hashem, H; Al-Hayli, S; Al-Husaini, H; Darwish, A; Edesa, W; Elghamry, W; Elhassan, T; Eltigani, A; Madkhali, I; Omar, A; Soudy, H | 1 |
| Chang, J; Du, Z; Li, D; Lin, D; Shen, H; Tan, W; Wei, L; Wu, C; Wu, T; Xu, B; Yu, D; Yuan, P | 1 |
| Huang, H; Kang, H; Li, C; Peng, B; Peng, Y; Wang, D; Xiong, Y; Xu, M; Yang, X; Zhou, Z | 1 |
| Arce-Lara, C; Devisetty, K; Gore, EM; Kelley, MJ; Moran, A; Santana-Davila, R; Sparapani, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Chen, L; Chen, Y; Pan, B; Song, H; Wang, R; Xu, Y | 1 |
| Ando, R; Etani, T; Iida, K; Kawai, N; Kohri, K; Naiki, T; Tozawa, K | 1 |
| Ambrosio, F; Ardizzoni, A; Baldini, E; Boni, L; Camerini, A; Cinieri, S; Crino, L; D'Alessandro, V; Dazzi, C; Defraia, E; Passalacqua, R; Riccardi, F; Tibaldi, C; Tiseo, M; Turolla, GM; Vitale, MG; Zanelli, F; Zilembo, N | 1 |
| Auliac, JB; Baize, N; Berard, H; Chouaid, C; Falchero, L; Gervais, R; Le Caer, H; Monnet, I; Olivero, G; Thomas, P | 1 |
| Bai, Y; Guo, L; Liu, H; Wang, W | 1 |
| Cai, XW; Fan, M; Fu, XL; Hong, LZ; Liu, Q; Mao, JF; Wu, KL; Xia, B; Yang, HJ; Zhao, KL; Zhu, ZF | 1 |
| Choi, HK; Choi, KC; Choi, Y; Kwak, S; Park, SY; Yoon, HG | 1 |
| Maneechawakajorn, J; Suksuperm, J | 1 |
| Chan, WH; Ibrahim, ZA; Narihan, MZ; Ong, EJ; Wong, SL | 1 |
| Bai, Y; Lan, H; Luo, S | 1 |
| Bulanov, A; Chekini, D; Fedyanin, M; Figurin, K; Garin, A; Sekhina, O; Tjulandin, S; Tjulandina, A; Tryakin, A; Vybarava, A | 1 |
| Bentayeb, H; Cotrel, R; Dayen, C; Douadi, Y; Garoute, C; Iacob, E; Lecuyer, E; Plouvier, N; Suguenot, R | 1 |
| Berry, JM; Desai, PT; Fillmore, CM; Hammerman, PS; Kim, CF; Lin, YJ; Marquez, VE; Rowbotham, SP; Wong, KK; Xu, C; Zhang, H | 1 |
| Baudin, E; Caplin, ME; Ferolla, P; Filosso, P; Garcia-Yuste, M; Lim, E; Oberg, K; Pelosi, G; Perren, A; Rossi, RE; Travis, WD | 1 |
| Chen, P; Chen, Z; Guo, S; Hu, C; Huang, C; Li, B; Li, L; Li, W; Liao, M; Lu, S; Luo, Y; Song, X; Wu, G; Xu, L; Yu, Y; Zhang, L; Zhang, Y; Zhou, C | 1 |
| Barlesi, F; Barre, P; Chatellain, P; Dayen, C; Derollez, M; Fournel, P; Herman, D; Jeannin, G; Lamy, PJ; Langlais, A; Lavole, A; Le Caer, H; Molinier, O; Morin, F; Moro-Sibilot, D; Mourlanette, P; Oster, JP; Pujol, JL; Quoix, E; Renault, A; Souquet, PJ; Zalcman, G | 1 |
| Costa, DB; Desai, NV; Folch, E; Gangadharan, SP; Huberman, MS; Karp, RS; Kent, MS; Le, X; Majid, A; Rangachari, D; VanderLaan, PA | 1 |
| Fitzgerald, TJ; Gandara, DR; Gaspar, LE; Kelly, K; Mack, PC; Moon, J; Pandya, KJ; Raben, D; Thomas, CR; Wozniak, AJ | 1 |
| Baggstrom, M; Bogart, J; Crawford, J; Graziano, SL; Gu, L; Masters, GA; Miller, AA; Otterson, GA; Pang, HH; Ready, NE; Thomas, SP; Vokes, EE | 1 |
| Li, D; Liu, L | 1 |
| Park, MJ | 1 |
| De Leyn, P; De Ruysscher, D; Eberhardt, WE; Felip, E; Hoffmann, H; Le Péchoux, C; Peters, S; Stahel, R; Weder, W; Westeel, V | 1 |
| Baldi, L; Boni, C; Braglia, L; Gnoni, R; Pagano, M; Savoldi, L; Zanelli, F | 1 |
| Choi, KH; Hwang, KE; Jeong, ET; Jung, JW; Kim, HR; Oh, SJ; Park, MJ; Shon, YJ | 1 |
| Belderbos, J; De Ruysscher, D; Deasy, JO; Din, S; Dingemans, AM; Houben, R; Lambin, P; Oberije, C; Rimner, A; Uyterlinde, W; van de Heuvel, M | 1 |
| Bongiovanni, A; Burgio, MA; Califano, R; Carloni, F; Casanova, C; Cavallo, G; Di Battista, M; Genestreti, G; Kazushige, W; Kenmotsu, H; Korkmaz, T; Metro, G; Roopa, K; Scarpi, E; Selcuk, S; Tiseo, M | 1 |
| Aggarwal, C; Belani, CP; Dahlberg, SE; Dowell, J; Gerber, DE; Hann, CL; Khan, SA; Moss, RA; Owonikoko, TK; Ramalingam, SS | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Harada, M; Inoue, A; Ishida, T; Kinoshita, I; Maemondo, M; Mori, Y; Morikawa, N; Nakagawa, T; Nukiwa, T; Oizumi, S; Saito, R; Sugawara, S; Suzuki, T; Taima, K; Watanabe, H | 1 |
| Artal, A; Barneto, I; De Castro, J; Esteban, E; Gascó, P; Gasent, JM; Montalar, J; Muñoz-Langa, J; Sanchez, A; Vidal, S | 1 |
| Chang, PY; Chen, CY; Chen, JC; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Wang, TJ | 1 |
| Liang, G; Xu, T; Yang, L; Zhang, F | 1 |
| Bianco, V; Francini, E; Ghiribelli, C; Laera, L; Luzzi, L; Martellucci, I; Paladini, P; Petrioli, R; Roviello, G; Voltolini, L | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Gomez, D; Komaki, R; Lee, MS; Levy, LB; Liao, Z; Lu, C; Tang, C; Zhuang, Y | 1 |
| Chen, P; Jiang, Q; Li, J; Tang, XP; Zhu, LR | 1 |
| Chen, Y; He, HL; He, LJ; Lin, S; Luo, HQ; Pang, HW; Ren, PR; Shang, CL; Wen, QL; Wu, JB; Xiang, L; Yang, B; Yang, HR; Zhang, JW | 1 |
| Hoffmann, L; Khalil, AA; Knap, MM; Moeller, DS; Winther-Larsen, A | 1 |
| Chen, W; Jun, HZ; Kang, JR; Long, LH; Wei, WW; Yan, SW | 1 |
| Brames, MJ; Einhorn, LH; Mulherin, BP | 1 |
| Cacciola, NA; De Stefano, A; Federico, A; Forzati, F; Fusco, A; Malapelle, U; Pallante, P; Pellecchia, S; Rocco, D; Sepe, R | 1 |
| Hanna, N; Jalal, SI; Mamdani, H | 1 |
| Abdi, S; Coleman, RE; Hancock, BW; Lo, C; Price, JM; Tidy, J; Winter, MC | 1 |
| Bluhme, H; Farr, KP; Grau, C; Kallehauge, JF; Khalil, AA; Kramer, S; Morsing, A; Møller, DS | 1 |
| Koo, DH; Lee, HS; Lee, SS; Lee, YG; Lim, SY; Nam, H; Oh, S; Song, JU | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Bonventre, JV; Ichimura, T; Ikemi, Y; Kim, YH; Masuda, S; Matsubara, K; Mishima, M; Ozawa, A; Sato, T; Shinke, H; Togashi, Y | 1 |
| Akarsu, Z; Duman, E; Gunduz, S; Inal, A; Kaya, V; Ozturk, D; Yildirim, M; Yildiz, M | 1 |
| Haixia, P; Honglin, H; Yifeng, B | 1 |
| Mo, J; Murphy, EP; Yoon, JM | 1 |
| Wang, Q; Wang, S; Wang, Z; Wu, B; Wu, X; Zhang, H; Zhu, R; Zhu, Y | 1 |
| Huang, L; Satterlee, A; Srinivas, R; Wang, Y; Zhang, Y | 1 |
| Aasebø, U; Aksnessæther, BY; Bremnes, RM; Brunsvig, PF; Brustugun, OT; Fløtten, Ø; Grønberg, BH; Halvorsen, TO; Hornslien, K; Liaaen, ED; Sundstrøm, S; Tollåli, T | 1 |
| Brousset, P; Delisle, MB; Desquesnes, A; Escourrou, G; Filleron, T; Hieblot, C; Lawson, M; Martineau, Y; Nicaise, Y; Pannese, M; Philippe, C; Prats, H; Pyronnet, S; Quelen, C; Renaud, C; Rintoul, RC; Touriol, C; Vaysse, C | 1 |
| Brickman, A; Gallo, K; Gattuso, P; Seder, CW; Warren, WH | 1 |
| Čebron Lipovec, N; Čufer, T; Grabnar, I; Mrhar, A; Režonja Kukec, R; Vovk, T | 1 |
| Shiau, AL; Shieh, GS; Su, BH; Tseng, YL; Wu, CL | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Das, S; Dunphy, FR; Gu, L; Kelsey, CR; Marks, LB; Ready, NE | 1 |
| Kim, ES | 1 |
| Bian, K; Chen, T; Elkhadragy, L; Jung, S; Long, W; Muppani, NR; Seternes, OM; Wang, W; Zhang, C | 1 |
| Bogart, JA; Crawford, J; Gu, L; Pang, HH; Ready, NE; Salama, JK; Schild, SE; Vokes, EE; Wang, X | 1 |
| Aliustaoglu, M; Aydin, D; Ercelep, O; Gemici, C; Gumus, M; Isik, D; Korkmaz, T; Mayadagli, A; Mert, AG; Odabas, H; Ozcelik, M; Ozdemir, P; Seker, M; Surmeli, H; Yuksel, S | 1 |
| Aoyagi, H; Chubachi, S; Ikemura, S; Iwami, E; Matsuzaki, T; Nakajima, T; Terashima, T | 1 |
| Aerts, J; Biesma, B; Brade, A; Chouaki, N; Choy, H; Dakhil, S; Gandara, D; Govindan, R; Hossain, A; Iscoe, N; Koustenis, A; Lewanski, C; Martinez Aguillo, M; Mok, T; Rubio-Viqueira, B; San Antonio, B; Senan, S; Treat, J; Vansteenkiste, J; Vokes, E; Wang, LH | 1 |
| Janssen, S; Kaesmann, L; Rades, D; Schild, SE | 1 |
| Adhav, R; Chanukuppa, V; Paul, D; Rapole, S; Reddy, PJ; Santra, MK; Srivastava, S; Taunk, K | 1 |
| Biner Uslu, I; Dikmen, A; Erdoğan, Y; Yilmaz Demirci, N; Yılmaz, A; Yilmaz, Ü | 1 |
| Lee, AC | 1 |
| Chen, L; Chen, Y; Feng, X; Peng, L; Wang, J; Zhong, D | 1 |
| Belani, CP; Chen, HX; Dahlberg, SE; Fleisher, M; Hann, CL; Monga, M; Ramalingam, SS; Rudin, CM; Schiller, JH; Shanks, JC; Sturtz, K; Takebe, N; Tester, WJ; Velasco, MR | 1 |
| Almadana Pacheco, V; Benito Bernáldez, C; Romero Muñoz, C | 1 |
| Hathaisanguan, S; Maneechawakajorn, J | 1 |
| Arriola, E; Cave, J; Cross, N; Danson, S; Galea, I; Geldart, T; Griffiths, R; Hamid, D; Maishman, T; Mulatero, C; Nolan, L; Ottensmeier, C; Potter, V; Stanton, L; Wheater, M; Woll, PJ | 1 |
| Chatfield, M; Friedlander, M; Grimison, P; Gurney, H; Houghton, B; Roncolato, FT; Rosenthal, M; Stockler, M; Thomson, D; Toner, G | 1 |
| Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N | 1 |
| Akhtari, M; Bernicker, EH; Teh, BS | 1 |
| Cheng, Y; Cui, HX; Li, ZL; Ma, LX; Sun, SY; Yang, CL | 1 |
| Hatfield, LA; Huskamp, HA; Lamont, EB | 1 |
| Wolin, EM | 1 |
| Darling, GE | 1 |
| Chanvorachote, P; Chaotham, C; Puchsaka, P | 1 |
| Fujimoto, S; Imai, H; Kaira, K; Minato, K; Mori, K; Watase, N; Yamada, M | 1 |
| Aerts, J; Akerley, W; Fairchild, J; Felip, E; Gold, K; Havel, L; Horn, L; Kim, SW; Kong Sanchez, T; Lorigan, P; Luft, A; Nakagawa, K; Pietanza, MC; Pieters, A; Reck, M; Spigel, D; Szczesna, A; Thomas, M; Wu, YL; Zielinski, C | 1 |
| Janssen, S; Käsmann, L; Rades, D | 1 |
| Aydiner, A; Ciftci, R; Demir, A; Eralp, Y; Firat, P; Guveli, ME; Oral, EN; Ozkan, B; Ozkaya, K; Saglam, EK; Saip, P; Sen, F; Tambas, M; Toker, A | 1 |
| Akyuz, MD; Büttner, R; Erkel, M; Florin, A; Fritz, C; Jokić, M; Klümper, N; Kümpers, C; Maintz, D; Michels, S; Nowak, M; Offermann, A; Ozretić, L; Perner, S; Persigehl, T; Reinhardt, HC; Riabinska, A; Rinneburger, M; Schmitt, A; Schumacher, B; Spiro, J; Thomale, J; Vlašić, I; Vogel, W; Welcker, D; Wittersheim, M; Wolf, J | 1 |
| Feng, T; Huang, Y; Li, HM; Lin, DX; Ma, F; Tan, W; Tan, WW; Xu, BH; Yang, J; Yu, DK; Yuan, P | 1 |
| Aasebø, U; Bremnes, RM; Brunsvig, P; Brustugun, OT; Fløtten, Ø; Grønberg, BH; Halvorsen, TO; Kaasa, S; Sundstrøm, S | 1 |
| Berger, MF; Fleisher, M; Holodny, AI; Kris, MG; Krug, LM; Litvak, AM; Ng, KK; Pietanza, MC; Rudin, CM; Sima, CS; Teitcher, JB; Varghese, AM; Won, HH; Woo, KM | 1 |
| Jang, TW; Jeong, JH; Kim, KS; Kim, SY; Kim, YC; Lee, HK; Lee, JE; Lee, KH; Lee, KY; Lee, SY; Oh, IJ; Park, CK; Shin, KC | 1 |
| Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J | 1 |
| Adra, N; Albany, C; Einhorn, LH; Giannatempo, P; Hanna, NH; Necchi, A; Nicolai, N; Pond, GR; Raggi, D; Salvioni, R | 1 |
| Jeong, JS; Kim, SR; Lee, JH; Lee, YC | 1 |
| Einhorn, LH; Kesler, KA; Ranganath, P | 1 |
| Hanai, K; Higure, T; Hoshi, A; Kawamura, Y; Nakajima, N; Nitta, M; Shimizu, Y; Terachi, T | 1 |
| Msaouel, P; Tu, SM; Zhang, M | 1 |
| Fujimoto, S; Imai, H; Kaira, K; Kazama, T; Minato, K; Mori, K; Watase, N; Yamada, M | 1 |
| Amini, M; Belderbos, JSA; Biesma, B; Bootsma, GP; Brouns, -JWM; Bussink, J; De Ruysscher, DKM; Dingemans, AC; Hendriks, LEL; Oei, SB; Stigt, JA; Uyterlinde, W; Van den Heuvel, MM; Wijsman, R | 1 |
| Braun, F; Burger, M; Catusse, J; Kayser, G; Reichardt, W; Taromi, S; von Elverfeldt, D; Weber, WA; Zeiser, R | 1 |
| Brown, JF; Brzezniak, C; Cabrales, P; Caroen, S; Carter, CA; Day, R; Dean Abrouk, N; Degesys, A; Kim, MM; Larson, C; Oronsky, A; Oronsky, B; Reid, TR; Scicinski, J | 1 |
| Asao, T; Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Kitahara, S; Nokihara, H; Ohe, Y; Okuma, HS; Sunami, K; Yamamoto, N | 1 |
| Adam, V; Balvan, J; Dostalova, S; Heger, Z; Krizkova, S; Masarik, M; Moulick, A; Polanska, H; Raudenska, M | 1 |
| Daly, M; Kelly, K; Tam, K | 1 |
| Behera, M; Belani, CP; Curran, WJ; Ernani, V; Higgins, KA; Khuri, FR; Owonikoko, TK; Pakkala, S; Pillai, RN; Ramalingam, SS; Saba, NF; Shin, DM; Steuer, CE | 1 |
| Pagliaro, LC | 1 |
| Chao, TK; Hou, WC; Kao, CC; Lai, YJ; Li, HM; Su, HY; Yu, MH | 1 |
| Cao, J; Cao, S; Jin, S; Meng, Q; Shen, J; Wang, C; Yu, Y; Zhang, A; Zhang, H; Zhang, P | 1 |
| Abdalla, B; Alfaar, AS; Awad, M; Rashed, WM; Taha, H; Zekri, W | 1 |
| Barbolosi, D; Barlesi, F; El Cheikh, R; Faivre, C | 1 |
| Shi, A; Shi, C; Song, M; Wang, X; You, J; Yu, H; Yu, R; Zheng, Y; Zhu, G | 2 |
| Hosoda, Y; Imamura, M; Kawai, J; Kiyochi, H; Komoto, I; Nishiyama, K; Ogura, N; Okabe, A; Oshima, Y; Sugimoto, T; Taki, Y; Tsunekawa, S | 1 |
| Ambrosio, F; Ardizzoni, A; Baldini, E; Boni, L; Brighenti, M; Camerini, A; Chiari, R; Cinieri, S; D'Alessandro, V; Dazzi, C; Defraia, E; Grossi, F; Riccardi, F; Tibaldi, C; Tiseo, M; Trolese, AR; Turolla, GM; Zanelli, F; Zilembo, N | 1 |
| Bi, N; Chen, D; Chen, M; Chen, W; Du, L; Feng, Q; He, J; Hui, Z; Jiang, W; Li, J; Liang, J; Liu, L; Lv, C; Lv, J; Shi, A; Shyr, Y; Wang, L; Wang, W; Wang, X; Wu, S; Xiao, Z; Xu, Y; Yin, W; Zhang, H; Zhang, T; Zhao, L; Zhou, Z | 1 |
| Neal, JW; Wakelee, HA | 1 |
| Du, ZL; Feng, T; Huang, Y; Li, HM; Lin, DX; Ma, F; Tan, W; Tan, WW; Xu, BH; Yang, J; Yu, DK; Yuan, P | 1 |
| Flynt, A; Hamid, O; McCleod, M; Polzer, J; Roberson, S; Salgia, R; Spigel, DR; Stille, JR; Weaver, RW | 1 |
| Crosse, B; Cullen, M; Fife, KM; Hackshaw, A; Harden, S; Middleton, G; Muthukumar, D; Nash, S; Ngai, Y; Ottensmeier, CH; Schmid, P; Seckl, MJ; Taylor, P; Thompson, J | 1 |
| Grüllich, C; Grüner, M; Hadaschik, B; Hofheinz, RD; Jäger, D; Jentsch-Ullrich, K; Lasitschka, F; Zschäbitz, S | 1 |
| Azuma, M; Goto, H; Hanibuchi, M; Kakiuchi, S; Kawano, H; Nishioka, Y; Ogushi, F; Otsuka, K; Saijo, A; Sakaguchi, S; Tezuka, T; Toyoda, Y | 1 |
| Fan, M; Fu, XL; Liu, D; Wu, KL; Zhang, J; Zhao, KL; Zhao, WX; Zhu, ZF | 1 |
| Ayas, S; Cetiner, H; Gurbuz, A; Karateke, A | 1 |
| Bacillo, E; Calogero, R; Cappia, S; Ceppi, P; Longo, M; Novello, S; Papotti, M; Saviozzi, S; Scagliotti, GV; Selvaggi, G; Volante, M | 1 |
| Artal-Cortes, A; Barneto, I; Camps, C; Carrato, A; Gómez-Codina, J; González-Larriba, JL; Isla, D; Rosell, R; Safont, MJ; Sirera, R | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Han, J; Hwang, IG; Kim, J; Lee, S; Park, BB; Park, K; Shim, YM | 1 |
| DiBernardo, C; Handa, JT; Khurana, RN | 1 |
| Aschroft, L; Baka, S; Blackhall, F; Califano, R; Faivre-Finn, C; Ferraldeschi, R; Lorigan, P; Taylor, P; Thatcher, N | 1 |
| Kamdar, O; Le, W; Rosen, GD; Upadhyay, D; Zhang, J | 1 |
| Algara, M; Fernández-Velilla, E; Foro, P; Lacruz, M; López, JL; Lozano, J; Membrive, I; Quera, J; Reig, A; Rodríguez, N; Sanz, X | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Fukuoka, M; Nakagawa, K; Okamoto, I; Takezawa, K | 1 |
| Ross, HJ; Seung, SK | 1 |
| Aasebø, U; Bergman, B; Bremnes, R; Ek, L; Fluge, S; Hermes, A; Sederholm, C; Sörenson, S; Sundstrøm, S; Thaning, L; Vilsvik, J | 1 |
| de Lima, MC; Moreira, JN; Santos, A; Sarmento-Ribeiro, AB; Simões, S | 1 |
| Eisen, T; Ferry, DR; Gilligan, D; Gower, NH; Harper, PG; Hocking, M; James, LE; Lee, SM; Prendiville, J; Qian, W; Rudd, RM; Spiro, S | 1 |
| Friedrichs, N; Gorschlüter, M; Gressner, O; Mey, U; Popp, H; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J | 1 |
| Arndt, CA; Hawkins, DS; Hoots, WK; Inwards, CY; Kleinerman, ES; Koshkina, NV; Morales-Arias, JA; Munsell, MF; Rodriguez, NI | 1 |
| Cassoni, A; Craft, AW; Douglas, C; Dunst, J; Grimer, R; Hackshaw, A; Hunold, A; Jürgens, H; Köhler, G; Ladenstein, R; Lewis, I; McTiernan, A; Paulussen, M; Poremba, C; Schuck, A; Spooner, D; van den Berg, H; Whelan, J; Winkelmann, W; Zoubek, A | 1 |
| Antoniou, D; Athanasiadis, A; Dimitroulis, J; Giamboudakis, P; Karaindros, D; Katis, K; Koutantos, J; Rapti, A; Rigatos, S; Stathopoulos, GP; Stathopoulos, J; Toumbis, M; Tsikritsaki, K | 1 |
| Basu, AK; Basu, N; Roy, PP | 1 |
| Hirami, Y; Kawagoe, N; Mandai, M; Mio, T; Mishima, M; Sakuma, K; Takahashi, M; Yoshimura, N | 1 |
| Brahim, JS; Jaffe, ES; Shanti, RM; Torres-Cabala, CA; Wilson, WH | 1 |
| Bao, Y; Chen, M; Chen, YY; Gao, JM; He, H; Hu, X; Liu, Y; Poudel, S; Sun, ZW; Wang, WH; Wang, Y; Zhang, L; Zhuang, TT | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Crawford, J; Evans, J; Kelsey, CR; Meyer, J; Shofer, S; Wahidi, M | 1 |
| Chen, ZF; Han, H; Li, YH; Liu, ZW; Qin, ZK; Ye, YL; Yu, SL; Zhou, FJ | 1 |
| Anderson, T; Ansari, R; Arseneau, J; Breen, T; Bruetman, D; Chowhan, N; Einhorn, L; Fisher, W; Govindan, R; Hanna, N; Johnson, C; Mantravadi, P; McGarry, R; Melnyk, A; Nattam, S; Neubauer, M; Reynolds, C; Richards, D; White, A; Yiannoutsos, C | 1 |
| Ball, DL; Macmanus, MP; Michael, M; Millward, MJ; Plumridge, NM; Rischin, D; Wirth, A; Yuen, K | 1 |
| Aguilar-Ponce, JL; Chilaca-Rosas, F; Cruz-López, JC; Martínez-Cedillo, J; Molina-Calzada, C; Vidal-Millán, S | 1 |
| Cordier, JF; Cottin, V; Girard, N; Lapalus, MG; Tronc, F | 1 |
| Annereau, JP; Bailly, C; Barret, JM; Brel, V; Delcros, JG; Guilbaud, N; Guminski, Y; Imbert, T; Kruczynski, A; Lansiaux, A; Vispé, S | 1 |
| Ciszak, L; Frydecka, I; Jankowska, R; Kosmaczewska, A; Szteblich, A; Werynska, B | 1 |
| Aguero, EG; Fortney, JA; Garrett-Mayer, E; Sharma, AK; Sherman, CA; Shirai, K; Wahlquist, AE; Watkins, JM | 1 |
| Shao, S; Wang, J; Wang, Q; Wang, S; Wang, W; Wang, Y | 1 |
| Cao, Y; Feng, FZ; Li, L; Wan, XR; Xiang, Y; Yang, XY | 1 |
| Carocha, AP; Issa, MC; Pereira, GB; Pinto, JM; Vergueiro, Tde R; Vilar, EG; Xavier, MH | 1 |
| Coosemans, W; De Leyn, P; Decaluwé, H; Decker, G; Lerut, T; Lievens, Y; Moons, J; Nafteux, P; Van Raemdonck, D; Vansteenkiste, J | 1 |
| Chen, D; Li, M; Rayburn, ER; Wang, H; Zhang, J; Zhang, R | 1 |
| Bregni, M; Pedrazzoli, P | 1 |
| Hann, CL; Rudin, CM | 1 |
| Cao, Y; Feng, FZ; Wan, XR; Xiang, Y; Yang, XY | 1 |
| Choi, YJ; Jang, WS; Kim, CH; Lee, JC; Lee, SJ; Lee, SS; Rho, JK | 1 |
| Anderson, ML; Beasley, AD; Coleman, NM; Kolomeyevskaya, NV; Miller, HJ; Tanyi, JL | 1 |
| Bingcheng, L; Feng, Y; Jiarui, W; Li, J; Lichuan, Z; Qi, W; Siyan, W; Yingyan, W | 1 |
| Baggstrom, MQ; Burdette-Radoux, S; Govindan, R; Green, MR; Hodgson, L; Vokes, EE; Wang, X | 1 |
| Anraku, M; Bezjak, A; Darling, GE; de Perrot, M; Hwang, DM; Johnston, MR; Keshavjee, S; Leighl, N; Lewis, SJ; Pierre, AF; Rampersaud, YR; Shepherd, FA; Sun, AY; Tsao, MS; Waddell, TK; Zener, RE | 1 |
| Kane, SE; Mudry, RR; Sadava, D; Still, DW | 1 |
| Gatzemeier, U; Heigener, DF; Jäger, E; Manegold, C; Saal, JG; Zuna, I | 1 |
| Bono, K; Fujita, Y; Ito, S; Kawabata, A; Kawaishi, M; Kuwano, K; Mikami, J; Numata, T; Tamura, K; Wakui, H; Yumino, Y | 1 |
| Hu, X; Jiang, L; Li, S; Wang, J; Wang, Q; Wang, S; Wang, Y; Zhang, L | 1 |
| Arcaro, A; Dhillon, T; Lane, HA; Lemoine, NR; Marinov, M; Mauri, FA; Pardo, OE; Seckl, MJ; Tan, LT; Zangemeister-Wittke, U; Ziogas, A | 1 |
| Brüne, B; Schnitzer, SE; Weigert, A; Zhou, J | 1 |
| Bernardo, P; Horn, L; Johnson, DH; Levitan, N; Levitt, ML; Sandler, A; Wagner, H | 1 |
| Amaro, T; Arúajo, AM; Azevedo, I; Barata, F; Coelho, AL; Figueiredo, A; Mendez, JC; Soares, M; Sousa, B | 1 |
| Kakavelas, P; Kontakiotis, T; Lithoxopoulou, H; Mylonaki, E; Rapti, E; Tsiouda, T; Zarogoulidis, K; Zarogoulidis, P; Zarogoulidou, V | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 2 |
| Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R | 1 |
| Fujime, M; Hojo, M; Kato, J; Kodani, T; Nagahara, A; Nagao, K; Ogihara, T; Osada, T; Otaka, M; Saito, H; Shibuya, T; Ueyama, H; Watanabe, S | 1 |
| Carleton, JE; Chansky, K; Crowley, J; Dakhil, SR; Gandara, DR; Jett, J; Kuebler, JP; Langer, CJ; Lara, PN; Lenz, HJ; Natale, R; Redman, MW | 1 |
| Crowley, JJ; Gandara, DR; Gaspar, LE; Goldberg, Z; Lara, PN; Le, QT; Moon, J; Moore, DF; Redman, M; Williamson, SK | 1 |
| Chen, WT; Choy, CO; Chu, JS; Chu, KL; Din, R; Hsu, HL; Huang, SF; Kasiappan, R; Liu, HP; Shih, HJ; Shu, CL | 1 |
| Baud, M; Chouaïd, C; Febvre, M; Lebeau, B; Masanès, MJ | 1 |
| Bernard, C; Grushka, JR; Laberge, JM; Mueller, C; Nguyen, VH; Puligandla, PS; Roessingh, Ade B; Ryckman, J; St Vil, D; Walton, JM | 1 |
| Al Balushi, Z; Bulduc, S; Lallier, M; Mulleur, C | 1 |
| Iscoe, NA; Senan, S; Treat, JA; Vokes, EE | 1 |
| Baba, T; Hanagiri, T; Ichiki, Y; Ohga, T; Sugio, K; Takenoyama, M; Uramoto, H; Yasuda, M; Yasumoto, K | 1 |
| Britschgi, A; Britschgi, C; Fey, MF; Helin, K; Jenal, M; Leprince, D; Roh, V; Tobler, A; Trinh, E; Tschan, MP; Vorburger, SA | 1 |
| Cao, Y; Feng, F; Wan, X; Xiang, Y; Yang, X | 1 |
| Hansen, KH; Hansen, O; Sørensen, P | 1 |
| Ji, W; Lü, JM; Ou, GF; Ren, H; Wang, LH; Wang, XZ; Yin, WB; Zhou, ZM | 1 |
| Deutsch, E; Loriot, Y; Mordant, P; Olaussen, KA; Soria, JC | 1 |
| Hiroshima, K; Iwadate, Y; Iyoda, A; Moriya, Y; Nakatani, Y; Takiguchi, Y; Uno, T; Yoshino, I | 1 |
| Albain, KS; Chen, Y; Cox, JD; Darling, G; Feins, RH; Fry, WA; Gandara, DR; Green, MR; Johnson, DH; Ley, J; Livingston, RB; Miller, RC; Rusch, VW; Sause, WT; Shepherd, FA; Smith, C; Swann, RS; Turrisi, AT | 1 |
| Choe, DH; Kang, MS; Kim, CH; Lee, JC; Noh, GY | 1 |
| Basu, S; Faber, LP; Kim, AW; Liptay, MJ; Miller, C; Milman, S; Warren, WH | 1 |
| Grün, R; Koch, B; Tannapfel, A; Vieth, M | 1 |
| Blakely, J; Ciuleanu, T; Dediu, M; Guba, SC; Hanauske, AR; Hong, S; Jassem, J; Karaseva, NA; Konduri, K; Lorigan, P; Obasaju, CK; Reck, M; Serwatowski, P; Smit, EF; Socinski, MA; Szczesna, A; Thatcher, N; Visseren-Grul, C | 1 |
| Che, G; Gong, Y; Hou, M; Huang, M; Li, L; Li, T; Li, W; Liu, L; Liu, Y; Lu, Y; Ren, L; Tang, B; Wang, J; Xu, Y; Zhou, L; Zhu, J; Zou, B | 1 |
| Boersma, L; Bootsma, G; De Ruysscher, D; Dehing-Oberije, C; Dingemans, AM; Geraedts, W; Hochstenbag, M; Lambin, P; Oellers, M; Pitz, C; Rhami, A; Simons, J; Snoep, G; Teule, J; Thimister, W; van Loon, J; Wanders, R | 1 |
| Chelis, L; Christophyllakis, Ch; Georgoulias, V; Giassas, S; Kakolyris, S; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Polyzos, A; Vamvakas, L; Vardakis, N; Xenidis, N | 1 |
| Glisson, BS; Johnson, FM | 1 |
| Fu, J; Hanes, J; Tang, BC; Watkins, DN | 1 |
| Hayashi, K; Kimura, H; Nishida, H; Ohnari, I; Shirai, T; Takeuchi, A; Tomita, K; Tsuchiya, H | 1 |
| Adjei, AA; Baas, P; Choy, H; Gandara, DR; Gaspar, LE; Goss, G; Lara, PN; Saijo, N; Sangha, R; Schiller, JH; Vokes, EE | 1 |
| Arvelo, F; Assayag, F; Bourgeois, Y; Daniel, C; Decaudin, D; Froget, B; Legrier, ME; Livartowski, A; Némati, F; Poupon, MF | 1 |
| Dahlberg, SE; Dowlati, A; Horn, L; Moore, DF; Murren, JR; Sandler, AB; Schiller, JH | 1 |
| Fukuoka, M; Nakagawa, K; Nishimura, Y; Okamoto, I; Okamoto, K; Tachibana, I; Takezawa, K | 1 |
| Inagaki, H; Iwashima, Y; Kusumoto, S; Kutsuna, T; Maeno, K; Miyazaki, M; Nakamura, A; Nakao, M; Oguri, T; Ota, C; Ozasa, H; Sato, S; Takakuwa, O; Ueda, R; Uemura, T | 1 |
| Musallam, KM; Taher, AT | 1 |
| Fujiwara, Y; Hotta, K; Kiura, K; Ochi, N; Oze, I; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Berz, D; Birnbaum, AE; Dipetrillo, TA; Fontaine, JP; Ng, T; Safran, HP | 1 |
| Adachi, M; Hirose, T; Nakamura, A; Ohnishi, T; Okuda, K; Yamaoka, T; Yashiki, C | 1 |
| Dianov, GL; Fanta, M; Freschauf, GK; Grassot, JM; Hall, DG; Mani, RS; Mereniuk, TR; Virgen, CA; Weinfeld, M | 1 |
| Inoue, K; Kamada, M; Kuno, T; Nishigawa, H; Ookouchi, H; Shuin, T; Tamura, K; Yoshimichi, J | 1 |
| Enting, D; Forster, M; Nicholson, AG; O'Brien, M; Popat, S | 1 |
| Endo, K; Hara, Y; Hirabayashi, M; Hirai, T; Hirano, K; Narabayashi, T; Terashita, S | 1 |
| Gopalan, D; Raj, V; Shaida, N | 1 |
| Manapov, F | 1 |
| Arimoto, T; Hara, H; Iwasaki, Y; Kubota, Y; Nakanishi, M; Ueda, M | 1 |
| Fan, S; Li, B; Meng, Q; Shao, S; Wang, Q; Wang, Z; Zhao, L | 1 |
| Baldi, A; Beleford, D; Boccellino, M; Liu, Z; Maguire, J; Molina, J; Quagliuolo, L; Rattan, R; Shridhar, V; Staub, J | 1 |
| Crvenkova, S; Krstevska, V | 1 |
| Blackwell, S; Christensen, JD; Crawford, J; D'Amico, T; Kelsey, CR; Sporn, TA; Zagar, TM | 1 |
| Beleford, D; Chien, J; Rattan, R; Shridhar, V | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Nakamura, A; Ohmori, T; Shirai, T; Sugiyama, T; Yashiki, C | 1 |
| García-López, P; Guerrero-Vargas, NN; Jurado, R; Virto-Aguilar, J | 1 |
| Gupta, A; Mittal, B; Natu, SM; Negi, MP; Prasad, R; Srivastava, AN; Srivastava, S | 2 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Karp, DD; Peeples, BO; Stewart, DJ; Uyeki, J; William, WN | 1 |
| Barriger, RB; Fakiris, AJ; Hanna, N; Mantravadi, P; McGarry, RC; Yu, M | 1 |
| Cardenal, F; Cisar, L; Domine, M; Gorbunova, V; Moiseyenko, V; Soria, JC; Szczesna, A; Thomas, M; Zatloukal, P; Zhang, X | 1 |
| Hirashima, T; Kawase, I; Kobayashi, M; Kusunoki, Y; Matsui, K; Morishita, N; Okamoto, N; Sasada, S; Suzuki, H; Tamiya, M | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Bai, Y; Guo, L; Guo, Y; Liu, Y; Sun, Y; Xiao, F | 1 |
| Charpidou, A; Gkiozos, I; Makrilia, N; Stratakos, G; Syrigos, K; Tsagouli, S; Tsimpoukis, S; Vassias, A | 1 |
| Aoki, K; Iio, S; Ikeda, T; Kikugawa, T; Nishid, T; Ozaw, A; Sawada, Y; Shimamoto, K; Tanji, N; Yanagihara, Y; Yokoyam, M | 1 |
| Beckles, M; Chao, D; Lang, B; McCabe, DJ; Ng, K; Simister, RJ | 1 |
| He, J; Song, Y; Wang, JW; Wang, LH; Wu, LY | 1 |
| Jalalvand, E; Kaminskyy, V; Surova, O; Vaculova, A; Zhivotovsky, B | 1 |
| Abdelouafi, A; Benchakroun, N; Benider, A; Benkirane, A; Elbenna, N; Kadiri Fatmi, ME; Lakhrib, N; Mansouri, I; Mharech, A; Roubal, M; Tawfiq, N; Zamiati, S | 1 |
| Albelda, SM; Burny, A; Crisanti, C; Crisanti, MC; Hubaux, R; Kapoor, V; Mascaux, C; Vandermeers, F; Willems, L | 1 |
| Guan, Y; Lin, D; Liu, Y; Liu, Z; Ott, J; Shen, Y; Wu, C; Xu, B; Yu, D; Yuan, P | 1 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Fijuth, J; Jesien-Lewandowicz, E; Kordek, R; Spych, M | 1 |
| Batum, O; Emin Erbaycu, A; Gunduz, A; Tuksavul, F; Zeki Guclu, S; Zeren Ucar, Z | 1 |
| Akaza, H; Fukuhara, Y; Joraku, A; Kandori, S; Kawai, K; Miyanaga, N; Shimazui, T | 1 |
| Aliev, MD; Chernov, IS; Machak, GN; Meluzova, OM; Polotskiĭ, BE | 1 |
| Fukunaga, K; Hajiro, T; Hashimoto, S; Ikezoe, K; Kaji, Y; Minakuchi, M; Nakajima, T; Okumura, N; Sakuramoto, M; Sato, E; Sugimura, M; Taguchi, Y; Tanaka, E; Tanizawa, K; Yasuda, T | 1 |
| Buchbinder, D; Casillas, J; Linetsky, M; Steinberg, G | 1 |
| Endo, M; Kaira, K; Murakami, H; Naitou, T; Nakamura, Y; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM | 1 |
| Frings, V; Maassen van den Brink, KI; Melissant, CF; Phernambucq, ECJ; Postmus, PE; Senan, S; Smit, EF; Spoelstra, FOB; van de Ven, PM; Verbakel, WFAR | 1 |
| Le Péchoux, C; Paumier, A | 1 |
| Abolmaali, ND; Abramyuk, AM; Tokalov, SV | 1 |
| Baandrup, L; Hauggaard, A; Holm, B; Winberg, BH | 1 |
| Bao, Y; Chen, J; Chen, M; Cheng, Y; He, H; Hu, X; Li, K; Liang, Y; Liu, Y; Sun, Z; Wang, F; Wang, W; Wang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhuang, T | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Baka, S; Georgoulias, V; Gerogianni, A; Kalbakis, K; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Pavlakou, G; Tsaroucha, E; Vamvakas, L; Veslemes, M | 1 |
| Abbruzzese, A; Addeo, R; Caraglia, M; Carbone, SF; Correale, P; Francini, G; Gotti, G; Licchetta, A; Martellucci, I; Migali, C; Remondo, C; Ricci, V; Rotundo, MS; Sperlongano, P; Tagliaferri, P; Tassone, P; Volterrani, L | 1 |
| Baier, K; Flentje, M; Guckenberger, M; Richter, A; Wilbert, J | 1 |
| Fujisawa, M; Miyake, H; Muramaki, M; Takenaka, A; Terakawa, T | 1 |
| Chansky, K; Crowley, J; Fukuda, H; Gandara, DR; Lara, PN; Natale, R; Redman, MW; Saijo, N; Shibata, T; Tamura, T | 1 |
| Joseph, B; Muppani, NR; Nyman, U; Zhivotovsky, B | 1 |
| Jaiswal, AK; Niture, SK | 1 |
| Cantor, A; Miley, D; Reddy, V; Robert, F; Rossman, J | 1 |
| Sebolt, JT; Sun, Y; Wang, S; Xu, X; Yang, J; Zheng, M | 1 |
| Chen, L; Fan, S; Gao, F; Molnár, J; Wang, H; Wang, J; Wang, Q; Xiao, GG; Yang, Z; Zhao, L | 1 |
| Aglione, S; Bareggi, C; Blackhall, F; Califano, R; Collovà, E; Farina, G; Fatigoni, S; Galetta, D; Gallerani, E; Garassino, MC; Ghidini, A; La Verde, N; Lo Dico, M; Lorigan, P; Mancuso, A; Martelli, O; Michetti, G; Rossi, A; Saggia, C; Thatcher, N; Torri, V | 1 |
| Aguero, EG; Garrett-Mayer, E; Sharma, AK; Sherman, CA; Shirai, K; Silvestri, GA; Wahlquist, AE; Watkins, JM; Zauls, AJ | 1 |
| dos Santos, LV; Lima, CS; Lima, JP; Sasse, AD; Sasse, EC | 1 |
| Albain, K; Bae, K; Curran, WJ; Gore, EM; Komaki, R; Machtay, M; Movsas, B; Paulus, R; Sause, WT | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Guan, Y; Lin, D; Liu, Y; Miao, X; Shen, H; Wu, C; Wu, T; Xu, B; Xu, J; Yu, D; Yuan, P; Zhang, T | 1 |
| Abdelbar, O; Asmae, N; Fouad, E; Hassane, S; Houcine, C; Karim, R; Said, I | 1 |
| Braidotti, P; Fabbri, A; Galetta, D; Manzotti, M; Pelosi, G; Perrone, F; Sonzogni, A; Spaggiari, L; Veronesi, G; Viale, G | 1 |
| Feng, FZ; Wan, XR; Xiang, Y; Zhou, Y | 1 |
| Akaza, H; Bando, M; Itoh, K; Kawai, K; Kondo, Y; Nakayama, M; Saito, T; Sugiyama, Y | 1 |
| Feng, F; Geng, S; Wan, X; Wang, T; Xiang, Y | 1 |
| Chandna, S; Mathur, R; N Kapoor, P; S Dwarakanath, B | 1 |
| Guo, S; Liang, Y; Zhou, Q | 1 |
| Binder, D; Caca, K; Eberhardt, WE; Fischer von Weikersthal, L; Fischer, B; Fischer, JR; Gauler, TC; Hortig, P; Kaufmann, C; Keilholz, U; Link, H; Martus, P; Schmittel, A; Sebastian, M | 1 |
| Engel-Riedel, W; Gieseler, F; Guetz, S; Kellner, O; Nagel, S; Schuette, W; Schumann, C | 1 |
| Peng, XS; Qin, BF; Wei, Q; Zhou, FX; Zhou, ZT; Zou, LY | 1 |
| Azuma, A; Gemma, A; Kitamura, K; Kosaihira, S; Kudoh, S; Kuribayashi, H; Minegishi, Y; Mizutani, H; Okano, T; Seike, M; Yoshimura, A | 1 |
| Brammer, JE; Lulla, P; Lynch, GR | 1 |
| Ashcroft, L; Blackhall, F; Califano, R; Colaco, R; Faivre-Finn, C; Lorigan, P; Sheikh, H; Taylor, P; Thatcher, N | 1 |
| Maceneaney, P; Moylan, EJ; O'Reilly, SP; Power, DG; Ryan, SA | 1 |
| Cegovnik, U; Kern, I; Korošec, P; Košnik, M; Rijavec, M; Silar, M; Triller, N | 1 |
| Descourt, R; Noel-Savina, E; Paleiron, N; Quéré, G; Tromeur, C | 1 |
| Berger, M; Blackhall, F; Cummings, J; Dean, EJ; Dive, C; Ranson, M; Roulston, A | 1 |
| Dahlberg, SE; Johnson, DH; Keller, SM; Kolesar, JM; Marsh, S; McLeod, HL; Schiller, JH | 1 |
| Kanintronkul, Y; Pattanapanyasat, K; Ruchirawat, S; Surarit, R; Svasti, J; Thasana, N; Winayanuwattikun, P; Worayuthakarn, R | 1 |
| Adiguzel, I; Fang, L; Faoro, L; Huang, JE; Karlin, DA; Scappaticci, FA; Socinski, MA; Spigel, DR; Townley, PM; Waterhouse, DM | 1 |
| Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ | 1 |
| Abbruzzese, A; Addeo, R; Apollinari, S; Basile, A; Bestoso, E; Botta, C; Caraglia, M; Correale, P; Gotti, G; Lamberti, M; Licchetta, A; Luzzi, L; Martellucci, I; Misso, G; Pagliuchi, M; Romano, O; Rotundo, MS; Tagliaferri, P | 1 |
| Abrams, RA; Basu, S; Batus, M; Bonomi, P; Faber, LP; Fidler, MJ; Gielda, BT; Liptay, M; Marsh, JC; Warren, WH; Zusag, TW | 1 |
| Chen, DF; Feng, QF; Liang, J; Ou, GF; Wang, LH; Xiao, ZF; Zhang, HX; Zhang, XR; Zhou, ZM; Zhu, H | 1 |
| Anchisi, S; Bieri, S; Elhfidh, M; Khanfir, K; Matzinger, O; Mirimanoff, RO; Ozsahin, M; Zouhair, A | 1 |
| Jeremić, B; Miličić, B; Milisavljevic, S | 4 |
| Brenton, JD; Cummings, NM; Lawson, MH; Murphy, G; Rassl, DM; Rintoul, RC; Russell, R | 1 |
| Amin, NP; Camidge, DR; Gaspar, LE; Kavanagh, B; Miften, M; Raben, D; Rochford, N; Thornton, D | 1 |
| Iwaba, A; Kato, T; Nagaoka, A; Naito, S; Sakurai, T; Tomita, Y; Tsukigi, M; Yamagishi, A; Yamakawa, M | 1 |
| Baud, M; Chouaïd, C; Febvre, M; Lebeau, B; Masanes, MJ; Mokhtari, T | 1 |
| Palma, DA; Phernambucq, EC; Senan, S; Smit, EF; Vincent, A | 1 |
| Baas, P; Bosquee, L; Bustin, F; Dingemans, AM; Fink, C; Hasan, B; Konopa, K; Lorigan, P; Margerit, S; Marshall, E; O'Brien, ME; Stigt, JA; Van Meerbeeck, J | 1 |
| Byhardt, R; Curran, WJ; Paulus, R; Werner-Wasik, M | 1 |
| Dingemans, AM; Giaccone, G; Lee, JH; Pham, T; Voeller, DM; Voortman, J; Wang, Y | 1 |
| Montes-Mollón, MÁ; Paz Moreno-Arrones, J | 1 |
| Cathomas, R; Frick, H; Furrer, M; Potocnik, P; Schwitter, M; von Moos, R | 1 |
| Fan, S; Gao, F; Kong, Y; Wang, J; Wang, Q; Xiao, GG; Yang, Z; Zhang, J; Zhang, L; Zhao, L | 1 |
| Chen, LK; Dinglin, XX; Huang, H; Liao, H; Liu, GZ; Wei, WD; Xu, GC; Zeng, YD | 1 |
| Cox, JD; Curran, WJ; Gore, E; Hauser, S; Komaki, R; Langer, CJ; Lee, JS; Machtay, M; Movsas, B; Paulus, R; Rosenthal, SA; Sause, W; Wasserman, T | 1 |
| Chen, MC; Lee, KH; Li, TK; Pan, SL; Shi, Q; Teng, CM; Xiao, Z | 1 |
| Hiratsuka, A; Itoi, A; Kawana, A; Matsumoto, T; Nishiyama, T; Ogura, K; Ohnuma, T | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Chaudhari, K; Gude, R; Manjappa, AS; Murthy, RS; Rajyaguru, T; Ukawala, M | 1 |
| Bang, SM; Beom, SH; Choi, Y; Chung, JH; Kim, JH; Kim, YJ; Lee, JS; Lee, KW; Song, KH; Yang, Y | 1 |
| Ashcroft, L; Blackhall, F; Califano, R; Colaco, R; Faivre-Finn, C; Hulse, P; Lorigan, P; Sheikh, H; Taylor, P; Thatcher, N | 1 |
| Barbera, S; Barletta, E; Ceribelli, A; De Maio, E; Di Maio, M; Favaretto, A; Filipazzi, V; Gallo, C; Gamucci, T; Gridelli, C; Iaffaioli, RV; Isa, L; Maione, P; Morabito, A; Perrone, F; Piccirillo, MC; Rocco, G; Rossi, A; Signoriello, S; Vecchione, A | 1 |
| Chen, HJ; Chiu, YF; Huang, YC; Kuo, YH; Lin, YW; Tsai, MS; Tseng, SC; Weng, SH | 1 |
| Gao, Z; He, Z; Li, E; Meng, Q; Wang, Q; Yang, D; Zhang, L; Zhang, Q; Zhang, X; Zhao, L; Zou, L | 1 |
| Munoz, J; Sanchez, BE; Wang, D | 1 |
| Charoentum, C; Chewaskulyong, B; Permsuwan, U; Ruengorn, C; Thongprasert, S | 1 |
| Bell-McGuinn, KM; Brogi, E; Elie, BT; Garfall, AL; Joyce, JA; Kester, JC; Olson, OC; Shree, T; Simpson, K; Zabor, EC | 1 |
| Agarwala, A; Ansari, R; Breen, T; Bruetman, D; Einhorn, L; Fisher, W; Govindan, R; Hanna, N; Jalal, SI; Johnson, CS; Melnyk, A; Neubauer, M; Richards, D; Riggs, HD; Yu, M | 1 |
| Ciuleanu, T; Guba, SC; Hong, S; Hozak, RR; Karaseva, NA; Lorigan, P; Mullaney, BP; Myrand, SP; Ohannesian, D; Powell, E; Reck, M; Scagliotti, GV; Smit, EF; Socinski, MA; Szczesna, A; Thatcher, N; von Pawel, J | 1 |
| Anish, C; Bagchi, T; Jinturkar, KA; Kumar, MK; Misra, AR; Panda, AK | 1 |
| Bradford, BR | 1 |
| Baybay, H; Berrady, R; Bono, W; El Hatimi, A; Gallouj, S; Khammar, Z; Lahlou, M; Lamchachti, L; Mernissi, FZ | 1 |
| Jin, S; Shao, N; Zhu, W | 1 |
| Cho, YJ; Duk Lee, J; Go, SI; Hwang, YS; Jeong, YY; Kim, DC; Kim, HC; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Oh, S; Yang, JW | 1 |
| Chang, TC; Chen, CH; Chen, RJ; Chou, CH; Sheu, BC | 1 |
| Berger, MS; Blakely, J; Chiappori, AA; Chu, QS; Moezi, MM; Ross, HJ; Salgia, R; Schnyder, J; Schreeder, MT; Stephenson, JJ; Subramaniam, DS | 1 |
| Belda-Iniesta, C; Cejas, P; De Castro Carpeño, J; Feliu, J; López, R; Moreno, V; Nistal, M; Sereno, M | 1 |
| Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ | 1 |
| Bi, N; Cao, J; Li, J; Li, W; Liang, J; Lv, J; Ou, G; Ren, H; Wang, L; Wu, S; Zhang, X; Zhou, Z | 1 |
| Cohen, S; Condous, G; Harnett, P; Pixton, S; Reid, S | 1 |
| Hai-Yan, S; Jian-Qing, Z; Lan-Fang, L; Ya-Qing, C; Zuo-Ming, Y | 1 |
| Baudrin, L; Belmont, L; Cadranel, J; Danel, S; Epaud, C; Gounant, V; Lavolé, A; Milleron, B; Rosencher, L; Ruppert, AM | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Breitenbuecher, F; Guyot, M; Hoffarth, S; Höhn, Y; Meiler, J; Schuler, M; Wesarg, E | 1 |
| Boccetta, M; Chauhan, K; Daniels, SR; Do, PM; Fan, S; Garrett, MR; Kubacka, I; Li, C; Li, R; Martinez, LA; Newman, V; Varanasi, L | 1 |
| Guan, QL; Jiang, L; Mi, DH; Wang, J; Yang, KH | 1 |
| Cufer, T; Kern, I; Knez, L; Košnik, M; Ovčariček, T; Sadikov, A; Sodja, E | 1 |
| Bradley, JD; Choy, H; Curran, WJ; Ettinger, DS; Glisson, BS; Komaki, R; Langer, CJ; Paulus, R; Sause, WT; Videtic, GM | 1 |
| Kaminskyy, VO; Piskunova, T; Tchevkina, EM; Zborovskaya, IB; Zhivotovsky, B | 1 |
| Abedallaa, N; Baey, C; Besse, B; de Montpreville, VT; Fabre, D; Guigay, J; Pechoux, CL; Pignon, JP; Planchard, D; Soria, JC; Tremblay, L | 1 |
| Comans, EF; Hartemink, KJ; Paul, MA; Phernambucq, EC; Postmus, PE; Senan, S; Smit, EF | 1 |
| Barriger, RB; Bradley, JD; De Petris, L; Kim, TH; Marks, LB; Moreno, M; Palma, DA; Ramella, S; Rengan, R; Rodrigues, G; Senan, S; Stitt, L; Tsujino, K | 1 |
| Andersen, ME; Chen, Y; Dong, J; Fu, J; Hou, Y; Pi, J; Qu, W; Tokar, EJ; Waalkes, MP; Wang, A; Woods, CG; Xu, Y; Xue, P; Yarborough, K; Zhan, L; Zhang, H; Zhang, Q | 1 |
| Aziz, SI; Khattak, MA; Ladipeerla, N; Pittman, K; Usmani, Z | 1 |
| Huang, JJ; Jiang, WQ; Li, ZM; Xia, Y; Zhu, YJ | 1 |
| Abate, ME; Barbieri, E; Bisogno, G; Daolio, P; Eriksson, M; Fagioli, F; Ferrari, S; Gandola, L; Grignani, G; Hall, KS; Lindholm, P; Luksch, R; Picci, P; Podda, M; Prete, A; Ruggieri, P; Smeland, S; Tamburini, A; Tienghi, A | 1 |
| Gafton, GI; Gudz', IuV; Ivanova, TV; Krzhivitskiĭ, PI; Kupatadze, DD; Lazareva, IuR; Levchenko, EV; Nabokov, VV; Novik, VI; Petrov, VG; Punanov, IuA; Safonova, SA | 1 |
| Dong, XJ; Li, LY; Wang, MZ; Xia, Y; Zhang, L; Zhang, XT; Zhao, J; Zhong, W | 1 |
| Cufer, T; Kern, I; Knez, L; Ovčariček, T; Sadikov, A; Sodja, E | 1 |
| Eijk, PP; Groenendijk, MR; Paul, MA; Postmus, PE; Smit, EF; Thunnissen, E; van de Wiel, MA; Ylstra, B | 1 |
| Egbert, SF; Hartemink, KJ; Koen, HJ; Marinus, PA; Paul, MA; Pieter, PE; Postmus, PE; Romane, SM; Schook, RM; Smit, EF | 1 |
| Guven, M; Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Nas, N; Urakci, Z | 1 |
| Han, TJ; Heo, DS; Kim, HJ; Kim, YW; Lee, SH; Wu, HG | 1 |
| Chyczewska, E; Korniluk, M; Mroz, RM; Ossolinska, M; Panek, B | 1 |
| Afonso, M; Amaro, T; Begonha, R; Maurício, J; Sousa, N; Teixeira, A; Vieira, C | 1 |
| Acker, T; Banik, N; Bogenrieder, T; Eberhardt, F; Eschbach, C; Fink, TH; Heigener, DF; Huber, RM; Hummler, S; Ittel, T; Schroeder, M; Schweisfurth, H; Steinhauer, EU; Virchow, JC; Waller, C; Wolf, M | 1 |
| Bai, W; Bepler, G; Dong, H; Khochbin, S; Nicosia, SV; Wang, L; Williams, KA; Xiang, S; Zhang, X | 1 |
| Granell, M; Mozos, A; Pajares, V; Puzo, C; Szafranska, J; Torrego, A | 1 |
| Dai, J; Han, M; Jia, J; Jiang, M; Lin, Q; Liu, Q; Xu, X; Zhang, Y | 1 |
| Guba, SC; Liepa, AM; Lorigan, P; Peterson, P; Reck, M; Smit, EF; Socinski, MA; Szutowicz-Zielinska, E; Thatcher, N; Winfree, KB | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Blaauwgeers, JL; Hartemink, KJ; Oosterhuis, JW; Paul, MA; Senan, S; Smit, EF; Thunnissen, E; Vos, CG | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Osawa, M; Takigawa, N; Tanimoto, M; Yamane, H | 1 |
| Di Maio, M; Martelli, O; Rossi, A | 1 |
| Abdu, A; Arora, S; Duffoo, F; Kalra, A; Macera, M; Mir, P; Mishra, S; Patel, H; Sawhney, H; Thelmo, W | 1 |
| Spigel, DR | 1 |
| Dimitroulis, J; Kosmas, Ch; Stathopoulos, GP; Stathopoulos, J; Trafalis, D; Tsavdaridis, D | 1 |
| Li, AW; Liu, JM; Luo, J; Wu, FY; Zheng, D | 1 |
| Ansari, RH; Atkins, JN; Bogart, JA; Green, MR; Hodgson, LD; Kelley, MJ; Pang, H; Vokes, EE | 1 |
| Bootsma, G; Borger, J; De Ruysscher, D; Dingemans, AM; Geraedts, W; Lambin, P; Lunde, R; Pitz, C; Reymen, B; van Baardwijk, A; Van Loon, J; Wanders, R | 1 |
| Demura, Y; Kimura, H; Morikawa, M; Okazawa, H; Tsuchida, T; Umeda, Y | 1 |
| Hou, M; Li, Z; Pu, D; Zeng, X | 1 |
| Herbst, RS; Isobe, T; Itasaka, S; Jacoby, JJ; Koo, PJ; Morgensztern, D; O'Reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Beck, R; Ellis, PM; Fandi, A; Jungnelius, U; Shepherd, FA; Zhang, J | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
| Berkarda, S; Cakir, E; Cermik, TF; Doğanay, L; Karlikaya, C; Salan, A; Yüksel, M | 1 |
| Daliani, DD; Logothetis, CJ; Papandreou, CN; Reyes, A; Thall, PF; Troncoso, P; Tu, SM; Wang, X | 1 |
| Ding, L; Lang, W; Wang, H; Xiao, L | 1 |
| Faccio, AA; Ramos, SG; Rezende, GG | 1 |
| Albain, KS; Beasley, KR; Clark, JI; Crowley, JJ; Farrar, WB; Gandara, DR; Livingston, RB; Turrisi, AT | 1 |
| Arance, A; Ashcroft, L; Burgers, JA; Hodgetts, J; Lomax, L; Thatcher, N | 1 |
| Berghmans, T; Efremidis, A; Klastersky, J; Lafitte, JJ; Lecomte, J; Mommen, P; Ninane, V; Paesmans, M; Sculier, JP; Thiriaux, J; Van Cutsem, O | 1 |
| Bissett, D; Culligan, D; Petty, R | 1 |
| Cool, RM; Herrington, JD; Wong, L | 1 |
| Adak, S; Herskovic, A; Johnson, DH; Keller, SM; Komaki, R; Livingston, RB; Marks, RS; Perry, MC; Schiller, JH; Vangel, MG; Wagner, H | 1 |
| Brown, JM; Peters, KB | 1 |
| Chak, K; Chan, AT; Johnson, P; Lee, TW; Leung, TW; Mok, TS; Wong, H; Yeo, W; Yim, A; Yu, KH; Zee, B | 1 |
| Ekedahl, J; Grigoriev, MY; Joseph, B; Lewensohn, R; Magnusson, C; Müller, M; Zhivotovsky, B | 1 |
| Bonner, JA; Geyer, SM; Goetz, SP; Jett, JR; Kugler, JW; Kuross, SA; Mailliard, JA; Marks, RS; McGinnis, WL; Schaefer, PL; Schild, SE; Stella, PJ | 1 |
| Atasalihi, A; Halezeroglu, S; Okur, E; Somay, A | 1 |
| Ellis, PA; Galani, E; Harper, PG | 1 |
| Ardizzoni, A; Biesma, B; Buchholz, E; Burghouts, J; Debruyne, C; Dziadziuszko, R; Gans, S; Giaccone, G; Karnicka-Mlodkowska, H; Legrand, C; Manegold, C; Postmus, PE; Tjan-Heijnen, VC; Van Meerbeeck, JP | 1 |
| Asai, M; Iwahori, K; Komuta, K; Kouga, K; Minami, S; Nishiyama, A | 1 |
| Agelidou, M; Ferdoutsis, E; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Samonis, G; Souglakos, J; Toumbis, M; Tselepatiotis, E; Tzanakis, N; Veslemes, M; Ziotopoulos, P | 1 |
| Cosaert, J; Quoix, E | 1 |
| Berdel, WE; Dölken, G; Kienast, J; Klinke, F; Macha, H; Mohr, M; Oelmann, E; Schmidt, EW; Serve, H; Thomas, M; Zühlsdorf, M | 1 |
| Bisset, D; Jaehde, U; Kloft, C; McLeod, HL; Nicolson, MC; Reid, M; Reif, S | 1 |
| Jazieh, AR; Kyasa, MJ; Muirhead, MJ | 1 |
| Buyukberber, S; Camci, C; Elbeyli, L; Sari, I; Sivrikoz, C; Tuncozgur, B; Turk, HM | 1 |
| Berkow, RL; Hilliard, LM; Watts, RG | 1 |
| Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
| Kawasaki, T; Nakayama, M; Oka, K; Okane, M; Shiina, H; Tanno, W | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Chen, XB; Li, DX | 1 |
| Kosmidis, P | 1 |
| Finckenstein, FG; Graf, N; Gruhn, B; Hasan, C; Hero, B; Klingebiel, T; Koscielniak, E; Kremens, B; Laws, HJ; Niemeyer, C; Schulz, A; Selle, B; Wawer, A; Zintl, F | 1 |
| Gawron, A; Jakubowicz-Gil, J; Kandefer-Szerszeń, M; Paduch, R | 1 |
| Choy, H; Gandara, D; Mattson, K; Vokes, EE | 1 |
| Krystal, GW; Litz, J; Sulanke, G | 1 |
| Johnson, DH | 6 |
| Aamdal, S; Aasebø, U; Boye, N; Bremnes, RM; Dahle, R; Hannisdal, E; Hatlevoll, R; Kaasa, S; Skovlund, E; Sundstrøm, S; Vigander, T; Vilsvik, J; Wang, M | 1 |
| Gatzemeier, U; Grunwald, F; Hessler, S; Jagos, U; Kaukel, E; Koschel, G; Reck, M; von Pawel, J | 1 |
| Agelaki, S; Androulakis, N; Apostolopoulou, F; Blazoyiannakis, G; Georgoulias, V; Kakolyris, S; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Pavlakou, G; Samonis, G; Vardakis, N; Veslemes, M | 1 |
| Antón, LM; Constenla, M; Domínguez, S; Dorta, J; Esteban, E; García-Girón, C; Gómez Aldavarí, JL; Gonzalez-Barón, M; Gracia, M; Lacave, AJ; López, E; López, R; Martín, G; Mel, JR; Peláez, I; Rodríguez, R; Sevilla, I; Valladares, M; Vieitez, JM | 1 |
| Jodkiewicz, Z; Radzikowska, E; Rowińska-Zakrzewska, E; Sakowicz, A; Szturmowicz, M; Słodkowska, J; Załeska, J; Załeska, M; Zych, J | 1 |
| Fietkau, R; Sauer, R | 1 |
| Fan, Y; Huang, ZY; Sun, L; Zhang, YP | 1 |
| Turrisi, AT | 4 |
| Smit, EF | 1 |
| Mornex, F | 1 |
| Brunetto, AL; de Almeida, SG; de Castro, CG; Gregianin, LJ; Loss, JF; Rivero, LF; Schwartsmann, G | 1 |
| Baker, J; Hand, S; Macbeth, FR; Smith, AP | 1 |
| Kuriyama, T; Kurosu, K; Moriya, T; Nagao, K; Oda, S; Takiguchi, Y; Tanabe, N; Tatsumi, K; Watanabe, R | 1 |
| Ardizzoni, A; Biesma, B; Buccholz, E; Burghouts, JT; Caleo, S; Crott, R; Debruyne, C; Giaccone, G; Gorlia, T; Manegold, C; Postmus, PE; Tjan-Heijnen, VC | 1 |
| Cai, GR; Jiao, LP; Li, PW | 1 |
| Catalano, GP; Curigliano, G; De Braud, F; De Pas, T; Leo, F; Pastorino, U; Solli, PG; Spaggiari, L; Veronesi, G | 1 |
| Liu, J; Tang, WJ; Yu, RC | 1 |
| Duan, P; Wang, ZM | 1 |
| Chang, H; Hsien Lee, Y; Lee, CC; Lin, S; Shyu, KG; Tsai, SC; Wang, BW | 1 |
| Ebert, BL; Niemierko, E; Salgia, R; Shaffer, K | 1 |
| Ariganello, O; Cipri, A; Cortesi, E; De Marinis, F; Gamucci, T; Gasperoni, S; Martelli, O; Migliorino, MR; Nelli, F; Paoluzzi, L; Portalone, L | 1 |
| Hirai, I; Honda, K; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T | 1 |
| Lachmann, E; Lin, JT | 1 |
| Bunn, PA; Simon, GR | 1 |
| Eguchi, K; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yoshimura, K | 1 |
| Brouwer, E; de Boer-Dennert, M; Ma, J; Maliepaard, M; Planting, AS; Schellens, JH; van den Bent, MJ; van der Burg, ME; van der Gaast, A; van Zandwijk, N; Verweij, J | 1 |
| Joe, H; Lesperance, M; Lim, J; Ludbrook, JJ; MacNeil, MV; Martins, H; Truong, PT; Webber, A | 1 |
| Beitler, JJ | 1 |
| Ohtsuka, M; Satoh, H; Sekizawa, K | 1 |
| Avilés, A; Calva, A; Fernández, R; Huerta-Guzmán, J; Nambo, MJ; Neri, N | 1 |
| Aleksandrovic, J; Dagovic, A; Jeremic, B; Milicic, B; Nikolic, N | 1 |
| Forster, KM; Gopal, R; Kelly, JF; Komaki, R; Liao, Z; Starkschall, G; Stevens, C; Tucker, SL | 1 |
| Cox, JD; Gopal, R; Hanus, M; Kelly, JF; Komaki, R; Liao, Z; Starkschall, G; Stevens, CW; Tucker, SL | 1 |
| Bonomi, P; Cella, D; Eton, DT; Fairclough, DL; Johnson, DH; Yount, SE | 1 |
| Munck, JN | 1 |
| Achanzar, WE; Mori, M; Nagamine, T; Qu, W; Shimoda, R; Takagi, H; Waalkes, MP | 1 |
| Khanna, N; Sen, S; Sharma, H; Singh, N | 1 |
| Broaddus, VC; Liu, W; Vivo, C | 1 |
| Kamata, J; Kitoh, K; Kotake, Y; Koyanagi, N; Nagasu, T; Nakamura, K; Niijima, J; Okada, T; Sugumi, H; Taniguchi, T; Uenaka, T; Yamaguchi, A; Yoshimatsu, K; Yoshino, H | 1 |
| Hansen, LT; Helleday, T; Lundin, C; Petersen, LN; Poulsen, HS; Spang-Thomsen, M; Sørensen, CS | 1 |
| Hansen, LT; Helleday, T; Lundin, C; Petersen, LN; Spang-Thomsen, M | 1 |
| Bauman, MD; Hatfield, AK; Hillman, S; Jett, JR; Kugler, JW; Levitt, R; Mailliard, JA; Marks, RS; Morton, RF | 1 |
| Albain, KS; Bearden, JD; Burris, H; Chansky, K; Crowley, J; Gandara, DR; Gaspar, LE; Gumerlock, P; Kuebler, JP; Lara, PN; Leigh, BR; Livingston, R | 1 |
| Hasinoff, BB; Hofland, KF; Jensen, PB; Langer, SW; Schroeder, PE; Sehested, M | 2 |
| Ding, H; Duan, W; Ju, R; Otterson, GA; Srinivasan, K; Villalona-Calero, MA; Zhu, WG | 1 |
| Jiang, P; Lawrence, TS; Li, J; Robinson, M; Sun, Y | 1 |
| Coldman, BJ; Fossella, FV; Glisson, BS; Komaki, R; Kurie, JM; Lee, JS; Lu, C; Palmer, JL; Pisters, KM; Shin, DM | 1 |
| Bauman, MD; Ebbert, LP; Kugler, JW; Mahoney, MR; Mailliard, JA; Marks, RS; Schaefer, PL; Sloan, JA; Tazelaar, HD; Wiesenfeld, M | 1 |
| Cowlishaw, D; McKendrick, JJ; Mead, GM | 1 |
| Snee, MP | 1 |
| Amdur, RJ; Hinerman, RW; Mendenhall, WM; Monroe, AT; Morris, CG | 1 |
| Huang, J; Jiao, SC; Lu, SX; Sun, Y | 1 |
| Cao, X; Deng, X; May, WS | 1 |
| Fujita, T; Honoki, H; Inomata, M; Kashii, T; Kawagishi, Y; Kobayashi, M; Maruyama, M; Matsui, S; Miwa, T; Oda, H | 1 |
| Harada, M; Hiraki, S; Hiraki, Y; Hiyama, J; Kiura, K; Moritaka, T; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y; Yonei, T | 1 |
| Dastidar, AG; Sur, PK | 1 |
| Erturk, D; Unsal, M | 1 |
| Arslan, M; Demiray, M; Evrensel, T; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Ozkan, A | 1 |
| Bonner, JA; Brindle, J; Geyer, SM; Jatoi, A; Jett, JR; Mailliard, JA; McGinnis, WL; Schild, SE; Stella, PJ | 1 |
| Blumenschein, GR; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| Langer, CJ | 2 |
| Chuang, CY; Kao, A; Kuo, TH; Liu, FY; Wang, JJ; Wu, HS | 1 |
| Johnson, DH; Laskin, J; Sandler, A | 1 |
| Bonnet, R; Deppermann, KM; Gatzemeier, U; Hessler, S; Kaukel, E; Macha, HN; Reck, M; Ulm, K; von Pawel, J | 2 |
| Cai, RG; Huang, J; Qu, T; Sun, Y; Wang, JW; Wang, JY; Yang, L | 1 |
| Cheremisina, OV; Evtushenko, VA; Khodkevich, BS; Kolomiets, SA; Miller, SV; Rudyk, IuV; Tropin, SV; Zav'ialov, AA; Zyrianov, BN | 1 |
| Bosse, U; Froeschle, P; Granetzny, A; Klinke, F; Koch, O; Striehn, E; Vogt, U; Wagner, W | 1 |
| Cermik, H; Isitmangil, T; Kandemir, G; Kunter, E; Ozturk, A; Turken, O; Yaylaci, M | 1 |
| Davey, MW; Davey, RA; Locke, VL | 1 |
| Berkarda, S; Cermik, TF; Doğanay, L; Karlikaya, C; Türe, M; Yüksel, M | 1 |
| Ren, T; Wan, XR; Xiang, Y; Yang, XY; Zhang, ZY | 1 |
| Grassin, F; Guigay, J; L'her, P; Le Moulec, S; Margery, J; Vaylet, F | 1 |
| Li, LN; Liu, WS; Xu, K | 1 |
| Bamberg, M; Jeremic, B; Molls, M; Zimmermann, FB | 1 |
| Changlai, SP; Ding, HJ; Hsu, WH; Huang, WT; Kao, A; Tsai, CS | 1 |
| Dar, AR; Stitt, LW; Truong, PT; Videtic, GM; Yu, EW | 1 |
| Einhorn, LH; Foster, RS; Henley, JD; Sheski, FD | 1 |
| Bavieri, M; Cavazza, A; Crinò, L; Facciolongo, N; Longo, L; Marchioni, A; Migaldi, M; Petruzzelli, S; Rossi, G; Tamberi, S | 1 |
| Greco, FA | 2 |
| Eckardt, J; Green, M; Thatcher, N | 1 |
| Ahn, YC; Im, YH; Jung, CW; Kang, WK; Kim, H; Kim, K; Lee, KE; Lee, MH; Lee, SH; Lim, DH; Park, J; Park, K; Park, SH | 1 |
| Ball, ED; Chen, J; Mokotoff, M; Shultz, LD; Zhong, R; Zhou, J | 1 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Lee, JJ; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| Goto, H; Hanibuchi, M; Miki, T; Sone, S; Uehara, H; Yano, S; Zhang, H | 1 |
| Gude, RP; Nagarsenker, MS; Rao, SG; Sant, VP | 1 |
| Dietrich, PY; Kaiser, L; Kurt, AM; Matthes, T; Weber, D | 1 |
| Hashimoto, H; Inada, F; Ishida, H; Kaneko, S; Kita, M; Okuyama, M; Saga, Y; Sasaki, Y; Tokumitsu, M; Yachiku, S | 1 |
| Saijo, N | 2 |
| Gomi, K; Inoue, A; Kikuchi, T; Maemondo, M; Miki, M; Nukiwa, T; Saijo, Y; Sato, T; Suzuki, T | 1 |
| Hirao, K; Hirasaki, S; Hyodo, I; Moriwaki, T; Tsuzuki, T | 1 |
| Chansky, K; Crowley, J; Edelman, MJ; Gandara, DR; Gaspar, LE; Leigh, B; Livingston, R; Taylor, SA; Weiss, GR | 1 |
| Hammerschmidt, S; Pohlink, C; Rother, T; Wirtz, H | 1 |
| Antoch, G; Debatin, JF; Gutzeit, A | 1 |
| Braig, G; Brueck, M; Kramer, W; Vogel, S; Waeger, S | 1 |
| Arriagada, R; Bergman, B; Dunant, A; Le Chevalier, T; Pignon, JP; Vansteenkiste, J | 1 |
| Azevedo, CH; Fernandes, DC; Lo Prete, AC; Maranhão, RC; Rodrigues, DG; Valduga, CJ | 1 |
| Ash, RB; Dar, AR; Stitt, LW; Truong, PT; Videtic, GM; Whiston, F; Yu, EW | 1 |
| Bartling, B; Lewensohn, R; Michod, D; Widmann, C; Yang, JY; Zhivotovsky, B | 1 |
| Alhamany, Z; Cherradi, N; Khattab, M; Malihy, A; Regragui, A; Sefiani, S | 1 |
| Acquati, M; Ardizzoia, A; Casartelli, C; Fagnani, D; Fusco, O; Giordano, M; Malugani, F; Quattrone, A; Scanni, A; Tagliabue, P; Vergani, C; Visini, M | 1 |
| Ahn, YC; Im, YH; Jung, CW; Kang, WK; Kim, HJ; Kim, K; Kim, WS; Lee, KE; Lee, MH; Lee, SH; Lee, SI; Lim, DH; Nam, E; Park, J; Park, JO; Park, K; Park, SH | 1 |
| Ishizuka, O; Mizuno, H; Mizusawa, H; Nishizawa, O; Satoh, T; Seki, S | 1 |
| Berdel, WE; Braunheim, M; Heinecke, A; Hoffknecht, P; Klinke, F; Macha, HN; Riesenbeck, D; Schmidt, EW; Schumacher, A; Semik, M; Thomas, M; Wewers, D; Willich, N | 1 |
| Burholt, DR; Donovan, M; George, LD; Kornblith, PL; Marsh, JW | 1 |
| Edelman, MJ; Hoffman, PC; Karnauskas, R; Kozloff, M; Rudin, CM; Szeto, L; Tomek, R; Vokes, EE | 1 |
| Basu, A; Huang, J; Kumar Biswas, S; Persaud, S | 1 |
| Allen, PK; Blumenschein, GR; Cox, JD; Fossella, FV; Garza, VP; Glisson, BS; Herbst, RS; Kaplan, B; Kies, MS; Komaki, R; Kurie, J; Lee, HK; Lee, JS; Liao, Z; Lu, C; Milas, L; Mooring, D; Papadimitrakopoulou, VA; Pisters, KM; Stevens, CW; Tucker, SL; Zinner, RG | 1 |
| Shimizu, E | 1 |
| Cheong, K; Chrystal, K; Harper, P | 1 |
| MacLeod, P; Maziak, DE; Shamji, FM; Stewart, DJ; Tomiak, E | 1 |
| Beganovic, S; Niell, HB; Richey, S; Wan, JY | 1 |
| Abed, N; Chakrabarty, G; Chang, CC; Chitambar, CR; Hanson, G; Kampalath, B; Rao, RN; Shidham, VB; Vantuinen, P | 1 |
| Buttery, RC; Rintoul, RC; Sethi, T | 1 |
| Abker, S; Bosse, U; Junker, K; Klinke, F; Müller, KM; Thomas, M | 1 |
| Farr, GH; Geoffroy, FJ; Hatfield, AK; Hillman, S; Johnson, EA; Krook, JE; Levitt, R; Maillard, JA; Marks, RS; Perez, EA; Tazelarr, HD | 1 |
| Homma, S; Satoh, H; Sekizawa, K | 1 |
| Qiao, TK; Shu, L; Wu, W; Xin, L; Zhou, DA | 1 |
| Gillenwater, HH; Wolf, T | 1 |
| Nakanishi, Y; Uchino, J | 1 |
| Dong, M; Feng, FY; Fu, M; Liang, X; Lin, C; Lu, HY; Wu, M; Zha, YY; Zhang, XY | 1 |
| Arusell, RM; Bonner, JA; Brooks, BJ; Farr, GH; Geoffroy, FJ; Geyer, SM; Hillman, SL; Jett, JR; Krook, JE; Mailliard, JA; Marks, RS; Salim, M; Schaefer, PL; Schild, SE; Shanahan, TG; Tazelaar, HD | 1 |
| Bartling, B; Lewensohn, R; Zhivotovsky, B | 1 |
| Horiike, A; Saijo, N | 2 |
| Cheng, ZW; Zhang, L | 1 |
| Goto, K; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsui, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Nokihara, H; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Sugiura, T; Tamura, T; Yamamoto, N; Yoshida, K | 1 |
| Atsu, MN; Dogan, R; Ekici, S; Eskicorapci, SY; Ozen, H | 1 |
| Aleksandrovic, J; Dagovic, A; Jeremic, B; Milicic, B; Milisavljevic, S | 2 |
| Fujisawa, M; Hara, I; Kamidono, S; Kanomata, N; Kawabata, G; Kumano, Y; Takeda, M; Tanaka, K | 1 |
| Gavrilov, BA; Grudinkin, PS; Kropotov, AV; Pleskach, NM; Tomilin, NV; Zhivotovsky, B | 1 |
| Dudzisz-Sledź, M; Korobowicz, E; Korszeń-Pilecka, I; Mańdziuk, S; Milanowski, J; Wojcierowski, J | 2 |
| Bélanger, MM; Couet, J; Gaudreau, M; Roussel, E | 1 |
| Crowley, JJ; Dakhil, SR; Edelman, MJ; Gandara, DR; Gaspar, LE; Le, QT; McCoy, J; Ryu, J; Sides, SD; Williamson, S | 1 |
| Chuman, H | 1 |
| Camlica, H; Demir, C; Tas, F; Topuz, E; Ustuner, Z | 1 |
| Doyle, A; Edelman, MJ; Gamliel, Z; Hausner, P; Krasna, M; Patel, AB; Sonett, JR; Suntharalingam, M | 1 |
| Andrade, RS; Brooks, JA; Brown, JW; Einhorn, LH; Kesler, KA; Reichwage, BD; Rieger, KM; Wilson, JL | 1 |
| Akansel, G; Arisoy, AE; Calişkan, M; Corapcioglu, F; Dillioğlugil, O; Sarper, N | 1 |
| Enomoto, Y; Hatta, Y; Horie, T; Sawada, U; Takahashi, M; Takahashi, N | 1 |
| de Cremoux, P; Decaudin, D; Fréneaux, P; Judde, JG; Livartowski, A; Nemati, F; Pouillart, P; Poupon, MF; Sastre, X; Tran-Perennou, C | 1 |
| Amano, H; Ishigatsubo, Y; Kakemizu, N; Kaneko, T; Kobayashi, M; Komatsu, S; Matsuse, T; Mishima, W; Miura, K; Miyashita, A; Nishihira, R; Nishiyama, H; Noda, K; Saito, H; Satoh, T; Shinohara, T; Tsukiji, J; Yamakawa, Y | 1 |
| Batchelor, AG; Liddington, MI; Rawlins, JM; Towns, G | 1 |
| Fujimoto, N; Fujiwara, K; Hamazaki, S; Kiura, K; Kozuki, T; Mizobuchi, K; Shiomi, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Alonso, C; Arrivi, A; Artal-Cortés, A; Barneto, I; Campbell, J; Camps, C; Carrato, A; Font, A; Garcia-Giron, C; Gomez-Codina, J; Gonzalez-Larriba, JL; Isla, D; Lomas, M; Maestu, I; Meana, A; Rosell, R; Vadell, C | 1 |
| Chen, LK; Liang, Y; Liu, JL; Xu, GC; Yang, QY; Zhang, LN | 1 |
| Adachi, M; Horichi, N; Ichikawa, I; Imai, T; Kashiwabara, Y; Kiuchi, Y; Kogo, M; Koichi, K; Murayama, J; Saito, Y | 1 |
| Aravantinos, G; Bamias, A; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kalofonos, H; Kouroussis, C; Papadimitriou, C; Rodolakis, A; Skarlos, D; Vlahos, G | 1 |
| Lilenbaum, R; Raez, L; Samuels, M | 1 |
| Chen, GY; Fu, XL; Jiang, GL; Qian, H; Wang, LJ; Wu, KL; Yang, H; Zhao, S | 1 |
| Barbera, S; Barni, S; Bertetto, O; De Marinis, F; Ferraú, F; Gridelli, C; Labianca, R; Lombardo, M; Michetti, G; Nelli, F | 1 |
| Neville, A | 1 |
| Berta, M; Bertoni, F; del Prever, AB; Fagioli, F; Ferrari, S; Mercuri, M | 1 |
| Altieri, AM; Antilli, A; Antonelli, P; Ardizzoni, A; Baldini, E; Barbera, S; Boni, L; Cacciani, G; Castiglioni, F; Favaretto, A; Monfardini, S; Paccagnella, A; Pari, F; Raimondi, M; Rosso, R; Stefani, M; Tibaldi, C; Tixi, L | 1 |
| Bogart, J; Evans, L; Green, MR; Herndon, JE; McClay, EF; Seagren, SL; Watson, D | 1 |
| Blayney, DW; Cruickshank, SE; Johnson, DH; McGuire, BW | 1 |
| Fukui, I; Hanada, E; Ishikawa, Y; Nakagawa, K; Okubo, Y; Satoh, Y; Tadokoro, M; Tsukamoto, T; Yonese, J | 1 |
| Nakayama, H; Takahashi, H; Teramoto, A; Yamada, S; Yamada, SM | 1 |
| Buchdunger, E; García-Echeverría, C; Hofmann, F; Krystal, GW; Litz, J; Warshamana-Greene, GS | 1 |
| Burger, JA; Burger, M; Fujii, N; Glodek, A; Hartmann, TN | 1 |
| Aamdal, S; Aasebø, U; Bremnes, RM; Kaasa, S; Sundstrøm, S | 1 |
| Ren, T; Wan, XR; Xiang, Y; Yang, XY; Zhang, Y | 1 |
| Atkins, JN; Blackstock, AW; Bogart, JA; Ho, C; Livengood, K; Lovato, JF; Matthews, C; McCoy, T; Miller, AA; White, D | 1 |
| Adjei, AA; Bonner, JA; Brooks, BJ; Deming, RL; Jatoi, A; Jett, JR; Krook, JE; Mailliard, JA; Mandrekar, S; McGinnis, WL; Schild, SE; Stella, PJ | 1 |
| Ariyoshi, Y; Fukuoka, M; Furuse, K; Hatae, M; Hirabayashi, K; Noda, K; Ogawa, M; Takaku, F; Yakushiji, M | 1 |
| Ansari, R; Belani, CP; Lee, JS; Lilenbaum, R; Natale, RB; Robert, F; Rowland, K; Socinski, MA; Waterhouse, D | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Livingston, RB; Rusch, V; Vallieres, E | 1 |
| Brünner, N; Christensen, IJ; Hofland, KF; Jensen, PB; Lademann, U; Larsen, L; Rømer, MU | 1 |
| Ichinose, Y; Ishizuka, N; Kato, H; Suzuki, K; Tsuchiya, R; Watanabe, Y; Yasumitsu, T | 1 |
| Ashcroft, LF; Lorigan, P; O'Brien, ME; Sampson, MR; Thatcher, N; Woll, PJ | 1 |
| Bakalarz, R; Banasik, A; Góźdź, S; Lankoff, A; Lesisz, D; Lisowska, H; Padjas, A; Wojcik, A | 1 |
| Byhardt, RW; Ettinger, DS; Glisson, BS; Komaki, R; Movsas, B; Sandler, AB; Suh, J; Swann, RS | 1 |
| Herskovic, A; Johnson, DH; Keller, SM; Komaki, R; Livingston, RB; Marks, RS; Perry, MC; Stephenson, P; Wagner, H; Wakelee, HA | 1 |
| Buchholz, E; Gatzemeier, U; Goetz, E; Groth, G; Manegold, C; Reck, M | 1 |
| Chang, KT; Chiu, CH; Huang, CY; Lok, YY; Tsai, CM | 1 |
| Chen, WL; Chiu, CC; Fang, K; Fuh, TS; Li, CH; Ung, MW | 1 |
| Cho, KH; Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, JS; Lee, SY | 1 |
| Chiu, CC; Fang, K; Lin, CH | 1 |
| Fujinami, K; Miura, T; Osada, Y; Takizawa, A | 1 |
| Fantini, M; Fattori, PP; Fochessati, F; Genestreti, G; Imola, M; Ioli, G; Lazzari-Agli, L; Mianulli, AM; Papi, M; Pasquini, E; Poggi, B; Ravaioli, A; Sartori, S; Tamburini, E; Tassinari, D | 1 |
| Ansari, RH; Ellerton, J; Green, MR; Herndon, JE; Kelly, K; Marks, RS; Miller, AA; Niell, HB; Otterson, G; Perry, MC; Sandler, AB; Vokes, EE; Watson, DM | 1 |
| Allen, K; Barth, NM; Beutel, LD; Chico, S; Dillman, RO; VanderMolen, LA | 1 |
| Abrams, RA; Berkey, BA; Byhardt, RW; Curran, WJ; Duncan, PJ; Ettinger, DS; Fontanesi, J; Machtay, M; Movsas, B | 1 |
| Besse, B; Le Chevalier, T; Soria, JC | 1 |
| Bamias, A; Briasoulis, E; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Makatsoris, T; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Agostini, V; Arcangeli, V; Fantini, M; Fattori, PP; Fochessati, F; Genestreti, G; Imola, M; Ioli, G; Mianulli, AM; Oliverio, G; Papi, M; Pasquini, E; Poggi, B; Ravaioli, A; Tamburini, E; Tassinari, D | 1 |
| Negoro, S | 2 |
| Dunant, A; Le Chevalier, T; Pignon, JP | 1 |
| Chak, K; Chan, AT; Lam, KC; Lee, C; Mok, TS; Wong, H; Yeo, W; Yim, AP; Zee, B; Zhang, L | 1 |
| Adjei, AA; Creagan, ET; Croghan, G; Frytak, S; Giordano, KF; Jatoi, A; Jett, JR; Marks, R; Molina, J; Okuno, S; Richardson, RL | 1 |
| Asamura, H; Kodama, T; Kunitoh, H; Matsuno, Y; Ohe, Y; Saijo, N; Sekine, I; Takei, H; Tamura, T; Tsuchiya, R; Yamamoto, N; Yamazaki, S | 1 |
| Breton, JL; Cardenal, F; Gervais, R; Lymboura, M; Mattson, K; Preston, A; Quoix, E; Ross, G; Schramel, F; Wilson, J | 1 |
| Ariyoshi, Y; Fukuda, Y; Fukuoka, M; Isobe, T; Katakami, N; Komuta, K; Kudoh, S; Nakamura, S; Nakano, T; Takada, M; Takada, Y | 1 |
| Cho, KH; Han, JY; Kim, HY; Lee, DH; Lee, JS; Pyo, HR; Yoon, SJ | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Imamura, F; Kawahara, M; Kubota, K; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K | 1 |
| Hatashita, M; Hayashi, S; Jin, ZH; Kano, E; Matsumoto, H; Shioura, H | 1 |
| Bozóky, G; Gábor, G; Góhér, I; Lengyel, M; Mohos, A; Ruby, E | 1 |
| Faivre-Finn, C; Lorigan, P; Thatcher, N; West, C | 1 |
| Akkoclu, A; Cakir, E; Cikrikicioglu, S; Firat, H; Goksel, T; Gorguner, M; Guzelant, A; Hatipoglu, ON; Itil, O; Kiyik, M; Ozturk, C; Sanal, S; Soyer, S; Tabakoglu, E; Tasbakan, S; Tutar, U; Yilmaz, U | 1 |
| Alshehadat, S; Sahmoun, AE | 1 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Arcaro, A; Downward, J; Khanzada, UK; Meier, C; Pardo, OE; Seckl, MJ | 1 |
| Arnaiz Fernández, MD; Cardenal Alemany, F; Guedea Edo, F; Jeremic, B; Lucas Calduch, A; Montes Borinaga, A; Navarro Pérez, V; San José Maderuelo, S; Serrano Bermúdez, G | 1 |
| Bunn, P; Kelly, K; Magree, L; Rabinovitch, R; Sunpaweravong, P | 1 |
| Donahue, A; Faucette, S; Gillenwater, HH; Kirstein, MN; Lindley, C; McCune, JS; Moore, D; Shord, S; Socinski, MA; Stewart, CF; Zamboni, WC | 1 |
| Fujikawa, N; Hirai, K; Hirokawa, S; Kita, K; Kitami, K; Mikata, K; Sano, H; Ueki, T | 1 |
| Khuri, FR; Liu, X; Sun, SY; Yue, P | 1 |
| Kaneda, T; Narita, Y; Suzuki, A; Takahashi, N; Tsunematsu, K | 1 |
| Arimoto, T; Hara, H; Iwasaki, Y; Kubota, Y; Nagata, K; Nakanishi, M; Natuhara, A; Ueda, M | 1 |
| Igawa, Y; Kinebuchi, Y; Nishizawa, O; Noguchi, W | 1 |
| Burris, HA; Corso, SW; Erland, JB; Greco, FA; Hainsworth, JD; Joseph, G; Morrissey, LH; Spigel, DR; Spremulli, E; Thompson, DS | 1 |
| Adang, EM; Akkermans, J; Biesma, B; Bootsma, GP; Cheragwandi, SA; de Boo, TM; Hensing, CA; Smit, HJ; Termeer, A; Timmer-Bonte, JN; Tjan-Heijnen, VC; Wilschut, FA | 1 |
| Barrera-Rodríguez, R; de Lucio, B; Manuel, V | 1 |
| Handa, M; Hirai, S; Ihaya, A; Imamura, Y; Kawabe, M; Morioka, K; Sasaki, K; Shinoda, T; Tanabe, S; Tanaka, K; Uesaka, T; Yamada, N | 1 |
| Endou, K; Kaira, K; Kamiyoshihara, M; Mori, M; Takise, A; Watanabe, R | 1 |
| Hiramatsu, Y; Ishida, M; Masuyama, H; Murakami, K; Sakurai, M | 1 |
| Clark, PI; Girling, DJ; Hopwood, P; Owens, R; Qian, W; Sambrook, RJ; Stephens, RJ; Thatcher, N | 1 |
| Alexopoulos, A; Papacharalambous, A; Rigatos, G; Scartsilas, C; Stavrakakis, J; Stavrinidis, E | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Grillo, R | 1 |
| Agelidou, A; Agelidou, M; Boukovinas, J; Georgoulias, V; Gerogianni, A; Ignatiadis, M; Mavroudis, D; Nikolakopoulos, J; Pavlakou, G; Syrigos, K; Tselepatiotis, E; Veslemes, M | 1 |
| Ajufo, II; Canty, SH; Lindow, SW | 1 |
| Lin, LZ; Zhou, DH; Zhou, YQ | 1 |
| Elliott, T; Haslett, C; Hodkinson, PS; Mackinnon, AC; Rintoul, RC; Sethi, T; Wong, WS | 1 |
| Choi, JH; Chun, M; Hwang, SC; Kang, S; Kim, HC; Lee, HW; Lim, HY; Oh, YJ; Oh, YT; Park, JS; Park, KJ; Sheen, SS | 1 |
| Fischer von Weikersthal, L; Hortig, P; Keilholz, U; Martus, P; Reeb, M; Schmittel, A; Schulze, K; Sebastian, M; Thiel, E | 1 |
| Han, SK; Kim, YW; Lee, CT; Lee, SM; Shim, YS; Yoo, CG | 1 |
| Doi, S; Fukuda, M; Kasai, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Oka, M; Soda, H; Soejima, Y; Takatani, H | 1 |
| Baas, P; Belderbos, JS; Burgers, JA; Kwa, HB; Senan, S; van Bochove, A; van Meerbeeck, JP; van Tinteren, H | 1 |
| Cha, SI; Jung, TH; Kim, CH; Kim, EJ; Lee, JT; Lee, SJ; Lee, SY; Park, JY; Sohn, JW | 1 |
| Cho, EK; Heo, DS; Jung, KH; Kim, JH; Kim, SY; Kim, YH; Lim, HY; Park, BJ; Park, K; Ryoo, BY; Suh, CW | 1 |
| Fukuoka, Y; Hasegawa, Y; Hitsuda, Y; Igishi, T; Kodani, M; Kurai, J; Miyata, M; Shimizu, E; Suyama, H; Touge, H; Yasuda, K | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Husain, SJ; Jamil, S; Yunus, A; Zubairi, AB | 1 |
| Butts, C; Halperin, R; Hanson, J; Nijjar, T; Reiman, T; Roa, W; Smylie, M; Yee, D | 1 |
| de Jong, WK; Groen, HJ; ten Hacken, NH | 1 |
| Hemström, TH; Sandström, M; Zhivotovsky, B | 1 |
| Jankovic, D; Kanazir, S; Markovic, ID; Markovic, JZ; Pesic, M; Rakic, L; Ruzdijic, S | 1 |
| Amikura, T; Aoki, Y; Banzai, C; Nishikawa, N; Sekine, M; Suzuki, M; Tanaka, K; Yokoo, T | 1 |
| Eberhardt, W; Pöttgen, C; Stuschke, M | 1 |
| Chen, LK; Liang, Y; Xu, GC; Yang, QY; Zhang, LN | 1 |
| Bisogno, G; Casale, F; Cecchetto, G; De Salvo, G; Di Martino, M; Di Tullio, MT; Donfrancesco, A; Donofrio, V; Ferrari, A; Indolfi, P; Martone, A | 1 |
| Baldini, E; Conte, PF; Del Freo, A; Fabbri, A; Falcone, A; Innocenti, F; Pennucci, MC; Prochilo, T; Russo, F; Tibaldi, C | 1 |
| Gandara, DR; Lara, PN; Natale, RB | 1 |
| Perry, MC | 2 |
| Ansari, R; Beck, T; Bunn, PA; Byrne, M; Einhorn, L; Ellis, P; Guthrie, T; Hanna, N; Hariharan, S; Langer, C; Morrison, M; Sandler, A; Wang, B | 1 |
| Brannon, S; Crofts, TE; Eckardt, JR; Papai, Z; Ross, G; Tomova, A; Tzekova, V; von Pawel, J; Wissel, P | 1 |
| Comhair, SA; Erzurum, SC; Farver, C; Peikert, T; Specks, U | 1 |
| Gridelli, C; Maione, P; Rossi, A | 1 |
| Bojke, L; Girling, D; Qian, W; Sculpher, M; Stephens, R; Thatcher, N | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Argyraki, A; Christophylakis, Ch; Georgoulias, V; Geroyianni, A; Kakolyris, S; Karvounis, N; Kouroussis, Ch; Tsaroucha, E; Veslemes, M | 1 |
| Depierre, A | 1 |
| Fournel, P | 1 |
| Bearz, A; Colussi, AM; Corona, G; Crivellari, D; Libra, M; Sorio, R; Talamini, R; Toffoli, G; Veronesi, A | 1 |
| Kawashima, O; Morishita, Y; Nagashima, T; Sugano, M | 1 |
| Fujimura, M; Herai, Y; Kasahara, K; Mizuguchi, M; Nishi, K; Yamamoto, H | 1 |
| Cerretani, D; Correale, P; Di Bisceglie, M; Francini, G; Giorgi, G; Gotti, G; La Placa, M; Marsili, S; Martellucci, I; Paolelli, L; Pascucci, A; Remondo, C; Rossi, M; Sciandivasci, A | 1 |
| Ansink, AC; Grootfaam, D; Lok, CA; ten Kate-Booij, MJ; van der Velden, J; Verheijen, RH | 1 |
| Daly, BD; Dipetrillo, TA; Fernando, HC; Kachnic, LA; Ketchedjian, A; Morelli, DM; Shemin, RJ | 1 |
| Bayless, KJ; Davis, GE; Mavila, A; Maxwell, SA; Rivera, A | 1 |
| Titulaer, MJ; van Gerven, J; Verschuuren, JJ; Willems, LN; Wirtz, PW | 1 |
| Arozarena, I; Aubert, M; Bowen, F; Davidson, S; Downward, J; Filonenko, VV; Gout, IT; Khanzada, UK; Marais, R; Pardo, OE; Parker, PJ; Sebire, N; Seckl, MJ; Wellbrock, C | 1 |
| Kunitoh, H; Sekine, I; Yonemori, K | 1 |
| Akcay, C; Aktas, S; Diniz, G; Gayaf, M; Gokce, T; Karadogan, I; Kilciksiz, S; Komurcuoglu, B; Unlu, I | 1 |
| Angeli, A; Berruti, A; Dogliotti, L; Gorzegno, G; Paccotti, P; Porpiglia, F; Sperone, P; Terzolo, M | 1 |
| Akgun, A; Burak, Z; Cok, G; Goksel, T; Karapolat, I | 1 |
| Faderl, S; Hwang, CS; Khuri, FR; Kim, KB | 1 |
| Boesewetter, DE; Boussard-Plédel, C; Bureau, B; Collier, JL; DeRosa, DM; Juncker, C; Katterman, ME; Le Coq, D; Lucas, P; Riley, MR | 1 |
| Katakami, N | 1 |
| Gilligan, D; Gower, NH; Hackshaw, AK; Harper, PG; James, LE; Murray, PA; O'Donnell, KM; Rudd, RM; Ruiz de Elvira, MC; Snee, M; Spiro, SG; Tobias, JS; Trask, CW | 1 |
| Atil, H; Aysan, T; Cok, G; Göksel, T; Güzelant, A; Soyer, S | 1 |
| Debeljak, A; Kern, I; Korosec, P; Kosnik, M; Triller, N | 1 |
| Akaza, H; Kawai, K; Minami, M; Mori, K; Naoi, M; Shimazui, T; Takaoka, E | 1 |
| Butz, K; Crnković-Mertens, I; Hartenstein, B; Hoppe-Seyler, F; Meister, M; Muley, T; Semzow, J | 1 |
| Fukumori, T; Harada, A; Hayashi, H; Izaki, H; Kanayama, HO; Kishimoto, T; Nishitani, MA; Takahashi, M; Tanimoto, S; Taue, R; Yamamoto, Y | 1 |
| Carlander, B; Charif, M; Gaillard, N; Pujol, JL; Touchon, J | 1 |
| Ariyoshi, Y; Fukuoka, M; Katakami, N; Kawahara, M; Negoro, S; Sawa, T; Sugiura, T; Takada, M; Takada, Y; Yamamoto, H; Yana, T; Yokota, S | 1 |
| Al Omari, A; Case, D; Miller, AA; Murry, DJ | 1 |
| Ashley, S; Banerji, U; Benepal, T; Coward, J; Eisen, T; Hughes, S; Norton, A; O'Brien, M; Zee, Y | 1 |
| Fujisawa, T; Hiroshima, K; Iizasa, T; Iyoda, A; Kimura, H; Moriya, Y; Nakatani, Y; Sekine, Y; Shibuya, K; Takiguchi, Y | 1 |
| Casali, C; Morandi, U | 1 |
| Alloisio, M; Banna, GL; Castagna, L; De Giorgi, U; Ferrari, B; Marangolo, M; Rosti, G; Santoro, A | 1 |
| Cai, Y; Wang, WL; Xu, B; Zhang, SW; Zhu, GY | 1 |
| Doba, S; Funaki, K; Kawashima, A; Kiriyama, M; Kita, T; Kojima, Y; Kurosaka, Y; Michiwa, Y; Sasaki, S; Takekawa, S; Tamura, M | 1 |
| Azuma, T; Hirazawa, K; Matsuda, E; Matsuoka, T; Okabe, K; Sugi, K; Umemori, Y | 1 |
| Chansky, K; Crowley, JJ; Davies, AM; Gandara, DR; Gaspar, LE; Lau, DH; Leigh, BR; Weiss, GR; Wozniak, AJ | 1 |
| Ando, M; Eguchi, K; Fukuoka, M; Ichinose, Y; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Saito, H; Tada, T; Takada, M; Takada, Y; Tamura, K | 1 |
| Diebolder, H; Kaiser, W; Kurrat, C; Petrovitch, A; Runnebaum, IB | 1 |
| Lee, E; Lim, SJ | 1 |
| Ahn, YC; Han, J; Kim, J; Kim, K; Kim, KJ; Lim, DH; Park, JO; Park, K; Shim, YM | 1 |
| Anderson, E; Andrews, C; Bjurstrom, T; Blackwell, S; Campagna, L; Crawford, J; Garst, J; Herndon, JE; Maravich-May, D; Padilla, K; Shafman, T | 1 |
| Florschütz, A; Kachel, R; Knolle, J; Schelle, M; Schreiber, C; Schreiber, J | 1 |
| Su, Y | 1 |
| Kudriavtsev, DV; Mardynskiĭ, IuS; Zolotkov, AG | 1 |
| Boudrias, M; Fortin, D; Garant, MP; Gendron, C | 1 |
| Crowley, J; Deschamps, C; Gandara, D; Giroux, DJ; Hazuka, M; Johnson, DH; Kraut, MJ; Livingston, RB; Rusch, VW; Shepherd, F; Shulman, L; Winton, T | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Nakamura, R; Ohta, F; Okamura, Y; Oura, S; Tamaki, T; Tanino, H; Yoshimasu, T | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Banerjee, S; Chiritescu, G; Dahrouge, S; Stewart, DJ; Tomiak, EM | 1 |
| Anderson, MG; Chen, J; Elmore, SW; Fesik, SW; Morgan-Lappe, SE; Ng, SC; Rosenberg, SH; Sarthy, AV; Tahir, SK; Tse, C; Warner, RB; Yang, X | 1 |
| Berishvili, G; Blum, WF; Figge, AM; Flyvbjerg, A; Frystyk, J; Klöppel, G; Lankisch, PG; Nauck, MA; Perren, A; Reinecke, M; Schmiegel, W; Zapf, J; Zwimpfer, C | 1 |
| Akyurek, S; Andrieu, MN; Cagar, A; Hicsonmez, A; Kurtman, C; Onal, C | 1 |
| Jeremić, B; Milićić, B | 1 |
| Kasai, S; Nishine, H; Otsuka, Y; Tokuda, H; Yoshikawa, M | 1 |
| Aboody, KS; Gevorgyan, A; Gutova, M; Metz, MZ; Najbauer, J; Shih, CC; Weng, Y | 1 |
| Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB | 1 |
| Ono, A; Yamamoto, N | 1 |
| Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Harita, S; Hotta, K; Kiura, K; Kuyama, S; Okimoto, N; Segawa, Y; Shinkai, T; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Cheng, S; Evans, WK; Shepherd, FA; Stys-Norman, D | 1 |
| Dahrouge, S; Jeyabalan, N; Laurie, SA; MacRae, R; Nicholas, G | 1 |
| Buchholz, E; Drings, P; Manegold, C; Pilz, L; Thatcher, N | 1 |
| Catalano, G; De Braud, F; De Pas, T; Gandini, S; Leo, F; Pelosi, G; Scanagatta, P; Spaggiari, L; Veronesi, G | 1 |
| Burke, MJ; Duerst, RE; Jacobsohn, DA; Kletzel, M; Walterhouse, DO | 1 |
| Häring, HU; Horger, M; Müssig, K; Wehrmann, M | 1 |
| Yoneda, S | 1 |
| Hiraoka, M; Shibuya, K | 1 |
| Buyyounouski, MK; Cohen, RB; D'Ambrosio, DJ; Feigenberg, SJ; Glass, J; Konski, A | 1 |
| Boven, E; Meijer, OW; Smorenburg, CH; van Groeningen, CJ; Visser, M | 1 |
| Ferraldeschi, R; Lorigan, P; Thatcher, N | 1 |
| Drosik, K; Jankowska, R; Jassem, J; Konopa, K; Koralewski, P; Kowalski, D; Kozielski, J; Krzakowski, M; Olszewski, W; Orłowski, T; Ramlau, R; Reinfuss, M; Roszkowski, K; Wojtukiewicz, M | 1 |
| Hotta, K; Ichimura, K; Kiura, K; Matsuoka, J; Osawa, M; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH | 1 |
| Asakawa, T; Kudoh, S; Kunikane, H; Kunitoh, H; Okamoto, H; Saijo, N; Shibata, T; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Bezjak, A; Darling, G; De Perrot, M; Johnston, MR; Keshavjee, S; Pierre, AF; Shepherd, FA; Uy, KL; Waddell, TK; Xu, W; Yi, QL | 1 |
| Bogart, JA; Green, MR; Hodgson, LD; Miller, AA; Radford, JE; Rocha Lima, CM; Vokes, EE; Wang, XF | 1 |
| Adjei, A; Bonner, JA; Graham, DL; Hillman, S; Kozelsky, TF; Kugler, JW; Marks, RS; Schild, SE; Soori, GS; Tenglin, RC; Vigliotti, AP; Wender, DB | 1 |
| Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N | 1 |
| Biesterfeld, S; Hoffarth, S; Huber, C; Kröll, M; Schuler, M; Wesarg, E; Wiewrodt, R | 1 |
| Briasoulis, E; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Pectasides, D; Samantas, E; Skarlos, D; Syrigos, K | 1 |
| Azar, JM; Einhorn, LH; Schneider, BP | 1 |
| Kishimoto, R; Matsushima, M; Motomura, M; Nakadate, M; Sasaki, H; Shiraishi, H; Tsuji, S; Yabe, I; Yaguchi, H | 1 |
| Biesma, B; de Jong, WK; Groen, HJ; Koolen, MG; Kwa, HB; Smit, EF; van Bochove, A; van Tinteren, H; Willems, LN | 1 |
| Goulet, K; Grignon, S | 1 |
| Seto, T | 1 |
| Björk-Eriksson, T; Hallqvist, A; Nyman, J; Rylander, H | 1 |
| Bilgi, O; Doğan, B; Kandemir, EG; Karagoz, B; Kunter, E; Turken, O | 1 |
| Buchler, T; Ellis, P; Hackshaw, A; James, L; Lee, SM; Snee, M | 1 |
| Bai, ZG; Jiang, L; Liu, YL; Ma, B; Mi, DH; Tan, JY; Tian, JH; Yang, KH | 1 |
| Bordier, V; de Cremoux, P; Decaudin, D; Ekue, R; Garcia, M; Grandjean, I; Lokiec, F; Poupon, MF; Rezaï, K; Weill, S | 1 |
| Cohen, RB; Dahlberg, S; Hidalgo, M; Johnson, DH; Lee, MW; Pandya, KJ; Schiller, JH | 1 |
| Fujisawa, M; Hara, I; Miyake, H; Nakano, Y; Takenaka, A; Tanaka, K; Terakawa, T | 1 |
| Hajji, N; Hermanson, O; Joseph, B; Nyman, U; Vlachos, P; Wallenborg, K | 1 |
| Czyzewicz, G; Jasiówka, M; Kojs-Pasińska, E; Rolski, J; Zemełka, T | 1 |
| Corn, PG; El-Deiry, WS | 1 |
| Allen, PK; Davenport, SD; Grosshans, DR; Komaki, R; Meyers, CA | 1 |
| Barbetti, A; Buccoliero, AM; Castiglione, F; Garbini, F; Gheri, CF; Moncini, D; Rossi Degl'Innocenti, D; Taddei, GL; Villanucci, A | 1 |
| Edelman, MJ; Kluetz, PG | 1 |
| Isobe, H; Matsui, K; Mori, K; Nakagawa, K; Nishiwaki, Y; Nokihara, H; Saijo, N; Sekine, I; Takeda, K; Tamura, T | 1 |
| Green, M; Hodgson, LD; Masters, GA; Rudin, CM; Salgia, R; Vokes, EE; Wang, X | 1 |
| Chinen, T; Hirayasu, T; Ishikawa, K; Kawabata, T; Kawasaki, H; Kuniyoshi, M; Ogawa, K; Ohta, M; Oshiro, Y; Samura, H; Teruya, J; Teruya, T; Uehara, T; Yohena, T | 1 |
| Ikari, H; Kamimura, H; Kamohara, R; Tamashima, S; Yoshioka, H | 1 |
| Hilgers, W; Mineur, L; Molinari, N; Naafa, N; Pourel, N; Reboul, F; Santelmo, N; Serre, A | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
| Cope, L; Daniel, VC; Dobromilskaya, I; Hann, CL; Hierman, JS; Lin, X; Murphy, SC; Rudin, CM; Sugar, EA; Watkins, DN; Wilburn, DL | 1 |
| Lau, CP; Leung, WK | 1 |
| Aversa, S; Brunsvig, P; Lange, A; Leyvraz, S; Martinelli, G; Montes, A; Pampallona, S; Perey, L; Peters, S; Ploner, F; Rosti, G; Yilmaz, U | 1 |
| Bunn, PA | 3 |
| Losonczy, G; Magyar, P; Müller, V; Tamási, L | 1 |
| Chabaud, S; Court-Fortune, I; Falandry, C; Fournel, C; Freyer, G; Girard, P; Ribba, B; Souquet, PJ; Tod, M; Tranchand, B; Trillet-Lenoir, V; You, B | 1 |
| Aigner, C; Bachleitner, T; Bichler, C; Eberhardt, W; End, A; Hudec, M; Kandioler, D; Kappel, S; Klepetko, W; Kührer, I; Mittlböck, M; Müller, MR; Roth, E; Stamatis, G; Tichy, V; Zöchbauer-Müller, S; Zwrtek, R | 1 |
| Bandoh, S; Fujita, J; Fukunaga, Y; Ishida, T; Ishii, T; Kanaji, N; Kubo, A; Ohtsuki, Y; Tojo, Y; Ueda, Y | 1 |
| Berchier, MC; Berghmans, T; Efremidis, A; Florin, MC; Koumakis, G; Lafitte, JJ; Leclercq, N; Lecomte, J; Meert, AP; Paesmans, M; Richez, M; Scherpereel, A; Sculier, JP; Van Houtte, P | 1 |
| de Vries, EG; De Vries-Hospers, HG; Holthuis, JJ; Mulder, NH; Postmus, PE; Sibinga, CT; Sleijfer, DT; van Imhoff, GW; Vriesendorp, R | 1 |
| Jacobsen, M; Nissen, MH; Olsen, J; Rørth, M; Vindeløv, L | 1 |
| Drings, P; Gropp, C; Havemann, K; Konrad, RM; Liesenfeld, A; Mahnke, HG; Seifert, W; Thomas, C; Wellens, W; Westerhausen, M | 1 |
| Adachi, K; Aiba, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakata, H; Ogawa, M; Tada, A; Usui, N | 1 |
| Alberto, P; Barrelet, L; Cavalli, F; Goldhirsch, A; Holdener, EE; Joss, RA; Mermillod, B; Obrecht, JP; Siegenthaler, P | 1 |
| Haaxma-Reiche, H; Meinesz, AF; Mulder, NH; Postmus, PE; Sleijfer, DT; Vencken, LM | 1 |
| Hodson, DI; Levitt, M; Malaker, K; Meikle, AL | 1 |
| Birch, R; Buchanan, R; Durant, J; Krauss, S; Lowenbraun, S; Mill, W; Ogden, L; Perez, C; Vollmer, R | 1 |
| Antman, K; Canellos, G; Karp, G; Pomfret, E; Skarin, A | 1 |
| Caldwell, RD; Case, LD; Harding, RW; Hopkins, JO; Jackson, DV; Muss, HB; Richards, F; Slatkoff, ML; White, DR; Zekan, PJ | 1 |
| De Vries, EG; Meinesz, AF; Mulder, NH; Orie, JL; Postmus, PE; Sleijfer, DT; Van der Geest, S; Vriesendorp, R | 1 |
| Huberman, MS; Lokich, JJ; Matelski, HW; Paul, S; Philips, D; Sonneborn, H; Zipoli, TE | 1 |
| Lamanna, S; Lopes-Pegna, A; Marino, C; Mazzei, T; Nozzoli, F; Periti, P; Righi, R; Santomaggio, C | 1 |
| Arnold, AM; Whitehouse, JM | 1 |
| Bagshawe, KD; Begent, RH; Newlands, ES; Parker, D; Rustin, GJ | 1 |
| Eddleston, B; Johnson, RJ; Read, G; Wilkinson, PM | 1 |
| Donohue, JP; Einhorn, LH; Kamer, M; Rowland, RG | 1 |
| Foster, BJ; Javadpour, N; Ozols, RF | 1 |
| Allan, SG; Cornbleet, MA; Crompton, GK; Grant, IW; Gregor, A; Leonard, RC; Smyth, JF | 1 |
| Klastersky, J; Sculier, JP | 3 |
| Bunn, PA; Cohen, MH; Fossieck, BE; Ihde, DC; Johnston-Early, A; Makuch, R; Matthews, MJ; Minna, JD; Paxton, LM | 1 |
| Aisner, J; Wiernik, PH | 1 |
| Barkley, HT; Bodey, GP; Burgess, MA; Hersh, EM; Mountain, CF; Rodriguez, V; Tenczynski, TF; Valdivieso, M | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, RA; Sonntag, RW | 1 |
| Kessinger, A; Lemon, HM; Tempero, M | 1 |
| Hilaris, BS; Natale, RB; Shank, B; Wittes, RE | 2 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, R; Ryssel, HJ; Sonntag, RW | 1 |
| Coles, DT; Creagan, ET; Eagan, RT; Fleming, TR; Frytak, S; Ingle, JN; Kvols, LK; Lee, RE; Nichols, WC | 1 |
| Aisner, J; Van Echo, DA; Whitacre, M; Wiernik, PH | 1 |
| Kennedy, BJ; Raghavan, D; Vogelzang, NJ | 1 |
| Bunn, PA; Cohen, MH; Hawley, RJ; Ihde, DC; Matthews, MJ; Minna, JD; Smith, MT; Thant, M; West, W | 1 |
| Fearon, F; Geddes, DM; Guimaraes, M; Harper, PG; Smyth, JF; Souhami, RL; Spiro, SG | 1 |
| Ettinger, DS; Lagakos, S | 1 |
| Aroney, RS; Bell, DR; Chan, WK; Dalley, DN; Levi, JA | 1 |
| Dillman, RO; Green, MR; Lea, JW; Lehar, TJ; Mendelsohn, J; Rentschler, RE; Royston, I; Seagren, SL; Stanton, W; Taetle, R; Young, JA | 1 |
| Cortés Funes, H; Dominguez, P; Lanzos, E; Mendez, M; Mendiola, C; Torrubia, AP | 1 |
| Aisner, J; VanEcho, DA; Wesley, M; Whitacre, M; Wiernik, PH | 1 |
| Arwidi, A; Hellekant, C; Jonsson, K; Lindahl, SA; Mattsson, W; Tennvall, L; von Eyben, FE | 1 |
| Gomez, RG; Madrigal, PA; Manga, GP; Palomero, I | 1 |
| Gracia, JM; Jimenez, A | 1 |
| Denck, H; Karrer, K; Pridun, N; Zwintz, E | 1 |
| Boutin, P; Carcassone, Y; Cupissol, D; Michel, FB; Plagne, R; Serrou, B | 1 |
| Bowden, GT; Giever, RJ; Heusinkveld, RS; Manning, MR | 1 |
| Bitran, JD; DeMeester, TR; Golomb, HM; Hoffman, PC; Newman, SB; Raghavan, V | 1 |
| Bremer, K; Krischke, W; Niederle, N; Schmidt, CG; Seeber, S | 1 |
| Ammon, J; Essers, U; Knechten, H; Seelis, R | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, R | 1 |
| Natale, RB; Wittes, RE | 2 |
| Havemann, K | 1 |
| Nakhosteen, JA; Niederle, N | 1 |
| Agusti, A; Estape, J; Milla, A; Rozman, C; Sanchez-Lloret, J; Santabarbara, P | 1 |
| Klastersky, J; Sculier, JP; Stryckmans, P | 2 |
| Bitran, JD; Golomb, HM; Hoffman, PC | 1 |
| Cooper, MR; Jackson, DV; Muss, HB; Pope, EK; Richards, F; Spurr, CL; Stuart, JJ; Wells, HB; White, DR | 1 |
| Antic, R; Drew, MJ; Gill, PG; McLennan, G; Robinson, PC | 1 |
| Dhingra, HM; Dicke, KA; Farha, P; Minnhaar, G; Spitzer, G; Umsawasdi, T; Valdivieso, M; Vellekoop, L; Verma, DS; Zander, A | 1 |
| Asbury, RF; Bennett, JM; Rubins, J | 1 |
| Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Wolff, SN | 1 |
| Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, FR; Osterlind, K; Rørth, M; Sörenson, S | 1 |
| Brower, M; Bunn, PA; Carney, DN; Cohen, MH; Ihde, DC; Johnston-Early, A; Makuch, RW; Matthews, MJ; Minna, JD; Radice, PA | 1 |
| Hansen, HH; Pedersen, AG | 1 |
| Deboer, G; Dill, J; Evans, WK; Feld, R; Osoba, D; Shepherd, FA | 1 |
| Canellos, GP; Garnick, MB; Lederman, GS; Richie, JP | 1 |
| Aisner, J; de Jongh, CA; Finley, RS; Joshi, JH; Schimpff, SC; Wade, JC; Wiernik, PH | 1 |
| Haaxma-Reiche, H; Holthuis, JJ; Mulder, NH; Postmus, PE; Sleijfer, DT; Sluiter, HJ; van Oort, WJ; Vencken, LM | 1 |
| Barkley, HT; Bodey, GP; Burgess, MA; Cabanillas, F; Chen, T; Frazier, H; Keating, M; Murphy, WK; Valdivieso, M | 1 |
| Eguchi, K; Saijo, N; Sasaki, Y; Seki, S; Shimizu, E; Shinkai, T; Takahashi, K; Tominaga, K | 1 |
| Caracandas, JE; Chen, TY; Lane, WW; Reddy, SK; Regal, AM; Takita, H; Vincent, RG | 1 |
| Chen, TT; Costanzi, JJ; Livingston, RB; McGavran, M; Mira, JG; Samson, M | 1 |
| Araya, Y; Dosaka, H; Isobe, H; Ito, M; Kawakami, Y; Miyamoto, H; Onodera, S; Shimizu, T; Takaoka, K | 1 |
| Edmundson, JM; Shiu, W; Steward, WP; Thatcher, N; Wilkinson, PM | 1 |
| Díaz Pérez, MA; García de Paredes, ML; González Larriba, JL; Montero García, JM; Ordóñez Gallego, A; Zamora, P | 1 |
| Bosl, GJ; Dukeman, M; Golbey, R; Herr, H; Sogani, P; Vugrin, D; Whitmore, WF; Yagoda, A | 1 |
| Płuzańska, A; Robak, T | 1 |
| Blum, RH; Foreman, JD; Muggia, FM | 1 |
| Berdel, WE; Diehl, V; Graubner, M; Gropp, C; Klippstein, T; Mende, S; Mitrou, PS | 1 |
| Cattaneo, MT; Piazza, E; Varini, M | 1 |
| Creech, RH; Day, R; Ruckdeschel, JC; Stolbach, LL; Weissman, CH | 1 |
| Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, RA; Mermillod, B | 1 |
| Ardizzoni, A; Canobbio, L; Colombara, M; Felletti, R; Ravazzoni, C; Rosso, R; Serrano, S | 1 |
| Naus, A; Utama, I; Verschueren, TA; Wils, JA | 1 |
| Chahinian, AP; Green, G; Holland, JF | 1 |
| Fujita, K; Murayama, T; Sayama, T | 1 |
| Gozzelino, F; Lodico, D; Pescetti, G; Scagliotti, G | 1 |
| Albain, KS; Bitran, JD; Blough, RR; DeMeester, TR; Golomb, HM; Hoffman, PC; Noble, S; Skosey, C | 1 |
| Berdel, WE; Diehl, V; Graubner, M; Gropp, C; Klippstein, TH; Mende, S; Mitrou, PS | 1 |
| Booser, DJ; Carr, DT; Chiuten, DF; Dhingra, HM; Farha, P; Issell, BF; Murphy, WK; Spitzer, G; Umsawasdi, T; Valdivieso, M | 1 |
| Bitran, JD; Ward, K | 1 |
| Fukuoka, M; Kimura, I; Kuraishi, Y; Ogawa, M; Ohnoshi, T; Ota, K; Oyama, A; Sanpi, K; Takada, M; Yoshida, S | 1 |
| Jameson, CH; Solanki, DL | 1 |
| Galligioni, E; Grigoletto, E; Santarossa, M; Tirelli, U; Trovo', MG; Tumolo, S; Veronesi, A; Zagonel, V | 1 |
| Aisner, J; Fuks, JZ; Levitt, M; Ostrow, S; Schipper, H; Van Echo, DA; Wiernik, PH | 1 |
| Brattain, MG; Long, BH; Musial, ST | 3 |
| Hussain, M; Ruckdeschel, JC; Zimmerman, MS | 1 |
| Araya, Y; Dosaka, H; Inoue, S; Isobe, H; Ito, M; Kawakami, Y; Miyamoto, H; Mizuno, S; Takaoka, K | 1 |
| Barkley, HT; Benjamin, RS; Bodey, GP; Ertel, M; Freeman, MB; Mountain, CF; Smith, TL; Valdivieso, M | 1 |
| Broggini, M; Colombo, T; D'Incalci, M; Erba, E; Morasca, L; Torti, L; Ubezio, P; Vaghi, M | 1 |
| D'Incalci, M; Erba, E; Morasca, L; Vaghi, M | 1 |
| Gralla, RJ; Itri, LM | 1 |
| Eagan, RT | 1 |
| Klastersky, J; Longeval, E; Nicaise, C; Weerts, D | 1 |
| Berdel, WE; Diehl, V; Fink, U; Fischer, M; Graubner, M; Gropp, C; Liesenfeld, A; Mitrou, PS; Schmidt, M; Weissenfels, I | 1 |
| Klastersky, J; Longeval, E | 1 |
| Dombernowsky, P; Hansen, HH; Nissen, NI; Pedersen, AG | 1 |
| Casper, ES; Chapman, RA; Golbey, RB; Gralla, RJ; Itri, LM; Kelsen, DP | 1 |
| Broggini, M; Colombo, T; D'Incalci, M; Erba, E; Torti, L | 1 |
| Casper, E; Chapman, R; Golbey, R; Gralla, R; Itri, L; Kelsen, D | 1 |
| Bianchi, C; Casali, W; Cogo, R; Marsoni, S; Morasca, L; Piazza, E; Pisoni, MB; Scapaticci, R; Vago, G | 1 |
| Anderson, G; Broderick, NJ; Cheong, CM; Peel, ET | 1 |
| Dicato, M | 1 |
| Creagan, ET; Eagan, RT; Kvols, LK | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, R; Kaplan, S; Obrecht, JP; Sonntag, R; Weber, W | 1 |
| Anderson, G; Bowyer, F; Williams, L | 1 |
| Cantwell, B | 1 |
| Ogura, T; Shimizu, E; Sone, S; Takaue, Y; Yamamoto, A | 1 |
| Csoka, K; Larsson, R; Liliemark, J; Nygren, P | 1 |
| Bunn, PA; Kelly, KL | 1 |
| Andoh, A; Gemba, K; Harada, M; Hiyama, J; Matsushita, A; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Ueoka, H | 1 |
| Bandou, K; Hajiro, T; Hasegawa, T; Ishihara, K; Katagami, N; Matsumoto, H; Nishimura, T; Okazaki, M; Umeda, B; Watanabe, I | 1 |
| Abratt, RP; Malan, JR; Salton, DG; Willcox, PA | 1 |
| Arjona, A; Corral, F; López Lozano, JJ; Provencio, M | 1 |
| Bleehen, NM; Girling, DJ; Machin, D; Stephens, RJ | 2 |
| Ishibashi, K; Kawai, T; Kawakami, S; Kokuho, M; Ueda, T; Yamauchi, T; Yonese, J | 1 |
| Kawai, T; Kawakami, S; Ohno, Y; Tachibana, Y; Ueda, T; Yamauchi, T; Yonese, J | 1 |
| Dieckmann, KP; Loy, V | 1 |
| Inagaki, T; Matsumoto, M; Shintani, Y; Uekado, Y | 1 |
| Lokich, J | 1 |
| Fukuoka, M; Furuse, K; Kawahara, M; Kodama, N; Masuda, N; Takada, M | 1 |
| Fukuoka, M; Furuse, K; Ikegami, H; Masuda, N; Nishiwaki, Y; Saijo, N; Takada, M | 1 |
| Bowman, CA; Fetherstonhaugh, EM; Gelmon, K; Karsai, H; Knowling, MA; Mclaughlin, MJ; Murray, N; Osoba, D; Page, R; Shah, A | 1 |
| Lurain, JR | 1 |
| Berenson, RJ; Brugger, W; Heimfeld, S; Henschler, R; Kanz, L; Mertelsmann, R | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Takada, M; Tsukada, H; Yana, T | 1 |
| Dexter, TM; Pettengell, R; Testa, NG; Thatcher, N; Woll, PJ | 1 |
| Galimberti, M; Misrachi, D; Villani, F | 1 |
| Brugger, W; Frommhold, H; Kanz, L; Mertelsmann, R; Pressler, K | 1 |
| Bellezza, A; Bindi, M; Crastolla, AM; Crociani, M; Farzad, M; Pepi, F; Pirtoli, L; Sebaste, L; Tucci, E | 1 |
| Bildet, F; Cour-Chabernaud, V; Hodgetts, J; Lomax, L; Thatcher, N; Woll, PJ | 1 |
| Dahrouge, S; Evans, WK; Goss, G; Logan, DM; Maroun, JA; Martins, H; Radwi, A; Stewart, DJ; Tomiak, E | 1 |
| Carpentier, AF; Chantelard, JV; Henin, D; Poisson, M | 1 |
| Alberto, P; Bacchi, M; Cerny, T; Hürny, C; Joss, RA; Leyvraz, S; Ludwig, C; Martinelli, G; Stahel, R; Thürlimann, B | 1 |
| Anderson, H; Bleehen, NM; Girling, DJ; Lallemand, G; Machin, D; Stephens, RJ; Thatcher, N | 1 |
| Ben-Itzhak, O; Drumea, K; Haim, N; Kuten, A; Stein, ME | 1 |
| de Mulder, PH; de Pauw, M; de Wit, R; Kaye, SB; Sleijfer, DT; Spaander, PJ; Stoter, G; Sylvester, R; ten Bokkel Huinink, WW | 1 |
| Mead, GM; Simmonds, PD; Whitehouse, JM | 1 |
| Feng, FY; Shi, YK; Sun, Y | 1 |
| Crawford, J; George, M | 1 |
| Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ | 1 |
| Blackwell, S; Buchanan, M; Clark, RE; Crawford, J; Grichnik, JM; Hitchcock, MG; Jimenez, F; Kurtzberg, J | 1 |
| Baroni, C; Bonsignore, G; Ciriaco, P; Cortesi, E; De Giacomo, T; Della Rocca, G; Flaishman, I; Rendina, EA; Ricci, C; Venuta, F | 1 |
| Cardenal, F; Garciá del Muro, X; Vicente, P | 1 |
| Barduagni, M; Carlini, P; Carpi, A; Ceci, G; Clerici, M; Cortesi, E; Crinò, L; Di Costanzo, F; Figoli, F; Santini, A | 1 |
| Checcaglini, F; Crinò, L; Darwish, S; Fiaschini, P; Giansanti, M; Maranzano, E; Mercati, U; Minotti, V; Rossetti, R; Todisco, T | 1 |
| Postmus, PE; Smit, EF | 1 |
| Carney, DN | 2 |
| Greco, FA; Hainsworth, JD | 5 |
| Mauer, AM; Miller, AA; Tolley, EA | 1 |
| Arneson, M; Blumenschein, G; Dicke, JA; Dicke, KA; Fulbright, L; Hanks, S; Hood, DL; Vaughan, M | 1 |
| Arakawa, M; Chou, T; Ebe, T; Hoshino, M; Kurita, Y; Yokoyama, A; Yoshizawa, H | 1 |
| Charloux, A; Dietemann, A; Fraisse, P; Jung, GM; Purohit, A; Quoix, E; Schumacher, C | 1 |
| Fujie, M; Fujishiro, S; Gotoh, J; Kobayashi, H; Shinohara, H; Terao, T | 1 |
| Iigo, M; Sagawa, K; Shimamura, M; Tsuda, H | 1 |
| Ansari, R; Einhorn, LH; Fisher, W; Gonin, R; Loehrer, PJ; Monaco, F; Sandler, A | 1 |
| Brewster, AE; Burt, PA; Hopwood, P; Stout, R; Thatcher, N | 1 |
| Griffin, JP; Miller, AA; Niell, HB | 1 |
| Dajczman, E; Frank, H; Kreisman, H; Srolovitz, H | 1 |
| Bonomi, PD; Comis, RL; Ettinger, DS; Johnson, DH; Neuberg, D; Ruckdeschel, JC; Wolff, AC | 1 |
| de Campos, E; Dougal, M; Milroy, R; Radford, J; Steward, W; Swindell, R; Testa, N; Thatcher, N | 1 |
| Beasley, K; Bunn, PA; Crowley, J; Gandara, DR; Hazuka, MB; Hicks, WJ; Kelly, K; Livingston, R; Upchurch, C; Weiss, GR | 1 |
| Betticher, D; Hanley, S; Hardy, C; Lee, SM; Lorigan, P; Thatcher, N; Weir, D; Woodhead, M | 1 |
| Asbury, RF; Boros, L; Chang, AY; Garrow, GC | 1 |
| Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hsieh, S | 1 |
| Boni, C; Carlini, P; Carpi, A; Ceci, G; Clerici, M; Cortesi, E; Crinò, L; Di Costanzo, F; Figoli, F; Santini, A | 1 |
| Choi, CW; Choi, MS; Choi, YH; In, KH; Kang, KH; Kim, CY; Kim, JS; Nam, YJ; Shin, SW | 1 |
| Maestroni, GJ | 1 |
| Klinke, F; Micke, O; Rübe, C; von Eiff, M; Wagner, W; Willich, N | 1 |
| Ellerton, J; Green, MR; Herndon, JE; Hollis, DR; Langleben, A; Miller, AA; Richards, F | 1 |
| Albain, KS; Crowley, JJ; Gandara, DR; Lonchyna, VA; McKenna, RJ; Presant, CA; Rice, TW; Rusch, VW; Turrisi, AT; Weick, JK | 1 |
| Beattie, EJ; Berson, AM; Harvey, J; Malamud, S; Pisch, J; Vikram, B | 1 |
| Bonomi, P; Faber, LP; Lincoln, S; Recine, D | 1 |
| Greco, FA; Hainsworth, JD; Stroup, SL | 2 |
| Bicknell, S; Cassidy, J; Hatton, MQ; Semple, P; Stack, B; Steward, WP | 1 |
| Beltrán, M; Canals, E; Dorca, J; Fuentes, R; Izquierdo, A; Viladiu, P | 1 |
| Shi, W; Zhang, S; Zhang, X | 1 |
| Guan, C; Huang, N; Ying, Z | 1 |
| Chen, DF; Sun, Y; Yin, WB; Zhang, DW; Zhang, RG; Zhang, XR | 1 |
| Albeck, M; Bruderman, I; Catane, R; Kalechman, Y; Kaufman, B; Shani, A; Shapira, J; Sredni, B; Tichler, T | 1 |
| Haku, T; Hanibuchi, M; Hiramatsu, K; Nabioullin, R; Pai, K; Sone, S; Tsuruo, T; Yanagawa, H; Yano, S | 1 |
| Belani, CP; Doyle, LA; Gao, Y; Gutheil, JC; Ordonez, JV; Ross, DD; Tong, Y; Yang, W | 1 |
| Bower, M; Brock, C; Fisher, RA; Newlands, ES; Rustin, GJ | 1 |
| Adelstein, DJ; Budd, GT; Kirby, TJ; Koka, A; Olencki, TE; Peereboom, D; Rice, TW; Taylor, ME; Tefft, M; Van Kirk, MA | 1 |
| Blayney, DW; Burke, JS; Doroshow, JH; Goldberg, DA; Leong, LA; Margolin, KA | 1 |
| Hansen, LJ; Madsen, EL; Møller, MN | 1 |
| Urushizaki, I | 1 |
| Jakobsen, A; Jakobsen, P; Strömgren, AS; Sørensen, BT | 1 |
| Decoster, G; Depierre, A; Gatzemeier, U; Green, J; Johnson, P; Lebeau, B; Manegold, C; Tomita, D; Trillet-Lenoir, V; Von Pawel, J | 1 |
| Pfeiffer, P; Rose, C; Sørensen, P | 1 |
| Alberto, P; Bleher, EA; Joss, RA; Ludwig, C; Martinelli, G; Sauter, C; Schatzmann, E; Senn, HJ; Siegenthaler, P | 1 |
| Billing, B; Lewensohn, R; Sirzea, F; Westberg, R | 1 |
| Akiyama, Y; Fujii, Y; Kimura, S; Kondo, H | 1 |
| Broxterman, HJ; de Vries, EG; Kuiper, CM; Mulder, NH; Scheper, RJ; Versantvoort, CH; Withoff, S | 1 |
| Ansari, R; Einhorn, LH; Faylona, EA; Gonin, R; Loehrer, PJ; Sandler, AB | 1 |
| Arnaud, A; Blanchon, F; Bonnaud, F; Castelnau, O; Guérin, JC; Kleisbauer, JP; Pérol, M; Taytard, A; Vergnenegre, A | 1 |
| Benchokroun, Y; Larsen, AK; Lelièvre, S | 1 |
| Coolen, L; Demedts, M; Deneffe, G; Van den Eeckhout, A; Vansteenkiste, J | 1 |
| Ettinger, DS; Finkelstein, DM; Johnson, DH; Sarma, RP | 1 |
| Belani, CP; Greco, FA; Hainsworth, JD; Levitan, N; Randolph, J; Schacter, LP; Seyedsadr, MS; Wampler, GL | 1 |
| Crowell, EB; Higa, GM; Wise, TC | 1 |
| Ando, M; Eguchi, K; Katsumata, N; Maeda, M; Ohe, Y; Oshita, F; Shinkai, T; Shiraishi, J; Tamura, T; Yamamoto, N | 1 |
| Plasswilm, L | 1 |
| Engelholm, SA; Jensen, PB; Petersen, LN; Spang-Thomsen, M; Sørensen, BS | 1 |
| Ihde, DC | 1 |
| Bacchi, M; Bernhard, J; Cerny, T; Hürny, C; Joss, RA; Leyvraz, S; Martinelli, G; Senn, HJ; Siegenthaler, P; Stahel, R | 1 |
| Fujiwara, Y; Ohune, T; Sumiyoshi, H; Yamakido, M; Yamaoka, N | 1 |
| Kuriyama, T; Miyamoto, T; Nagao, K; Takamura, M; Takiguchi, Y; Yasukawa, T | 1 |
| Kim, K | 1 |
| Ando, Y; Minami, H; Sakai, S; Shimokata, K | 2 |
| Ogawa, M; Tanaka, H; Tanaka, T; Tanizawa, M; Watanabe, Y | 1 |
| Andoh, S; Fujisawa, Y; Hasegawa, Y; Itoh, K; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Sagiyama, K; Ueda, T | 1 |
| Liu, YY; Sun, Y; Zhang, XR | 1 |
| Fukunishi, H; Kitazawa, S; Takeuchi, S; Yukimura, N | 1 |
| Boyter, AC; Cargill, RI; Lipworth, BJ | 1 |
| Jassem, E; Jassem, J; Karnicka-Młodkowska, H; Malak, S; Moś-Antkowiak, R; Pilarska-Machowicz, A; Szymaczek-Meyer, L; Słupek, A; Wiatr, E; Zych, J | 1 |
| Gromova, II; Razin, SV; Thomsen, B | 1 |
| Helle, L; Hinkka, S; Huovinen, R; Jakobsson, M; Järvinen, M; Liippo, K; Ojala, A; Paloheimo, S; Salmi, R; Viren, M | 1 |
| Astaldi Ricotti, GC; Baas, F; Borst, P; de Haas, M; de Nooij, J; Eijdems, EW; Kamst, E; Timmerman, AJ; Van der Schans, GP | 1 |
| Alberto, P; Bonnefoi, H; Mermillod, B; Mirimanoff, RO; Zulian, GB | 1 |
| Brambilla, E; Clavier, J; Gouva, S; Le Reste, N; Leroy, JP; Robinet, G | 1 |
| Cartei, G; Crivellari, D; Della Valentina, M; Foladore, S; Magri, MD; Nascimben, O; Sibau, A; Talamini, R; Trovò, MG; Veronesi, A | 1 |
| Brock, I; Cole, SP; Deeley, RG; Hipfner, DR; Jensen, PB; Nielsen, BS; Sehested, M | 1 |
| Acimovic, L; Djuric, L; Jeremic, B; Shibamoto, Y | 1 |
| Ekberg, L; Elisson, LO | 1 |
| Berchier, MC; Bureau, G; Giner, V; Kroll, F; Küstner, U; Michel, J; Mommen, P; Sculier, JP; Thiriaux, J; Van Cutsem, O | 1 |
| Ettinger, DS | 4 |
| Einhorn, LH; Loehrer, PJ | 1 |
| Bitran, JD; Green, M; Herndon, JE; Hollis, DR; Perry, M | 1 |
| Burt, P; Hicks, F; Leahy, B; Lorigan, P; Prendiville, J; Stout, R; Thatcher, N | 1 |
| Fossella, FV; Garden, AS; Glisson, BS; Hong, WK; Komaki, R; Murphy, WK; Oswald, MJ; Peters, LJ; Roth, JA; Shin, DM | 1 |
| Chang, AY; Ettinger, DS; Johnson, DH | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Burris, H; Grunberg, SM; Livingston, R | 1 |
| Hasegawa, T; Inui, H; Ishihara, K; Katakami, N; Matsumoto, H; Nishiyama, H; Okazaki, M; Sakamoto, H; Tomioka, H; Umeda, B | 1 |
| Murray, N; Payne, DG; Warde, P | 1 |
| Shi, YK; Su, M; Sun, Y | 1 |
| Shi, TZ; Yan, JL | 1 |
| Barni, S; Fossati, V; Frigerio, F; Lissoni, P; Meregalli, S; Paolorossi, F; Tancini, G | 1 |
| Coen, V; De Neve, W; Storme, G; Van Lancker, M | 1 |
| Arriagada, R; Arvelo, F; Bourgeois, Y; Goguel, AF; Le Chevalier, T; Lizard, G; Poupon, MF | 1 |
| Iigo, M; Moriyama, M; Tsuda, H | 1 |
| Edison, M; Gazdar, AF; Ihde, DC; Kramer, BS; Lesar, M; Linnoila, RI; Mulshine, JL; Phares, JC; Phelps, RM; Steinberg, SM | 1 |
| Horikawa, S; Katagami, N; Kobayashi, H; Maekawa, N; Matsumoto, H; Matsunaga, K; Nishiyama, H; Okazaki, M; Sugita, T; Suzuki, Y | 1 |
| Bleehen, NM; Falk, SJ; Gottlieb, T; Osborne, RJ; Smith, PJ; Souès, S; Watson, JV | 1 |
| Fujita, N; Goto, H; Inaba, T; Moriguchi, T; Seto, M; Shimazaki, C; Tatsumi, T; Ueda, R; Yamagata, N; Yamamoto, K | 1 |
| Hayot, M; Le Chevalier, T; Michel, FB; Pujol, JL; Rouanet, P | 1 |
| Kanzawa, F; Kondo, H; Nishio, K; Saijo, N; Saito, S | 1 |
| Arioka, H; Eguchi, K; Karato, A; Nakashima, H; Ohe, Y; Oshita, F; Shinkai, T; Tamura, T; Uenaka, K; Yamamoto, N | 1 |
| Deigert, FA; Eagan, RT; Jett, JR; Maksymiuk, AW; Shaw, EG; Su, JQ | 1 |
| Ariyoshi, Y; Fukuoka, M; Furuse, K; Ikegami, H; Nishiwaki, Y; Saijo, N; Shimoyama, M; Suemasu, K; Tamura, T | 1 |
| Asbury, R; Boros, L; Chang, AY; Hsieh, RK | 1 |
| Broder, LE; Charyulu, KN; Donnelly, EJ; Rao, RK; Raub, WA; Saldana, MJ; Selawry, OS; Sridhar, KS | 1 |
| Furuse, K; Kawahara, M; Kodama, N | 1 |
| Ohnoshi, T; Ueoka, H | 1 |
| Cuffie, C; Fisher, RI; Hamm, J; Kaiser, G; Oken, M; Schiller, JH; Shepherd, F | 1 |
| Hayashi, I; Ichiki, M; Sakurai, M | 3 |
| Angelidou, M; Fountzilas, G; Klouvas, G; Kosmidis, P; Mylonakis, N; Palamidas, P; Papadakis, E; Provata, A; Samantas, E; Skarlos, DV | 1 |
| Calabresi, F; Giannarelli, D; Masciulli, R; Moreschi, M; Peschle, C; Pollera, CF; Ruggeri, EM; Testa, U | 1 |
| Ficalora, M; Glynn, P; Higby, D; Koletsky, A; Moriarty, E; Volpe, B; White, C | 1 |
| Cole, SP; Danks, MK; Evans, CD; Mirski, SE | 1 |
| Gemba, K; Hiraki, S; Hiyama, J; Kamei, H; Kimura, I; Miyatake, K; Ohnoshi, T; Shibayama, T; Tabata, M; Ueoka, H | 1 |
| Airoma, G; Bianco, AR; Gridelli, C; Incoronato, P; Palazzolo, G; Pepe, R; Rossi, A | 1 |
| Bleehen, NM; Girling, DJ; Gregor, A; Leonard, RC; Machin, D; McKenzie, CG; Morgan, DA; Smyth, JF; Spittle, MF; Stephens, RJ | 2 |
| Clark, PI; Gregory, W; Joel, SP; Johnson, PW; Masud, T; Osborne, RJ; Reznek, R; Slevin, ML; Talbot, DI; Wrigley, PF | 1 |
| Gandara, DR; Gardner, SL; Perez, EA; Sowray, PC | 1 |
| Huang, XL; Mei, QD; Yan, M | 1 |
| Berchier, MC; Bureau, G; Dabouis, G; Libert, P; Michel, J; Paesmans, M; Ries, F; Sculier, JP; Van Cutsem, O; Vandermoten, G | 1 |
| Jones, DN | 1 |
| Nardini, S | 2 |
| Apostolopoulou, F; Fountzilas, G; Kosmidis, PA; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Gatzemeier, U; Hossfeld, DK; Laumen, R; Neuhauss, R; Pawel, JV | 1 |
| Burt, P; Lorrigan, P; Stout, R; Thatcher, N | 1 |
| Blackwell, S; Crawford, J; Deutsch, M; Foster, W; Herndon, J; Leopold, K; Wolfe, W; Yost, R | 1 |
| Fujii, S; Iwabuchi, K | 1 |
| Aggarwal, S; Fisk, B; Glisson, BS; Ioannides, CG; O'Brian, CA; Restifo, N; Wharton, JT | 1 |
| Arakawa, M; Koike, R; Nagai, H; Takano, H; Tanaka, M; Tsuji, S | 1 |
| Ardiet, JM; Boyer, J; Chauvin, F; Fournel, P; Laennec, E; Mornex, F; Perol, M; Piperno, D; Trillet-Lenoir, V; Voloch, A | 1 |
| Abbasciano, V; Aleotti, A; Grandi, E; Nielsen, I; Sartori, S; Tassinari, D; Trevisani, L | 1 |
| Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Aisner, J; Belani, CP; Doyle, LA | 1 |
| Muggia, FM | 1 |
| Joel, SP; Shah, R; Slevin, ML | 1 |
| Byrne, A; Carney, DN | 1 |
| Oshita, F; Saijo, N | 1 |
| Bartoli, GC; Casaretti, R; Comella, G; Comella, P; Daponte, A; Palmieri, G; Parziale, AP | 1 |
| de Jonge, A; Karim, AB; Meyer, OW; Njo, KH; Slotman, BJ | 1 |
| Burghouts, JT; Haaxma-Reiche, H; Postmus, PE; van der Graaf, WT | 1 |
| Broniek, A; Polowiec, Z; Rowinska-Zakrzewska, E; Wiatr, E; Zych, J | 1 |
| Brancaccio, L; Comella, G; Curcio, C; D'Aprile, M; Ferrante, G; Gentile, M; Gridelli, C; Palmeri, S; Rossi, A; Veltri, E | 1 |
| Anania, C; Casaretti, R; Comella, G; Comella, P; Curcio, C; Daponte, A; Maiorino, A; Musetta, G; Scoppa, G | 1 |
| Davison, AG; Gower, N; Harper, PG; James, L; Partridge, MR; Rudd, R; Ruiz de Elvira, MC; Souhami, RL; Tobias, JS; Trask, C | 1 |
| Gray, RJ | 1 |
| Byhardt, RW; Cox, JD; Komaki, R; Pajak, TF; Perez, CA; Sause, WT | 1 |
| Arriagada, R; Bunn, P; Choi, N; Feld, R; Gregor, A; Jett, J; Johnson, B; Komaki, R; Kristjansen, P; Murray, N | 1 |
| Arriagada, R; Chomy, P; de Cremoux, H; Le Chevalier, T; Ruffié, P | 1 |
| Gazdar, AF; Ghosh, B; Johnson, BE; Kramer, BS; Minna, JD; Mitsudomi, T; Mulshine, JL; Pass, H; Phelps, R; Shaw, GL | 1 |
| Bailey, A; Chen, S; Molthrop, D; Robert, F; Wheeler, RH | 1 |
| Christensen, IJ; Hansen, HH; Jensen, PB; Sehested, M; Vindeløv, L | 1 |
| Ayass, M; Cassano, W; Dickson, N; Enneking, W; Graham-Pole, J; Heare, M; Heare, T; Marcus, R; Saleh, R; Spanier, S | 1 |
| Cook, J; Fisher, J; Goldspiel, B; Hahn, SM; Kaufman, D; Liebmann, JE; Mitchell, JB; Venzon, D | 1 |
| Almquist, KC; Cole, SP; Evans, CD; Mirski, SE; Slovak, ML | 1 |
| Broxterman, HJ; Eekman, CA; Kuiper, CM; Lankelma, J; Pinedo, HM; Schuurhuis, GJ; Versantvoort, CH | 1 |
| Lorico, A; Rappa, G; Sartorelli, AC | 2 |
| Bisail, M; Farris, A; Intini, C; Sanna, G; Sarobba, MG; Scotto, T; Valzelli, S | 1 |
| Koshiba, K; Mukai, N; Rokkaku, S; Soh, S; Uchida, T | 1 |
| Corgna, E; Crinò, L; Darwish, S; Latini, P; Maranzano, E; Meacci, M; Minotti, V; Santucci, A; Tonato, M | 1 |
| Earl, HM; Jones, A; Radford, JA; Smith, IE; Thatcher, N; Van Hoef, ME; Woll, PJ | 1 |
| Greco, FA; Hainsworth, JD; Johnson, DH; Lamar, RE; Murphy, PB | 1 |
| Brancaccio, L; Comella, G; Curcio, C; D'Aprile, M; Gentile, M; Gridelli, C; Ianniello, GP; Maiorino, A; Palmeri, S; Pedicini, T | 1 |
| Blumenreich, MS; Farnsley, ES; Hagan, PC; Hamm, JT; Joseph, UG; Kellihan, MJ; Miller, CL; Robinson, LH; Seeger, J; Sheth, SP | 1 |
| Halme, M; Maasilta, PK; Mattson, KV; Pyrhönen, SO | 1 |
| Budach, V; Eberhardt, W; Greschuchna, D; Konietzko, N; Sack, H; Seeber, S; Stamatis, G; Stuschke, M; Wilke, H | 1 |
| Ettinger, DS; Gradishar, W; Johnson, DH; Larson, MM; Merkel, D; Schiller, JH | 1 |
| Kim, HJ; Kim, HK; Kim, SJ; Lee, DY; Paik, HC | 1 |
| Conti, A; Covacci, V; Maestroni, GJ | 1 |
| Miller, AA; Tolley, EA | 1 |
| Akaogi, E; Inagaki, M; Ishibashi, O; Ishikawa, S; Kinoshita, T; Mitsui, K; Morita, R; Okazaki, H; Onizuka, M; Suga, M | 1 |
| Demant, EJ; Grue, P; Hansen, HH; Jensen, PB; Sehested, M; Sørensen, BS | 1 |
| Bokemeyer, C; Poliwoda, H; Schmoll, HJ | 1 |
| Bonomi, P; Chang, A; Finkelstein, D | 1 |
| Greco, FA; Hainsworth, JD; Hande, KR; Holzmer, M; Thompson, DS | 1 |
| Cardenal, F; Garcia-del-Muro, X; Portal, I | 1 |
| Kietlińska, Z; Sablińska, B; Zieliński, J | 1 |
| Ghosh, C; Goldberg, RM; Jett, JR; Kugler, JW; Kuross, SA; Loprinzi, CL; Mailliard, JA; Maksymiuk, AW; Pfeifle, DM; Su, JQ | 1 |
| Comis, R; Haas, N; Kilpatrick, D; Krigel, RL; Langer, C; Padavic, K; Palackdharry, CS | 1 |
| Dahrouge, S; Evans, WK; Goss, G; Latreille, J; Logan, D; Maroun, JA; Shepherd, FA; Stewart, DJ; Warner, E; Wierzbicki, R | 1 |
| Gandara, DR; Perez, EA | 1 |
| Krigel, RL; Palackdharry, CS | 1 |
| Hiraki, S; Kiura, K; Moritaka, T; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H; Yonei, T | 1 |
| Cattan, A; Desoize, B; Maréchal, F | 1 |
| Gazdar, AF; Ghosh, BC; Ihde, DC; Johnson, BE; Linnoila, RI; Oie, HK; Pass, HI; Phelps, R; Shaw, GL; Steinberg, SM | 1 |
| Blackwell, S; Crawford, J; Deutsch, MA; Foster, W; Leopold, KA; Wolfe, W; Yost, R | 1 |
| Cataldo, I; De Toma, D; Gramaglia, A; Milani, F; Palazzi, M; Ravasi, G | 1 |
| Ashley, S; Holborn, J; Jones, AL; Smith, IE | 2 |
| Fujii, M; Kumamoto, T; Okamoto, M; Okamura, A; Saitoh, Y; Toyoda, T; Umemoto, M; Yonezu, S | 1 |
| Kimura, T; Onodera, K; Sato, T | 1 |
| Arriagada, R; Chomy, P; Le Chevalier, T; Monnet, I; Pignon, JP; Rivière, A; Ruffié, P; Tarayre, M; Tuchais, C | 1 |
| Ichiyama, S; Nagura, E; Nomura, F; Saito, H; Saka, H; Sakai, S; Shimokata, K; Watanabe, A | 1 |
| Cheson, BD; Feigal, EG; Phillips, PH | 1 |
| Bando, H; Shinohara, T; Sumitani, H; Takishita, Y; Tanaka, H; Yanagawa, H | 1 |
| Donaldson, AN; Machin, D; Stephens, R; Whitehead, J | 1 |
| Donahue, JP; Dulmadge, EA; Vasanthakumar, G; Wilkoff, LJ | 1 |
| Diegert, FA; Earle, JD; Jett, JR; Kardinal, CG; Krook, JE; Mailliard, JA; Maksymiuk, AW; Su, JQ; Veeder, MH; Wiesenfeld, M | 1 |
| Kunitoh, H; Watanabe, K | 1 |
| Amdemichael, E; Chalvardjian, P; Coates, R; Evans, WK; Hogg-Johnson, S; Paul, K; Shepherd, FA | 1 |
| Hirabayashi, M; Kuno, K; Nakagawa, M; Tanaka, Y; Yoshida, H | 1 |
| de Veber, LL; Del Maestro, RF; Ramsay, DA; Sahjpaul, RL | 1 |
| Heike, Y; Nishio, K; Ohmori, T; Okamoto-Kubo, S; Saijo, N; Yoshida, M | 1 |
| Checcaglini, F; Crinò, L; Darwish, S; Fiaschini, P; Maranzano, E; Mercati, U; Minotti, V; Penza, O; Rossetti, R; Vitali, R | 1 |
| Gramer, EM; Hiremath, V; Howard, LM; Kasimis, BS; Pokorney, ES; Ruddy, P | 1 |
| Chan, JC; Chan, JK; Lam, SY; Wong, KF | 1 |
| Hibi, S; Imashuku, S; Kataoka, Y; Morimoto, M; Naya, M; Takaya, K; Todo, S | 1 |
| Barker, LJ; Jones, SE; Mennel, RG; Savin, MA | 1 |
| Ando, Y; Minami, H; Nomura, F; Saito, H; Saka, H; Sakai, S; Senda, K; Shimokata, K | 1 |
| Ando, M; Araki, N; Ikuta, N; Matsumoto, K; Suzuki, R; Takagi, K; Taki, F | 1 |
| Albain, KS; Benfield, JR; Crowley, JJ; Griffin, BR; Livingston, RB; Lonchyna, V; McKenna, R; Rice, TW; Rusch, VW | 1 |
| Azzarello, G; Bari, M; Pappagallo, GL; Rosetti, F; Sampognaro, E; Segati, R; Vinante, O | 1 |
| Kirkpatrick, A; Postmus, PE; Smit, EF; Splinter, TA | 1 |
| Clamon, G; Ellerton, J; Green, MR; Herndon, J; Kreisman, H; Maher, T; Ozer, H; Perry, MC | 1 |
| Engel, RE; Frank, AR; Jett, JR; Mailliard, JA; McGinnis, WL; Rowland, KM; Shaw, EG; Su, JQ; Wiesenfeld, M | 1 |
| Blanchard, R; Caguioa, PB; Carney, D; DiMartino, N; Hesketh, A; Hesketh, PJ; Tansan, S | 1 |
| Harada, T; Jinnai, H; Ohe, T; Saegusa, S; Suzuki, Y; Ueno, N | 1 |
| Beitz, J; Browne, M; Calabresi, P; Clark, J; Cummings, F; Glicksman, AS; Murray, C; Posner, M; Weitberg, AB; Yashar, J | 1 |
| Deshmukh, AA; Hall, MR; Lee, CR; Nicholson, PW; Slevin, ML; Souhami, RL | 1 |
| Chastang, C; Fabre, C; Lebeau, B; Massin, F; Muir, JF; Vincent, J | 1 |
| Nomura, S; Yasunaga, K | 1 |
| Difino, S; Goutsou, M; Green, MR; Luikart, SD; Mitchell, ED; Modeas, CR; O'Donnell, J; Perry, MC; Propert, KJ; Van Echo, DA | 1 |
| Abe, T; Imaizumi, M; Kojima, H; Nakagawaji, K; Tokumaru, T; Uchida, T | 1 |
| Gemba, K; Kiura, K; Matsumura, T; Moritaka, T; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H | 1 |
| Hayashi, I; Ichiki, M; Ohashi, Y; Sakurai, M | 1 |
| Burgut, R; Doran, F; Erkişi, M; Tunali, C; Unsal, M | 1 |
| Johnson, BE | 1 |
| Curran, WJ; Fowler, WC; Keller, SM; Langer, CJ | 1 |
| Cornelius, AS; Murry, DJ; Teresi, ME | 1 |
| Ardizzoni, A; Bracarda, S; Bruzzi, P; Crinò, L; Garrone, O; Mariani, GL; Pennucci, MC; Rosso, R; Sertoli, MR; Venturini, M | 1 |
| Butcher, M; Joel, SP; Johnson, PW; Love, S; Pandian, MR; Slevin, ML; Squires, L; Wrigley, PF | 1 |
| Saito, H; Saka, H; Sakai, S; Shimokata, K; Yamamoto, M | 1 |
| Blum, R; Bonomi, P; Chang, AY; Ettinger, D; Johnson, DH; Turrisi, AT; Wagner, H | 1 |
| Kamei, H; Kiura, K; Kodani, T; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H; Yonei, T | 1 |
| Elias, AD; Frei, E; Kalish, LA; Kass, F; Lynch, TJ; Shulman, LN; Skarin, A; Strauss, G; Sugarbaker, DJ | 1 |
| Crowley, JJ; Livingston, RB; Meyers, FJ; Neefe, JR; O'Rourke, T; Thompson, T; Williamson, SK | 1 |
| Jeremic, B; Jevremovic, S; Mijatovic, L; Milisavljevic, S | 1 |
| Clark, F; Edwards, A; Gibson, GJ; Tong, P; White, A; White, J; Winocour, PH | 1 |
| Griffin, JP; Mauer, AM; Miller, AA; Niell, HB; Tolley, EA | 1 |
| Anderson, H; Ashcroft, L; Hopwood, P; Prendiville, J; Radford, JA; Thatcher, N | 1 |
| Bagchi, P; Blankstein, K; Catalano, R; Comis, R; Curran, WJ; Fowler, W; Keller, SM; Langer, CJ; Litwin, S; Nash, S | 1 |
| Bartolucci, A; Bass, D; Crawford, J; Einhorn, LH; Greco, FA; Johnson, DH; Omura, GA; Perez, CA | 1 |
| Bakker, W; Burghouts, JT; Dalesio, O; Giaccone, G; Kirkpatrick, A; Koolen, MG; McVie, GJ; Postmus, PE; Roozendaal, KJ; Vendrik, CP | 1 |
| Genba, K; Horiguchi, T; Kiura, K; Matsumura, T; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H | 1 |
| Ishihara, T; Matsunaga, W; Yasuno, K | 1 |
| Chieco-Bianchi, L; Comis, S; Danova, M; Favaretto, A; Ghiotto, C; Giordano, M; Paccagnella, A; Panozzo, M; Pappagallo, G; Riccardi, A | 1 |
| Balcerzak, SP; Braun, T; Crowley, J; Gill, I; Grunberg, SM; Livingston, R; Marshall, ME; O'Rourke, T; Weick, JK; Williamson, SK | 1 |
| Albain, KS; Crowley, JJ; Gandara, D; Griffin, B; Hutchins, L; Livingston, RB; O'Bryan, RM; Von Hoff, DD | 1 |
| Bailey, CC; Giles, GR; Heney, D; Lewis, IJ; Lockwood, L | 1 |
| Hiraki, S; Horiguchi, T; Kamei, H; Kiura, K; Kodani, T; Maeda, T; Ohnoshi, T; Shibayama, T; Tabata, M; Ueoka, H | 1 |
| Sufarlan, AW; Zainudin, BM | 1 |
| Ekman, A; Halme, M; Hand, A; Husgafvel-Pursiainen, K; Linnainmaa, K; Mattson, K; Mattson, M; Pelin, K; Vallas, M | 1 |
| Hida, T | 1 |
| Joel, SP; Slevin, ML | 1 |
| Alerci, M; Cavalli, F; D'Incalci, M; deJong, J; Gentili, D; Martinelli, G; Pagani, O; Sessa, C; Torri, V; Zucchetti, M | 1 |
| Alberto, P; Beris, P; Cabrol, C; Jotterand Bellomo, M; Mermillod, B; Zulian, GB | 1 |
| Hansen, HH; Kristjansen, PE; Skov Hansen, M; Soelberg Sørensen, P | 1 |
| Mori, K; Suga, Y; Takahashi, T; Tominaga, K | 1 |
| Milroy, R | 1 |
| Herrmann, C; Hiddemann, W; Meyer, T; Schauer, A | 1 |
| Nakano, K; Takechi, T; Takeda, S; Uchida, J | 1 |
| Crown, J; Currie, V; Gilewski, T; Hakes, T; Hudis, C; Lebwohl, D; Reichman, B; Seidman, A; Surbone, A; Yao, TJ | 1 |
| Fujita, J; Kubo, A; Takahara, J; Takigawa, K; Yamagishi, Y; Yamaji, Y | 1 |
| Imoto, M; Kakusui, M; Kashima, K; Misawa, S; Takashima, T; Taniwaki, M | 1 |
| Auerbach, M; Essig, L; Fryer, D; Fryer, J; Lokich, J | 1 |
| Beasley, K; Bunn, PA; Crowley, JJ; Gandara, DR; Hazuka, MB; Hicks, WJ; Kelly, K; Rivkin, S; Upchurch, C; Weiss, GR | 1 |
| Jeremic, B; Shibamoto, Y | 2 |
| Bando, T; Fukuse, T; Hirata, T; Hitomi, S; Ike, O; Inui, K; Mizuno, H; Tanaka, F; Wada, H; Yokomise, H | 1 |
| Köpf-Maier, P; Sass, G | 1 |
| Ives, RK | 1 |
| Fujita, M; Kawakami, Y; Kobayashi, S; Munakata, M; Nasuhara, Y | 1 |
| Fukumura, M; Furuie, H; Hayashi, Y; Kakuta, Y; Kimura, M; Konishi, T; Morikawa, T; Takeuchi, K; Tashiro, Y | 1 |
| Kishiro, I; Mori, K; Ohta, S; Suga, Y; Tominaga, K; Yokoyama, K | 1 |
| Arvelo, F; Bastian, G; Bichat, F; Bourgeois, Y; Grossin, F; Jacrot, M; Le Chevalier, T; Poupon, MF | 1 |
| Ellis, PA; Jones, AL; Priest, K; Smith, IE; Talbot, DC | 1 |
| Kaneko, T; Okoshi, T; Okubo, T; Shoji, A; Tsubakihara, M | 1 |
| Barrantes, JC; García, I; Lobo-Sanahuja, F; Santamaría, S | 1 |
| Akimoto, K; Akimoto, S; Kasahara, T; Kato, M; Kinoshita, M; Kizu, O; Komatsu, T; Maeda, T; Minami, K; Nakaoka, Y; Sekikawa, S; Shimizu, T | 1 |
| Memon, AS | 1 |
| Fujita, T; Hagiwara, Y; Hiraoka, M; Kanayama, T; Kubo, S; Nakagawa, H; Nakanomyo, H; Tokiyoshi, K; Yamada, M | 1 |
| Fujiwara, Y; Niitani, K; Ohune, T; Okusaki, K; Sumiyoshi, H; Takemoto, Y; Yamakido, M; Yamaoka, N | 1 |
| Ariyoshi, Y; Hida, T; Miyara, H; Morishita, M; Nishida, K; Sugiura, T; Takahashi, T; Ueda, R | 1 |
| Chen, YM; Kuo, BI; Liu, JM; Perng, RP; Tsai, CM; Wang, SY; Whang-Peng, J | 1 |
| Ghosh, C; Jett, JR; Jung, SH; Kugler, JW; Kuross, SA; Loprinzi, CL; Mailliard, JA; Maksymiuk, AW; Owen, D; Rowland, KM; Schaefer, PL; Shaw, EG; Tschetter, LK; Washburn, JH; Webb, TA | 1 |
| Clark, PI; Joel, SP; Shah, R; Slevin, ML | 1 |
| Fang, Y; Song, M; Wang, G; Xu, H | 1 |
| Anderson, H; Clark, PI; Girling, DJ; Jenkins, B; Lallemand, G; Machin, D; Smith, DB; Stephens, RJ; Thatcher, N | 1 |
| Best, LA; Dale, J; Daoud, K; Kuten, A; Milstein, D; Robinson, E; Saute, M; Zen-Al-Deen, I | 1 |
| Berger, M; Geyer, JR; Sievers, EL | 1 |
| Carranza, L; Cresta, C; Richardet, E; Tolocka, H; Uribe, A; Uribe, E; Uribe, M | 1 |
| Cera, PJ; Cha, SS; Creagan, ET; Goldberg, RM; Jung, SH; Marschke, RF; Myers, JL; Schleusener, JT; Tazelaar, HD | 1 |
| Ando, M; Ando, Y; Minami, H; Saka, H; Sakai, S; Shimokata, K | 2 |
| Fujii, H; Hasebe, T; Igarashi, T; Itoh, K; Ohtsu, T; Sasaki, Y; Wakita, H; Yoshida, J | 1 |
| Creagan, ET; Eagan, RT; Foote, RL; Frytak, S; Jett, JR; Lee, RE; Richardson, RL; Schaid, DJ; Shaw, EG; Su, JQ | 1 |
| Creagan, ET; Eagan, RT; Foote, RL; Frytak, S; Jett, JR; Richardson, RL; Shaw, EG; Su, JQ | 1 |
| Bridges, JD; Edison, M; Frame, JN; Gazdar, AF; Glatstein, E; Gray, J; Hankins, L; Holden, D; Ihde, DC; Johnson, BE; Linnoila, RI; Mulshine, JL; Nesbitt, J; Pass, H; Sobczeck, M; Steinberg, SM | 1 |
| Feld, R; Murray, N; Pater, J; Shepherd, FA; Siu, LL; Zee, B | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Stroup, SL | 1 |
| Perry, MC; Rapp, JS; Rotche, RM | 1 |
| Arriagada, R; Le Chevalier, T; Le Péchoux, C | 1 |
| Jones, WB; Lewis, JL; Schneider, J; Shapiro, F | 1 |
| Noguchi, M; Ono, R; Saijo, N; Sasaki, Y; Sekine, I | 1 |
| Ariyoshi, Y; Fujita, J; Fukuoka, M; Furuse, K; Ikegami, H; Katakami, N; Negoro, S; Ota, K; Takada, M | 1 |
| Chang, KT; Chen, JY; Chen, MH; Chen, YM; Perng, RP; Tsai, CM | 1 |
| Pignon, JP; Stewart, LA | 1 |
| Brewer, Y; Chauvet, B; Faure, CF; Reboul, F; Taulelle, M; Vincent, P | 1 |
| Eguchi, K; Fakuda, M; Kasai, T; Kurata, T; Ohe, Y; Oshita, F; Saijo, N; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Hung, MC; Zhang, L | 1 |
| Ezawa, K; Fueki, N; Hoshino, H; Ishihara, S; Makimoto, T; Minato, K; Mori, M; Nakano, H; Naruse, I; Nomoto, T; Saito, R; Takei, Y; Takise, A; Tsuchiya, S; Watanabe, S | 1 |
| Axelsen, RA; Dickinson, IC; Smithers, BM; Theile, DE; Thomson, DB | 1 |
| Fukuoka, M; Hirashima, T; Kubo, A; Masuda, N; Nakagawa, K; Takada, M; Takahara, J; Yoshikawa, A | 1 |
| Campling, BG; Jain, N; Lam, YM; Pym, J | 1 |
| Broxterman, HJ; Dingemans, AM; Flens, MJ; Gazdar, AF; Giaccone, G; Pinedo, HM; Rubio, GJ; Scheper, RJ; van Ark-Otte, J | 1 |
| Byhardt, RW; Curran, WJ; Dundas, GS; Fossella, FV; Komaki, R; Lee, JS; McDonald, S; Scott, C | 1 |
| Acimovic, L; Jeremic, B; Milisavljevic, S; Shibamoto, Y | 3 |
| Jensen, PB; Sehested, M | 1 |
| Bonsignore, G; Capomolla, E; D'Aprile, M; Della Giulia, M; Favalli, C; Garaci, E; Lopez, M; Rasi, G; Santini, S; Vici, P | 1 |
| Curcio, C; D'Aprile, M; Gridelli, C; Ianniello, G; Lorusso, V; Palmeri, S; Palmieri, G; Perrone, F; Rossi, A; Veltri, E | 1 |
| Constantinou, A; Ellis, P; Hall, M; Joel, SP; Nicholls, S; Nicholson, M; O'Byrne, K; O'Donnell, C; Papamichael, D; Penson, R; Slevin, M; Smith, I; Talbot, D; Woodhull, J | 1 |
| Gower, NH; Harper, PG; James, LE; Partridge, M; Rudd, RM; Ruiz de Elvira, MC; Souhami, RL; Spiro, SG; Trask, CW | 1 |
| Aoyagi, K; Kobunai, T; Oh-hara, T; Shibata, J; Sugimoto, Y; Terada, T; Tsuruo, T; Utsugi, T; Wierzba, K; Yamada, Y | 1 |
| Kanazawa, M; Kumegawa, H; Mori, S; Morinaga, K; Tanaka, T | 1 |
| Arai, T; Fujiwara, H; Hayakawa, K; Ito, H; Ito, Y; Nawada, M; Shibayama, M; Shibuya, C; Takaya, T; Toshima, S; Yasuda, Y; Yoshimi, N | 1 |
| Brewer, Y; Chauvin, G; Félix-Faure, C; Reboul, F; Taulelle, M; Vincent, P | 1 |
| Bando, T; Fujimura, M; Kasahara, K; Matsuda, T; Nakatsumi, Y; Shibata, K | 1 |
| Hanada, T; Isobe, H; Kawakami, Y; Ogura, S; Sukoh, N; Yamazaki, K | 1 |
| Copley-Merriman, C; Corral, J; Dorr, FA; King, K; McDonald, RC; Voi, M; Whiteside, R | 1 |
| Shen, H; Xiong, W | 1 |
| Xu, J; Zhang, X; Zhu, H | 1 |
| Gatzemeier, U; Schneider, A; von Pawel, J | 1 |
| Berchier, MC; Bureau, G; Giner, V; Klastersky, J; Kroll, F; Küstner, U; Lecomte, J; Michel, J; Mommen, P; Paesmans, M; Sculier, JP; Sergysels, R; Van Cutsem, O | 1 |
| DeVore, R; Glick, J; Hutson, P; Johnson, D; Kim, K; Schiller, JH; Stewart, J | 1 |
| Andersen, S; Blatter, J; Bosanquet, N; Copley-Merriman, K; Drings, P; Johnson, N; Koch, P; van Schaik, J | 1 |
| Berkowitz, I; Cirrincione, C; Clamon, G; Green, MR; Herndon, JE; Muscato, JJ; Omura, G; Perry, MC; Reid, T | 1 |
| Conrad, CA; Hong, WK; Verschraegen, C | 1 |
| Inoue, H; Miyaji, N; Miyazono, N; Moriyama, T; Mukai, H; Nakajo, M; Oyama, T; Tanohata, S | 1 |
| Shimada, K; Yano, S | 1 |
| Brewer, Y; Chauvet, B; Reboul, F; Taulelle, M; Vincent, P | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Lokich, J; Moore, C | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Gonzalves, L; Lokich, J; Moore, C; Zipoli, T | 1 |
| Komiya, T; Takada, M | 1 |
| Fukabori, T; Mizobuchi, K; Nakamura, M; Yokomura, I | 1 |
| Nakanishi, Y | 1 |
| Ariyoshi, Y; Fukuoka, M; Furuse, K; Kudoh, S; Kurihara, N; Kurita, Y; Ogawa, M; Sawa, T; Takada, M; Takaku, F | 1 |
| Aapro, MS | 1 |
| Girling, DJ | 1 |
| Crowley, JJ; Figlin, RA; Goodwin, JW; Jacobs, EL; Livingston, RB; Muirhead, M; Rinehart, JJ | 1 |
| Arpin, D; Bohas, C; Cordier, JF; Court-Fortune, I; Ecochard, D; Perol, M; Riou, R; Soler, P; Trillet-Lenoir, V | 1 |
| Gautier, V; Michel, FB; Pujol, JL; Zinaï, A | 1 |
| Clamon, G; Crawford, J; Graziano, SL; Green, MR; Herndon, JE; Rege, VB; Richards, F; Valone, FH | 1 |
| Baughman, TM; Bumol, TF; Cao, J; Dantzig, AH; Ehlhardt, WJ; Law, KL; Shepard, RL; Starling, JJ | 1 |
| Gazdar, AF; Ghosh, BC; Ihde, DC; Johnson, BE; Linnoila, RI; Minna, JD; Mulshine, JL; Oie, HK; Pass, HI; Phelps, R; Russell, EK; Shaw, GL; Steinberg, SM | 1 |
| Hyouchi, N; Kamata, S; Kano, H; Machida, T; Saito, H; Takeuchi, S; Tanizawa, A; Yamada, T | 1 |
| Hayasaka, S; Kinuwaki, E; Komatsu, H; Nakabayashi, T; Nakai, Y; Niitani, H; Nishikawa, H; Ohizumi, K; Saito, R; Shimizu, T | 1 |
| Chen, S; Lee, BC; Miller, AA; Molthrop, DC; Robert, F; Wheeler, RH | 1 |
| Bolzicco, G; Crinó, L; De Marinis, F; Emiliani, E; Figoli, F; Gentile, A; Marangolo, M; Maranzano, E; Masiero, P; Meacci, L; Morandi, MG; Ricardi, U; Rosti, G; Scagliotti, GV; Tonato, M | 1 |
| Grunberg, SM; Unger, P; Valentine, J; Zackon, I | 1 |
| Comella, G; Comella, P; Frasci, G; Menzella, G; Perillo, G; Persico, G; Polverino, M | 1 |
| Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Osby, E; Peterson, C; Sirzea, F; Söderhäll, S; Zhou, R | 1 |
| Aras, AB; Arican, AH; Esassolak, MA; Haydaroğlu, A; Ozkök, S; Yalman, D | 1 |
| Ang, PT; Tan, EH | 1 |
| Fountzilas, G; Karabelis, A; Kattis, K; Kosmidis, P; Mylonakis, N; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Belan, V; Cársky, S; Hornák, M; Kausitz, J; Matośka, J; Ondrus, D; Schnorrer, M | 1 |
| Jasti, R; Kalemkerian, GP; Kaufmann, SH; Mabry, M | 1 |
| Fujimura, T; Fushida, S; Hirono, Y; Kawamura, T; Kinami, S; Minami, M; Miwa, K; Miyazaki, I; Nishimura, G; Noguchi, M; Nojima, N; Sato, T; Shiobara, S; Yonemura, Y | 1 |
| Fujii, M; Iwai, S; Kochi, M; Otsuka, Y; Tsuneda, Y; Wakabayashi, K; Yamagata, M | 1 |
| Ardizzoni, A; Danova, M; Giorgi, G; Mariani, GL; Mereu, C; Pennucci, MC; Rosso, R; Scolaro, T; Venturini, M; Viscoli, C | 1 |
| Clynes, M; Coyle, S; Daly, C; Daly, N; McBride, S; O'Driscoll, L; Scanlon, K | 1 |
| Clynes, M; Dolan, E; Heenan, M; Kavanagh, K; Maher, M; Moriarty, M; O'Neill, P; Redmond, A | 1 |
| Gallant, G; Tsao, MS; Viallet, J | 1 |
| Biondi, E; Cioffi, R; Comella, G; Comella, P; Curcio, C; De Cataldis, G; Frasci, G; Ianniello, GP; Micillo, E; Nicolella, D; Panza, N; Perchard, J | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Charitopoulos, K; Dimitriadis, K; Economides, D; Maglaveras, N; Papagiannis, A; Vamvalis, C; Zarogoulidis, K; Ziogas, E | 1 |
| Cirrincione, CT; Clamon, G; Green, MR; Herndon, JE; Luikart, SD; Maurer, LH; Mitchell, EP; Perry, MC; Van Echo, DA | 1 |
| Irisawa, C; Kayada, K; Muraki, O; Yamaguchi, O | 1 |
| Ang, PT; Soh, LT | 1 |
| Andoh, T; Ariyoshi, Y; Hida, T; Nishizawa, M; Takahashi, T; Ueda, R | 1 |
| Atagi, S; Fukuoka, M; Furuse, K; Kawahara, M; Kodama, N; Kubota, K; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Ogawara, M; Takada, M | 1 |
| Bosquée, L; Cetto, GL; Hamdan, O; Humblet, Y; Lange, A; Leyvraz, S; Marangolo, M; Pampallona, S; Pasini, F; Perey, L; Rosti, G | 1 |
| Brandt, A; Palmer, AJ | 1 |
| Burghouts, JT; Curran, D; Giaccone, G; Gozzelino, F; Groen, HJ; Kirkpatrick, A; Postmus, PE; Sahmoud, T; Scagliotti, G; Splinter, TA | 1 |
| Bentley, P; Thomas, A; Thomas, J | 1 |
| Airoma, G; Bianco, AR; Cognetti, F; D'Aprile, M; De Placido, S; Gallo, C; Gebbia, V; Gridelli, C; Incoronato, P; Leonardi, V; Natali, M; Palazzolo, G; Palmeri, S; Pepe, R; Perrone, F; Rossi, A; Russo, A; Scinto, AF; Veltri, E | 1 |
| Basu, A; Saijo, N; Weixel, K | 1 |
| Bianco, AR; Curcio, C; D'Aprile, M; Gebbia, V; Gridelli, C; Palmeri, S; Pepe, R; Pistillucci, G; Rossi, A; Veltri, E | 1 |
| Arwidi, A; Brink, J; Brodin, O; Lindén, CJ; Lundström, R; Mercke, C; Nou, E; Ringborg, U | 1 |
| Fuyuno, G; Kondo, T; Kumagai, M; Kutsuzawa, T; Ohta, Y; Shioya, S | 1 |
| Belli, M; Bianco, A; Cioffi, R; Comella, G; Comella, P; Curcio, C; De Cataldis, G; Della Vittoria, M; Frasci, G; Ianniello, G; Maiorino, L; Panza, N; Perchard, J | 1 |
| Ashihara, E; Fujita, N; Goto, H; Hatta, T; Hirai, H; Inaba, T; Kikuta, T; Nakagawa, M; Shimazaki, C; Sudo, Y; Sumikuma, T; Yamagata, N | 1 |
| Asai, Y; Matsushita, K; Naitoh, T; Suetsugu, S | 1 |
| Belón, J; Blanco, E; Espinosa, E; Feliu, J; Garcia Alfonso, P; Garcia Girón, C; Garrido, P; González Barón, M; Jara, C; Ruiz, A; Vincent, JM; Zamora, P | 1 |
| Ueoka, H | 1 |
| Nakakawaji, K; Sakamoto, J; Uchida, T | 1 |
| Anderson, E; Anderson, T; Cameron, DA; Chetty, U; Craig, J; Dixon, M; Gabra, H; Hawkins, A; Jack, W; Kunkler, I; Lee, L; Leonard, R; Leonard, RC; MacKay, J; Matheson, L; Miller, W; Parker, AC | 1 |
| Berthiot, G; Coninx, P; Desoize, B; Dumont, P; Manot, L | 1 |
| Boerrigter, L; Mooi, WJ; Rodenhuis, S; Slebos, RJ; Top, B; van Zandwijk, N; van't Veer, L | 1 |
| Ebi, N; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Matsumoto, T; Nishiwaki, Y; Ohmatsu, H; Sekine, I; Yokozaki, M | 1 |
| Abe, S; Fujita, A; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Noda, K; Oshita, F; Saijo, N; Suzuki, S; Takahashi, S; Tamura, T; Tobise, K; Tsuchiya, S | 1 |
| Betsuyaku, T; Hanada, T; Hasegawa, A; Hizawa, N; Isobe, H; Kawakami, Y; Ogura, S; Yamazaki, K | 1 |
| Schacter, L | 1 |
| Abrahamsen, D; Boddy, A; Brampton, M; Calvert, AH; Lind, M; Newell, D; Porter, D; Robson, L; Thomas, H; Winograd, B | 1 |
| Dezii, CM; Doyle, JJ; Sadana, A | 1 |
| Buckwalter, CA; Perez, EA; Reid, JP | 1 |
| Bunn, PA; Kelly, K | 2 |
| Fukuoka, M; Furuse, K; Kawahara, M; Kodama, N; Kubota, K; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Ogawara, M; Takada, M; Yana, T | 1 |
| Bury, T; Radermecker, MF; Skaventzos, I; Weber, T | 1 |
| Calabro, F; Chiarion-Sileni, V; Cipriani, A; Favaretto, A; Fiorentino, MV; Ghiotto, C; Loreggian, L; Oniga, F; Paccagnella, A; Rea, F; Reffosco, L; Sartori, F; Tomio, L; Zuin, R | 1 |
| Clamon, GH; Crawford, J; Green, MR; Herndon, JE; Hollis, DR; Luikart, SD; MacDonald, M; Maurer, LH; Ozer, H; Perry, MC; Wright, J | 1 |
| Ezawa, K; Fueki, N; Ishihara, S; Makimoto, T; Minato, K; Mori, M; Nakano, H; Naruse, I; Nomoto, T; Saitoh, R; Takei, Y; Takise, A; Tsuchiya, S; Watanabe, S | 1 |
| Hastürk, S; Kocabaş, A; Kurt, B; Nadirler, F; Orüc, O | 1 |
| Aigner, K; Hausmaninger, H; Huber, H; Kummer, F; Oberaigner, W; Oroszy, S; Peschel, C; Prior, C; Schenk, E | 1 |
| Blanke, C; DeVore, R; Epstein, B; Hande, K; Johnson, D; Murray, M; Shyr, Y; Stewart, S | 1 |
| Osann, K; Slater, LM; Stupecky, M; Sweet, P | 1 |
| El-Deiry, WS; Somasundaram, K | 1 |
| Kobayashi, M; Mizushima, Y; Sassa, K; Shinoda, K; Yoshida, Y | 1 |
| Clemm, C; Gerl, A; Hentrich, M; Lamerz, R; Schmeller, N; Wilmanns, W | 1 |
| Brugger, W; Engelhardt, R; Fetscher, S; Frommhold, H; Hasse, J; Kanz, L; Lange, W; Mertelsmann, R; Wenger, M | 2 |
| Bialy-Golan, A; Brenner, S; Gat, A; Golan, H | 1 |
| Hatakeyama, S; Morita, M; Okano, H; Suzuki, K; Tachibana, A | 1 |
| Edwards, CL; Kavanagh, JJ; Kudelka, AP; Piamsomboon, S; Termrungruanglert, W; Tornos, C | 1 |
| Burgut, R; Hastürk, S; Kocabas, A; Kurt, B; Orüç, O | 1 |
| Fujimori, K; Kurita, Y; Terashima, M; Yokoyama, A | 1 |
| Gower, NH; Harper, PG; James, LE; Lamont, A; Rudd, RM; Ruiz de Elvira, MC; Souhami, RL; Spiro, SG | 1 |
| Benhammouda, A; Borel, C; Coeffic, D; Derenne, JP; Khayat, D; Maitre, B; Orcel, B; Petit, T; Rixe, O | 1 |
| Fukuda, M; Fukuoka, K; Kanzawa, F; Kunimoto, T; Nishio, K; Saijo, N | 1 |
| Bonomi, P; Johnson, D; Kim, K; Kusler, J | 1 |
| Katschinski, DM; Mentzel, M; Mulkerin, DL; Robins, HI; Touhidi, R; Wiedemann, GJ | 1 |
| Chen, YM; Chou, CM; Lin, WC; Liu, JM; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, MF; Yang, KY | 1 |
| Falkowski, S; Romejko-Jarosińska, J; Siedlecki, P; Walewski, J; Zwoliński, J | 1 |
| Cole, SP; Mirski, SE; Sparks, KE; Yu, Q | 1 |
| Bates, SE; Dickstein, B; Fojo, AT; Gamelin, E; Regis, J; Sandor, VA; Wilson, W; Zhan, Z | 1 |
| Zukowska, H; Zwoliński, J | 1 |
| Fujimura, S; Kobayashi, S; Okada, S; Yoshida, H | 1 |
| Bardonnet-Comte, M; Berthaud, P; Chomy, F; Chomy, P; Douillard, JY; Gautier, V; Lagrange, JL; Le Chevalier, T; Milleron, B; Polin, V; Pujol, JL; Quoix, E; Rivière, A; Spaeth, D | 1 |
| Chen, YM; Lin, WC; Ming-Liu, J; Perng, RP; Tsai, CM; Whang-Peng, J; Yang, KY | 1 |
| Arita, K; Daido, K; Ishii, N; Kohjima, N; Sakamoto, N; Sugihara, M | 1 |
| Dardoufas, K; Dosios, T; Kosmas, C; Polyzos, A; Tsavaris, N; Veslemes, M | 1 |
| Forman, SJ; Margolin, KA; Wright, C | 1 |
| Blatter, J; Depenbrock, H; Gatzemeier, U; Hanauske, AR; Rassmann, I; Rastetter, J; Thödtmann, R | 1 |
| Daido, H; Hara, A; Ishizuka, T; Sarui, H; Shibata, T; So, T; Takuno, Y; Yamada, K; Yasuda, K; Yoshimura, M; Yoshino, K | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, P; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, P; ten Bokkel Huinink, W; van Walree, N; von Pawel, J; Wagenius, G | 1 |
| Li, JH | 1 |
| Barişta, I; Başçil, N; Celik, I; Güllü, IH; Kars, A; Tekuzman, G; Yalçin, S | 1 |
| Byhardt, RW; Curran, W; Ettinger, D; Evans, RF; Fossella, FV; Komaki, R; Lee, JS; Rubin, P; Scott, C | 1 |
| Gandara, DR; Lau, DH; Rosenthal, SA; Ryu, JK | 1 |
| Bardet, E; Charloux, A; Douillard, JY; Ducoloné, A; Henry-Amar, M; Le Groumellec, A; Pellae-Cosset, B; Rivière, A; Spaeth, D | 1 |
| de Boer-Dennert, M; Goey, H; Kho, S; Planting, A; Schellens, J; Stoter, G; van den Bent, M; van der Burg, M; van der Gaast, A; Verweij, J | 1 |
| Boyer, MJ; McKeage, MJ; Millward, MJ; Olver, IN; Richardson, G; Zalcberg, J | 1 |
| Hayashi, M; Ishimori, S; Kimura, K; Tabata, M; Tamada, T; Tsuburaya, T | 1 |
| Heilmann, HP | 1 |
| Fukuoka, M; Furuse, K; Ikegami, H; Kawahara, M; Nishiwaki, Y; Saijo, N; Shimoyama, M; Suemasu, K; Tamura, T | 1 |
| Burghouts, J; Dalesio, O; Drings, P; Giaccone, G; Gregor, A; Kirkpatrick, A; Morgan, D; Postmus, PE; Sahmoud, T | 1 |
| Donnelly, E; Feun, LG; Lai, S; Lampidis, T; Savaraj, N; Solomon, J; Wu, CJ; Xu, R | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, P; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, RA; ten Bokkel-Huinink, W; van Pawel, J; van Walree, N; Wagenius, G | 1 |
| Araki, T; Hara, R; Hatano, K; Imai, Y; Ogata, H; Ohnishi, H; Okada, J; Takizawa, Y; Yamaguchi, M | 1 |
| Imamura, H; Minami, K; Okamura, A; Omiya, H; Saitoh, Y; Tokunou, M; Umemoto, M; Yonezu, S | 1 |
| Bible, KC; Kaufmann, SH | 1 |
| Fukuoka, M; Furuse, K; Masuda, N; Negoro, S; Saijo, N | 1 |
| Brewer, Y; Reboul, F; Taulelle, M; Vincent, P | 1 |
| Bozóky, G; Góhér, I; Lengyel, M; Mohos, A; Ruby, E | 1 |
| Bentzen, SM; Fode, K; Nielsen, OS; Palshof, T; Work, E | 1 |
| Junker, K; Rübe, C; Semik, M; Thomas, M; von Eiff, M | 1 |
| Kimura, H; Momiki, S; Obata, S; Ogawa, T; Urabe, N; Yamaguchi, Y | 1 |
| Hayashi, Y; Kimoto, H; Matsumoto, Y; Nagai, A; Tsujiguchi, H | 1 |
| Bojanowski, K; Fukuda, M; Fukumoto, H; Fukuoka, K; Ishida, T; Kanzawa, F; Kurokawa, H; Nishio, K; Nomoto, Y; Saijo, N | 1 |
| Evans, TR; Gogas, H; Lofts, FJ; Mansi, JL; Millard, FJ; Wilson, R | 1 |
| Harstrick, A; Kasimir-Bauer, S; Stahl, M | 1 |
| Acimovic, L; Jeremic, B; Milicic, B; Milisavljevic, S; Nikolic, N; Shibamoto, Y | 1 |
| Cho, J; Downey-Hurtado, N; Osann, K; Ramsinghani, N; Ross, HJ; Slater, LM; Williams, J; Wong, SF | 1 |
| Murray, N | 3 |
| Glickman, B; Karnaoukhova, L; Martins, H; Moffat, J | 1 |
| Benito, D; Camps, C; Felip, E; González-Larriba, JL; López-Cabrerizo, MP; Massuti, B; Puerto-Pica, J; Rosell, R; Salamanca, O | 1 |
| Carey, RW; Elias, AD; Grossbard, ML; Herbst, R; Jacobs, C; Kwiatkowski, DJ; Leong, T; Lynch, C; Lynch, TJ; Skarin, AT; Strauss, GM | 1 |
| Gandara, DR; Lau, DH; Ryu, JK | 1 |
| Bonomi, P; Faber, LP; LaFollette, S; Lincoln, S; Recine, D; Sharma, M; Warren, W | 1 |
| Clamon, GH; Crawford, J; Green, MR; Miller, AA; Neill, HB; Perry, MC | 1 |
| Birch, R; Bobo, C; Greco, FA; Hainsworth, JD; Weaver, CH | 1 |
| Gatzemeier, U; Jagos, U; Kaukel, E; Koschel, G; von Pawel, J | 1 |
| Anderson, IC | 1 |
| Radzikowska, E; Rowińska-Zakrzewska, E; Sakowicz, A; Załeska, J; Zych, J | 1 |
| Broniek, A; Byszewska, D; Jereczek, B; Obłakowski, P; Roszkowski, K; Starzyńska, T; Zych, J | 1 |
| Andras, EJ; Asbell, SO; Byhardt, RW; Cox, JD; Emami, B; Komaki, R; Lee, JS; Rotman, M; Scott, C; Urtasun, RC | 1 |
| Camoriano, JK; Fitch, TR; Frytak, S; Rajkumar, SV; Rubin, J | 1 |
| Chen, YM; Liu, JM; Perng, RP; Whang-Peng, J; Wu, MF; Yang, SL | 1 |
| Aisner, J; Carey, RW; Eaton, WL; Green, MR; Hammond, S; Herndon, JE; Hollis, DR; Maurer, LH; Perry, MC; Skarin, AT; Zacharski, LL | 1 |
| Yokoyama, A | 3 |
| Naruse, I; Saijo, N | 1 |
| Cole, SP; Falck, J; Jensen, PB; Mirski, SE; Sehested, M; Wessel, I | 1 |
| Ardizzoia, A; Barni, S; Chilelli, M; Conti, A; Lissoni, P; Maestroni, GJ; Mancuso, M; Paolorossi, F; Tancini, G | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Hopkins, LG; Kalman, LA; Patten, JE; Stroup, SL; Thomas, M | 1 |
| Chang, WC; Chen, LH; Lee, CH; Leung, WM; Liaw, CC; Yang, CT | 1 |
| Ando, M; Eguchi, K; Hojo, N; Kakinuma, R; Kasai, T; Kodama, T; Kubota, K; Kurata, T; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Cellerino, R; Cetto, G; Graziano, F; Isidori, P; Mari, D; Pasini, F; Santo, A; Tummarello, D | 1 |
| de Crevoisier, R; le Cesne, A; le Chevalier, T | 1 |
| Bentzen, S; Hansen, O; Madsen, EL; Moeholt, K; Palshof, T; Pfeiffer, P; Rose, C; Rytter, C | 1 |
| Aoyagi, K; Aoyagi, Y; Asao, T; Okazaki, S; Sano, M; Utsugi, T; Wierzba, K; Yamada, Y | 1 |
| Amano, A; Hojo, F; Nabuchi, A; Suma, H | 1 |
| Armstrong, S; Crawford, J; Dziem, G; Garewal, H; Jones, SE; Kreisman, H; Pupa, MR; Shoemaker, D; Tomita, D | 1 |
| Bom, HS; Kim, JY; Kim, YC; Min, JJ; Park, KO; Song, HC | 1 |
| Blum, RH; Bonomi, P; Boucher, H; Chang, AY; Karp, DD; Kim, K; Stewart, JA | 1 |
| Fossella, F; Glisson, B; Hong, WK; Lee, JS; Murphy, WK; Palmer, J; Perez-Soler, R; Shin, DM | 1 |
| Caron, F; Meurice, JC; Patte, F; Perault, MC; Valy, Y | 1 |
| Drescher, CW; Swisher, E | 1 |
| Fossella, F; Glisson, B; Komaki, R; Kurie, J; Lee, JS; Murphy, WK; Perez-Soler, R; Schea, R; Shin, DM; Vadhan-Raj, S | 1 |
| Belch, A; Hanson, J; Hewitt, J; Kinney, B; Palmer, M; Urtasun, RC | 1 |
| Acimovic, L; Jeremic, B; Milicic, B; Milisavljevic, S; Shibamoto, Y | 1 |
| Kasai, H; Maekawa, R; Sugita, K; Takeda, Y; Uchida, N; Yoshioka, T | 1 |
| Fink, FM; Heitger, A; Maurer, K; Niederweiser, D; Schwaighofer, H | 1 |
| Budach, V; Eberhardt, W; Flasshove, M; Greschuchna, D; Harstrick, A; Konietzko, N; Krause, B; Menker, H; Müeller, MR; Sack, H; Seeber, S; Stahl, M; Stamatis, G; Stuschke, M; Wilke, H | 1 |
| Clancy, L; de Wit, R; Fennelly, J; Frisch, J; Gatzemeier, U; Koschel, G; Pfeifer, W; Steward, WP; Thatcher, N; Verweij, J; von Eiff, M; von Pawel, J; Woll, P | 1 |
| Chewaskulyong, B; Thongprasert, S | 1 |
| Bruera, E; Hewitt, J; Palmer, M; Rapp, E; Thaell, JF; Urtasun, R; Wood, L | 1 |
| Minami, H; Saka, H; Sakai, S; Shimokata, K; Yamamoto, M | 1 |
| Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M | 1 |
| Berg, M; Leutz, M; Schlimmer, P; Sybrecht, GW; Ukena, D; Zell, L | 1 |
| Ahuja, RK; Bonner, JA; Creagan, ET; Johnson, PA; Mailliard, JA; Marschke, RF; McGinnis, WL; Shaw, EG; Sloan, JA; Stella, PJ | 1 |
| Greco, FA; Hainsworth, JD; Hopkins, LG; Thomas, M | 1 |
| Morii, K; Yoshida, S | 1 |
| Bacci, G; Bertoni, F; Briccoli, A; Campanacci, M; Cesari, M; Fabbri, N; Ferrari, S; Forni, C; Gasbarrini, A; Mercuri, M | 1 |
| Eisenhauer, E; Shepherd, FA | 1 |
| Sandler, AB | 1 |
| Engstrom, C; Green, M; Lilenbaum, RC; MacManus, D | 1 |
| Cowie, FJ; Pinkerton, CR; Pritchard-Jones, K; Renshaw, J | 1 |
| Craig, JB; Crowley, JJ; Giroux, DJ; Goodwin, JW; Laufman, LR; Livingston, RB; Stelzer, KJ; Taylor, SA; Thomas, CR | 1 |
| Buckwalter, CA; Perez, EA | 1 |
| Hara, N; Hirose, N; Inutsuka, S; Kanegae, H; Kawarada, Y; Kurita, Y; Miyazaki, M; Miyazaki, N; Nakanishi, Y; Ninomiya, K; Ogata, K; Ohgushi, O; Yamazaki, H | 1 |
| Fossella, FV; Glisson, BS; Khuri, FR; Lee, JS; Markowitz, AB; Murphy, WK; Shin, DM | 1 |
| Chrysanthopoulos, K; Dougenis, D; Ginopoulos, P; Gogos, CH; Kardamakis, D; Onyenadum, A; Solomou, E; Spyropoulos, K | 1 |
| Furudate, M; Hanada, T; Ishida, T; Isobe, H; Itoh, K; Kawakami, Y; Ogura, S; Saito, K; Takekawa, H; Tokuchi, Y | 1 |
| Joensuu, H; Mattson, K; Ruotsalainen, T; Salven, P | 1 |
| Amy, R; Gelmon, K; Goddard, K; Grafton, C; McKenzie, M; Morris, J; Murphy, K; Murray, N; Page, R; Parsons, C; Shah, A; Sheehan, F; Tsang, V; Westeel, V; Wong, F | 1 |
| Ahles, TA; Aisner, J; Eaton, WL; Green, MR; Herndon, J; Holland, JC; Kornblith, AB; Maurer, LH; Perry, MC; Silberfarb, PM; Zacharski, LL | 1 |
| De Leyn, PR; Demedts, MG; Deneffe, GJ; Lerut, TE; Lievens, YN; Nackaerts, KL; van der Schueren, E; Van Raemdonck, DE; Vansteenkiste, JF | 1 |
| Dardoufas, C; Dimitroulis, J; Jordanoglou, J; Katsilambros, N; Latsi, P; Polyzos, A; Rasidakis, A; Stamatiadis, D; Veslemes, M | 1 |
| Davey, MW; Davey, RA; Su, GM | 1 |
| Dermitzakis, G; Fahantidou, E; Gioulekas, D; Papagiannis, A; Vamvalis, C; Zarogoulidis, K; Ziogas, E | 1 |
| Dizdarević, Z; Lovre, V; Mehić, B; Pećanac, M; Zutić, H | 1 |
| Ariyoshi, Y; Fukuoka, M; Furuse, K; Kurita, Y; Nishiwaki, Y; Noda, K; Saijo, N; Tamura, T; Watanabe, K | 1 |
| Dubois, I; Hirsch, A; Lubin, R; Milleron, B; Schlichtholz, B; Soussi, T; Trédaniel, J; Urban, T; Zalcman, G | 1 |
| Ansari, R; Blanke, C; Carey, MA; Einhorn, L; Fisher, B; Monaco, F; Nichols, C; Sandler, A; Spiridonidis, CH | 1 |
| Rowinsky, EK; Siu, LL | 1 |
| Arita, K; Daido, K; Isii, N; Sakamoto, N; Sakao, N; Sugihara, M | 1 |
| Hirota, S; Hishikawa, Y; Honda, K; Kono, K; Obayasi, K; Soejima, T; Takada, Y; Watanabe, H | 1 |
| Obłakowski, P; Radzikowska, E; Rowińska-Zakrzewska, E; Słodkowska, J; Załeska, J; Zych, J | 1 |
| Folga, A; Fryze, W; Jassem, E; Mincewicz, H; Olszewska, A; Słomiński, JM | 1 |
| Atagi, S; Fukuoka, M; Furuse, K; Hirashima, T; Kawahara, M; Kobayashi, M; Komiya, T; Kudoh, S; Masuda, N; Matsui, K; Negoro, S; Ogawara, M; Yana, T | 1 |
| Gemba, K; Harada, M; Hiraki, S; Hiraki, Y; Kamei, H; Kiura, K; Sakae, K; Segawa, Y; Tabata, M; Ueoka, H | 1 |
| Grenìer, J; Pujol, JL; Quantin, X; Ray, P | 1 |
| Miller, AA; Niell, HB; Tolley, EA | 1 |
| Bobichon, H; Delvincourt, C; Faroux, MJ; Gorisse, MC; Jardillier, JC; Poitevin, G; Trussardi, A | 1 |
| Biesma, B; Cox, A; Festen, J; Postmus, PE; Splinter, TA; Tjan-Heijnen, VC; Wagener, DJ | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Gotthardt, S; Lokich, J; Oliynyk, P | 1 |
| Crawford, J; Graziano, SL; Herndon, JE; Mehdi, SA; Perry, MC; Young, R | 1 |
| Manegold, C | 1 |
| Albain, KS; Crowley, JJ; Fletcher, WS; Gandara, DR; Hazuka, MB; Keiser, WL; Lanier, KS; Lau, DH; Leigh, B; Livingston, RB | 1 |
| Dorighi, JA; Ettinger, DS; Jiroutek, M; Johnson, DH; Kalemkerian, GP; Mabry, M | 1 |
| Arvelo, F; Bastian, G; Bichat, F; Canitrot, Y; Cole, SP; Deeley, RG; Gerlach, JH; Poupon, MF | 1 |
| Choh, S; Fukuoka, K; Hamada, K; Mikasa, K; Narita, N; Tomoda, K; Tsujimoto, M; Tsukaguchi, K; Yoneda, T | 1 |
| Hiraki, S; Ueoka, H | 1 |
| Goya, T; Koshiishi, Y; Miya, T; Nogami, H; Sasaki, Y; Yanagida, O | 1 |
| Ishigaki, T; Kodaira, T; Matsubara, K; Taniguchi, H; Yamakawa, K | 1 |
| Brown, E; Coldman, A; Coppin, C; Gelmon, K; Grafton, C; Kostashuk, E; Murray, N; Page, R; Shah, A | 1 |
| Fukuoka, M; Hirashima, T; Kawase, I; Kobayashi, M; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Sawaguchi, H; Tada, T; Takeda, K; Takifuji, N; Ushijima, S; Yana, T | 1 |
| Giaccone, G; Gregor, A; Scagliotti, GV | 1 |
| Agelaki, S; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kalbakis, K; Koukourakis, M; Samonis, G; Souglakos, I; Toloudis, P; Vlachonicolis, I | 1 |
| Luedke, GH; Schenker, T; Stahel, RA; Zangemeister-Wittke, U | 1 |
| Akaza, H; Hinotsu, S; Kawai, K; Tomobe, M | 1 |
| Arguiñano, JM; Gorosquieta, AM; Pérez Equiza, E | 1 |
| Clavier, J; Daniel, C; Gouva, S; Guillodo, MP; Guillou, B; Robinet, G | 1 |
| Cox, JD; Fossella, FV; Glisson, BS; Hong, WK; Komaki, R; Lee, JS | 1 |
| Huang, ZM; Long, H | 1 |
| Benjamin, RS; Gano, J; Gianan, MA; Jaffe, N; Jia, SF; Kleinerman, ES; Papadopoulos, NE; Patel, S; Raymond, AK; Rodriguez, C; Worth, LL | 1 |
| Green, MR; Hollis, DR; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL | 1 |
| Abe, S; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Saijo, N; Suzuki, S; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| D'Incalci, M; De Fusco, M; de Jong, J; Gentili, D; Martinelli, G; Pagani, O; Sessa, C; Tinazzi, A; Torri, V; Zucchetti, M | 1 |
| Bernard, S; Carey, RW; Choi, NC; Chung, CT; Green, M; Herndon, JE; Leone, L; Rosenman, J; Seagren, S | 1 |
| Kamath, SS; McCarley, DL; Zlotecki, RA | 1 |
| Brown, JM; Hosker, HS; Muers, MF; Peake, MD; Poulter, KM; Shevlin, PM; Stead, ML | 2 |
| Baselga, J; Benito, D; Camps, C; Felip, E; González-Larriba, JL; Isla, D; López-Cabrerizo, MP; Massuti, B; Moyano, A; Puerto-Pica, J; Rosell, R; Salamanca, O | 1 |
| Breton, C; Meyn, RE; Story, MD | 1 |
| Callegaro, D; Fantoni, U; Favaretto, A; Festi, G; Loy, M; Paccagnella, A; Rea, F; Sartori, F | 1 |
| Bergman, B; Helsing, M; Hero, U; Thaning, L | 1 |
| Bergman, B; Mercke, C; Nyman, J | 1 |
| Higgins, A; Joel, S; O'Byrne, K; Papamichael, D; Penson, R; Robertshaw, H; Rudd, R; Slevin, M; Talbot, D | 1 |
| Ali, MA; Du, W; Herskovic, AM; Kalemkerian, GP; Kraut, MJ; Valdivieso, M | 1 |
| Cuomo, AM; Pavesi, L; Poggi, G; Preti, P; Robustelli della Cuna, FS; Zambelli, A | 1 |
| Asamoto, H; Furuse, K; Iwami, F; Kawahara, M; Kuba, M; Saijo, N; Shimoyama, M; Tamura, T | 1 |
| Christmas, TI; Lee, YC; McCrystal, MR | 1 |
| Cioffi, R; Comella, G; Comella, P; De Cataldis, G; Del Gaizo, F; Della Vittoria, M; Frasci, G; Gravina, A; Marcatili, P; Monfardini, S; Panza, N; Pozzo, C; Ruffolo, P | 1 |
| DeVore, RF; Higa, GM; Sarkar, MA | 1 |
| Aisner, S; Blum, R; Johnson, DH; Kim, K; Komaki, R; Livingston, RB; Sause, WT; Turrisi, AT; Wagner, H | 1 |
| Horie, T; Masutani, M; Sawada, U; Tsujino, I; Yamazaki, T | 1 |
| Kalemkerian, GP; Ou, X | 1 |
| Cupissol, D; Khial, F; Lafontaine, T; Michel, FB; Pujol, JL; Quantin, X; Reme-Saumon, M | 1 |
| Blandino, G; Levine, AJ; Oren, M | 1 |
| Armand, JP; Couteau, C | 1 |
| Guechev, A; Loves, WJ; Peters, GJ; Pinedo, HM; Postmus, PE; Smid, K; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Idezuki, Y; Ishizuka, N; Kobayashi, M; Murata, N; Suwata, J; Takada, S | 1 |
| Asano, K; Futagami, F; Kawahara, E; Matsumura, A; Ohhori, I; Sasaki, M | 1 |
| Bom, HS; Jeong, HJ; Kim, JY; Kim, YC; Lee, J; Lim, SC; Min, JJ; Park, KO; Song, HC | 1 |
| Coy, P; Feld, R; Murray, N; Pater, J; Payne, DG; Quon, H; Sadura, A; Shepherd, FA; Zee, B | 1 |
| Fukui, I; Hiratsuka, H; Izutani, T; Kin, T; Maeda, Y; Nakagawa, K; Okumura, S; Oyama, H; Shishido, T; Yonese, J | 1 |
| Bando, K; Fukuda, H; Horikawa, T; Inui, H; Katakami, N; Nishiuchi, S; Nishiyama, H; Okazaki, M | 1 |
| Fountzilas, G; Kalofonos, C; Klouvas, G; Panoussaki, E; Pavlidis, N; Pectasides, D; Poulakis, N; Samantas, E; Skarlos, DV; Tsiakopoulos, E | 1 |
| Chen, LM; Elahi, R; Evans, R; Ignacio, L; Jacobs, R; Kozloff, M; Telfer, M; Vijayakumar, S | 1 |
| Ambrosch, G; Huber, H; Mohn-Staudner, A; Oberaigner, W; Oroszy, S; Pfeifer, W; Pirker, R; Prior, C | 1 |
| Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H | 1 |
| Cormier, Y; Earle, CC; Evans, WK; Gertler, SZ; Mihalcioiu, C; Stewart, DJ; Walde, PD | 1 |
| Matsushima, K; Mukaida, N; Nishioka, Y; Nokihara, H; Sone, S; Tsuruo, T; Yano, S | 1 |
| Jobe, DR; Kuhn, J; Rizzo, J; Schreeder, MT; Walton, GD | 1 |
| Chikazawa, H; Fujimoto, S | 1 |
| Anton, A; Barneto, I; Font, A; Garcia-Giron, C; Moyano, AJ; Puerto, JM; Rosell, R; Salvador, A; Sanchez, JJ; Tres, A | 1 |
| Leyvraz, S; Perey, L; Rollier, P; Wasserfallen, JB | 1 |
| Hara, N; Harada, T; Inoue, K; Minami, T; Nakanishi, Y; Osaki, S; Takano, K; Takayama, K | 1 |
| Aragane, K; Kitada, O; Matsuyama, T; Meguro, T; Nakahama, H; Nakamura, H; Nishioka, Y; Sugita, M; Takamitsu, Y; Takenaka, Y; Tanimukai, T; Yano, T | 1 |
| Coleman, RE; Gillespie, AM; Hancock, BW; Siddiqui, N | 1 |
| Fukuoka, K; Kanzawa, F; Nishio, K; Saijo, N; Sunami, T | 1 |
| Johnson, DH; Pashko, S | 1 |
| Boher, JM; Daurès, JP; Grenier, J; Pujol, JL | 1 |
| Boni, C; Carlini, P; Cocconi, G; Di Costanzo, F; Di Sarra, S; Fosser, V; Franciosi, V; Michiara, M; Tonato, M | 1 |
| Fujita, M; Higashino, K; Tsuchida, T | 1 |
| Hillgenberg, M; Klein-Bauernschmitt, P; Schlehofer, JR; von Knebel Doeberitz, M | 1 |
| Hennequin, C; Maylin, C | 1 |
| Fountzilas, G; Kalofonos, H; Kosmidis, P; Mylonakis, N; Nicolaides, P; Pavlidis, N; Pectasides, D; Samantas, E; Skarlos, DV; Vardoulakis, Th | 1 |
| Bando, E; Fujimura, T; Fujita, H; Fushida, S; Michiwa, Y; Miwa, K; Nishimura, G; Oyama, K; Taniguchi, K; Yonemura, Y | 1 |
| Astoul, P; Boutin, C; Gouvernet, J; Irisson, M; Juin, P; Pignon, T; Ruggieri, S | 1 |
| Dressler, V; Müller, G; Sühnel, J | 1 |
| Drag-Zalesińska, M; Gebarowska, E; Wysocka, T; Zabel, M | 1 |
| Gebarowska, E; Kołodziej, J; Majewski, A; Zabel, M | 1 |
| Cavalli, F; Conti, A; de Jong, J; Ghielmini, M; Maestroni, G; Pagani, O; Pampallona, S; Sessa, C | 1 |
| Hirano, K; Honma, T; Mino, K; Nakabayashi, T; Saitoh, H; Takada, M; Takeda, T; Wada, I; Yokouchi, M | 1 |
| Constantopoulos, S; Elisaf, M; Konstantinidis, A; Panteli, K | 1 |
| Fujiwara, Y; Isobe, T; Katoh, O; Kurata, T; Miyazaki, M; Oguri, T; Ohashi, N; Takahashi, T; Yamakido, M; Yokozaki, M | 1 |
| Chilvers, ER; Choo, C; Donnelly, SC; Dransfield, I; Haslett, C; MacKinnon, AC; Moore, SM; Rintoul, RC; Salter, D; Sethi, T; Strieter, R | 1 |
| de Boer-Dennert, MM; Goey, SH; Loos, WJ; Ma, J; Pronk, LC; Schellens, JH; Stoter, G; van Zuylen, L; Verweij, J | 1 |
| Stuschke, M | 1 |
| Fukuda, M; Hayakawa, A; Itoh, N; Kohno, S; Mori, H; Oka, M; Sakamoto, T | 1 |
| Dagovic, A; Jeremic, B; Milicic, B; Milisavljevic, S; Nikolic, N; Radosavljevic-Asic, G; Shibamoto, Y | 1 |
| Abbasciano, V; Bianchi, MP; Bononi, A; Crepaldi, G; Ferrazzi, E; Gilli, G; Nielsen, I; Sartori, S; Toso, S; Trevisani, L; Zavagli, G | 1 |
| Kametani, T; Koshida, H; Masuda, S | 1 |
| Brugger, W; Engelhardt, R; Fetscher, S; Frommhold, H; Hasse, J; Kanz, L; Lange, W; Mertelsmann, R | 2 |
| Falck, J; Jensen, LH; Jensen, PB; Nitiss, JL; Roerth, M; Rose, A; Sehested, M; Wessel, I | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Minami, H; Saka, H; Sakai, S; Shimokata, K; Shimono, Y; Sugiura, S | 1 |
| Cheng, AL; Lin, JF; Yang, CH; Yang, PC; Yeh, KH; Yu, CJ | 1 |
| Kashiwabara, K; Kishi, K; Kobayashi, K; Matsuoka, T; Nakamura, H; Sarashina, G; Yagyu, H | 1 |
| Kiss, I; Tomasek, J | 1 |
| Cho, S; Kanayama, Y; Maeda, N; Nishizaki, S; Sonoda, T; Yoshida, T | 1 |
| Biesma, B; Postmus, PE; Smit, EF | 1 |
| Alberola, V; Antón, A; Artal, A; Barneto, I; Cardenal, F; Carrato, A; García, M; González-Larriba, JL; Lianes, P; Lomas, M; López-Cabrerizo, MP; Massuti, B; Montalar, J; Nguyen, B; Rosell, R; Vadell, C | 1 |
| Ishizuka, T; Morita, H; Mune, T; Takeda, N; Yasuda, K; Yoshino, K | 1 |
| Nieder, C | 1 |
| Baleyte, T; Chastang, CL; Coetmeur, D; Delaval, P; Jeannin, L; Lebeau, B; Mornet, M; Urban, T; Zaegel, M | 1 |
| Beinert, T; Binder, D; Fleischhacker, M; Mergenthaler, HG; Oehm, C; Possinger, K; Priem, F; Schweigert, M; Sezer, O; Siebert, G; Stuschke, M; Werner, TG; Ziemer, S | 1 |
| Eady, A; Evans, WK; Gagliardi, A; Kocha, W; Newman, TE | 1 |
| Billy, C; Carette, MF; Ferroir, JP; Milleron, B; Nahum, L; Ropert, A; Tcherakian, S | 1 |
| Bauman, NM; Callaghan, EJ; McCulloch, TM; Victoria, L | 1 |
| Chang, WJ; Chen, CH; Liaw, CC; Tsao, TC; Yang, CT | 1 |
| Akutsu, M; Kano, Y; Mori, K; Suzuki, K; Tsunoda, S; Yazawa, Y | 1 |
| Belzer, K; Gaspar, LE; Kalemkerian, GP; Kraut, MJ; Valdivieso, M; Wozniak, AJ | 1 |
| Aleksandrovic, J; Dagovic, A; Jeremic, B; Milicic, B; Milisavljevic, S; Nikolic, N; Radosavljevic-Asic, G; Shibamoto, Y | 3 |
| Bréchot, JM; Chastang, C; L'Her, P; Lebas, FX; Lebeau, B; Leclerc, P; Meekel, P; Paillotin, D; Urban, T; Vincent, J | 1 |
| Curtin, NJ; Turner, DP | 1 |
| Hayashi, I; Isobe, H; Kurita, Y; Masutani, M; Mori, K; Nakata, K; Nishiwaki, Y; Okamoto, H; Saijo, N; Tsuchiya, S; Watanabe, K | 1 |
| Bosquée, L; Humblet, Y; Lange, A; Leyvraz, S; Marangolo, M; Pampallona, S; Pasini, F; Perey, L; Peters, R; Rosti, G | 1 |
| Balcerzak, SP; Crowley, J; Gandara, DR; Giroux, D; Grunberg, SM; Hande, KR; Hynes, HE; Lau, DH; Munshi, N; Schroder, LE; Zangmeister, MH | 1 |
| Choy, H; Ettinger, D; Teng, M | 1 |
| Biserte, J; Blois, N; Colomb, JB; Goullet, E; Mazeman, E | 1 |
| Fossella, FV; Fox, NJ; Glisson, BS; Hong, WK; Kurie, JM; Lee, JS; Murphy, WK; Nyberg, DA; Perez-Soler, R; Pisters, KM; Ross, MB; Shin, DM | 1 |
| Bearden, J; Croft, H; Gandara, D; Goodwin, JW; Grafton, C; James, K; Kraut, M; Langleben, A; Livingston, RB; Murray, N; Osoba, D; Ottaway, J; Shepherd, FA; Turrisi, A; Walde, D; Zee, B | 1 |
| Bonner, JA; Brooks, BJ; Gerstner, JB; Hillman, S; Jett, JR; Krook, JE; Levitt, R; Mailliard, JA; Maksymiuk, A; Marks, RS; Shanahan, TG; Sloan, JA; Tazelaar, HD | 1 |
| Ichiya, Y; Kuwabara, Y; Maehara, Y; Masuda, K; Nakagawa, M; Sasaki, M; Soeda, H; Sugio, K; Yoshida, T | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, PL; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, RA; ten Bokkel Huinink, WW; von Pawel, J; Wagenius, G; Walree, NV | 1 |
| An, T; Gurjal, A; Kalemkerian, GP; Valdivieso, M | 1 |
| Bosquée, L; Canon, JL; Humblet, Y; Rosier, JF; van de Velde, H; Weynants, P | 1 |
| Campioni, N; Cognetti, F; Del Vecchio, MR; Ferraresi, V; Milella, M; Nardi, M; Pasquali-Lasagni, R; Santomaggio, C; Scinto, AF; Tucci, E | 1 |
| Antonelli, G; Ardizzoni, A; Cafferata, M; Grossi, F; Rosso, R; Tixi, L | 1 |
| Balaña, C; Martin, C; Rosell, R | 1 |
| Langer, CJ; Socinski, MA | 1 |
| Bunn, PA; Kelly, K; Murphy, J; Pan, Z; Wood, ME | 1 |
| Adam, G; Bréchot, JM; Chastang, C; Darse, J; Duhamel, JP; Lebas, FX; Lebeau, B; Urban, T | 1 |
| Förster, B; Loddenkemper, R; Pannhorst, J; Riedel, U; Schönfeld, N; Serke, M | 1 |
| Andras, E; Byhardt, R; Cox, J; Dar, AR; Johnson, D; Komaki, R; Lawton, C; Lee, JS; Movsas, B; Roach, M; Sause, W; Scott, C; Wasserman, T | 1 |
| Girling, DJ; Hopwood, P; Qian, W; Sambrook, RJ; Stephens, RJ; Thatcher, N | 1 |
| Le Guen, Y; Lebeau, B | 1 |
| Bonomi, P; Cella, D; Fairclough, D; Jiroutek, M; Johnson, D; Kim, K; Kugler, J; Rowinsky, E | 1 |
| Arakawa, M; Chou, D; Gejyo, F; Ito, K; Kagamu, H; Sakai, K; Shimbo, T; Suzuki, E; Takahashi, M; Tanaka, H; Tanaka, J; Wakabayashi, M; Yoshizawa, H | 1 |
| Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A | 1 |
| Brummett, RE; Doolittle, ND; Egorin, MJ; Kroll, RA; Muldoon, LL; Neuwelt, EA; Pagel, MA; Zuhowski, EG | 1 |
| Saijo, N; Watanabe, H | 1 |
| Kurano, R; Ono, K; Semba, H; Seto, M; Seto, T | 1 |
| Alloisio, A; Bruzzi, P; Cafferata, MA; Costa, R; Melioli, G; Ratto, GB; Scolaro, T; Semino, C; Spessa, E | 1 |
| Bonner, JA; Klee, GG; Krook, JE; Kugler, JW; Mailliard, JA; Maksymiuk, AW; Marks, RS; Perez, EA; Rowland, KM; Shaw, EG; Sloan, JA; Wiesenfeld, M | 1 |
| Chang, A; Craffey, M; DeVore, R; Dowlati, A; Jett, J; Johnson, D; Levitan, N; Mackay, W; Remick, SC; Shina, D | 1 |
| Bosset, JF; Depierre, A; Dubiez, A; Jacoulet, P; Magnin, V; Mennecier, B; Westeel, V | 1 |
| Ali, MA; Cummings, G; Kalemkerian, GP; Kraut, MJ; Valdivieso, M; Wozniak, AJ | 1 |
| Clark, PI | 1 |
| Grunberg, SM | 1 |
| Comis, RL; Friedland, DM; Good, BC | 1 |
| Alberola, V; Antón, A; Cardenal, F; Carrato, A; Kennedy-Martin, T; Lomas, M; Massuti, B; Minshall, M; Rosell, R; Sacristán, JA | 1 |
| Choy, H; Cmelak, AJ; Johnson, DH; Mohr, PJ; Shyr, Y | 1 |
| Huang, J; Sun, Y; Zhang, X | 1 |
| Beviacqua, M; Bordenave, RH; Novellino, PS; Rumi, LS; Trejo, YG | 1 |
| Andras, EJ; Byhardt, RW; Graham, ML; Roach, M; Scott, C; Smith, C; Werner-Wasik, M | 1 |
| Anderson, H; Ashcroft, L; Jayson, GC; Ranson, M; Thatcher, N; White, SC | 1 |
| Jia, SF; Kleinerman, ES; Worth, LL | 1 |
| Alberto, P; Bolla, M; Bonnefoi, H; Hügli, A; Mermillod, B; Miralbell, R; Moro, D | 1 |
| Fueki, N; Hoshino, H; Ishihara, S; Kobayashi, G; Makimoto, T; Minato, K; Mori, M; Naruse, I; Nomoto, T; Saito, R; Sato, K; Sunaga, N; Takei, Y; Takise, A; Tsuchiya, S; Watanabe, S | 1 |
| De Ruysscher, D; Vansteenkiste, J | 1 |
| Halme, M; Isokangas, OP; Joensuu, H; Mäntylä, M; Mattson, K; Pekonen, M; Pyrhönen, S; Ruotsalainen, T; Sarna, S | 1 |
| Jin, X; Liu, Z; Luo, B; Yin, L; Zeng, P | 1 |
| Arvelo, F; Bourgeois, Y; De Cremoux, P; Livartowski, A; Nemati, F; Pouillart, P; Poupon, MF | 1 |
| Nakamura, T; Nishio, K | 1 |
| Arimoto, J; Bessho, T; Furukawa, T; Hirai, I; Maebeya, S; Matsuyama, K; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yano, T; Yoshimasu, T | 1 |
| Crawford, J; Glaspy, J; Mazanet, R; Ozer, H; Tomita, DK | 1 |
| Baumann, B; Fabbro, D; Leech, SH; Olie, RA; Simões-Wüst, AP; Stahel, RA; Zangemeister-Wittke, U | 1 |
| Thongprasert, S | 2 |
| Cohen, Y; Geffen, DB; Man, S | 1 |
| Carestia, L; Daurès, JP; Pujol, JL | 1 |
| Fujii, H; Katakami, N; Nishimura, T; Takakura, S; Umeda, B | 1 |
| Bandyopadhyay, S; Goodarzi, G; Gross, SC; Mashimo, T; Pai, SK; Watabe, K; Watabe, M | 1 |
| Cherrington, JM; Kabbinavar, F; Mann, E; Schwartz, DP; Shawver, LK; Slamon, DJ; Strawn, LM | 1 |
| Furuichi, S; Hachisuka, H; Horie, T; Kayama, Y; Miyagi, K; Nakayama, T; Nomura, Y; Omori, C | 1 |
| Imaizumi, M; Seki, Y; Takeuchi, M; Yamada, K; Yoshioka, H | 1 |
| Chan, AT; Johnson, P; Leung, SF; Leung, TW; Mok, TS; Nguyen, B; Yang, WT; Yeo, W; Yim, A; Zee, B | 1 |
| Glisson, B; Komaki, R; Movsas, B; Scott, C; Wagner, H | 1 |
| Araki, J; Ariyoshi, Y; Fukuoka, M; Isobe, T; Kawahara, M; Kudoh, S; Nakagawa, K; Negoro, S; Sugiura, T; Yamakido, M; Yokozaki, M | 1 |
| Okamoto, H; Watanabe, K | 2 |
| Masuda, N; Negoro, S | 1 |
| Hara, N; Inoue, K; Nakanishi, Y | 1 |
| Bonomi, PD; Kucuk, O; Pandya, KJ; Shevrin, DH | 1 |
| Cardenal, F; Drings, P; Gatzemeier, U; Kaukel, E; Kleisbauer, JP; Melo, MJ; Palisses, R; Robinet, G; Samaras, N; Snijder, RJ; von Pawel, J | 1 |
| Harani, N; Haslett, C; MacKinnon, AC; Rahman, I; Rintoul, R; Sethi, T; Waters, C | 1 |
| Campbell, MJ; George, SL; Julious, SA; Machin, D; Walker, SJ | 1 |
| Korobowicz, E; Zdunek, M | 1 |
| Arai, T; Hayakawa, K; Kashiki, Y; Shibayama, M; Shibuya, C; Takaya, T; Toshima, S; Yasuda, Y; Yoshimi, N | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Negoro, S | 1 |
| Fayers, PM; Girling, DJ; Parmar, MK; Qian, W; Sambrook, RJ; Stephens, RJ | 1 |
| Hamazaki, M; Honzumi, M; Inaba, H; Ito, M; Kawasaki, H; Komada, Y; Okugawa, T; Sakurai, M; Toyoda, N; Uchida, K | 1 |
| Ichikawa, Y; Kubo, T; Minami, R; Nishida, M; Nozue, A; Tsunoda, H | 1 |
| Berger, W; Elbling, L; Micksche, M | 1 |
| Blanke, CD; Hemmer, MP; Witte, RS | 1 |
| Berghmans, T; Branle, F; Lafitte, JJ; Lemaitre, F; Mascaux, C; Meert, AP; Paesmans, M; Sculier, JP; Vermylen, P | 1 |
| Ardiet, C; Boissel, JP; Court-Fortune, I; Freyer, G; Girard, P; Ligneau, B; Rebattu, P; Riou, R; Souquet, PJ; Tranchand, B; Trillet-Lenoir, V | 1 |
| Bozóky, G; Góhér, I; Mohos, A; Ruby, E | 1 |
| Andrieu, JM; Coscas, Y; Dabouis, G; Jaillon-Abraham, C; Tourani, JM | 1 |
| Aktoğu, S; Büyükşirin, M; Capa, G; Durak, H; Erkmen, G; Ertay, T; Ozbilek, E; Sayit, E | 1 |
| Aisner, SC; Blum, R; Johnson, DH; Komaki, R; Livingston, RB; Sause, W; Turrisi, AT; Wagner, H; Yuen, AR; Zou, G | 1 |
| Adak, S; Brooks, BJ; Herskovic, A; Johnson, DH; Keller, SM; Komaki, R; Livingston, RB; Perry, MC; Wagner, H | 1 |
| Koshiishi, H; Takahashi, E; Tamamoto, F; Utsumi, K | 1 |
| Bonilla, F; Corbacho, C; Dominguez, G; España, P; Garcia, JM; Portero, JL; Provencio, M; Rodriguez, R; Silva, J; Silva, JM | 1 |
| Kirov, I; Lones, MA; Neudorf, S; Said, JW; Shintaku, IP | 1 |
| Hochstenbag, MM; ten Velde, GP; Twijnstra, A; Wilmink, JT; Wouters, EF | 1 |
| Aoyagi, K; Kobunai, T; Saito, H; Utsugi, T; Wierzba, K; Yamada, Y; Yoshida, M | 1 |
| Bukowski, RM; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Tabata, M; Tabata, R | 1 |
| Catalano, G; De Cataldis, G; De Vita, F; Galizia, G; Infusino, S; Lieto, E; Orditura, M; Romano, C | 1 |
| Cornillet-Lefebvre, P; Doco-Fenzy, M; Gruson, N; Jardillier, JC; Masson, L; Potron, G; Proult, M; Struski, S; Trussardi, A; Ulrich, E | 1 |
| Brown, JM; Gurney, EM; Hepburn, PM; Johnson, PW; Muers, MF; Napp, VV; Peake, MD; Poulter, KM | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Aydiner, A; Disci, R; Koyuncu, H; Tas, F; Topuz, E | 1 |
| Fujishiro, M; Fukuda, H; Fukuda, M; Kunitoh, H; Nishiwaki, Y; Ohe, Y; Saijo, N; Sekine, I; Shinkai, T; Tamura, T | 1 |
| Burt, PA; Davies, R; Hodgetts, J; Lee, SM; Lomax, L; Pettengell, R; Simms, T; Stout, R; Thatcher, N; Woll, PJ | 1 |
| Breton, JL; Daurès, JP; Debieuvre, D; Le Chevalier, T; Lemarié, E; Milleron, B; Moro, D; Poudenx, M; Pujol, JL; Quantin, X; Quoix, E; Rivière, A; Westeel, V | 1 |
| Moriyama, N; Muranaka, K; Tanase, K; Tawada, M | 1 |
| Ahn, YC; Bae, HS; Hyun, IG; Jung, KS; Kim, HJ; Kim, WS; Kwon, SH; Lee, JA; Oh, DH; Park, CH; Park, K; Park, MJ; Park, YL; Park, YS; Woo, IS | 1 |
| Brandao, L; Cain, AM; Kun, LE; McCarville, MB; Pappo, AS; Poquette, CA; Spunt, SL | 1 |
| Doddoli, C; Fuentes, P; Giudicelli, R; Papazian, L; Reynaud-Gaubert, M; Thomas, P | 1 |
| Tamura, T | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Capuano, G; D'Alessandro, V; Lelli, G; Morelli, F; Nanni, L; Palomba, G; Piano, A; Rinaldi, B; Simeon, A; Sirotovà, Z | 1 |
| Rosien, B | 1 |
| Hoffman, B; Liebermann, DA; Zhang, W | 1 |
| Herman, ZS; Machalski, M; Scieszka, M; Zielinski, M | 1 |
| Berger, NA; Berger, SJ; Dowlati, A; Gordon, NH; Gosky, DM; Hoppel, CL; Ingalls, ST; Levitan, N; Remick, SC | 1 |
| Smith, PJ; Soués, S; Wiltshire, M | 1 |
| Czownicki, Z; Koźlik, H; Michałek, A; Pasz, P; Zientek, A; Zientek, J | 1 |
| Boyer, MJ; Clarke, SJ; Davis, I; Goldstein, D; Millward, MJ; Mitchell, P; Olver, IN; Richardson, G | 1 |
| Adak, S; Cella, D; DeVore, RF; Johnson, DH; Schiller, JH | 1 |
| De Marzi, P; Garavaglia, E; Mangili, G; Taccagni, G; Zanetto, F | 1 |
| Merriman, KW; Pisters, KM; Putnam, JB; Roth, JA; Siegenthaler, MP; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL | 1 |
| Smith, IE; Stebbing, J | 1 |
| Acimovic, L; Aleksandrovic, J; Dagovic, A; Jeremic, B; Milicic, B; Milisavljevic, S; Nikolic, N; Radosavljevic-Asic, G; Shibamoto, Y | 1 |
| Li, Y; Wang, P; Xie, J | 1 |
| Dingemans, AC; Giaccone, G; Postmus, PE; Scagliotti, GV; Span, S; van Ark-Otte, J; van der Valk, P | 1 |
| Crosby, L; Dowlati, A; Levitan, N; Makkar, V; Remick, SC | 1 |
| Baguley, BC; Baker, M; Bootle, D; Charlton, PA; Dangerfield, W; Denny, WA; Kofler, B; Mistry, P; Okiji, S; Stewart, AJ | 1 |
| Ali, MA; Kalemkerian, GP; Kraut, MJ; Luthra, K; Valdivieso, M; Wozniak, AJ | 1 |
| Goehle, S; Lamb, JR; Ludlow, C; Simon, JA | 1 |
| Mazeron, JJ; Noël, G | 1 |
| Baumann, M | 1 |
| Acimovic, L; Jeremic, B; Milicic, B; Nikolic, N; Shibamoto, Y | 1 |
| Aggarwal, AN; Behera, D; Gupta, D; Jindal, SK; Sharma, SC | 1 |
| Agelidou, M; Bania, E; Georgoulias, V; Jordanoglou, J; Kakolyris, S; Kouroussis, C; Mavroudis, D; Papadakis, E; Stavrakakis, J; Tsiafaki, X; Veslemes, M; Vlachonicolis, J | 1 |
| Ekedahl, J; Formstecher, P; Joseph, B; Lewensohn, R; Marchetti, P; Zhivotovsky, B | 1 |
| Ben-Arie, A; Biran, H; Dgani, R; Hagay, Z; Open, M; Piura, B | 1 |
| Smolanka, II | 1 |
| Ambrogi, V; Corsaro, V; Mineo, TC; Roselli, M | 1 |
| Hanibuchi, M; Higasida, T; Nishioka, Y; Nokihara, H; Sone, S; Tsuruo, T; Yano, S | 1 |
| Ponarska, A; Rogala, E; Rogińska, E; Rowińska-Zakrzewska, E; Szopiński, J | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Aasebø, U; Bremnes, RM; Sundstrøm, S; Vilsvik, J | 1 |
| Blatter, J; Bosquée, L; Gatzemeier, U; Hanauske, A; Manegold, C; Mansouri, K; Vansteenkiste, J; von Pawel, J; Weynants, P | 1 |
| Bunn, PA; Crowley, JJ; Gandara, DR; Kelly, K; Livingston, RB; Lovato, L; Roychowdhury, D; Taylor, SA; Zangmeister, J | 1 |
| Fukuoka, M | 1 |
| Fukuoka, M; Hirashima, T; Kobayashi, M; Masuda, N; Matsui, K; Nitta, T; Takada, Y; Yana, T | 1 |
| Steele, JP | 1 |
| Inoue, A; Saijo, N | 1 |
| Breton, JL; Coëtmeur, D; Daniel, C; Debieuvre, D; Jacoulet, P; Kessler, R; Lemarié, E; Milleron, B; Moreau, L; Paillot, N; Quoix, E | 1 |
| Böhmer, S; Goeschen, K; Gurlit, L; Hartlapp, HJ; Krech, R; Lampe, S | 1 |
| Kimura, T | 1 |
| Cohn, DA; Stuart-Harris, R | 1 |
| Fujita, K; Itoh, Y; Miki, T; Murosaki, N; Nakai, Y; Sugao, H; Takao, T; Tsujikawa, K | 1 |
| Baiardi, P; Cuomo, AM; Preti, P; Robustelli della Cuna, FS; Robustelli della Cuna, G; Torazzo, R | 1 |
| Gormand, F; Grangeon, V; Guibert, B; Harf, R; Mornex, F; Pacheco, Y; Vincent, L | 1 |
| Schiller, JH | 1 |
| Clark, PI; Hannigan, K; Marshall, E; O'Neill, P; Ross, G; Smith, D | 1 |
| Le Chevalier, T; Novello, S | 1 |
| Ahn, YC; Han, J; Huh, SJ; Kim, DY; Kim, HJ; Kim, J; Kim, KM; Kwon, J; Lee, JE; Lee, KS; Lim, DH; Noh, YJ; Park, K; Shim, YM | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Fujita, S; Hasegawa, T; Ikeda, A; Kaneshiro, E; Katakami, N; Nishimura, T; Nishio, C; Okazaki, M; Umeda, B | 1 |
| Briassoulis, E; Fountzilas, G; Kalofonos, HP; Kardamakis, D; Kosmidis, P; Kouvatseas, G; Panoussaki, E; Pavlidis, N; Samantas, E; Skarlos, DV; Tsavdaridis, D; Tsekeris, P; Tsiakopoulos, E; Tzitzikas, J; Zamboglou, N | 1 |
| Arquilla, ER; Eklof, A; Osann, K; Slater, LM; Stupecky, M; Sweet, P | 1 |
| Glicksman, AS; Liu, L; Weitberg, AB; Yashar, J | 1 |
| Berchier, MC; Berghmans, T; Florin, MC; Giner, V; Klastersky, J; Koumakis, G; Lafitte, JJ; Lecomte, J; Michel, J; Mommen, P; Ninane, V; Paesmans, M; Sculier, JP; Thiriaux, J; Van Cutsem, O | 1 |
| Cruz-Caudillo, JC; Liu, Z; Mira, JL | 1 |
| Basso, B; Boiocchi, M; Colussi, AM; Corona, G; Robieux, I; Sorio, R; Toffoli, G | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Bombaron, P; Dussopt, C; Fournel, P; Larive, S; Lecaer, H; Lena, H; Perol, M; Philip-Joet, F; Riou, R; Souquet, PJ; Touraine, F | 1 |
| Arai, T; Fujimura, H; Hayashi, S; Kimura, H; Morishita, H; Naba, I; Nakamori, M; Nakatsuji, Y; Osaki, T; Sugai, F; Suzuki, M; Tachibana, I | 1 |
| Ardizzoni, A; Biesma, B; Buchholz, E; Burghouts, J; Debruyne, C; Gans, S; Giaccone, G; Legrand, C; Manegold, CH; Mollers, M; Postmus, PE; Tjan-Heijnen, VC; van Meerbeeck, J | 1 |
| Eriksson, B; Fjällskog, ML; Granberg, D; Grimfjärd, P; Oberg, K; Skogseid, B; Wilander, E | 1 |
| Fukuoka, M; Kawahara, M; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K; Yamamoto, S; Yokoyama, A | 1 |
| Baptiste, N; Chen, X; Friedlander, P; Prives, C | 1 |
| Bonner, JA; Brown, PD; Creagan, ET; Foote, RL; Frytak, S; Marks, RS; Richardson, RL | 1 |
| Clarke, P; Geraci, MW; Johnson, GL; Jotte, RM; Scheinman, RI; Spalding, AC; Tyler, KL | 1 |
| Krammer, PH; Sartorius, UA | 1 |
| Feng, F; Peng, X; Zhang, W | 1 |
| Dudzisz-Sledź, M; Jakubowicz-Klecha, A; Korobowicz, E; Mańdziuk, S; Milanowski, J; Rybacka-Chabros, B; Wojcierowski, J; Zdunek, M | 1 |
| Hsu, NY; Kao, A; Lee, CC; Lin, CC; Shiun, SC; Sun, SS | 1 |
| Giaccone, G; Huisman, C; Postmus, PE; Smit, EF | 1 |
| Eberhardt, W; Hillejan, L; Müller, MR; Stamatis, G; Stüben, G | 1 |
| Amorino, GP; Cao, Q; Choy, H; Kim, JS; Pyo, H | 1 |
| Bernardo, P; Bonomi, P; Cella, D; Johnson, DH; Kugler, JW; Langer, CJ; Manola, J | 1 |
| Arush, MW; Beck, D; Ben-Izhak, O; Postovsky, S | 1 |
| Fukuhara, S; Kanazawa, S; Kuwana, M; Nomura, S; Yamaguchi, K; Yoshimura, C | 1 |
| Ansari, R; Einhorn, LH; Hanna, NH; Jung, SH; Lane, K; Loehrer, PJ; Sandier, AB | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Ettinger, DS; Komaki, R; Lee, JS; Sause, WT; Scott, CB | 1 |
| Fushimi, H; Nakajima, S; Obana, T; Okuda, K; Takenaka, M; Tanio, Y; Tsubakihara, Y; Watanabe, D; Yanagita, M | 1 |
| Allen, P; Cox, JD; Fossella, FV; Glisson, B; Herbst, R; Hong, WK; Kaplan, B; Kelly, JF; Khuri, F; Komaki, R; Kurie, J; Lee, JS; Liao, Z; Milas, L; Papadimitrakopoulou, V; Pisters, K; Ro, J; Stevens, CW; Thames, HD; Zinner, R | 1 |
| Bonnette, P | 1 |
| Brooks, SE; Goldstein, DP; Ioffe, O; Knox, S; Meisenberg, B; Wong-You-Cheong, J | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Bielawski, K; Falkiewicz, B; Granetzny, A; Klinke, F; Vogt, U; Zaczek, A | 1 |
| Hoogsteden, HC; Nowak, PJ; Surmont, VF; van Klaveren, RJ; van Meerbeeck, JP; Zondervan, PE | 1 |
| Bildat, S; Eberhardt, W; Hillejan, L; Pöttgen, C; Sack, H; Seeber, S; Sohrab, S; Stamatis, G; Stüben, G; Stuschke, M; Teschler, H | 1 |
| Ardizzoni, A; Postmus, PE; Tjan-Heijnen, VC | 1 |
| Bunn, PA; Chan, DC; Chan, KK; Covey, JM; Feng, WY; Gera, L; Helfrich, B; Stewart, JM; Zhao, TL | 1 |
| Aebi, S; Betticher, DC; Calderoni, A; Solenthaler, M; von Briel, C | 1 |
| Sandler, A | 1 |
| Minakata, Y; Mune, M; Nakanishi, H; Nakanishi, M; Nishimoto, T; Yamagata, T; Yukawa, S | 1 |
| Bang, YJ; Ha, SH; Heo, DS; Im, YH; Kang, WK; Kim, NK; Kim, TY; Lee, SH; Park, CI; Park, YS; Yang, SH | 1 |
| Aoe, K; Eguchi, K; Harita, S; Hiraki, S; Hiraki, Y; Hiyama, J; Kamei, H; Kawahara, S; Kiura, K; Kobayashi, M; Sato, T; Shibayama, T; Tabata, M; Tada, A; Takemoto, M; Tanimoto, M; Ueoka, H; Yamane, H | 1 |
| Mathisen, DJ; Wright, CD | 1 |
| Murray, N; Sheehan, F | 1 |
| Amato, RJ; Daliani, D; Do, KA; Finn, L; Fizazi, K; Kim, J; Logothetis, CJ; Millikan, RE; Pagliaro, LC; Papandreou, CN; Prow, DM; Tu, SM; Wang, X | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Nokihara, H; Ohe, Y | 1 |
| Carr, DT; Eagan, RT; Frytak, S; Lee, RE; Rubin, J | 1 |
| Beckmann, C; Flury, R; Frei, P; Holdener, E; Jungi, WF; Senn, HJ | 1 |
| Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, F | 1 |
| Ferguson, A; Hewitson, R; Levin, W; Sealy, R; Tucker, RD; Van Wyk, C | 1 |
| Bunn, PA; Chretien, PB; Cohen, MH; Fossieck, BE; Ihde, DC; Johnston, AV; Kenady, DE; Lipson, SD; Makuch, R; Matthews, MJ; Minna, JD; Shackney, SE | 1 |
| Bunn, PA; Cohen, MH; Fossieck, BE; Ihde, DC; Johnston-Early, A; Makuch, R; Matthews, MJ; Minna, JD; Shackney, SE | 1 |
| Fontana, JA | 1 |
| Abeloff, MD; Ettinger, DS; Khouri, NF; Lenhard, RE | 1 |
| Bunn, PA; Ihde, DC; Radice, PA | 1 |
| Henney, JE; Muggia, FM; Rozencweig, M; Von Hoff, DD | 1 |
| Brunner, KW; Cavalli, F; Jungi, F; Senn, HJ; Sonntag, RW | 1 |
| Crooke, ST; Issell, BF | 1 |
| Creagan, ET; Eagan, RT; Fleming, TR; Frytak, S; Ingle, JN; Kvols, LK; Rubin, J | 1 |
| Creagan, ET; Eagan, RT; Frytak, S; Ingle, JN; Kvols, LK; McMachon, RT; Rubin, J | 1 |
| Agusti, A; Estape, J; Lloret, JS; Milla, A; Palacin, A; Soriano, E | 1 |
| Brunner, KW; Cavalli, F; Hasler, E; Martin, J; Ryssel, HJ; Sonntag, RW; Tschopp, L | 1 |
| Barouh, M; Carpentier, Y; Cattan, A; Cattan, E; Pourny, C | 2 |
| Ban, Y; Iwata, H; Kanematsu, E; Kawada, Y; Kawamoto, S; Kuriyama, M; Saitoh, A; Takahashi, Y; Yamamoto, N | 1 |
| Broxterman, HJ; de Vries, EG; Feller, N; Kuiper, CM; Lankelma, J; Pinedo, HM; Versantvoort, CH | 1 |
| DeVore, RF; Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Murphy, PB | 1 |
| Hisanaga, S; Miyazaki, T; Nishikawa, K; Ono, S; Watanabe, K | 1 |
| Ansari, R; Einhorn, L; Loehrer, PJ; Pennington, K; Rynard, S; Songer, J | 1 |
| Broun, GO; Cherng, NC; Cohen, HJ; Crawford, J; Einhorn, LH; Goodlow, JL; Johnson, DH; Randolph, JA; Roth, BJ; Schacter, LP | 1 |
| Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Thomas, M; Waits, TM | 1 |
| Camacho, ES; Dill, PL; Hilliard, DA; Weisenthal, LM; Wilbur, DW | 1 |
| Fujiwara, Y; Kasahara, K; Matsuda, T; Nishio, K; Saijo, N; Sugimoto, Y; Tamura, T | 1 |
| Eisenhauer, EA; Goss, PE; Rusthoven, J; Shepherd, FA | 1 |
| Mans, DR; Sonneveld, P; Splinter, TA; van der Gaast, A | 1 |
| Ruffie, P | 1 |
| Ahlgren, JD; Alt, DE; Brereton, HD; Fryer, JG; Lokich, JJ; Rosenthal, CJ; Wampler, GL | 1 |
| Osoba, D | 1 |
| Ahlgren, JD; Schulof, RS; Wampler, GL | 1 |
| Beck, H; Capranico, G; Gazdar, AF; Giaccone, G; Zunino, F | 1 |
| Bernareggi, A; Castoldi, D; Cimino, G; Colombi, L; Fracasso, ME; Leone, R; Monzani, V; Soresi, E; Tedeschi, M; Usari, T | 1 |
| Hasegawa, K; Komatsu, H; Matsuoka, T; Nagao, K; Nakano, H; Niitani, H; Sato, H; Takizawa, H; Uchiyama, T; Yoshida, S | 1 |
| Balmes, P; Bonnaud, F; Kleisbauer, JP; Poirier, R; Reynaud-Gaubert, M; Targhetta, R; Taytard, A; Thomas, P; Vergeret, J | 1 |
| Burghouts, JT; Carney, DN; Festen, J; Palmen, FM; Planting, AS; Postmus, PE; Quoix, E; Roozendaal, K; Splinter, TA; Vendrik, C | 1 |
| Aisner, J; Budman, DR; Perry, M; Propert, K; Strauss, G; Van Echo, DA; Whitacre, MY | 1 |
| Achterrath, W; Gatzemeier, U; Hossfeld, DK; Lenaz, L; Neuhauss, R; Reck, M | 3 |
| Allard, P; Boita, F; Chastang, C; Fichet, D; Lebeau, B; Migueres, J | 1 |
| Bao, YH | 1 |
| Bergman, B; Sörenson, S; Sullivan, M | 1 |
| Dhingra, HM; Fossella, FV; Hong, WK; Lee, JS; Murphy, WK; Shin, DM | 1 |
| Kohn, KW; Orr, A; Pommier, Y; Riou, JF | 1 |
| Minna, J; Mulshine, J; Pass, HI; Pogrebniak, HW; Steinberg, SM | 1 |
| Fujita, J; Fujita, T; Irino, S; Kubo, A; Morikawa, N; Shiotani, T; Takahara, J; Takigawa, K; Yamagishi, Y; Yamaji, Y | 1 |
| Collard, P; Francis, C; Rodenstein, DO; Weynants, P | 1 |
| Chen, HC; Gazdar, AF; Johnson, BE; Ohsaki, Y | 1 |
| Fryer, JG; Wampler, GL | 1 |
| Cheson, BD | 2 |
| Abad, A; Barnadas, A; Carles, J; Haboubi, N; Jimeno, JM; Moreno, I; Ribelles, N; Rosell, R | 1 |
| Bishop, JF | 1 |
| Gatzemeier, U; Hossfeld, DK; Laumen, R; Lenaz, L; Neuhauss, R; Reck, M; von Pawel, J | 1 |
| Bonomi, P | 2 |
| Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Murphy, PB | 1 |
| DeVore, R; Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH | 1 |
| Furuse, K | 3 |
| Bando, H; Shinohara, T; Takishita, Y; Tanaka, H; Yanagawa, H | 1 |
| Fujii, T; Hamamoto, K; Higashino, H; Iio, A; Itoh, H; Kataoka, M; Kawamura, M; Mogami, H; Nishiyama, Y | 1 |
| Pate, RW | 1 |
| Lafleur, MV; Lankelma, J; Mans, DR; Pinedo, HM; Retèl, J; Schuurhuis, GJ; Treskes, M | 1 |
| Buzaid, AC; Sandler, AB | 1 |
| Bakri, YN; Ezzat, A; Pedersen, P | 1 |
| Goutsou, M; Green, MR; Herndon, JE; Lyss, AP; Mason-Coughlin, K; Perry, MC; Propert, K | 1 |
| Agustí, C; Biete, A; Daniels, M; Estapé, J; Grau, JJ; Palombo, H; Ramirez, J; Sánchez-Lloret, J; Solá, C; Viñolas, N | 1 |
| Comis, RL | 4 |
| Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M | 2 |
| Evans, WK; Goss, PE; Latreille, J; Logan, D; Maroun, J; Paul, K; Shepherd, FA; Stewart, D; Warner, E | 1 |
| Bishop, JF; Kefford, RF; Matthews, JP; Morstyn, G; Raghavan, D; Stuart-Harris, R; Zalcberg, J | 1 |
| Berendsen, HH; Haaxma-Reiche, H; Postmus, PE; Smit, EF | 1 |
| Bonfrer, JM; Jassem, E; Mooi, WJ; van Tinteren, H; van Zandwijk, N | 1 |
| DeVore, R; Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Thomas, M; Walls, J | 1 |
| Nyman, CR | 1 |
| Gabazza, EC; Ibata, H; Machishi, M; Suzuki, S; Taguchi, O; Tsutsui, K; Yamakami, T | 1 |
| Piers, DA; Postmus, PE; Smit, EF | 1 |
| Alpeter, MD; Glisson, BS | 1 |
| Berghmans, T; Klastersky, J | 1 |
| Campbell, ED; Carter, WH; Keefe, PA; Wampler, GL | 1 |
| Griffin, JP; Miller, AA; Niell, HB; Stewart, CF; Tolley, EA | 1 |
| García Arroyo, R; García Gómez, R; González del Val, R; Martínez del Prado, P; Meana García, A; Pérez Manga, G | 1 |
| Akita, H; Arimoto, T; Asakawa, M; Fujikane, T; Isobe, H; Kawakami, Y; Miyamoto, H; Nakabayashi, T; Shimizu, T; Suzuki, A | 1 |
| Helle, L; Jakobson, M; Järvinen, M; Liippo, K; Nikkanen, V; Ojala, A; Paloheimo, S; Salmi, R; Salomaa, ER; Virén, M | 1 |
| Dahrouge, S; Evans, WK; Goss, G; Latreille, J; Logan, D; Maroun, J; Shepherd, FA; Stewart, D; Warner, E | 1 |
| Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH | 3 |
| DeVore, R; Greco, FA; Hainsworth, J; Hande, K; Johnson, D | 1 |
| Clark, PI; Cottier, B | 1 |
| Carney, DN; Grogan, L; Keane, M | 1 |
| Loehrer, PJ | 1 |
| Ruckdeschel, JC | 2 |
| Bamberga, M; Bamberga, P; Gritti, G; Michetti, G; Ori-Belometti, M; Sarti, E; Villa, R | 1 |
| Kimura, I; Kiura, K; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H | 1 |
| Chariot, P; de Cremoux, H; Le Chevalier, T; Monnet, I; Quoix, E; Ruffié, P; Saltiel, JC; Voisin, S | 1 |
| Brodin, O; Lamberg, K; Nõu, E | 1 |
| Krochmal, M; Krzemieniecki, K; Pawlicki, M | 1 |
| Beltrami, V; Bianco, AR; Ferrante, G; Gentile, M; Gridelli, C; Iacobelli, S; Irtelli, L; Martino, T; Natoli, C; Rossi, A | 1 |
| Li, LY | 1 |
| Arpin, D; Bohas, C; Caillet, B; Fournel, P; Lasset, C; Pacheco, Y; Perol, M; Rebattu, P; Riou, R; Trillet-Lenoir, V | 1 |
| Kimura, I; Kiura, K; Ohnoshi, T; Takigawa, N; Ueoka, H | 1 |
| Christensen, IJ; Demant, EJ; Hansen, HH; Jensen, PB; Roed, H; Sehested, M; Vindeløv, L | 1 |
| Black, T; Estrada-Aguilar, J; Greenberg, H; Hvizdala, E; Morse, S; Schroer, K; Walling, A | 1 |
| Fukuoka, M; Itoh, K; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Nishioka, M; Takifugi, N; Tanaka, H | 1 |
| Harrell, JH; Miller, KL | 1 |
| Fukuoka, M; Furuse, K; Masuda, N | 1 |
| Lau, J; Leung, SF; Leung, WT; Pang, JC; Shiu, WC; Tao, M; Teo, P | 1 |
| Smith, IE | 1 |
| Hatakeyama, S; Nagayama, M; Okano, H; Suzuki, K; Tachibana, A | 1 |
| Higashihara, T; Hojo, K; Kajiyama, K; Kumasaka, Y; Nishiyama, S; Okada, M; Oku, Y | 1 |
| Demirkazik, A; Dinçol, D; Günel, N; Içli, F; Karaoğuz, H | 1 |
| Kennedy, A; Khansur, T | 1 |
| Achterrath, W; Lenaz, L; Niederle, N; Ostermann, J; Schmidt, CG | 1 |
| de Vries, EG; Meijer, C; Mulder, NH; Mulder, PO; Nanninga, AG; Uges, DR; van der Graaf, WT; Vellenga, E | 1 |
| Coltman, CA; Crowley, J; Hom, BL; Livingston, RB; Natale, RB; Rivkin, S; Taylor, SA; Weick, JK | 1 |
| Enokibori, T; Kato, H; Katsura, A; Mori, A; Watanabe, K | 1 |
| Arimoto, T; Asakawa, M; Fujikane, T; Kawakami, Y; Miyamoto, H; Nakabayashi, T; Onodera, S; Shimizu, T; Suzuki, A; Yasuda, S | 1 |
| Blijham, GH; Bron, H; Hupperets, PS; Schouten, L; ten Velde, GP | 1 |
| Ash, CM; Geddes, D; Goldman, J; Harper, PG; Souhami, RL; Spiro, SG; Tobias, JS; Twelves, CJ | 1 |
| Ball, D; Bishop, J; Bull, C; Duval, P; Laidlaw, C; Matthews, J; Ngan, S | 1 |
| Fukuoka, M; Furuse, K; Ikegami, H; Nishiwaki, Y; Saijo, N; Shimoyama, M; Suemasu, K; Tamura, T | 1 |
| Fukuoka, M; Furuse, K; Kawahara, M; Kudoh, S; Masuda, N; Matsui, K; Negoro, S; Ogawara, M; Takada, M; Takifuji, N | 1 |
| Becker, H; Drings, P; Flechtner, H; Hans, K; Heim, M; Hruska, D; Mende, S; Pritsch, M; Schroeder, M; Wolf, M | 1 |
| Eguchi, K; Goya, T; Kojima, A; Kondou, H; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T; Yamada, K | 1 |
| Ahlgren, JD; Ellison, NM; Fryer, JG; Heim, WJ; Wampler, GL | 1 |
| Burt, P; Prendiville, J; Radford, J; Ranson, M; Steward, W; Stout, R; Thatcher, N | 1 |
| Biscottini, B; Cellerino, R; Fatati, G; Guidi, F; Isidori, P; Raspugli, M; Tummarello, D | 1 |
| Cherryman, G; Hoskin, PJ; Parton, D; Smith, IE; Yarnold, JR | 1 |
| Hooi, LM; Iredale, JP; Kerr, KM; Sudlow, MF; Wathen, CG | 1 |
| Bergman, B; Bork, E; Dombernowsky, P; Ersbøll, J; Hansen, HH; Hansen, M | 1 |
| Fairey, R; Goddard, K; Grafton, C; Karsai, H; Murray, N; Osoba, D; Page, R; Shah, A; Voss, N | 1 |
| Ash, CM; Earl, HM; Eraut, D; Geddes, DM; Harper, PG; James, LE; Law, CS; Rudd, RM; Spiro, SG; Tobias, JS | 1 |
| Flaherty, L; Heilbrun, L; Kraut, M; Martino, S; Redman, B; Valdivieso, M; Wozniak, A | 1 |
| Airoma, G; Garufi, C; Gebbia, V; Gentile, M; Gridelli, C; Iacobelli, S; Palmeri, S; Palmieri, G; Pepe, R; Russo, A | 1 |
| Hirata, Y; Mitsugi, K; Mori, T; Nakano, S; Niho, Y; Otuka, T; Tamari, Y; Tsuda, Y | 1 |
| de Jong, S; de Vries, EG; Mulder, NH; Zijlstra, JG | 2 |
| Ansari, R; Einhorn, LH; Eklund, E; Fisher, WB; Miller, ME | 1 |
| Gatzemeier, U; Heckmayr, M; Hossfeld, DK; Kaukel, E; Koschel, G; Neuhauss, R | 2 |
| Ellerbroek, NA; Glisson, BS; Holoye, PY; Hong, WK; Komaki, R; Pang, AC; Roth, JA; Ryan, MB; Zatopek, NK | 1 |
| Fujita, M; Honda, I; Kawabe, T; Kawakami, Y; Matsushita, K; Ryu, M; Watanabe, K; Watanabe, S; Yoshida, M | 1 |
| Achterrath, W; Drings, P; Goerg, C; Havemann, K; Tessen, HW; Wolf, M | 1 |
| O'Connor, BM; Spaulding, MB; Ziegler, P | 1 |
| Ikeda, S; Ishida, H; Kado, M; Kusume, K; Matsubara, Y; Matsui, Y; Ohshima, S; Satake, N; Yamamoto, Y | 1 |
| Angeletti, CA; Balbarini, A; Del Tacca, M; Macchiarini, P; Mariani, M; Mariotti, R; Mengozzi, G; Palagi, C; Petronio, AS; Squartini, F | 1 |
| Aoki, Y; Hiura, K; Katoh, O; Kuroki, S; Yamada, H | 1 |
| Fujisue, M; Fukuoka, M; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Morino, H; Nakagawa, K; Negoro, S; Takifuji, N | 1 |
| Ansari, R; Einhorn, LH; Loehrer, PJ; Logie, K; Saxman, S; Scullin, D; Stephens, D; Workman, F | 1 |
| Atikachai, B; Jiemsripong, K; Phothirat, C; Thongprasert, S | 1 |
| Anderson, H; Prendiville, J; Radford, JA; Swindell, R; Thatcher, N | 1 |
| Bellmunt, J; Bodi, R; Jolis, L; Mur, E; Navarro, M; Rubio, D; Solé, LA | 1 |
| Airoma, G; Bianco, AR; Contegiacomo, A; De Placido, S; Ferrante, G; Gentile, M; Gridelli, C; Lauria, R; Perrone, F | 1 |
| Horio, Y; Minami, H; Saka, H; Sakai, S; Shimokata, K | 1 |
| Chanda, ER; Cole, SP; Dicke, FP; Gerlach, JH; Mirski, SE | 1 |
| Abratt, RP; du Preez, HM; Kaschula, R | 1 |
| Fukuoka, M; Ito, K; Kudoh, S; Masuda, N; Matsui, K; Negoro, S; Ryu, S; Sakai, N; Takada, M; Takifuji, N | 1 |
| Dimbeck, H; Schmoll, HJ; Vallée, D; von Pawel, J; Wilke, H | 1 |
| Bagshawe, KD; Ivory, C; Kelly, MP; Phillips, P; Rustin, GJ | 1 |
| Baguley, BC; Finlay, GJ | 1 |
| Fukuoka, M; Kudo, S; Masuda, N; Negoro, S; Takada, M | 1 |
| Chang, SC; Hsu, JR; Perng, RP | 1 |
| Brambilla, C; Brambilla, E; Brichon, PY; Gazzeri, S; Jacrot, M; Morel, F; Moro, D; Nagy-Mignotte, H | 1 |
| Bagshawe, KD; Begent, RH; Bradley, J; Dawson, PM; Kulkarni, RP; Makey, AR; Newlands, ES; Reynolds, KW; Rustin, GJ; Theodorou, NA | 1 |
| Crawford, J; Grous, J; Johnson, D; Kris, M; Lyman, G; Ozer, H; Picozzi, V; Rausch, G; Stoller, R; Tabbara, I | 1 |
| Coleman, RE; Cornbleet, MA; Howard, GC; Taylor, RE; Whillis, D | 1 |
| Brattain, MG; Casazza, AM; Long, BH; Lorico, A; Wang, L; Wang, RC | 1 |
| Maca, RD | 1 |
| Ando, M; Fukui, I; Goto, S; Hagiwara, T; Kihara, K; Kitahara, S; Noro, A; Toyoshima, T; Tsujii, T; Tsukamoto, T | 1 |
| Beltrami, D; Maestri, A; Nielsen, I; Pazzi, P; Sartori, S; Trevisani, L | 1 |
| Bakri, YN; Nassar, M; Pedersen, P | 1 |
| Anderson, N; Bern, M; Lokich, J; Moore, C | 1 |
| DeConti, RC; Johnson, DH; Kallas, GJ; Keller, JH; Lee, J; Lyman, GH; Macdonald, J; Patterson, WP; Ringenberg, QS; Ruckdeschel, JC | 1 |
| Ishikawa, S; Kawaji, K; Mukai, J; Ogura, T; Okubo, A; Sano, T; Shimizu, E; Tani, K; Yamashita, T | 1 |
| Ash, CM; Earl, HM; Harper, PG; James, L; Miles, DW; Rudd, R; Souhami, RL; Spiro, SG; Tobias, JS; Trask, CW | 1 |
| Karsai, H; Little, C; Murray, N; Osoba, D; Page, R; Shah, A | 1 |
| Bonomi, P; Gale, M; Kittle, CF; Lee, MS; Phillips, A; Purl, S; Reddy, S; Rowland, K; Taylor, SG; Warren, W | 1 |
| Einhorn, LH | 5 |
| Fujii, S; Masakane, I | 1 |
| Armstrong, JG; Fass, DE; Kris, MG; Rosenstein, MM; Scher, HI; Zelefsky, MJ | 1 |
| Albain, K; Crowley, J; Goodman, GE; Livingston, RB; McCulloch, JH; Rivkin, SE | 1 |
| Coldman, AJ; Klasa, RJ; Murray, N | 1 |
| Evans, WK; Feld, R; Ginsberg, RJ; Johansen, E; Shepherd, FA | 1 |
| Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, FR; Osterlind, K; Pedersen, AG; Sörenson, S | 1 |
| Bungo, M; Fujita, J; Futami, H; Hashimoto, Y; Hata, Y; Irino, S; Kamei, M; Nakamura, H; Shiotani, T; Yamaji, Y | 1 |
| Adachi, N; Fujii, T; Haraguchi, M; Komatsu, T; Kurihara, N; Nakaoka, Y; Ota, K | 1 |
| Abratt, RP; de Groot, M; Goodman, HT; Jansen, ER; Salton, DG; Willcox, PA | 1 |
| Angeletti, CA; Basolo, F; Bruno, J; Hardin, M; Macchiarini, P | 1 |
| Morgan, SA; Smith, PJ; Watson, JV | 1 |
| Berendsen, HH; Postmus, PE; Sleyfer, DT; Smit, EF | 1 |
| Hatlevoll, R; Høst, H; Kaasa, S; Lund, E; Thorud, E | 1 |
| Anderson, G; Bowen, DR; Chappell, G; Smith, AP | 1 |
| Clancy, L; Daly, P; Kelly, P; O'Brien, AA | 1 |
| Bitran, JD; Comis, RL; Ettinger, DS; Harris, CL; Harwood, KV; Keller, JH; Langer, CJ; Losada, M | 1 |
| Asamoto, H; Fujii, H; Kawaguchi, H; Kawakami, A; Ozawa, Y; Sawano, T; Tsutsumi, T | 1 |
| Bessonnat, JF; Brune, J; Gharib, C; Ploton, C; Sassolas, G; Trillet, V; Yoanidis, I | 1 |
| Ebe, T; Hatakeyama, S; Kohmura, K | 1 |
| Greifenberg, B; Kaukel, E; Koschel, G; Patzer, DC | 1 |
| Arnaud, A; Balmes, P; Bonnaud, F; Kleisbauer, JP; Poirier, R; Targhetta, R; Taytard, A; Thomas, P; Touron, D; Vergeret, J | 1 |
| Gazdar, AF; Ihde, DC; Kadoyama, C; Tsai, CM; Venzon, D | 1 |
| Bureau, G; Dabouis, G; Klastersky, J; Lecomte, J; Libert, P; Michel, J; Ravez, P; Sculier, JP; Thiriaux, J; Vandermoten, G | 1 |
| Fukuchi, Y; Ishida, K; Jo, C; Matsuse, T; Nagase, T; Orimo, H; Teramoto, S; Yamaoka, M | 1 |
| Canova, N; Casadio, M; Guaraldi, M; Lelli, G; Pannuti, F | 1 |
| Andersen, M; Hansen, HH; Kristjansen, PE | 1 |
| Fujiwara, Y; Kanzawa, F; Minato, K; Nakagawa, K; Nishio, K; Saijo, N | 1 |
| Ajarim, DS; Harakati, MS; Santhosh-Kumar, CR; Vijayaraghavan, R | 1 |
| Horie, S; Iwasaki, N; Nagai, S; Seki, Y; Shimada, K | 1 |
| Ekimoto, H; Ishii, T; Kusama, K; Okamoto, K; Takahashi, K | 1 |
| Akiba, Y; Fujikane, T; Fujiuchi, S; Ishida, S; Matsumoto, H; Nakano, H; Ohosaki, Y; Onodera, S; Osanai, S; Tsuji, T | 1 |
| Fukuoka, M; Kawahara, M; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Tachikawa, A; Takada, M; Takifuji, N | 1 |
| Comis, RL; Graziano, SL; Green, M; Hayes, DM; Lee, K; Propert, KJ; Tinsley, R | 1 |
| Gilsanz, V; Isaacs, H; Laug, W; Ortega, JA; Ozkaynak, MF | 1 |
| Brunk, SF; Dalton, RJ; Everson, L; Jett, JR; Krook, JE; Mailliard, JA; Marschke, RF; Therneau, TM; Twito, DI; Veeder, MH | 1 |
| Beck, TM; Blasko, JC; Bukowski, RM; Crowley, JJ; Demattia, MD; Goodman, GE; Livingston, RB | 1 |
| Amino, Y; Asada, Y; Fujita, J; Irino, S; Kobayashi, M; Nagai, M; Takigawa, K; Wakana, M | 1 |
| Ash, CM; Earl, HM; Geddes, DM; Harper, PG; Quinn, H; Souhami, RL; Spiro, SG; Tobias, JS; Twelves, CJ | 1 |
| Coltman, CA; Crowley, JJ; Epstein, RB; Kim, PN; Neilan, B; O'Bryan, RM; Pazdur, R; Stuckey, WJ | 1 |
| Abeloff, MD; Aisner, SC; Eggleston, JC; Ettinger, DS; Finkelstein, DM; Ruckdeschel, JC | 1 |
| Binaschi, M; Capranico, G; De Isabella, P; Mariani, M; Supino, R; Tinelli, S; Zunino, F | 1 |
| Dubbelman, R; Franklin, H; McVie, JG; Simonetti, G; ten Bokkel Huinink, WW; van Tinteren, H; van Zandwijk, N; Wanders, J | 1 |
| Bureau, G; Cordier, R; Dabouis, G; Klastersky, J; Lecomte, J; Libert, P; Ravez, P; Sculier, JP; Thiriaux, J; Vandermoten, G | 2 |
| Achterrath, W; Gatzemeier, U; Heckmayr, M; Hossfeld, D; Lenaz, L; Neuhauss, R | 1 |
| Einhorn, LH; McClean, J; Pennington, K | 1 |
| Lind, M; Thatcher, N | 1 |
| Berendsen, HH; Carney, DN; Grogan, L; Harford, P; Postmus, PE; Smit, EF | 1 |
| Greco, FA; Hainsworth, JD; Johnson, DH | 1 |
| Abratt, RP; Bolding, E; Hewitson, RH; Willcox, PA | 1 |
| Miller, AA; Stewart, CF; Tolley, EA | 1 |
| Ball, D; Bishop, JF; Bull, C; Friedlander, M; Kefford, R; Olver, IN; Raghavan, D; Stuart-Harris, R; Yuen, K; Zalcberg, J | 1 |
| Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Ohshima, S; Suzuki, A; Tagaki, S | 1 |
| Asamoto, H; Fujii, H; Kawakami, A; Ozawa, Y; Tsutsumi, T | 1 |
| Kajanti, M; Mattson, K; Niiranen, A; Tammilehto, L | 1 |
| Creger, RJ; Lazarus, HM; Spitzer, TR | 1 |
| Fukuoka, M; Kubota, K; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Ryu, S; Sakai, N; Takada, M; Takifuji, N | 1 |
| Anderson, H; Carroll, KB; Lind, MJ; Swindell, R; Thatcher, N; Woodcock, A | 1 |
| Ballatori, E; Buzzi, F; Corgna, E; Crino, L; Darwish, S; Di Costanzo, F; Fornari, G; Meacci, ML; Santi, E; Tonato, M | 1 |
| Baker, LH; Crowley, JJ; Giri, PG; Gordon, W; Janaki, LM; Kuebler, JP; Mansouri, A; McCracken, JD; Taylor, SA; Weiss, GB | 1 |
| Ashley, SA; Ford, HT; Forgeson, GV; Perren, TJ; Smith, IE; Woodiwiss, J; Yarnold, JR | 1 |
| Evans, WK; Goss, PE; Latreille, J; Logan, D; Maroun, J; Shepherd, FA; Stewart, D; Warner, E | 1 |
| Demant, EJ; Hansen, HH; Jensen, PB; Jensen, PS; Sehested, M; Sørensen, BS; Vindeløv, L | 1 |
| Bernard, JP; Brune, J; Champel, F; Chauvin, F; Clavel, M; Cordier, JF; Emonot, A; Guérin, JC; Kalb, JC; Trillet, V | 1 |
| Leung, WT; Pang, JC; Shiu, WC | 1 |
| Brandes, A; Cipriani, A; Favaretto, A; Festi, G; Fornasiero, A; Ghiotto, C; Paccagnella, A; Pappagallo, G; Vinante, O; Volpi, A | 1 |
| Creger, RJ; Fox, RM; Lazarus, HM | 1 |
| Ardizzoni, A; Belli, M; Castagneto, B; Ferrara, G; Fusco, V; Gallo Curcio, C; Rosso, R; Rubagotti, A; Salvati, F; Sassi, M | 1 |
| Horiguchi, T; Kawahara, S; Kiura, K; Mima, Y; Moritaka, T; Nishii, K; Numata, T; Ohnoshi, T; Ueoka, H; Yonei, T | 1 |
| Fukuoka, M; Furuse, K; Kawahara, M; Masuda, N; Matsui, K; Negoro, S; Takada, M; Takifuji, N | 1 |
| Brenez, D; Devriendt, J; Lenclud, C; Schmerber, J | 1 |
| Gatzemeier, U; Heckmayr, M; Hossfeld, DK; Koschel, G; Thies, F; Zschaber, R | 1 |
| Eich, F; Emser, W; Sybrecht, GW | 1 |
| Achterrath, W; Gatzemeier, U; Heckmayr, M; Hossfeld, DK; Neuhauss, R; Reck, M; Zschaber, R | 1 |
| Achterrath, W; Gatzemeier, U; Heckmayr, M; Hossfeld, DK | 1 |
| Arnold, A; Figueredo, A; Findlay, B; Goodyear, M; Jones, A; Neville, A; Normandeau, R | 1 |
| Blotta, A; Boltri, B; Busutti, L; Casadio, M; Falcone, F; Giordani, S; Lelli, G; Pannuti, F; Ramini, R | 1 |
| Alexander, RB; Gazdar, AF; Giaccone, G; Kadoyama, C; Maneckjee, R; Venzon, D | 1 |
| Chasen, MR; Falkson, G; Falkson, HC | 1 |
| Cellerino, R; Dazzi, C; Guidi, F; Isidori, P; Rossi, A; Torresi, U; Tummarello, D | 1 |
| Jakobsson, M; Järvinen, M; Liippo, K; Nikkanen, V; Nordman, E; Ojala, A; Paloheimo, S | 1 |
| Bureau, G; Dabouis, G; Klastersky, J; Lacroix, H; Libert, P; Ravez, P; Richez, M; Sculier, JP; Thiriaux, J; Vandermoten, G | 1 |
| Bronchud, MH; Kamthan, AG; Lind, MJ; Ranson, MR; Steward, WP; Stout, R; Thatcher, N | 1 |
| Ando, T; Hao, K; Miyashita, M; Onda, M; Sasajima, K; Takubo, K; Watanabe, M; Yamashita, K | 1 |
| Blancy, E; Bugat, R; Canal, P; Chatelut, E; Chevreau, C; Houin, G; Lequellec, A; Roche, H | 1 |
| Slevin, ML | 1 |
| Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Strupp, J | 1 |
| Bedini, AV; Bidoli, P; Casali, P; Guzzon, A; Santoro, A; Spinazzè, S | 1 |
| Doyle, LA; Goldstein, LH; Hamburger, AW; Park, HJ | 1 |
| Arriagada, R; Daurès, JP; Douillard, JY; Dubois, JB; Godard, P; Le Chevalier, T; Mary, H; Pujol, JL; Rossi, JF; Rouanet, P | 1 |
| Angeletti, CA; Chella, A; Macchiarini, P; Mengozzi, G; Riva, A; Silvano, G; Solfanelli, S | 1 |
| Bonomi, P; Faber, LP; Hendrickson, FR; Kittle, CF; Lee, MS; Recine, D; Reddy, S; Rowland, K; Taylor, S; Warren, W | 1 |
| Lacroix, H; Sculier, JP | 1 |
| Andres, DF; Etzell, PS; Goldberg, RM; Jett, JR; Johnson, PS; Krook, JE; Owen, D; Therneau, TM; Tschetter, LK; Veeder, MH | 1 |
| Arriagada, R; Baldeyrou, P; Cerrina, ML; Chomy, P; De Cremoux, H; le Chevalier, T; Martin, M; Pellae-Cosset, B; Ruffie, P; Tarayre, M | 1 |
| Fukuda, M; Matsuno, Y; Morita, M; Noguchi, M; Saijo, N; Sasaki, Y; Tsuchiya, R | 1 |
| Choi, NC | 1 |
| Glover, DJ; Turrisi, AT | 1 |
| Berthiot, G; Cattan, A; Marechal, F | 1 |
| Ardizzoni, A; Baldini, E; Corcione, A; Ferrarini, M; Intra, E; Mazzanti, P; Pennucci, MC; Pistoia, V; Rosso, R; Sertoli, MR | 1 |
| Beauduin, M; Bosly, A; Duprez, P; Humblet, Y; Majois, F; Prignot, J; Schallier, D; Symann, M; Weynants, P | 1 |
| Bacchi, M; Bassi, P; Belsanti, V; Bisagni, G; Boni, C; Cocconi, G; Lottici, R; Passalacqua, R; Tonato, M | 1 |
| Heinonen, E; Liippo, K; Nikkanen, V | 1 |
| D'Incalci, M; Figoli, F; Montaldo, PG; Sorio, R; Tirelli, U; Zanette, ML; Zucchetti, M | 1 |
| Senter, PD | 1 |
| Arai, K; Mori, H; Ogino, M; Okinaga, S; Sakamoto, T; Yamamoto, T | 1 |
| Berendsen, HH; Postmus, PE; Smit, EF | 1 |
| Herkert, A; Kleisbauer, JP; Soyez, F; Thomas, P | 1 |
| Basler, GA; Casazza, AM; Crosswell, AR; Rose, WC; Saulnier, M; Trail, PA | 1 |
| Ishii, Y; Matsumoto, S; Murashima, N; Ohsaki, A; Seno, N; Yoshimoto, A | 1 |
| Fujita, J; Saijo, N | 1 |
| Milani, A; Piva, L; Pizzocaro, G; Salvioni, R; Zanoni, F | 1 |
| Evans, WK; Osoba, D; Rusthoven, JJ; Shepherd, FA; Turnbull, KA | 1 |
| Babaya, K; Hirao, Y; Kubota, K; Natsume, O; Okajima, E; Ozono, S; Tsumatani, K; Yoshie, T | 1 |
| Bagshawe, KD; Begent, RH; Crawford, SM; Newlands, ES; Rustin, GJ | 1 |
| Cantwell, BM; Hall, RR; Harris, AL; Patrick, D | 1 |
| Bassoulet, J; Garetta, L; Raoul, Y | 1 |
| Evans, WK; Osoba, D; Rusthoven, JJ; Turnbull, KA | 1 |
| Ito, M | 1 |
| Cole, SP; Gerlach, JH; Mirski, SE | 1 |
| Dombrowski, H; Drings, P; Hans, K; Harms, V; Havemann, K; Holle, R; Victor, N; Wolf, M | 1 |
| Carter, GE; Daniels, JR; Lieskovsky, G; Skinner, DG | 1 |
| Beattie, EJ; Benedetto, P; Davila, E; Donnelly, E; Fountzilas, G; Hilsenbeck, S; Rao, RK; Sridhar, KS; Thurer, RJ; Varki, J | 1 |
| Bliss, B; MacLeod, PM; Tyrrell, CJ | 1 |
| Alton, NK; Bronchud, M; Crowther, D; Dexter, TM; Scarffe, JH; Souza, LM; Testa, NG; Thatcher, N | 1 |
| Carney, DN; Harford, P; Postmus, PE; Sleijfer, DT; Smit, EF | 1 |
| Bisagni, G; Boni, C; Ceci, G; Cocconi, G; Peracchia, G | 1 |
| Hasegawa, K; Hino, M; Kobayashi, K; Kurane, S; Niitani, H; Tuboi, E; Yamano, Y; Yano, T | 1 |
| Postmus, PE; Sleijfer, DT; Smit, EF | 1 |
| Comis, R; Goodlow, J; Hong, WK; Hurtubise, M; Lanzotti, V; Lawson, R; Luedke, D; Maroun, JA; Nicaise, C; Speer, J | 1 |
| Haaxma-Reiche, H; Kirkpatrick, A; Kleisbauer, JP; McVie, JG; Postmus, PE; Sleijfer, DT | 1 |
| Berendsen, HH; Haaxma-Reiche, H; Postmus, PE; Sleijfer, DT | 1 |
| Drings, P | 1 |
| Becker, H; Drings, P; Flechtner, H; Goerg, R; Hans, K; Havemann, K; Holle, R; Schroeder, M; Wolf, M | 1 |
| Bibby, RJ; Edge, JR; Horsfield, N; Johnson, CE; McIllmurray, MB; O'Reilly, JF; Ormerod, LP; Taylor, BE; Willey, RF; Wolstenholme, RJ | 1 |
| Jett, JR; Krook, JE; Little, C | 1 |
| Ash, CM; Eraut, D; Geddes, DM; Harper, PG; Partridge, M; Quinn, H; Souhami, RL; Spiro, SG; Tobias, JS | 1 |
| Alciato, P; Cantone, PA; Fico, D; Gagliardini, R; Petrella, V | 1 |
| Hiraki, S; Kawahara, S; Kiura, K; Kozuka, A; Nishii, K; Numata, T; Ohnoshi, T; Ueoka, H; Yamashta, H; Yonei, T | 1 |
| Collins, C; Griffin, BR; Higano, CS; Keppen, MD; Livingston, RB; Miller, TP | 1 |
| Hiraki, S; Kawahara, S; Kiura, K; Moritaka, T; Nishii, K; Numata, T; Ohnoshi, T; Ueoka, H; Yamashita, H; Yonei, T | 1 |
| Bungo, M; Fujita, J; Futami, H; Hashimoto, Y; Hata, Y; Irino, S; Iuchi, Y; Kamei, M; Nakamura, H; Yamaji, Y | 1 |
| Fujita, J; Futami, H; Hashimoto, Y; Irino, S; Murata, M; Shimada, Y; Shiotani, T; Yamaji, Y | 1 |
| Ash, CM; Earl, HM; Geddes, DM; Harper, PG; Morittu, L; Souhami, RL; Spiro, SG; Tobias, JS | 1 |
| Banham, SW; Milroy, R; Shapiro, D; Shenkin, A | 1 |
| Bitran, JD; Ferguson, MK; Golomb, HM; Hoffman, PC; Vokes, EE; Weichselbaum, RR | 1 |
| Dhingra, HM; Glisson, BS; Holoye, PY; Hong, WK; Lee, JS; Murphy, WK | 1 |
| Gazdar, AF; Ihde, DC; Linnoila, RI; Oie, HK; Russell, EK; Steinberg, SM; Stevenson, HC | 1 |
| Adamo, V; Alafaci, E; Altavilla, G; Buemi, B; Caristi, N; Condemi, G; Toscano, G | 1 |
| Granger, E; Hammer, BD; Negron, FJ; Paglen, PG; Spaide, RF | 1 |
| Ihde, DC; Viallet, J | 1 |
| Chahinian, AP; Comis, RL; Hirsh, V; Holland, JF; Kopel, S; Perry, MC; Propert, KJ; Skarin, A; Ware, JH; Zimmer, B | 1 |
| Cullinan, SA; Dalton, RJ; Everson, LK; Gerstner, JB; Jett, JR; Krook, JE; Mailliard, JA; Morton, RF; O'Fallon, JR; Tschetter, LK | 1 |
| Ash, CM; Earl, HM; Geddes, DM; Goldstone, AH; Hajichristou, HT; Harper, PG; Miles, DW; Souhami, RL; Spiro, SG; Tobias, JS | 1 |
| Holsti, LR; Holsti, P; Mattson, K; Niitamo-Korhonen, S; Pyrhönen, S | 1 |
| Benfield, GF; Collins, FJ; Cullen, MH; Matthews, HR; Watson, DC | 1 |
| Abrams, J; Aisner, J | 1 |
| Cerny, T; Lind, M; Stout, R; Swindell, R; Thatcher, N | 1 |
| Clark, PI; Gregory, WM; Joel, SP; Lowe, DG; Malik, S; Osborne, RJ; Reznek, RH; Slevin, ML; Wrigley, PF | 1 |
| Ohnoshi, T | 1 |
| Arriagada, R; de Cremoux, H; de The, H; Dewar, J; Duroux, P; Le Chevalier, T; Martin, M; Ruffie, P; Sancho-Garnier, H; Thomas, F | 1 |
| Amadori, D; Ardizzone, A; Cruciani, G; Fiorentini, G; Leoni, M; Marangolo, M; Ravaioli, A; Rosti, G; Sebastiani, L; Tienghi, A | 1 |
| Della Valentina, M; Errante, D; Figoli, F; Magri, MD; Monfardini, S; Talamini, R; Trovo, MG; Veronesi, A; Zagonel, V | 1 |
| Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A | 1 |
| Kawano, Y; Mukai, J; Nakamura, Y; Nakanishi, M; Ogura, T; Shimizu, E; Sone, S; Takaue, Y; Watanabe, T | 1 |
| Campbell, C; Carroll, KB; Lind, M; Moussalli, H; Payne, C; Stout, R; Thatcher, N | 1 |
| Carbone, PP; Dreicer, R; Frontiera, M; Rosenquist, D; Schiller, JH; Storer, B | 1 |
| Adachi, M; Fujii, S; Nakajima, K; Sugai, Y; Ueno, K | 1 |
| Eguchi, K; Fujiwara, Y; Kojima, A; Minato, K; Nakagawa, K; Nakajima, T; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Abrams, JS; Aisner, J; Belani, CP; Egorin, MJ; Eisenberger, M; Hiponia, D; Van Echo, DA | 1 |
| Burton, JK; Creagan, ET; Eagan, RT; Frytak, S; Ilstrup, DM; Jett, JR; Lee, RE; Richardson, RL; Robinow, JS; Shaw, EG | 1 |
| Biscottini, B; Cellerino, R; Fatati, G; Guidi, F; Isidori, P; Porfiri, E; Raspugli, M; Tummarello, D | 2 |
| Alberti, W; Budach, V; Eberhardt, W; Hirche, H; Niederle, N; Schmidt, CG; Schütte, J; Seeber, S | 1 |
| Beauduin, M; Bosly, A; Delaunois, L; Duprez, P; Francis, C; Gailly, C; Humblet, Y; Machiels, J; Majois, F; Weynants, P | 1 |
| Errington, RD; Green, JA; Hardman, PD; Myint, S; Warenius, HM | 1 |
| Bagshawe, KD; Begent, RH; Crawford, SM; Glaser, MG; Newlands, ES; Parker, D; Rustin, GJ; Southcott, BM; Ward, AJ | 1 |
| Carney, DN; Grogan, L; Harford, P; Kearns, F | 1 |
| Janic, G; Jassem, J; Karnicka-Młodkowska, H; Roszkowski, K; Rowińska-Zakrzewska, E; Szczepek, B; Traczyk, K; Zych, J | 1 |
| Ajani, JA; Baker, FL; Blaauw, AA; Dicke, KA; Spitzer, G; Thielvoldt, D; Tomasovic, B; Umbach, G; Zander, AR | 1 |
| Hezaber, JE; Hoshi, S; Ioritani, N; Kageyama, S; Oikawa, K; Orikasa, S; Taguchi, K; Takahashi, M; Tochigi, T; Yoshikawa, K | 1 |
| Fukuchi, Y; Homma, S; Marumo, K; Matsuse, T; Nagase, T; Orimo, H; Suruda, T; Yamaoka, M; Yoshikawa, M | 1 |
| Beattie, EJ; Saldana, MJ; Sridhar, KS; Thurer, RJ | 1 |
| Casadio, M; Farris, A; Giordani, S; Lelli, G; Pannuti, F; Tononi, A | 1 |
| Daugherty, JP; Fanning, J; Weese, JL | 1 |
| Ashe, SA; Hellström, I; Hellström, KE; Hirschberg, DL; Schreiber, GJ; Senter, PD | 1 |
| McVie, G; Muggia, FM | 1 |
| Clark, DA; Coy, P; Evans, WK; Feld, R; Levitt, M; MacDonald, A; Murray, N; Osoba, D; Shepherd, FA; Willan, A | 1 |
| Evans, WK; Feld, R; MacCormick, R; Shepherd, FA; Yau, JC | 1 |
| Fletcher, J; Gilson, D; Morgan, DA | 1 |
| Lankelma, J; Pinedo, HM; Stam, J; van Hoogenhuijze, J | 1 |
| Atassi, G; de Franquen, P; Dumont, P; Jacobovitz, D; Klastersky, J; Lejeune, F; Rocmans, P; Semal, P; Tueni, EA | 1 |
| Aroney, R; Bishop, JF; Gianoutsos, P; Kefford, R; Lee, J; Morstyn, G; Olver, IN; Raghavan, D; Stuart-Harris, R; Yuen, K | 1 |
| Buchanan, R; Herbert, A; Jefferys, M; Lea, R; McMillan, I; Mead, G; Sweetenham, J; Thompson, J; Whitehouse, JM; Williams, CJ | 1 |
| Bitran, JD; Hoffman, PC; Kaminer, LS; Larson, RA; Le Beau, MM; Purl, S; Ratain, MJ; Skosey, C; Vardiman, JW; Wade, J | 1 |
| Anderson, H; Barber, PV; Barnes, P; Cerny, T; Deiraniya, A; Stout, R; Thatcher, N; Wolstenholme, RJ | 1 |
| Chikata, E; Hara, K; Ito, F; Kado, M; Kanda, T; Matsui, Y; Nakayama, M; Oshima, S; Sakai, S; Shimokata, K | 1 |
| Bai, L; Feng, FY; Qiu, Q; Song, SZ; Sun, Y; Wang, JW; Wang, QL; Yin, WB; Zhou, JC | 1 |
| Bakker, W; Berendsen, HH; Burghouts, JT; Postmus, PE; Splinter, TA; van Zandwijk, N | 1 |
| Carey, RW; Choi, N; Green, M; Kwiatkowski, DJ; Propert, KJ | 1 |
| Dommes, M; Drings, P; Gropp, C; Hans, K; Havemann, K; Heim, M; Holle, R; Mende, S; Schroeder, M; Wolf, M | 1 |
| Chiuten, DF; Dhingra, HM; Holoye, PY; Jeffries, D; Lee, JS; Murphy, WK; Neidhart, JA; Umsawasdi, T | 1 |
| Lebeau, B | 1 |
| Sculier, JP | 1 |
| Arriagada, R; Baume, D; Beaujean, F; Gouyette, A; Hayat, M; Le Chevalier, T; Ostronoff, M; Pico, JL; Rebattu, P | 1 |
| Ardizzoni, A; Baracco, F; Capaccio, A; Fabiano, F; Felletti, R; Fusco, V; Gulisano, M; Nosenzo, M; Pastorino, G; Pronzato, P | 1 |
| Calciati, A; Donadio, M; Ferrati, P; Giaccone, G; Testore, F | 1 |
| Coy, P; Evans, WK; Feld, R; Hodson, I; MacDonald, AS; Osoba, D; Pater, JL; Payne, DG | 1 |
| Høst, H; Kaasa, S; Lien, HH; Lund, E; Sjølie, I; Thorud, E | 1 |
| Ito, K; Kanamori, K; Kanno, M; Kobayashi, K; Kondo, K; Matsuda, T; Nakamura, S; Nakazumi, Y; Yoshida, T | 1 |
| Brincker, H; Hansen, PV; Hindberg, J | 1 |
| Farmer, ER; Friedman, KJ; Hood, AF; Yokel, BK | 1 |
| Birch, R; Crawford, J; Einhorn, LH; Greco, FA; Johnson, DH; Omura, G | 1 |
| Bonomi, P; Lee, MS; Maffey, S; Reddy, S; Rowland, KM; Taylor, SG | 1 |
| Bonomi, P; Faber, LP; Kittle, CF; Lee, MS; Pincus, M; Reddy, S; Rowland, KM; Taylor, SG; Warren, W | 1 |
| Bandou, H; Doi, H; Fukuta, K; Kinoshita, S; Matsuura, A; Nakamura, T; Ogura, T; Shimizu, E; Yamasaki, K; Yamashita, T | 1 |
| Bozzino, JM; Cantwell, BM; Corris, P; Harris, AL | 1 |
| Ardizzoni, A; Bruschi, G; Canobbio, L; Figoli, F; Lo Re, G; Mazza, F; Monfardini, S; Rosso, R; Veronesi, A; Zagonel, V | 1 |
| Higuchi, Y; Hisa, S; Hoshi, K; Kimura, K; Moriya, H; Satoh, T; Suzuki, S | 1 |
| Maroun, JA; Natale, RB; Robert, F | 1 |
| Cellerino, R; Guidi, F; Isidori, P; Porfiri, E; Raspugli, M; Tummarello, D | 1 |
| Engelhardt, R | 1 |
| Becquart, D; Klastersky, J; Libert, P; Longeval, E; Ravez, P; Rocmans, P; Sculier, JP; Thiriaux, J; van Houtte, P; Vandermoten, G | 1 |
| Baba, M; Kimura, H; Momiki, S; Ogawa, T; Yamaguchi, Y | 1 |
| Fukuoka, M; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Ryu, S; Sakai, N; Takada, M; Takifuji, N; Yamamoto, H | 1 |
| Weitberg, AB | 1 |
| Glover, DJ; Mason, BA; Turrisi, AT | 2 |
| Bonomi, P; Faber, LP; Hendrickson, FR; Kittle, CF; Lee, MS; Pincus, M; Reddy, S; Rowland, K; Taylor, S; Warren, W | 1 |
| Creagan, ET; Kovach, JS; Richardson, RL | 1 |
| Benedetto, P; Charyulu, KK; Davila, E; Donnelly, E; Fountzilas, G; Kim, Y; Saldana, MJ; Sridhar, KS; Thompson, T; Thurer, R | 1 |
| Einhorn, LH; Greco, FA; Loehrer, PJ | 1 |
| Klastersky, J | 3 |
| Ishizuka, T; Minato, K; Saito, R; Tsuchiya, S | 1 |
| Ashley, SE; Cherryman, G; Glaholm, J; Magrini, S; Repetto, L; Smith, IE; Yarnold, JR | 1 |
| Carpenter, JT; Christian, ES; Salter, MM; Schreeder, M; Stephens, SB; Wheeler, RH | 1 |
| Akman, S; Carr, B; Doroshow, J; Leong, L; Margolin, K | 1 |
| Banham, SW; Blackie, RB; Cummings, J; Cunningham, D; Kaye, SB; McTaggart, L; Soukop, M | 1 |
| Evans, WK; Feld, R; Goodwin, PJ; Pater, J | 1 |
| Achterrath, W; Gunzer, U; Lenaz, L; Preusser, P; Schmoll, HJ; Wilke, H | 1 |
| Ardizzoni, A; Canobbio, L; Carbone, A; Franceschi, S; Magri, MD; Mazza, F; Rosso, R; Talamini, R; Tirelli, U; Veronesi, A | 1 |
| Boossy, J; Focan, C; Schallier, D; Vandermoten, G | 1 |
| Smeets, J; Utama, I; Wils, J | 1 |
| Arai, R; Furuse, K; Kawahara, M; Kawano, S; Kodama, N; Kubota, K; Nakai, R; Ogawara, M; Tsuruta, M; Yamamoto, M | 1 |
| Becker, H; Gropp, C; Hans, K; Havemann, K; Klasen, H; Maasberg, M; Schroeder, M; Stalleicken, D; von Bültzingslöwen, F; Wolf, M | 1 |
| Kaasa, S; Mastekaasa, A; Thorud, E | 1 |
| Ayoub, J; Eisenhauer, E; Evans, WK; Feld, R; Hughes, P; Maroun, JA; Shepherd, FA | 1 |
| Beaujean, F; Benard, J; Bettan-Renaud, L; Gavoille, A; Lopez, M; Pico, JL; Riou, G | 1 |
| Ardizzoni, A; Brunetti, I; Crucsiani, AR; DePalma, M; Fusco, V; Gallo-Curcio, C; Portalone, L; Rosso, R; Rubagotti, A; Salvati, F | 1 |
| Ballatori, E; Buzzi, F; Corgna, E; Crinó, L; Darwish, S; Di Costanzo, F; Fornari, G; Luccioli, L; Meacci, ML; Santi, F | 1 |
| Becker, H; Bülzebruck, H; Djawid, N; Drings, P; Ruchalla, E; Stiefel, P; Tessen, HW | 1 |
| Gatzemeier, U; Heilmann, HP; Hossfeld, DK; Kaukel, E; Koschel, G; Zschaber, R | 1 |
| Berendsen, HH; Haaxma-Reiche, H; Postmus, PE | 1 |
| Green, JA; Tarpey, AW; Warenius, HM | 1 |
| Brust, J; Paschke, R; Queisser, W; Worst, P | 1 |
| Devriendt, J; Klastersky, J; Michel, J; Mommen, P; Nguyen, H; Renaud, A; Sculier, JP; Van Houtte, P; Vandermoten, G | 1 |
| Achard, JL; Beaupain, R; Dionet, C; Fraysse, P; Roux, D; Rozan, R; Verrelle, P | 1 |
| Coy, P; Feld, R; Hodson, I; Payne, D | 1 |
| Høst, H; Kaasa, S; Olsnes, BT; Thorud, E | 1 |
| Figueredo, AT; Frank, G; Hryniuk, WM; Rendell, S; Strautmanis, I | 1 |
| Bazos, MJ; DeBoer, G; Evans, WK; Feld, R; Osoba, D; Shepherd, FA | 1 |
| Anderson, PN; Baker, LH; Comis, RL; Daniels, JR; Einhorn, LH; Harvey, HA; Issell, BF; Lanzotti, VA; Lawson, RD; Wampler, GL | 1 |
| D'Incalci, M; Mangioni, C; Rossi, C; Roviaro, G; Sessa, C | 1 |
| Greco, FA; Grosh, WW; Hainsworth, JD; Hande, KR; Johnson, DH; Porter, LL; Wolff, SN | 1 |
| Carr, DT; Chiuten, DF; Dhingra, HM; Farha, P; Murphy, WK; Spitzer, G; Umsawasdi, T; Valdivieso, M | 1 |
| Abeloff, MD; Berkman, AW; Markman, M; Waterfield, WC | 1 |
| Abratt, RP; Levin, W | 1 |
| Alonso, MT; Leyland-Jones, B; Marsoni, S; O'Dwyer, PJ; Wittes, RE | 1 |
| Ahmedzai, S; Banham, S; Burnett, A; Cunningham, D; Dorward, A; Hutcheon, A; Kaye, S; Lucie, N; Soukop, M | 1 |
| Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Porter, LL; Wolff, SN | 2 |
| Bateman, NT; Bellamy, D; Calman, FM; Costello, J; Farebrother, M; Rubens, RD; Slevin, ML; Timothy, AR | 1 |
| Drings, P; Manke, HG | 1 |
| Kimura, K; Niitani, H; Yamada, K | 1 |
| Holoye, PY | 1 |
| Becquart, D; Dalesio, O; Dumont, JP; Klastersky, J; Longeval, E; Michel, J; Rocmans, P; Sculier, JP; Vandermoten, G | 1 |
| Adelstein, DJ; Hines, JD | 1 |
| Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Porter, LL | 1 |
| Danigel, H; Dellbrügge, J; Jungclas, H; Pflüger, KH; Schmidt, L | 1 |
| Barber, PV; Carroll, KB; Feinmann, D; James, RD; Lawson, BA; Steward, WP; Thatcher, N | 1 |
| Cate, CC; Curphey, TJ; Douple, EB; Maurer, LH; Pettengill, OS; Sorenson, GD | 1 |
| Bonomi, P; Bunting, N; Creech, RH; O'Reilly, W; Ruckdeschel, JC; Stolbach, L; Vogl, SE | 1 |
| Chikata, E; Hara, K; Ito, F; Kado, M; Kanda, T; Matsui, Y; Nakayama, M; Ohshima, S; Sakai, S; Shimokata, K | 1 |
| Bassett, H; Carroll, KB; Grötte, G; Smith, DB; Stout, R; Thatcher, N; Winson, M | 1 |
| Harvey, VJ; Joel, SP; Johnston, A; Slevin, ML; Wrigley, PF | 1 |
| Kimura, K; Niitani, H | 1 |
| Ahmedzai, S; Banham, SW; Cunningham, D; Dorward, A; Hutcheon, AH; Kaye, SB; Soukop, M; Stack, BR; Stevenson, RD; Tansey, P | 1 |
| Hansen, HH; Hansen, M; Osterlind, K; Pedersen, AG; Pedersen-Bjergaard, J; Philip, P | 1 |
| Harvey, VJ; Joel, SP; Johnston, A; Slevin, ML; Smythe, MM; Wrigley, PF | 1 |
| Anderson, G; Chappell, AG; James, KW; Littlewood, TJ; Smith, AP | 1 |
| Hara, K; Kado, M; Kanda, T; Matsui, Y; Oshima, S; Shima, K; Shimokata, K; Takenaka, S | 1 |
| Evans, BD; Smith, IE | 1 |
| Coy, P; Fryer, C; Goldie, J; Gudauskas, G; Hadzic, E; Klimo, P; Murray, N; Shah, A; Voss, N; Wilson, K | 1 |
| Bakaert, AB; De Broe, ME; Holthuis, JJ; Van de Vyver, FL; van Oort, WJ; Verleun, H | 1 |
| Livingston, RB | 1 |
| de Vries, EG; de Vries-Hospers, HG; Maas, A; Meinesz, AF; Mulder, NH; Mulder, PO; Postmus, PE; Sleijfer, DT | 1 |
| Chak, LY; Cox, RS; Kushlan, PD; Porzig, KJ; Sikic, BI; Wasserstein, P; Zatz, LM | 1 |
| Hiraga, Y; Ito, T; Konno, K; Nagahama, F; Nakabayashi, T; Nakai, Y; Oizumi, K; Sato, M; Takebe, K; Tamura, M | 1 |
| Peters, W; Souhami, R | 1 |
| Kinameri, K; Kurita, Y; Matsuura, N; Sano, K; Yokoyama, A | 1 |
| Hara, K; Ikebe, A; Ishizaki, T; Iwasaki, H; Kanda, T; Koteda, T; Nakano, M; Oka, M; Okuno, K; Tsutsumi, T | 1 |
| Choo, YC; Ma, HK; Wong, LC | 1 |
| Birch, R; Greco, FA; Sarma, P; Wolff, SN | 1 |
| Batist, G; Bunn, PA; Carney, DN; Cowan, KH; Gilliom, M; Ihde, DC; Veach, SR | 1 |
| Fukuda, Y; Homma, T; Nakata, M; Noguchi, Y; Yoneda, S; Yoshida, S | 1 |
| Colozza, MA; Crinò, L; Davis, S; Grignani, F; Lubansky, K; Tonato, M | 1 |
| Kerstjens, HA; Lo, GT; Meinesz, AF; Postmus, PE; Sleijfer, DT; Sluiter, HJ | 1 |
| Bentley, DP; Littlewood, TJ; Smith, AP | 2 |
| Alberto, P; Cavalli, F; Joss, R; Kaplan, S; Martz, G; Mermillod, B; Obrecht, JP | 1 |
| Hoshino, T; Kimura, K; Moriya, H; Yaginuma, K | 1 |
| Cummings, J; Cunningham, D; Forrest, GJ; McTaggart, L; Soukop, M; Stuart, JF | 1 |
| Coy, P; Evans, WK; Feld, R; Hodson, I; Levitt, M; Murray, N; Osoba, D; Pater, J; Shelley, W; Willan, A | 1 |
| DeBoer, G; Evans, WK; Feld, R; Osoba, D; Shepherd, FA | 1 |
| Band, P; Brown, E; Goldie, J; Kostashuk, E; Laukkanen, E; Murphy, K; Murray, N; Shah, A; Sparling, T; Van den Hoek, J | 1 |
| Crowley, J; Giri, PG; Gordon, W; Janaki, LM; McCracken, JD; Taylor, SB; Vance, RB; Weiss, GB | 1 |
| Bunn, PA; Einhorn, L; Greco, FA | 1 |
| Abrams, J; Aisner, J; Propert, K; Whitacre, M | 1 |
| Evans, TL | 1 |
| Bouvy, J; Burghouts, J; Dalesio, O; Dolman, B; Kho, S; Kok, T; Lameris, H; Palmen, F; Splinter, T; ten Kate, F | 1 |
| Hayashibe, A; Hino, M; Honda, R; Kitaya, T; Matsuyama, T; Nishiwaki, Y; Yano, H | 1 |
| Casadio, M; Giordani, S; Giuliotti, C; Lelli, G; Martoni, A; Pannuti, F; Strocchi, E | 1 |
| Bonduelle, Y; Klastersky, J; Libert, P; Mairesse, M; Michel, J; Michiels, T; Ravez, P; Rocmans, P; Sculier, JP; Vandermoten, G | 1 |
| Aisner, J; Fuks, JZ; Hornedo, J; Moody, M; Patel, H; Van Echo, DA | 1 |
| Ahmedzai, S; Banham, SW; Cunningham, D; Dorward, AJ; Gregor, A; Hutcheon, AW; Kaye, SB; Mackay, NS; Soukop, M; Stack, BH | 1 |
| Meyer, JA | 1 |
| Budd, GT; Coltman, CA; Crowley, JP; Grever, MR; Harker, G; Livingston, RB; Mira, JG; Rivkin, SE; Schulman, S; Vogel, S | 1 |
| Dixon, RH; Gottleib, RJ; Harvey, HA; Hoffman, SL; Lipton, A; Messeih, AA; Ricci, JA; Schweitzer, JM; Simmonds, MA; Stryker, JA | 1 |
| Díaz-Rubio García, E; González Larriba, JL; Martín Jiménez, M; Sangro Gómez-Acebo, B; Vila Borrajo, C | 1 |
| Barkley, HT; Benjamin, RS; Bodey, GP; Frankmann, C; Jeffries, DG; McMurtrey, MJ; Murphy, WK; Valdivieso, M; Welch, SR | 1 |
| Ardizzoni, A; Baracco, F; Benvenuto, F; Canobbio, L; Faravelli, B; Nosenzo, M; Pronzato, P; Repetto, L; Serrano, J; Simonassi, C | 1 |
| Evans, BD; Ford, HT; Gore, ME; Repetto, L; Smith, IE; Vincent, MD; Yarnold, JR | 1 |
| Drings, P; Gropp, C; Hans, K; Havemann, K; Heim, M; Holle, R; Manke, HG; Schroeder, M; Victor, N; Wolf, M | 1 |
| Aisner, J; Poplin, E; Thompson, B; Whitacre, M | 1 |
| Abel, U; Bülzebruck, H; Drings, P; Kleckow, M; Manke, HG; Stiefel, P | 1 |
| Eguchi, K; Nakajima, T; Ochi, H; Saijo, N; Sakurai, M; Sasaki, Y; Shinkai, T; Suemasu, K; Suga, J; Tominaga, K | 1 |
| Coles, DT; Creagan, ET; Eagan, RT; Frytak, S; Jett, JL; Lee, RE; Richardson, RL | 1 |
| Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, FR; Osterlind, K; Sørensson, S; Vindeløv, LL | 1 |
| Chen, TT; Coltman, CA; Crowley, JJ; Grozea, PN; Kies, MS; Livingston, RB; Mira, JG; Pazdur, R; Rivkin, SE; Ward, JH | 1 |
| Creagan, ET; Eagan, RT; Frytak, S; Lee, RE; Richardson, RL; Therneau, TM | 1 |
| Green, MR; Luikart, SD; Modeas, CR; Perry, MC; Propert, KJ | 1 |
| Abeloff, MD; Adelstein, DJ; Baker, RR; Eggleston, JC; Ettinger, DS; McKneally, MF; Ruckdeschel, JD; Woll, J | 1 |
| DeLeo, MJ; Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Wolff, SN | 1 |
| Neville, AJ; Remick, SC; Willson, JK | 1 |
| Balice, A; Basilico, L; Morera, E; Nuzzo, A; Peretti, G; Ursini, LA | 1 |
| Dalesio, O; Kirkpatrick, A; McVie, JG; van Zandwijk, N | 1 |
| Haaxma-Reiche, H; Kirkpatrick, A; Kleisbauer, JP; Postmus, PE; Sleijfer, DT; ten Velde, G | 1 |
| Clamon, GH; Glauber, J | 1 |
| Bien, R; Keohane, M; Papac, RJ; Son, Y; Tiedemann, D; Yesner, R | 1 |
| Arraztoa, J; Orlandi, L; Ramírez, G; Rodríguez, R; Vogel, C | 1 |
| Abratt, RP; Hewitson, RH; Willcox, PA | 1 |
| Coy, P; Evans, WK; Feld, R; Hodson, I; MacDonald, AS; Osoba, D; Pater, JL; Payne, D; Shelley, W | 1 |
| Klastersky, J; Sculier, JP; Tueni, E | 1 |
| Chen, KM; Hamburger, AW; Hoshi, A; Ishihara, J; Lee, YC; Saijo, N; Sakurai, M; Sano, T; Sasaki, Y; Takahashi, H | 1 |
| Fukuoka, M; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Ryu, S; Sakai, N; Takada, M; Takifuji, N; Tsubura, E | 1 |
| Ansari, R; Einhorn, LH; Fisher, WB; Lauer, RC; Loehrer, PJ; Pennington, K | 1 |
| Arends, JW; Blijham, GH; Braat, SH; de Haan, J; Hoogland, HJ; van Krimpen, C | 1 |
| Ayela, P; Frenay, M; Lagrange, JL; Schneider, M; Thyss, A; Viens, P | 1 |
| Aarbakke, J; Aasebø, U; Prytz, PS; Slørdal, L | 1 |
| Barreras, L; Manten, H; Saldana, MJ; Sridhar, KS | 1 |
| Blaive, B; Carles, P; Clary, C; Dongay, G; Guerin, JC; Kleisbauer, JP; Orehek, J; Poirier, R; Saretto, S; Vesco, D | 1 |
| Kaasa, S; Mastekaasa, A; Olsnes, BT | 1 |
| Creech, RH; Ettinger, DS; Finkelstein, DM; Joss, RA; Mason, BA; Ruckdeschel, JC; Vogl, S | 1 |
| Chiuten, D; Dhingra, HM; Dicke, K; Farha, P; Murphy, WK; Spitzer, G; Umsawasdi, T; Valdivieso, M; Vellekoop, L; Zander, A | 1 |
| Creger, RJ; Diaz, D; Lazarus, HM | 1 |
| Beard, DB; Haskell, CM | 1 |
| Grosh, WW; Hande, KR; Prater, K; Wolff, SN | 1 |
| Holthuis, JJ; Hulshoff, B; Mulder, NH; Postmus, PE; Sleijfer, DT; Van Oort, WJ; Verleun, H | 1 |
| Amato, G; Broggini, M; Colombo, T; D'Incalci, M; Erba, E; Vaghi, M | 1 |
| Ettinger, DS; Finkelstein, DM; Ruckdeschel, JC | 1 |
| Barnadas, A; Izquierdo, A; Lopez Lopez, JJ; Pallares, C; Piera, JM | 1 |
| Ardizzoni, A; Baracco, F; Canobbio, L; De Palma, M; Faravelli, B; Nosenzo, M; Pronzato, P; Rubagotti, A; Serrano, J; Serrano, S | 1 |
| Canobbio, L; Fassio, T; Gasparini, G; Villani, F | 1 |
| Bresson, ML; Cattan, A | 1 |
| Nishikawa, K; Okamoto, K; Takahashi, K; Uchida, T | 1 |
| Bonomi, P; Faber, LP; Lee, MS; Reddy, S; Rowland, K; Taylor, SG; Warren, W | 1 |
| Ettinger, DS; Harwood, KV; Rowinsky, EK | 1 |
| Christensen, IJ; Hansen, HH; Roed, H; Spang-Thomsen, M; Vindelov, LL | 1 |
| Calabresi, F; Greco, C; Sacchi, A; Zupi, G | 1 |
| Villalon, AH | 1 |
| Anderson, G; Payne, H | 1 |
| Bentley, DP; Littlewood, TJ; Spragg, BP | 1 |
| Eguchi, K; Fujita, J; Futami, H; Kimata, M; Saijo, N; Sasaki, Y; Shimizu, E; Shinkai, T; Takahashi, K; Tominaga, K | 1 |
| Albain, K; Bitran, JD; Evans, R; Golomb, HM; Hoffman, PC; Little, AG; Purl, S; Skosey, C | 1 |
| Birch, R; Enas, G; Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Porter, LL; Wolff, SN | 1 |
| Buccheri, G; Curcio, A; Ferrigno, D; Mattalia, E; Vola, F | 1 |
| Aasebø, U; Myhr, K | 1 |
| Albera, C; Bardessono, F; Gatti, E; Gozzelino, F; Lodico, D; Pescetti, G; Scagliotti, GV | 1 |
| Klastersky, J; Mommen, P; Sculier, JP | 1 |
| Nishikawa, K; Okamoto, K; Seki, T; Shibasaki, C; Takahashi, K; Uchida, T | 1 |
| Bertrand, M; Blayney, DW; Carr, BI; Cecchi, G; Doroshow, JH; Emont, E; Goldberg, D; Multhauf, P; Presant, C; Rappaport, D | 1 |
277 review(s) available for etoposide and Lung Neoplasms
| Article | Year |
|---|---|
Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Coordination Complexes; Etoposide; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2021 |
Durvalumab: A Review in Extensive-Stage SCLC.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
Update 2021: Management of Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
[MDT Treatment of Small Cell Lung Cancer Complicated with Adenocarcinoma:
A Case Report and Literature Review].
Topics: Adenocarcinoma of Lung; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2021 |
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Research Design; Small Cell Lung Carcinoma | 2022 |
Evolving role of immunotherapy in small cell lung cancer.
Topics: Etoposide; Humans; Immunologic Factors; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine | 2022 |
Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis-Case Report and Literature Review.
Topics: Aged; Carboplatin; Etoposide; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy; Small Cell Lung Carcinoma | 2023 |
Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Small Cell Lung Carcinoma | 2023 |
Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cervix Uteri; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging; Platinum; Rare Diseases; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms | 2023 |
First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Platinum; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma | 2023 |
The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Small Cell Lung Carcinoma; Survival Analysis | 2023 |
Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |
Classic biphasic pulmonary blastoma: A case report and review of the literature from 2000 to 2022.
Topics: Adult; Etoposide; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Pulmonary Blastoma | 2023 |
Primary Ewing sarcoma of the larynx with distant metastasis: a case report and review of the literature.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy; Cyclophosphamide; Dactinomycin; Etoposide; Fluorodeoxyglucose F18; Humans; Ifosfamide; Laryngeal Neoplasms; Lung Neoplasms; Male; Middle Aged; Sarcoma, Ewing; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2019 |
Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: Case report and review of literature.
Topics: Antibodies, Antinuclear; Antibodies, Neoplasm; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Carboplatin; Carcinoma, Small Cell; Cerebellar Neoplasms; Combined Modality Therapy; Disease Progression; ELAV Proteins; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Nivolumab; Paraneoplastic Syndromes, Nervous System; Programmed Cell Death 1 Receptor; Radiotherapy, Adjuvant; Treatment Outcome | 2020 |
Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Melphalan; Procedures and Techniques Utilization; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Respiratory Function Tests; Risk; Sarcoma, Ewing; Whole-Body Irradiation; Young Adult | 2020 |
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecitabine; Carcinoid Tumor; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Everolimus; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymph Node Excision; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pneumonectomy; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Temozolomide; Watchful Waiting | 2020 |
Atezolizumab: A Review in Extensive-Stage SCLC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Lung Neoplasms; Progression-Free Survival; Quality of Life; Small Cell Lung Carcinoma | 2020 |
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2020 |
Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2021 |
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma; Tumor Microenvironment | 2021 |
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
Acute pancreatitis induced by etoposide-lobaplatin combination chemotherapy used for the treatment of lung cancer: A case report and literature review.
Topics: Acute Disease; Antineoplastic Agents; Cyclobutanes; Diagnosis, Differential; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Pancreatitis; Small Cell Lung Carcinoma | 2017 |
Postmenopausal choriocarcinoma: a rare case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin, beta Subunit, Human; Cyclophosphamide; Dactinomycin; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Methotrexate; Middle Aged; Postmenopause; Vaginal Neoplasms; Vincristine | 2018 |
Targeting DNA damage in SCLC.
Topics: Aurora Kinases; Azepines; Benzimidazoles; Carbolines; Cell Cycle Checkpoints; Cell Proliferation; Cytotoxins; DNA Damage; DNA Repair; Etoposide; Genomic Instability; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Rad51 Recombinase; Small Cell Lung Carcinoma | 2017 |
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors | 2018 |
Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Multiple metastatic gestational trophoblastic disease after a twin pregnancy with complete hydatidiform mole and coexisting fetus, following assisted reproductive technology: Case report and literature review.
Topics: Abortion, Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Human; Cyclophosphamide; Dactinomycin; Etoposide; Female; Fertilization in Vitro; Gestational Age; Gestational Trophoblastic Disease; Humans; Hydatidiform Mole; Hysterectomy; Lung Neoplasms; Methotrexate; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, Twin; Tomography, X-Ray Computed; Uterine Hemorrhage; Uterine Neoplasms; Vincristine | 2018 |
[Small cell lung cancer and immuno-oncologic agents: End of the cisplatin - etoposide era?]
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Molecular Targeted Therapy; Small Cell Lung Carcinoma | 2018 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposide; Hematologic Diseases; Humans; Incidence; Irinotecan; Lung Neoplasms; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vomiting | 2018 |
Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Clinical Protocols; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2019 |
Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2019 |
Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Colonic Neoplasms; Diagnosis, Differential; Diagnostic Imaging; Etoposide; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Platinum Compounds; Prognosis; Receptors, Somatostatin; Retrospective Studies; Small Cell Lung Carcinoma | 2013 |
Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2013 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
Current concepts in the management of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum; Randomized Controlled Trials as Topic; Recurrence; Small Cell Lung Carcinoma; Treatment Outcome | 2013 |
Assessing the relative effectiveness and tolerability of treatments in small cell lung cancer: a network meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic | 2013 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoid Heart Disease; Carcinoid Tumor; Cisplatin; Dacarbazine; Etoposide; Europe; Humans; Lung Neoplasms; Pneumonectomy; Positron-Emission Tomography; Receptors, Somatostatin; Societies, Medical; Temozolomide; Tomography, X-Ray Computed; Ultrasonography | 2015 |
Prolonged response of meningeal carcinomatosis from non-small cell lung cancer to salvage intrathecal etoposide subsequent to failure of first-line methotrexate: a case report and literature review.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Etoposide; Humans; Immunosuppressive Agents; Injections, Spinal; Lung Neoplasms; Male; Meningeal Carcinomatosis; Methotrexate; Middle Aged; Neoplasms, Multiple Primary; Treatment Failure | 2015 |
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Disease Management; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Etoposide; Europe; Humans; Lung; Lung Neoplasms; Lymph Nodes; Mediastinum; Multimodal Imaging; Pneumonectomy; Positron-Emission Tomography; Radiotherapy, Adjuvant; Societies, Medical; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2015 |
Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Patient Selection; Precision Medicine; Radiotherapy, Adjuvant; Risk Factors | 2015 |
Chemotherapy Resistance in Lung Cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Pemetrexed; Taxoids; Vinblastine; Vinorelbine | 2016 |
[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer:
A Network Meta-analysis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Network Meta-Analysis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2016 |
Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cisplatin; Disease Management; Etoposide; Everolimus; Humans; Lung Neoplasms; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Pneumonectomy; Small Cell Lung Carcinoma; Somatostatin | 2017 |
Treatment of Locally Advanced Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage | 2017 |
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Thorax | 2017 |
Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Complex and Mixed; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Testicular Neoplasms; Transplantation, Autologous | 2017 |
Management of small-cell lung cancer: incremental changes but hope for the future.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2008 |
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Child; Child, Preschool; Choristoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Diagnostic Errors; Doxorubicin; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Pyrazoles; Radiography; Sulfonamides; Teratoma; Thalidomide; Thymus Gland; Thyroid Neoplasms; Thyroidectomy | 2009 |
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Colorectal Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Drug Therapy; Etoposide; Genes, ras; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Mutation; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome | 2009 |
Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Randomized Controlled Trials as Topic; Regression Analysis; Small Cell Lung Carcinoma; Treatment Outcome; Vincristine | 2009 |
[Renal salt-wasting syndrome progressing to severe hyponatremia after chemotherapy--a case report].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Hyponatremia; Kidney Diseases; Lung Neoplasms; Small Cell Lung Carcinoma; Syndrome | 2010 |
A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2010 |
Radiotherapy in small-cell lung cancer: where should it go?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Early Detection of Cancer; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Radiotherapy; Small Cell Lung Carcinoma | 2010 |
Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma | 2010 |
Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Decision Trees; Etoposide; Europe; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; North America; Paclitaxel; Radiation Pneumonitis; Radiotherapy Dosage | 2013 |
Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Meta-Analysis as Topic | 2013 |
Platinum drugs in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Chemotherapy in NSCLC: historical review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; History, 20th Century; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2002 |
Adjuvant and neoadjuvant treatments for NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Survival; Taxoids | 2002 |
Limited stage small cell lung cancer: treatment and therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Treatment Outcome | 2003 |
Lambert-eaton myasthenic syndrome: a case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Respiratory Distress Syndrome | 2002 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Comorbidity; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Palliative Care; Patient Selection; Prognosis; Proton Therapy; Radiotherapy, High-Energy; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2003 |
The global role of irinotecan in the treatment of lung cancer: 2003 update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States; Vindesine | 2003 |
An advance in small-cell lung cancer treatment--more or less.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Greece; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States; Vincristine | 2003 |
Limited-disease small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis | 2003 |
[Pulmonary rhabdomyosarcoma generated during treatment of testicular tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Embryonal; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Administration Schedule; Endodermal Sinus Tumor; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Lymph Node Excision; Male; Orchiectomy; Pneumonectomy; Rhabdomyosarcoma; Seminoma; Testicular Neoplasms; Vincristine | 2003 |
Progress in treatment of small-cell lung cancer: role of CPT-11.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Topoisomerase I Inhibitors | 2003 |
Extragonadal retroperitoneal embryonal carcinoma successfully treated with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Embryonal; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Retroperitoneal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
[Molecular pathogenesis of lung cancers and the preservative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle Proteins; Cisplatin; Enzyme Inhibitors; Etoposide; Gefitinib; Gene Targeting; Genes, bcl-2; Genes, p53; Genetic Therapy; Humans; Lung Neoplasms; Mass Screening; Mutation; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2004 |
Chemotherapy of small cell lung cancer: state of the art.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2004 |
The impact of dose per cycle of etoposide and cisplatin on outcomes in patients with extensive small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Humans; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Randomized Controlled Trials as Topic; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2004 |
Small cell lung cancer: the importance of the extracellular matrix.
Topics: Apoptosis; Carcinoma, Small Cell; Cell Adhesion; Cell Movement; Etoposide; Extracellular Matrix; Fibronectins; Humans; Integrins; Lung Neoplasms | 2004 |
Treatment options for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant; Risk Factors; Sex Distribution; Smoking; Survival Rate; Treatment Outcome; United States | 2004 |
[Chemotherapy of the elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Retrospective Studies; Signal Transduction; Taxoids | 2004 |
Oncocytic adrenocortical carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality Therapy; Doxorubicin; Embolization, Therapeutic; Etoposide; Humans; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitotane; Nephrectomy; Ribs; Tomography, X-Ray Computed | 2004 |
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids | 2004 |
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Length of Stay; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancoast Syndrome; Pneumonectomy; Postoperative Complications; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, High-Energy; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Short- and long-term outcomes after large pulmonary resection for germ cell tumors after bleomycin-combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Follow-Up Studies; Germinoma; Humans; Life Tables; Lung Diseases; Lung Neoplasms; Male; Mediastinal Neoplasms; Pneumonectomy; Postoperative Complications; Respiratory Distress Syndrome; Retrospective Studies; Survival Analysis; Survivors; Testicular Neoplasms; Thrombosis; Time Factors; Treatment Outcome | 2004 |
In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Small Cell; Cell Proliferation; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Topotecan; Transplantation, Heterologous | 2005 |
Combined modality therapy for limited-disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Prognosis; Radiotherapy, Adjuvant | 2005 |
Lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Palliative Care | 2004 |
Small-cell lung cancer: current therapy and novel agents.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis | 2005 |
[Treatment of small cell lung cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis | 2005 |
Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Radiation Tolerance | 2005 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
Chemoradiation paradigm for the treatment of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Treatment of stage I-III non-small-cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy | 2006 |
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Antineoplastic Agents; Carcinoma, Small Cell; Cholinesterase Inhibitors; Cisplatin; Etoposide; Guanidine; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Immunotherapy; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Parasympathomimetics; Plasmapheresis; Potassium Channel Blockers; Prednisolone; Pyridostigmine Bromide; Randomized Controlled Trials as Topic | 2006 |
Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Etoposide; Female; Humans; London; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis; Time Factors; Treatment Outcome; Vincristine | 2006 |
Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2007 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Infusions, Intravenous; Lomustine; Lung Neoplasms; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ontario; Practice Guidelines as Topic; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Topotecan | 2007 |
[Radiation therapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated | 2007 |
Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Randomized Controlled Trials as Topic | 2007 |
Is the blood-brain barrier relevant in metastatic germ cell tumor?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood-Brain Barrier; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Fatal Outcome; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Retroperitoneal Space; Testicular Neoplasms | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Vomiting | 2007 |
[Etoposide. A new highly effective cytostatic agent in anaplastic small-cell bronchial carcinoma, other solid tumors and hemoblastoses].
Topics: Bronchial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Cell Division; Choriocarcinoma; Etoposide; Female; Humans; Leukemia; Liver Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Podophyllotoxin; Pregnancy; Testicular Neoplasms; Uterine Neoplasms | 1981 |
Chemotherapy of metastatic non-small cell bronchogenic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Prognosis; Vinblastine; Vindesine | 1983 |
Etoposide (VP-16) in the treatment of lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Time Factors | 1983 |
Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Mitoguazone; Vinblastine; Vindesine | 1984 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.
Topics: Animals; Antineoplastic Agents; Etoposide; Hodgkin Disease; Humans; Leukemia, Lymphoid; Lung Neoplasms; Podophyllotoxin; Teniposide | 1980 |
Response of metastasized sex cord gonadal stromal tumor of the testis to cisplatin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Sex Cord-Gonadal Stromal Tumors; Testicular Neoplasms | 1994 |
High-risk metastatic gestational trophoblastic tumors. Current management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Clinical Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Hysterectomy; Lung Neoplasms; Methotrexate; Neoplasm Staging; Pregnancy; Prognosis; Remission Induction; Risk Factors; Survival Rate; Thoracotomy; Treatment Outcome; Trophoblastic Neoplasms; Uterine Neoplasms; Vaginal Neoplasms; Vincristine | 1994 |
Spontaneous pneumothorax complicating chemotherapy for metastatic seminoma. A case report and a review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Orchiectomy; Pneumothorax; Radiography; Seminoma; Testicular Neoplasms | 1995 |
The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Interleukin-6; Lung Neoplasms; Neutropenia; Recombinant Proteins; Thrombocytopenia | 1995 |
Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: an effective treatment strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate | 1995 |
Oral therapy for small cell lung cancer.
Topics: Administration, Oral; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Lomustine; Lung Neoplasms; Methotrexate; Procarbazine | 1995 |
Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Radiography; Survival Rate | 1995 |
[Mega-dose chemotherapy with peripheral blood stem cell transplantation (PBS-CT) for small cell lung cancer (SCLC)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials as Topic; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Vincristine | 1995 |
T-helper-2 lymphocytes as a peripheral target of melatonin.
Topics: Animals; Bone Marrow; Carcinoma, Lewis Lung; Cyclophosphamide; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Interleukin-4; Lung Neoplasms; Melatonin; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Receptors, Cell Surface; Receptors, Melatonin; Th2 Cells | 1995 |
Small cell lung cancer. State-of-the-art therapy 1994.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Survival Rate | 1995 |
[A case of small cell lung cancer associated with fulminant hepatitis B].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Hepatitis B; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 1994 |
The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Salvage Therapy; Teniposide; Vincristine | 1995 |
Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy | 1994 |
[Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Radiotherapy Dosage; Survival Rate; Time Factors; Vincristine | 1994 |
[Recent changes in the management of advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Vindesine | 1994 |
[Treatment of small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Vincristine | 1994 |
[CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Vincristine | 1993 |
Small cell lung cancer and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Vincristine | 1994 |
Non small cell lung cancer and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fluorouracil; Humans; Indazoles; Lomustine; Lung Neoplasms; Methotrexate; Neoplasm Staging; Treatment Outcome | 1994 |
Intensive combined-modality therapy in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Vincristine | 1994 |
Prolonged administration of low-daily-dose etoposide: a superior dosing schedule?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Neoplasms; Pilot Projects; Time Factors | 1994 |
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
Etoposide: current status and future perspectives in the management of malignant neoplasms.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Germinoma; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Neoplasms; Sarcoma, Kaposi; Stomach Neoplasms | 1994 |
Teniposide: overview of its therapeutic potential in adult cancers.
Topics: Acquired Immunodeficiency Syndrome; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Etoposide; Female; Genital Neoplasms, Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoma, Kaposi; Teniposide | 1994 |
Etoposide dosage and pharmacodynamics.
Topics: Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Kidney Function Tests; Liver; Liver Function Tests; Lung Neoplasms; Lymphoma | 1994 |
Etoposide in the treatment of elderly/poor-prognosis patients with small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Small Cell; Etoposide; Humans; Incidence; Lung Neoplasms; Prognosis; Survival Rate; United States | 1994 |
Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Prospective Studies; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate; Vinblastine | 1994 |
Combined modality therapy in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Contraindications; Cranial Irradiation; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Treatment Failure | 1994 |
Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Resistance; Etoposide; Humans; Isotretinoin; Lung Neoplasms; Neoplasms, Second Primary; Neoplastic Stem Cells; Oncogenes; Phenotype; Tumor Cells, Cultured | 1994 |
Neoadjuvant chemotherapy for patients with osteosarcoma: University of Florida studies.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Florida; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Life Tables; Lung Neoplasms; Methotrexate; Osteosarcoma; Survival Analysis; Treatment Outcome | 1993 |
Surgical treatment of stage III lung cancer after chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Fluorouracil; Follow-Up Studies; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Radiotherapy Dosage; Remission Induction | 1994 |
[Secondary leukemias after etoposide chemotherapy].
Topics: Carcinoma, Bronchogenic; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia; Lung Neoplasms; Male; Testicular Neoplasms; Time Factors | 1994 |
Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Ifosfamide; Lung Neoplasms | 1994 |
Chronic etoposide administration: overview of clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Drug Administration Schedule; Etoposide; Female; Germinoma; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Ovarian Neoplasms | 1993 |
Brain metastasis from clear cell sarcoma of the kidney--a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Cisplatin; Combined Modality Therapy; Craniotomy; Dactinomycin; Doxorubicin; Etoposide; Fatal Outcome; Frontal Lobe; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Nephrectomy; Vincristine | 1993 |
Treatment of the elderly patient with small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Incidence; Lung Neoplasms; Male; United States | 1993 |
Incorporation of radiotherapy fractionation in the combined-modality treatment of limited small-cell lung cancer.
Topics: Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Radiation Dosage; Time Factors | 1993 |
Ifosfamide-induced hyperpigmentation.
Topics: Child, Preschool; Etoposide; Humans; Ifosfamide; Kidney Neoplasms; Lung Neoplasms; Male; Mesna; Pigmentation Disorders; Wilms Tumor | 1993 |
Recent developments in chemotherapy treatment of small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Drugs, Investigational; Etoposide; Humans; Lung Neoplasms | 1993 |
Roentgenographically occult small-cell lung cancer: case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Male; Radiography; Vincristine | 1996 |
Malignant sacrococcygeal germ cell tumour in an adult.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Bleomycin; Chemotherapy, Adjuvant; Cisplatin; Coccyx; Etoposide; Fatal Outcome; Germinoma; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Osteoarthropathy, Secondary Hypertrophic; Pelvic Neoplasms; Prognosis; Sacrum | 1996 |
Ifosfamide in the treatment of small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1996 |
Subacute encephalopathic toxicity of cisplatin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blindness; Brain Diseases; Cisplatin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Ondansetron | 1995 |
[Localized small-cell lung cancers: prospects of concomitant radiochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Prognosis; Radiotherapy; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 1995 |
[Chemotherapy of small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Vincristine | 1996 |
[An elderly case of squamous cell lung cancer showing partial response by daily administration of oral etoposide].
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male | 1996 |
The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Etoposide; Gemcitabine; Health Care Costs; Humans; Ifosfamide; Insurance, Health, Reimbursement; Italy; Lung Neoplasms; Mitomycin; Ribonucleotide Reductases; Vinblastine; Vinorelbine | 1996 |
[Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary | 1996 |
[Etoposide in the treatment of small-cell lung cancer].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Infusions, Intravenous; Lung Neoplasms | 1996 |
Etoposide phosphate: what, why, where, and how?
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Organophosphorus Compounds; Podophyllotoxin | 1996 |
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
Late relapse of germ cell tumors after cisplatin-based chemotherapy.
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Carcinoma, Embryonal; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Fatal Outcome; Germinoma; Humans; Life Tables; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Orchiectomy; Pelvic Neoplasms; Remission Induction; Retroperitoneal Neoplasms; Retrospective Studies; Salvage Therapy; Teratocarcinoma; Testicular Neoplasms; Treatment Failure | 1997 |
Paraneoplastic subacute cutaneous lupus erythematosus: report of a case associated with cancer of the lung.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dermatologic Agents; Doxorubicin; Etoposide; Female; Humans; Hydroxychloroquine; Lung Neoplasms; Lupus Erythematosus, Cutaneous; Middle Aged; Paraneoplastic Syndromes | 1997 |
[Concomitant radiochemotherapy for locally advanced bronchial cancers: current results and prospects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 1997 |
Small cell lung cancer in the elderly patient.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Survival Rate | 1997 |
[Prolonged oral etoposide therapy in advanced stage lung cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome | 1997 |
[Adjuvant chemotherapy of lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dactinomycin; Etoposide; Humans; Lung Neoplasms; Mitomycin; Neoplasm Recurrence, Local; Vincristine | 1987 |
[Multimodality therapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Radiotherapy Dosage; Survival Analysis; Vincristine | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
[International consensus for lung cancer treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Decision Making; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Radiotherapy Dosage; Vincristine | 1997 |
[Dose-effect of chemotherapy in bronchial small-cell cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Time Factors | 1997 |
The role of carboplatin in the treatment of small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 1998 |
Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Platinum Compounds | 1998 |
Etoposide plus ifosfamide plus cisplatin in the treatment of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Ifosfamide; Lung Neoplasms | 1998 |
[Small cell lung cancer associated with nephrotic syndrome: remission after chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Glomerulonephritis, IGA; Humans; Lung Neoplasms; Male; Middle Aged; Proteinuria; Remission Induction | 1998 |
[Recent issue in the treatment of small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms | 1998 |
[Chemotherapy of small cell bronchogenic carcinoma in a patient on hemodialysis for chronic renal failure. Apropos of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Renal Dialysis | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 1999 |
[Continuous radiosensitizing chemotherapy].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Nutritional Support; Radiation-Sensitizing Agents; Rectal Neoplasms | 1999 |
The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Neutropenia; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1999 |
Malignant triton tumor of the head and neck: A case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fatal Outcome; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Lung Neoplasms; Magnetic Resonance Imaging; Mesna; Neoplasm Recurrence, Local; Neurilemmoma; Radiotherapy Dosage; Vincristine | 1999 |
Combined chemoradiation therapy for limited-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1999 |
The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Quality of Life; Survival Analysis | 1999 |
Ifosfamide in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel | 1999 |
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1999 |
Management of small cell lung cancer: current state of the art.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 1999 |
Current role of oral etoposide in the management of small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms | 1999 |
Cyclophosphamide and etoposide for non-small cell and small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms | 1999 |
The role of oral etoposide in non-small cell lung cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms | 1999 |
Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2000 |
[Conquering drug resistance in lung cancer].
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Genetic Therapy; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Pharmacogenetics; Topoisomerase I Inhibitors | 2000 |
Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Risk; Survival Analysis; Treatment Outcome | 2000 |
[Recent topics in chemotherapy for elderly patients with lung cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Middle Aged | 2000 |
[Treatment of lung cancer--state of the art in 2000].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Survival Analysis; Vincristine | 2000 |
[Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Etoposide; Forecasting; Gemcitabine; Lung Neoplasms; Pancreatic Neoplasms | 2000 |
Irinotecan in small-cell lung cancer--Japanese trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Radiation-Sensitizing Agents | 2000 |
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis | 2000 |
Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Colonic Diseases; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Doxorubicin; Duodenal Ulcer; Epstein-Barr Virus Infections; Etoposide; Gastrointestinal Hemorrhage; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Large B-Cell, Diffuse; Male; Neuroblastoma; Orbital Neoplasms; Prion Diseases; Transplantation Conditioning; Transplantation, Autologous; Ulcer; Vincristine | 2000 |
[Intra-arterial infusion chemotherapy for liver metastases of testicular tumors: report of two cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Embryonal; Choriocarcinoma; Cisplatin; Etoposide; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Seminoma; Testicular Neoplasms; Treatment Outcome; Vinblastine | 2000 |
New state of the art in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Survival Rate | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[Meta-analysis of the value of cisplatin in primary therapy of small-cell bronchial carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Cisplatin; Data Interpretation, Statistical; Etoposide; Female; Humans; Lung Neoplasms; Male; Quality of Life; Retrospective Studies; Time Factors | 2001 |
Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endpoint Determination; Etoposide; Feasibility Studies; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Treatment Failure | 2001 |
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Topotecan | 2001 |
Role of topoisomerase I inhibitors in small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors | 2001 |
Recent advances in the chemotherapy of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Isolated central nervous system relapse of non-seminomatous germ cell tumour of the testis. A case report and review of the literature.
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Embryonal; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Occipital Lobe; Orchiectomy; Radiotherapy, Adjuvant; Remission Induction; Testicular Neoplasms; Tomography, X-Ray Computed; Vision Disorders | 2001 |
[A giant testicular tumor detected with dyspnea due to lung metastases: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Embryonal; Cisplatin; Dyspnea; Endodermal Sinus Tumor; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasms, Multiple Primary; Orchiectomy; Testicular Neoplasms | 2001 |
Current standards of care in small-cell and non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Prognosis; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Etoposide; Europe; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents | 2001 |
[Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Cytarabine; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Lymphoma; Mesna; Methylprednisolone; Mitoxantrone | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Survival Rate; Treatment Outcome | 2002 |
Secondary thyroid carcinoma after treatment for clear cell carcinoma of the uterus: case report and review of the literature.
Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphatic Metastasis; Mesna; Neoplasms, Second Primary; Radiotherapy, Adjuvant; Thyroid Neoplasms; Thyroidectomy; Uterine Neoplasms; Vincristine | 2001 |
[Lymph node excision in the surgical treatment of bronchopulmonary cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Axilla; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Lymph Node Excision; Postoperative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors | 2001 |
Unexpected response of a pulmonary blastoma on radiotherapy: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epithelial Cells; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Blastoma; Radiotherapy Dosage; Stromal Cells; Tomography, X-Ray Computed | 2002 |
Irinotecan therapy for small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors; United States | 2002 |
Superior sulcus tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Health Behavior; Humans; Lung Neoplasms; Neoplasm Invasiveness; Pancoast Syndrome; Thoracic Surgical Procedures | 2001 |
Limited stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cost-Benefit Analysis; Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging | 2001 |
[Irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Recent progress in the treatment of ED small cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Piperazines; Pyrimidines; Vincristine | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
VM 26 and VP 16-213: a comparative analysis.
Topics: Animals; Brain Neoplasms; Drug Evaluation; Etoposide; Humans; Kinetics; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms, Experimental; Podophyllotoxin; Teniposide; Urinary Bladder Neoplasms | 1977 |
Etoposide (VP-16-213).
Topics: Adult; Animals; Bone Marrow; Cell Cycle; Child; Digestive System; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Neoplasms; Neoplasms, Experimental; Podophyllotoxin; Rats | 1979 |
Carboplatin/etoposide in small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Hematopoietic Cell Growth Factors; Humans; Lung Neoplasms | 1992 |
Platinum/etoposide therapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging | 1992 |
The role of chemotherapy in the treatment of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Nursing Diagnosis | 1992 |
Lung cancer: a review of current therapeutic modalities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Peptichemio; Radiotherapy; Vincristine | 1992 |
Oral etoposide in oncology: an evolving role.
Topics: Administration, Oral; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms | 1992 |
[Small-cell lung cancer: survival analysis over the last 10 years: 1980-1990].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Survival Analysis | 1992 |
Chronic oral etoposide in the treatment of lung cancer.
Topics: Administration, Oral; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms | 1992 |
Oral etoposide in small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Survival Analysis; Treatment Outcome | 1992 |
Chronic oral etoposide: trials at Indiana University and with the Hoosier Oncology Group.
Topics: Administration, Oral; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasms; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms | 1992 |
The role of standard-dose etoposide in the management of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms | 1992 |
Developments in therapy for extensive-disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms | 1992 |
[A case of nephrotic syndrome associated with bronchogenic carcinoma].
Topics: Carcinoma, Bronchogenic; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Nephrotic Syndrome | 1992 |
[Dose intensity chemotherapy in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Mitomycin; Mitomycins; Progesterone; Recombinant Proteins; Remission Induction; Vinblastine; Vincristine | 1990 |
Current status of etoposide in the management of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms | 1991 |
Etoposide in the management of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms | 1991 |
Recent advances in etoposide therapy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging | 1991 |
Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Meta-Analysis as Topic; Podophyllotoxin; Vincristine | 1991 |
[A myelo dysplastic syndrome (refractory anemia with excess of blasts) occurred in a patient with small cell lung cancer during complete response].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Remission Induction; Vincristine | 1990 |
Second-line chemotherapy in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction | 1990 |
Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: a Cancer and Leukemia Group B Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Remission Induction; Survival Rate; Time Factors | 1990 |
Carboplatin in small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Organoplatinum Compounds | 1990 |
[Small cell lung carcinoma. Value of the evaluation of extension for the therapeutic strategy].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Prognosis; Prospective Studies; Spinal Cord Neoplasms | 1990 |
[Chemotherapy in non-small cell bronchial carcinoma. 12 years' experience in an international cooperative group: EORTC Lung Cancer Working Party].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Vindesine | 1990 |
Cancer of the testis: a new paradigm.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Cisplatin; Clinical Trials as Topic; Doxorubicin; Dysgerminoma; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Teratoma; Testicular Neoplasms; Vinblastine | 1986 |
Ifosfamide in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms | 1989 |
Cisplatin for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Remission Induction | 1989 |
[Recent trends of chemotherapy in small cell lung cancer: a slow but steady progress].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Vincristine | 1989 |
Primary choriocarcinoma of the lung: report of a case treated with intensive multimodality therapy and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Combined Modality Therapy; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Male | 1989 |
[Chemotherapy of small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Organoplatinum Compounds; Vincristine | 1988 |
Cisplatin plus etoposide in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms | 1988 |
Cisplatin and carboplatin in combination with etoposide as a treatment for non-small cell lung cancer: the experience of the EORTC Lung Cancer Working Party.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Organoplatinum Compounds | 1988 |
Etoposide (VP-16-213). Current status of an active anticancer drug.
Topics: Animals; Carcinoma, Small Cell; Clinical Trials as Topic; DNA; Drug Administration Schedule; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Podophyllotoxin; Testicular Neoplasms; Tissue Distribution | 1985 |
Current chemotherapy of small cell lung cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Complement Membrane Attack Complex; Complement System Proteins; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lomustine; Lung Neoplasms; Methotrexate; Mitomycin; Mitomycins; Podophyllotoxin; Procarbazine; Prognosis; Time Factors; Vincristine | 1986 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neoplasms; Carcinoma, Small Cell; Carmustine; Cell Separation; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Etoposide; Glioma; Humans; Lung Neoplasms; Male; Melanoma; Melphalan; Neoplasms; Testicular Neoplasms; Whole-Body Irradiation | 1986 |
The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Prospective Studies; Random Allocation; Remission Induction; Vincristine | 1986 |
Therapy with cisplatin and etoposide for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms | 1986 |
Cisplatin plus VP-16 in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms | 1986 |
Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Random Allocation; Vincristine | 1986 |
Initial therapy with cisplatin plus VP-16 in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Prospective Studies; Random Allocation; Remission Induction; Vincristine | 1986 |
Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Prognosis; Remission Induction | 1986 |
Oral etoposide in small-cell lung cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms | 1986 |
Outpatient administration of VP-16 and cisplatin.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms | 1986 |
Pharmacologic aspects of lung cancer chemotherapy.
Topics: Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Methotrexate; Sclerosing Solutions; Vinca Alkaloids | 1986 |
Chemotherapy of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Tolerance; Etoposide; Humans; Lung Neoplasms; Mitomycin; Mitomycins; Vindesine | 1985 |
1005 trial(s) available for etoposide and Lung Neoplasms
| Article | Year |
|---|---|
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Double-Blind Method; Etoposide; Follow-Up Studies; Humans; Immunotherapy; Lung Neoplasms; Markov Chains; Medicare; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; United States | 2021 |
Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2021 |
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Research Design; Small Cell Lung Carcinoma | 2022 |
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Convalescence; Deglutition Disorders; Dose Fractionation, Radiation; Dyspnea; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Patient Reported Outcome Measures; Quality of Life; Radiotherapy; Small Cell Lung Carcinoma | 2022 |
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Etoposide; Humans; Indoles; Lung Neoplasms; Platinum; Prospective Studies; Quinolines; Small Cell Lung Carcinoma | 2022 |
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2022 |
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Digestive System; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2022 |
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Etoposide; Female; Humans; Immune Checkpoint Inhibitors; Ligands; Lung Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma | 2022 |
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Small Cell Lung Carcinoma | 2022 |
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Topics: Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Prospective Studies; Small Cell Lung Carcinoma; Turtles | 2023 |
Preliminary results of randomized phase II study of etoposide plus lobaplatin or etoposide plus cisplatin with concurrent thoracic radiotherapy in the treatment of limited-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagitis; Etoposide; Humans; Lung Neoplasms; Radiation Pneumonitis; Small Cell Lung Carcinoma | 2023 |
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Irinotecan; Lung Neoplasms; Platinum | 2023 |
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
Topics: Etoposide; Humans; Hypertension; Lung Neoplasms; Prospective Studies; Proteinuria; Small Cell Lung Carcinoma; Stomatitis | 2023 |
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Topotecan | 2023 |
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Safety; Survival Rate; Vinorelbine | 2019 |
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Paclitaxel; Prognosis; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma; Survival Rate; Tissue Distribution | 2019 |
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitro Compounds; Small Cell Lung Carcinoma; Treatment Outcome; Young Adult | 2019 |
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Tre
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Double-Blind Method; Etoposide; Humans; Lung Neoplasms; Picornaviridae; Platinum | 2020 |
Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonia; Prospective Studies; Pulmonary Fibrosis; Radiotherapy Dosage; Research Report; Small Cell Lung Carcinoma | 2020 |
Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Sweden; Treatment Outcome | 2020 |
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Patient Reported Outcome Measures; Quality of Life | 2020 |
Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2020 |
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Small Cell Lung Carcinoma; Survival Analysis | 2020 |
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Small Cell Lung Carcinoma | 2020 |
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Patient Reported Outcome Measures; Platinum; Quality of Life | 2020 |
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Analysis | 2021 |
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Radiotherapy Dosage; Small Cell Lung Carcinoma; Treatment Outcome | 2021 |
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2021 |
Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial.
Topics: Adult; Aged; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Dose Hypofractionation; Small Cell Lung Carcinoma | 2021 |
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Etoposide; Humans; Immunoconjugates; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2017 |
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Decision Trees; Disease Management; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2017 |
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiation Pneumonitis; Small Cell Lung Carcinoma; Survival Rate | 2017 |
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2018 |
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome | 2018 |
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Republic of Korea; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2019 |
Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Risk Factors; Survival Rate; Treatment Outcome; Vincristine; Wilms Tumor | 2018 |
The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Positron-Emission Tomography; Progression-Free Survival; Survival Analysis | 2018 |
Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2018 |
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Follow-Up Studies; Humans; Immunosuppressive Agents; Immunotherapy; International Agencies; Leflunomide; Lung Neoplasms; Maintenance Chemotherapy; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Toll-Like Receptor 9 | 2018 |
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Small Cell Lung Carcinoma | 2018 |
Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease Progression; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Prospective Studies; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Time Factors | 2019 |
The effects of carboplatin and etoposide on advanced small cell lung cancer and serum tumor markers in correlation with long-term survival rate.
Topics: Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoembryonic Antigen; Endostatins; Etoposide; Female; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfoxides | 2019 |
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost of Illness; Cost-Benefit Analysis; Double-Blind Method; Etoposide; Health Care Costs; Humans; Lung Neoplasms; Neoplasm Staging; Placebos; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Analysis | 2019 |
Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 2013 |
Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Small Cell Lung Carcinoma; Survival; Treatment Failure | 2013 |
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicente
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survivors; Treatment Outcome | 2013 |
Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome | 2013 |
Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Early Termination of Clinical Trials; Etoposide; Humans; Hydroxamic Acids; Indoles; Lung Neoplasms; Middle Aged; Panobinostat | 2013 |
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2014 |
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2014 |
A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quality of Life; Small Cell Lung Carcinoma; Survival Rate | 2014 |
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Everolimus; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Sirolimus; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Sorafenib; Treatment Outcome | 2014 |
A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Catechin; Chemoradiotherapy; Cisplatin; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage | 2014 |
A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Clinical Protocols; Disease-Free Survival; Etoposide; Female; Humans; Incidence; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Patient Selection; Survival Analysis; Treatment Outcome | 2014 |
Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2013 |
NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma | 2014 |
A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Gamma Rays; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Radiation Dosage; Small Cell Lung Carcinoma; Thorax | 2014 |
Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-cisplatin alone in patients with extensive disease combined with small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2014 |
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Comorbidity; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Time Factors | 2014 |
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Patient Selection; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2015 |
Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Radiosurgery; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Small Cell; Cisplatin; Clinical Protocols; Etoposide; Female; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Research Design; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Feasibility Studies; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vincristine | 2015 |
Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Small Cell Lung Carcinoma | 2015 |
A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Disease-Free Survival; Endostatins; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Young Adult | 2015 |
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Etoposide; Female; France; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome; Young Adult | 2015 |
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2015 |
Bioequivalence study of two formulations of etoposide in advanced lung cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Capsules; Chemistry, Pharmaceutical; China; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Monitoring; Etoposide; Female; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Therapeutic Equivalency; Young Adult | 2015 |
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Etoposide; Fatigue; Female; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Thrombocytopenia | 2015 |
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Small Cell Lung Carcinoma; Survival Rate | 2015 |
Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in Combination With Regional Positive Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: A Phase 1 Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumothorax; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Remission Induction; Safety; Survival Rate; Time Factors | 2015 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; beta 2-Microglobulin; Biomarkers; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemokine CCL2; Cisplatin; Creatinine; Etoposide; Female; Hepatitis A Virus Cellular Receptor 1; Humans; Lipocalin-2; Lipocalins; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Proteins; Proto-Oncogene Proteins; Receptors, Virus; ROC Curve; Vinblastine; Vinorelbine | 2015 |
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Norway; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose Fractionation, Radiation; Esophagus; Etoposide; Female; Heart; Humans; Lung; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organ Sparing Treatments; Quality of Life; Radiation Injuries; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Small Cell Lung Carcinoma | 2015 |
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Pyrroles; Retrospective Studies; Small Cell Lung Carcinoma; Sunitinib | 2016 |
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed | 2016 |
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Pyridines; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Biomarkers, Tumor; Carboplatin; Etoposide; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
The effect of pulmonary function testing on bleomycin dosing in germ cell tumours.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Bleomycin; Carbon Monoxide; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Prognosis; Radiography, Thoracic; Respiratory Function Tests; Testicular Neoplasms; Vital Capacity; Young Adult | 2016 |
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2016 |
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Diarrhea; Etoposide; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Comorbidity; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2016 |
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cisplatin; Etoposide; Female; Hedgehog Proteins; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Neoplastic Cells, Circulating; Pyridines; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged | 2016 |
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma | 2017 |
[A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
Topics: Adult; Aged; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Safety; Small Cell Lung Carcinoma; Time Factors | 2017 |
[Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
Topics: Adult; Aged; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Safety; Small Cell Lung Carcinoma; Treatment Outcome; Young Adult | 2017 |
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2017 |
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models | 2017 |
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Peptides, Cyclic; Proportional Hazards Models; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2017 |
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pravastatin; Response Evaluation Criteria in Solid Tumors; Small Cell Lung Carcinoma; Survival Rate | 2017 |
Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubicin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Survival Analysis | 2008 |
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids; Topotecan | 2009 |
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 2008 |
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cause of Death; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Hospitalization; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Ifosfamide; Infant; Lung Neoplasms; Male; Neoplasm Staging; Prospective Studies; Sarcoma, Ewing; Vincristine | 2008 |
Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance | 2008 |
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Taxoids; Time Factors; Treatment Outcome | 2008 |
Long-term survival following chemoradiation for inoperable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Rate | 2008 |
A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Sulindac; Survival Rate; Treatment Outcome | 2009 |
Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease"
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Recombinant Proteins; Safety; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Young Adult | 2009 |
A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel | 2009 |
Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Cyclooxygenase 2 Inhibitors; Disease Progression; Etoposide; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Portugal; Pyrazoles; Quality of Life; Small Cell Lung Carcinoma; Spain; Sulfonamides; Time Factors; Treatment Outcome | 2009 |
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Topics: Administration, Oral; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leucovorin; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Tegafur; Uracil | 2009 |
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Diarrhea; Etoposide; Female; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Factors; Small Cell Lung Carcinoma | 2009 |
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma; Survival Rate; Tirapazamine; Triazines | 2009 |
Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2010 |
PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III no
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Survival Rate | 2009 |
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Logistic Models; Lung Neoplasms; Male; Markov Chains; Middle Aged; Pneumonectomy; Proportional Hazards Models; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2009 |
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Fatigue; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Pemetrexed; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Topics: Aged; Camptothecin; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2010 |
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Cisplatin; Disease-Free Survival; E-Selectin; Etoposide; Female; Fibroblast Growth Factor 2; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Risk Assessment; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome; United States; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
Central nervous system relapse continues to be a therapeutic challenge in extensive disease small-cell lung cancer patients with initial symptomatic brain metastases and good response to chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Secondary Prevention; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2010 |
Sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: our experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Conformal; Survival Rate | 2009 |
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2010 |
Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Humans; Lung; Lung Neoplasms; Middle Aged; Radiation Pneumonitis; Radiotherapy Dosage; Retrospective Studies; Taxoids; Tumor Burden | 2010 |
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; International Agencies; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2010 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
[Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Proteins; Phosphopyruvate Hydratase; Prospective Studies; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2010 |
[Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Doxorubicin; Etoposide; Female; Follow-Up Studies; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Osteosarcoma; Treatment Outcome; Young Adult | 2010 |
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
[A prospective randomized study of the radiotherapy volume for limited-stage small cell lung cancer: a preliminary report].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lung Injury; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Small Cell Lung Carcinoma; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Tumor Burden | 2010 |
Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2010 |
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Angiopoietin-1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Survival Rate; Thrombospondins; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Middle Aged; Organs at Risk; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Remission Induction; Spinal Cord; Statistics, Nonparametric; Tomography, X-Ray Computed; Tumor Burden; Vinblastine; Vinorelbine | 2011 |
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2011 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Relative Biological Effectiveness; Retrospective Studies; Survival Analysis; Treatment Failure; Vinblastine | 2012 |
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Etoposide; Female; Germany; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2011 |
Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carboplatin; Darbepoetin alfa; Disease-Free Survival; Erythropoietin; Etoposide; Female; Hematinics; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Small Cell Lung Carcinoma | 2011 |
Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Endostatins; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Survival Rate; Treatment Outcome | 2011 |
Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease Progression; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Transfusion; Small Cell Lung Carcinoma; Survival Analysis; Thrombocytopenia | 2011 |
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2011 |
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2011 |
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2011 |
Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Retrospective Studies; Treatment Outcome | 2012 |
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Etoposide; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Treatment Outcome | 2011 |
Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2012 |
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Confounding Factors, Epidemiologic; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Radiotherapy Dosage; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; United States; Vinblastine | 2011 |
Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Thorax | 2012 |
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2011 |
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier O
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2012 |
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System; Drug Administration Schedule; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Small Cell Lung Carcinoma | 2012 |
Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Radiation Pneumonitis; Treatment Outcome | 2012 |
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Protocols; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Small Cell Lung Carcinoma; Topotecan | 2012 |
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome | 2012 |
Combination of three cytotoxic agents in small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Paclitaxel; Small Cell Lung Carcinoma | 2013 |
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Cisplatin; Confidence Intervals; Dehydration; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Small Cell Lung Carcinoma | 2013 |
Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Diffusion Magnetic Resonance Imaging; Early Detection of Cancer; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
[A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Safety; Small Cell Lung Carcinoma | 2013 |
Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Radiotherapy; Time Factors | 2013 |
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Thalidomide | 2013 |
99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Single-Blind Method; Survival Rate; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2002 |
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Small Cell; Cisplatin; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2002 |
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Probability; Prognosis; Reference Values; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sex Factors; Survival | 2002 |
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan | 2002 |
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Survival Analysis | 2002 |
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Europe; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2002 |
Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with stem cell rescue for small-cell lung cancer: brief report on the results of a phase-I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cells; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2002 |
Effect of grapefruit juice intake on etoposide bioavailability.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Beverages; Biological Availability; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Citrus paradisi; Cross-Over Studies; Etoposide; Female; Food-Drug Interactions; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pilot Projects | 2002 |
Prolonged administration of infusional cisplatin and oral etoposide in advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 2002 |
[Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2002 |
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Remission Induction; Survival Rate; Vincristine | 2002 |
Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study.
Topics: Adult; Aged; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Topotecan; Treatment Outcome | 2003 |
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.
Topics: Adult; Aged; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Time Factors; Treatment Outcome | 2003 |
[Teniposide and cisplatin compared with etoposide and cisplatin for treatment of small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Teniposide; Treatment Outcome | 2002 |
Outpatient intensive chemotherapy for small cell lung cancer: five years experience of modified 'ICE' ifosfamide carboplatin and etoposide.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Outpatients; Prognosis; Survival | 2002 |
Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Renal Dialysis; Renal Insufficiency; Treatment Outcome | 2003 |
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).
Topics: Administration, Oral; Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cost Savings; Cost-Benefit Analysis; Cyclophosphamide; Double-Blind Method; Doxorubicin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hospitalization; Humans; Incidence; Leukopenia; Lung Neoplasms; Male; Middle Aged; Placebos; Risk Factors; Survival | 2003 |
[Clinical observation of music therapy combined with anti-tumor drugs in treating 116 cases of tumor patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drugs, Chinese Herbal; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Music Therapy; Phytotherapy; Stomach Neoplasms | 2001 |
[Influence of combined therapy of guben yiliu III, moxibustion and chemotherapy on immune function and blood coagulation mechanism in patients with mid-late stage malignant tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Drugs, Chinese Herbal; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphocyte Count; Male; Mitomycin; Moxibustion; Phytotherapy; Stomach Neoplasms; T-Lymphocyte Subsets | 2002 |
[Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astragalus propinquus; CD4-CD8 Ratio; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Drugs, Chinese Herbal; Etoposide; Female; Fluorouracil; Humans; Immunoglobulin G; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Mitomycin; Phytotherapy; Stomach Neoplasms | 2002 |
Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival; Treatment Outcome | 2003 |
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia | 2003 |
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Adducts; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Killer Cells, Natural; Leucovorin; Lung Neoplasms; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Nose Neoplasms; Radiotherapy, Adjuvant; Remission Induction; Skin Neoplasms; Treatment Outcome | 2003 |
Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Prospective Studies; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Health Status; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Time Factors; Treatment Outcome; United States | 2003 |
Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Illinois; Indiana; Iowa; Lung Neoplasms; Male; Middle Aged; Minnesota; Nebraska; Neoplasm Staging; North Dakota; Paclitaxel; South Dakota; Survival Analysis; Topotecan; Treatment Outcome | 2003 |
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; United States | 2003 |
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan | 2003 |
Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome | 2003 |
Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
Role of mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer).
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Bacterial Vaccines; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Mycobacterium; Quality of Life; Treatment Outcome | 2003 |
Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Saudi Arabia; Survival Rate; Vincristine | 2003 |
Cisplatin plus etoposide in advanced non-small cell lung cancer patients age of 70 years or older.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Health Services for the Aged; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2003 |
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2003 |
To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Organophosphorus Compounds; Organotechnetium Compounds; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Thorax; Treatment Outcome; Vault Ribonucleoprotein Particles | 2003 |
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2003 |
[Long-term results of multimodality therapy of testicular germ cell tumor].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Etoposide; Follow-Up Studies; Germinoma; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Seminoma; Survival Rate; Testicular Neoplasms; Treatment Outcome | 2003 |
[Complications of intraoperative radiotherapy and adjuvant chemotherapy in patients with lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Gamma Rays; Humans; Intraoperative Period; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Treatment Outcome | 2003 |
Thallium-201 SPECT in advanced non-small cell lung cancer: in relation with chemotherapeutic response, survival, distant metastasis and p53 status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Survival Analysis; Thallium; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tumor Suppressor Protein p53 | 2003 |
[Effect of combination of syndrome differentiation depending treatment and chemotherapy on prognostic factors in treating mid-late patients with non-small call lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Drugs, Chinese Herbal; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Phytotherapy; Prognosis; Regression Analysis | 2003 |
A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiation Pneumonitis; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carcinoma, Small Cell; Catheters, Indwelling; Chromatography, High Pressure Liquid; Etoposide; Humans; Infusions, Intravenous; Lung Neoplasms; Razoxane | 2004 |
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2004 |
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Survival Rate; Vinblastine; Vindesine; Vinorelbine | 2004 |
Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophagitis; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Premedication; Remission Induction; Stomatitis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 2003 |
Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Dyspnea; Etoposide; Female; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Quality of Life; Vindesine | 2004 |
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Thionucleotides; United States | 2004 |
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Confidence Intervals; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Pneumonitis; Radiation-Protective Agents; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 2004 |
Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Synergism; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
[Concurrent radiotherapy combined with carboplatin and etoposide in limited stage small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, High-Energy; Survival Rate | 2004 |
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Survival Analysis | 2004 |
Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Topoisomerase I Inhibitors | 2004 |
Irinotecan in advanced lung cancer: focus on North American trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; North America; Radiotherapy, Adjuvant; Ribonucleotide Reductases; Survival Rate; Taxoids; Topoisomerase I Inhibitors; Vindesine | 2004 |
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2004 |
Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Treatment Outcome | 2003 |
Expression of p53 gene in stage IIIA non-small cell lung cancer in patients after neoadjuvant chemotherapy with Vepesid and Cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Cytophotometry; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Staging; Tumor Suppressor Protein p53 | 2003 |
Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tirapazamine; Triazines; Vomiting | 2004 |
Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2004 |
Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cranial Irradiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Erythrocyte Transfusion; Etoposide; Female; Hospitalization; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Transfusion; Prospective Studies; Radiotherapy, Adjuvant | 2004 |
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cisplatin; Disease Progression; Etoposide; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prospective Studies | 2004 |
Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Radiotherapy Dosage | 2005 |
A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmona
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lenograstim; Lung Neoplasms; Male; Recombinant Proteins; Treatment Outcome | 2005 |
A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Survival Analysis; Tamoxifen | 2005 |
Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prednisone; Recombinant Proteins; Thrombocytopenia; Treatment Outcome; Vincristine | 2005 |
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cross-Over Studies; Cyclophosphamide; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Palliative Care; Prognosis; Treatment Outcome; Vincristine | 2005 |
Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vincristine | 2005 |
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2005 |
[An early phase II clinical study of YM 294 (rhlL-11) in patients with solid tumors and malignant lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administration Schedule; Edema; Etoposide; Female; Fever; Humans; Interleukin-11; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Platelet Count; Recombinant Proteins; Thrombocytopenia | 2005 |
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life | 2005 |
Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Postoperative Care; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Ifosfamide; Incidence; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Recombinant Proteins; Severity of Illness Index; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2005 |
Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Endpoint Determination; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Radiotherapy Dosage; Survival Rate; Vomiting | 2005 |
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Lung Neoplasms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Sex Factors | 2005 |
Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome | 2005 |
Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recombinant Proteins; Survival Rate; Time Factors | 2005 |
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Cohort Studies; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mitoxantrone; Organ Specificity; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2005 |
Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2005 |
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis | 2005 |
Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Treatment Outcome | 2005 |
Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate; Treatment Outcome | 2005 |
A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2005 |
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2005 |
Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Remission Induction; Vinblastine; Vinorelbine | 2005 |
Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Time Factors; Treatment Outcome | 2005 |
[The effect of chemo-radiotherapy on the remission and survival in patients with limited stage small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonia; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Turkey | 2005 |
A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Treatment Outcome | 2006 |
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival; Topotecan; Treatment Outcome | 2005 |
Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Diarrhea; Etoposide; Female; Humans; Ifosfamide; Kidney; Leukocyte Count; Lung Neoplasms; Male; Radiotherapy Dosage; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2005 |
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel; Topotecan | 2005 |
Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Ciprofloxacin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Risk Factors; Roxithromycin; Treatment Outcome | 2005 |
Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter ran
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quality of Life; Statistics, Nonparametric; Survival Analysis; United Kingdom; Vincristine | 2005 |
Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2006 |
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan | 2005 |
[Analysis of short-term therapeutic efficacy of integrated traditional and Western medicine in treating non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Chinese Herbal; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Phytotherapy; Prospective Studies | 2005 |
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Etoposide; Female; Gastrointestinal Tract; Humans; Injections, Intravenous; Liver Function Tests; Lung Neoplasms; Male; Nausea; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2006 |
Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Radiation Injuries; Survival Analysis; Treatment Outcome | 2006 |
Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Korea; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2006 |
Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy, Conformal; Treatment Outcome | 2006 |
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Epirubicin; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2006 |
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2006 |
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Topotecan | 2006 |
Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vincristine | 2006 |
Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Survival Rate | 2006 |
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 2006 |
Evaluation of curative and palliative radiotherapy efficacy in extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Survival Analysis; Turkey | 2006 |
Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis; Survival Rate; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Turkey | 2006 |
Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Etoposide; Female; Humans; London; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis; Time Factors; Treatment Outcome; Vincristine | 2006 |
Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Time Factors; Treatment Outcome | 2007 |
Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Prospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2006 |
Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Etoposide; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Etoposide; Female; Fever; Humans; Infections; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Topotecan; Treatment Outcome | 2006 |
Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Carboplatin; Cyclophosphamide; Etoposide; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Lymphoma; Male; Methotrexate; Middle Aged; Osmosis; Ovarian Neoplasms; Prospective Studies; Survival Rate | 2007 |
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction | 2007 |
Influence of interfraction interval on local tumor control in patients with limited-disease small-cell lung cancer treated with radiochemotherapy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy; Retrospective Studies | 2007 |
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan | 2007 |
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2007 |
Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Disease Progression; Erythrocyte Transfusion; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Platelet Transfusion; Prognosis; Recombinant Proteins; Survival Rate | 2007 |
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Severity of Illness Index; Survival Rate; Topotecan; Treatment Outcome | 2007 |
Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy, High-Energy; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Topics: Adult; Aged; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2007 |
Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cause of Death; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progression; Etoposide; Female; Humans; Lung Neoplasms; Male; Prognosis; Survival Rate; Thalidomide; Treatment Outcome | 2008 |
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Survival Rate; Treatment Outcome | 2007 |
Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cognition; Cognition Disorders; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Psychomotor Performance; Speech | 2008 |
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2008 |
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Thionucleotides; Treatment Outcome | 2008 |
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Ifosfamide; Incidence; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Prognosis; Research Design; Survival Analysis; Treatment Outcome | 2008 |
Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Chromatography, High Pressure Liquid; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesna; Metabolic Clearance Rate; Middle Aged; Prognosis; Proportional Hazards Models; Small Cell Lung Carcinoma | 2008 |
A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents | 2008 |
Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins | 1984 |
Combination chemotherapy in small cell lung carcinoma. A randomized study of two intensive regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1984 |
VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Vincristine | 1984 |
Chemoimmunotherapy of small cell bronchogenic carcinoma with VP-16-213, ifosfamide, vincristine, adriamycin, and Corynebacterium parvum.
Topics: Adult; Aged; Antineoplastic Agents; Bacterial Vaccines; Brain; Carcinoma, Small Cell; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Propionibacterium acnes; Vincristine | 1981 |
An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Vincristine | 1981 |
Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Humans; Leukopenia; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Procarbazine; Vincristine | 1982 |
VP-16-213 (etoposide): the mandrake root from Issyk-Kul.
Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Cell Cycle; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dysgerminoma; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Mice; Podophyllotoxin | 1982 |
Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung.
Topics: Aged; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Probability; Vincristine | 1982 |
Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1982 |
Parenteral intravenous nutrition (PIVN) as an adjunct to chemotherapy in small cell anaplastic lung carcinoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marrow; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Gastrointestinal Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Middle Aged; Parenteral Nutrition; Procarbazine; Random Allocation; Vincristine | 1981 |
Chemotherapy of metastatic non-small cell bronchogenic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Prognosis; Vinblastine; Vindesine | 1983 |
Lack of potentiation of vincristine-induced neurotoxicity by VP-16-213.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Podophyllotoxin; Random Allocation; Vincristine | 1983 |
Early crossover of induction chemotherapy in small cell lung carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Procarbazine; Prospective Studies; Vincristine | 1983 |
Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Lomustine; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Vincristine | 1983 |
Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Prognosis; Vincristine | 1983 |
Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Double-Blind Method; Doxorubicin; Etoposide; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Random Allocation; Sulfamethoxazole; Trimethoprim | 1983 |
Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Humans; Leukopenia; Lung Neoplasms; Methotrexate; Random Allocation; Stomatitis; Vincristine | 1984 |
[New antineoplastic drugs of the podophyllotoxin derivative group].
Topics: Adult; Child; Clinical Trials as Topic; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Teniposide; Urinary Bladder Neoplasms | 1983 |
Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Mitoguazone; Vinblastine; Vindesine | 1984 |
Chemotherapy for metastatic non-small cell bronchogenic carcinoma: cyclophosphamide, doxorubicin, and etoposide versus mitomycin and vinblastine (EST 2575, generation IV).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins; Neoplasm Metastasis; Vinblastine | 1984 |
[Cisplatin, vindesine and VP 16-213 in the treatment of inoperable non-small cell bronchial carcinoma. A clinical phase II study].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Vinblastine; Vindesine | 1984 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
Low-dose cisplatin and etoposide in advanced non-small cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged | 1984 |
Phase II randomized trial of radiotherapy alone vs the sequential use of chemotherapy and radiotherapy in stage III non-small cell lung cancer. Phase II trial of chemotherapy alone in stage IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Evaluation; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Radiotherapy, High-Energy; Random Allocation | 1984 |
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Mitomycin; Mitomycins; Neoplasm Metastasis; Thrombocytopenia; Vomiting | 1984 |
Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Random Allocation | 1983 |
Role of intravenous hyperalimentation as an adjunct to intensive chemotherapy for small cell bronchogenic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marrow; Carcinoma, Bronchogenic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Gastrointestinal Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neutropenia; Parenteral Nutrition; Procarbazine; Vincristine | 1981 |
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Premedication; Taxoids; Treatment Outcome | 1995 |
[Induction chemotherapy followed by adjuvant surgery (IC-AS) in patients with stage I-II small cell lung cancer (SCLC)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Nimustine; Salvage Therapy; Vincristine | 1995 |
[Five-day continuous intravenous infusion of cisplatin and etoposide for extensive stage small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 1995 |
A prospective randomised study in limited disease small cell carcinoma--doxorubicin and vincristine plus either cyclophosphamide or etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Vincristine | 1995 |
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carcinoma, Small Cell; Cyclophosphamide; Depression; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Medical Records; Methotrexate; Middle Aged; Nausea; Palliative Care; Patient Compliance; Quality of Life; Self-Assessment; Vincristine; Vomiting | 1993 |
Dose-intensive chemotherapy in extensive-stage small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Rate; Vincristine | 1994 |
[Chemotherapy for small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Recombinant Proteins; Vincristine | 1993 |
Phase II trial of megestrol in the supportive care of patients receiving dose-intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Megestrol; Middle Aged; Mitomycins; Vincristine; Weight Loss | 1994 |
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bleomycin; Blood Transfusion, Autologous; Breast Neoplasms; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Epirubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Vincristine | 1994 |
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1994 |
Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Carboplatin; Carcinoma, Small Cell; Cause of Death; Combined Modality Therapy; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Platelet Transfusion | 1995 |
Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Middle Aged; Survival Analysis | 1995 |
[Radiotherapy of limited pulmonary microcytoma in current clinical practice].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nimustine; Patient Selection; Peplomycin; Radiotherapy Dosage; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vincristine | 1994 |
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lenograstim; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neutropenia; Neutrophils; Prognosis; Recombinant Proteins; Survival Rate; Vincristine | 1995 |
Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Frail Elderly; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Remission Induction; Survival Rate | 1995 |
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexa
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Palliative Care; Prospective Studies; Quality of Life; Surveys and Questionnaires; Survival Rate; Teniposide; Vincristine | 1995 |
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Prognosis; Survival Rate; Testicular Neoplasms; Time Factors; Vinblastine | 1995 |
[Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cross-Over Studies; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Recombinant Proteins | 1994 |
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cohort Studies; Drug Tolerance; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia | 1995 |
Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Dendrites; Disease Susceptibility; Etoposide; Follow-Up Studies; Hematopoietic Cell Growth Factors; Humans; Hyperpigmentation; Hyperplasia; Injections, Subcutaneous; Lung Neoplasms; Melanins; Melanocytes; Recombinant Proteins; Stem Cell Factor | 1995 |
Preoperative chemotherapy and immunochemotherapy for locally advanced stage IIIA and IIIB non small cell lung cancer. Preliminary results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Interferons; Lung Neoplasms; Male; Middle Aged; Mitomycin; Multivariate Analysis; Neoplasm Staging; Pneumonectomy; Remission Induction; Survival Rate; Vinblastine | 1995 |
Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mitomycin; Survival Rate; Treatment Outcome; Vindesine | 1995 |
A phase II trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 1995 |
Etoposide phosphate or etoposide with cisplatin in the treatment of small cell lung cancer: randomized phase II trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organophosphorus Compounds; Treatment Outcome | 1995 |
Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 1995 |
Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Radiography; Regression Analysis; Survival Rate | 1995 |
Single fraction prophylactic cranial irradiation for small cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cognition; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Memory; Psychomotor Performance; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Vincristine | 1995 |
Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Rate | 1995 |
Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Rate | 1995 |
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Colony-Forming Units Assay; Drug Administration Schedule; Erythrocyte Transfusion; Erythropoietin; Etoposide; Female; Granulocytes; Hemoglobin A; Humans; Ifosfamide; Iron; Leukocyte Count; Lung Neoplasms; Macrophages; Male; Mesna; Middle Aged; Platelet Count; Platelet Transfusion; Recombinant Proteins; Vincristine | 1995 |
Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prospective Studies; Thrombocytopenia | 1995 |
Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Adenoid Cystic; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Sarcoma | 1995 |
Ifosfamide/carboplatin/etoposide chemotherapy in patients with metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1995 |
Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Italy; Lung Neoplasms; Male; Middle Aged; Mitomycin; Multivariate Analysis; Neoplasm Staging; Retrospective Studies; Survival Rate; Vindesine | 1995 |
Combination chemotherapy with cyclophosphamide, vincristine, cisplatin and etoposide (COPE) combined with radiotherapy for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Combinations; Etoposide; Humans; Leukopenia; Life Tables; Lung Neoplasms; Middle Aged; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Vincristine | 1995 |
[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate; Vindesine | 1995 |
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Small Cell; Chi-Square Distribution; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Remission Induction; Survival Rate; United States | 1995 |
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Regression Analysis; Remission Induction; Survival Rate; Thoracotomy; United States | 1995 |
Chemoradiation in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiotherapy Dosage; Survival Rate | 1995 |
Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Tolerance; Etoposide; Feasibility Studies; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Thorax | 1995 |
Paclitaxel by 1-hour infusion in combination chemotherapy of stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Remission Induction | 1995 |
Phase II trial of carboplatin in combination with etoposide in locally advanced large cell carcinoma and adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
[Treatment of non-small-cell lung cancer by dual (bronchial and pulmonary) arterial drug infusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Pulmonary Artery; Survival Rate | 1995 |
[Single high-dose and fractionated low dose cisplatin in the EP protocol for advanced NSCLC--a prospective randomized trial on 72 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies | 1995 |
Prospective multimodality treatment of SCLC--experience during the past 18 years.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Pneumonectomy; Postoperative Care; Prednisone; Procarbazine; Radiotherapy Dosage; Vincristine | 1995 |
Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Colony-Stimulating Factors; Ethylenes; Etoposide; Female; Humans; Interleukin-1; Interleukin-6; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Remission Induction; Thrombocytopenia | 1995 |
High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Risk Factors; Vinblastine | 1993 |
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carcinoma, Small Cell; Cyclophosphamide; Double-Blind Method; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Recombinant Proteins | 1993 |
Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Contraindications; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prospective Studies; Radiotherapy; Radiotherapy, Adjuvant; Regression Analysis; Remission Induction; Switzerland; Thorax; Vincristine | 1994 |
Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
Topics: Administration, Oral; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Analysis | 1995 |
Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Salvage Therapy; Survival Analysis | 1995 |
Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Survival Analysis | 1995 |
[Role of radiotherapy in the framework of curative chemotherapy concept in local advanced non-small-cell bronchial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Mitomycins; Prospective Studies; Time Factors; Vindesine | 1995 |
Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Patient Acceptance of Health Care; Quality of Life; Remission Induction; Survivors; Treatment Outcome; Vincristine | 1995 |
Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 1995 |
[Pilot study of sequential chemotherapy and radiation therapy using of liniac and fast neutron for limited small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Fast Neutrons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Radiotherapy Dosage; Vincristine | 1995 |
Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Drug Resistance; Estrogens; Etoposide; Gonadotropin-Releasing Hormone; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Treatment Outcome | 1995 |
Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1994 |
Carboplatin and etoposide in extensive small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1994 |
Priming low-dose chest radiotherapy followed by chemotherapy for limited small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage | 1994 |
Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1994 |
Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiotherapy Dosage; Survival Rate; Time Factors | 1995 |
Ifosfamide, doxorubicin, vincristine, and etoposide in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Survival Analysis; Vincristine | 1995 |
Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis | 1995 |
The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Salvage Therapy; Teniposide; Vincristine | 1995 |
Hoosier Oncology Group studies in extensive and recurrent small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 1995 |
A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Interferon-gamma; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1995 |
Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Treatment Failure; Vincristine | 1995 |
[Concurrent chemoradiotherapy followed by surgery for advanced stage III non-small cell lung cancer (NSCLC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage | 1995 |
[Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Radiotherapy Dosage; Survival Rate; Time Factors; Vincristine | 1994 |
[Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cross-Over Studies; Doxorubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Recombinant Proteins | 1994 |
A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interleukin-2; Lung Neoplasms; Male; Melatonin; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 1994 |
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia; Weight Loss | 1994 |
[Phase II study of a continuous five-day intravenous infusion of cisplatin and etoposide with concurrent chest radiation therapy in limited stage small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prognosis | 1994 |
Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Survivors; Time Factors; Treatment Failure | 1994 |
CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer.
Topics: Bayes Theorem; Camptothecin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Metabolic Clearance Rate | 1994 |
Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Prospective Studies; Survival Rate; Thoracic Neoplasms; Vincristine | 1994 |
Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Remission Induction; Treatment Outcome | 1994 |
Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Remission Induction; Survival Analysis | 1994 |
A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Mitomycin; Procarbazine; Remission Induction; Vinblastine; Vincristine | 1994 |
Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infections; Lung Neoplasms; Male; Middle Aged; Neutropenia; Remission Induction; Survival Analysis | 1994 |
[Phase I/II study of a combination regimen composed of cisplatin, carboplatin and etoposide against small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1994 |
Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Follow-Up Studies; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate | 1994 |
High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Lung Neoplasms; Lymphocyte Count; Male; Middle Aged; Pilot Projects; Vincristine | 1994 |
Infusional cisplatin and etoposide in the treatment of stage III-B and IV non-small cell lung cancer: a well tolerated regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Staging | 1994 |
[CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Vincristine | 1993 |
Mitomycin C etoposide and vinorelbine (MEV II) in the treatment of metastatic stage IV non small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 1994 |
Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, High-Energy; Survival Analysis; Survival Rate | 1994 |
A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
Topics: Adult; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Regression Analysis; Survival Analysis; Treatment Outcome | 1994 |
Phase I study of high-dose cisplatin, ifosfamide, and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1994 |
[Small cell bronchial cancer. Comparison of results of weekly polychemotherapy using multiple drugs with standard chemotherapy. European Lung Cancer Working Party].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prognosis; Survival Rate; Vincristine; Vindesine | 1994 |
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Analysis | 1994 |
Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis; Vincristine | 1994 |
Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction; Survival Rate; Thoracotomy | 1994 |
Limited disease small cell lung cancer: alternating combination of doxorubicin, etoposide, ifosfamide and hyperfractionated radiotherapy. Final results of a multicentric pilot study for the Groupe Lyonnias d'Oncologie Thoracique (GLOT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Radiotherapy | 1993 |
Combination of vinorelbine, cisplatin, and etoposide in advanced non-small cell lung carcinoma: a pilot study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Vinblastine; Vinorelbine | 1994 |
Carboplatin plus epirubicin plus VP-16, concurrent 'split course' radiotherapy and adjuvant surgery for limited small cell lung cancer. Gruppo Oncologico Centro-Sud-Isole (GOCSI).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Digestive System Diseases; Epirubicin; Etoposide; Humans; Kidney Diseases; Life Tables; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Survival Analysis | 1994 |
Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1994 |
Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Vincristine | 1994 |
Alternating radiotherapy and chemotherapy in limited small cell lung cancer: the IGR protocols. French FNCLCC Lung Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Failure | 1994 |
Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1994 |
Neoadjuvant chemotherapy for patients with osteosarcoma: University of Florida studies.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Florida; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Life Tables; Lung Neoplasms; Methotrexate; Osteosarcoma; Survival Analysis; Treatment Outcome | 1993 |
Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vincristine | 1993 |
Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 1993 |
Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Treatment Outcome | 1993 |
Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 1994 |
Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Interferon Type I; Interferon-gamma; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1994 |
[Surgery of locally advanced non-small-cell bronchial cancer after intensive preoperative chemo-/radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Pilot Projects; Prospective Studies; Radiotherapy, High-Energy; Reoperation | 1994 |
Phase II trial of oral etoposide plus cisplatin in extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Treatment Outcome | 1994 |
[Chemotherapy with oral etoposide, UFT and carboplatin in non-small cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Tegafur; Uracil | 1994 |
Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Isoxazoles; Lung Neoplasms; Male; Remission Induction; Survival Analysis | 1994 |
Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study.
Topics: Adult; Bone Marrow; Carcinoma, Small Cell; Drug Administration Schedule; Drug Tolerance; Erythrocyte Transfusion; Etoposide; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Platelet Transfusion | 1994 |
Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; Etoposide; Female; Humans; Hydrazines; Lung Neoplasms; Male; Quality of Life; Survival Rate | 1994 |
Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia | 1994 |
Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1994 |
Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cisplatin; Dopa Decarboxylase; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosecretory Systems; Prospective Studies; Survival Analysis; Tumor Cells, Cultured | 1993 |
Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thoracotomy | 1993 |
Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 1993 |
CVM versus ACE in the treatment of small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant, Newborn; Infections; Leukopenia; Lung Neoplasms; Male; Methotrexate; Middle Aged; Thrombocytopenia; Treatment Outcome; Vinblastine | 1993 |
Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 1993 |
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Wor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cause of Death; Chi-Square Distribution; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prognosis; Proportional Hazards Models; Regression Analysis; Survival Analysis; Survival Rate; Treatment Outcome; Vincristine | 1993 |
Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Survival Analysis; Treatment Outcome | 1994 |
Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Middle Aged; Time Factors; Treatment Outcome | 1994 |
Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Treatment Outcome | 1994 |
A phase II trial of alternating chemotherapy in patients with inoperable non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Survival Analysis; Treatment Outcome | 1994 |
Phase II evaluation of carboplatin and VP-16 for patients with metastatic breast cancer and only one prior chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Salvage Therapy; Thoracic Neoplasms; Treatment Outcome | 1993 |
Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
Topics: Adult; Aged; Catheterization, Central Venous; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusion Pumps; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 1993 |
Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Decision Trees; Etoposide; Feasibility Studies; Female; Humans; Illinois; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; New York City; Ohio; Postoperative Complications; Prospective Studies; Radiotherapy; Remission Induction; Survival Rate; Thoracotomy; Washington | 1993 |
The combination of mitomycin, vinblastine and cisplatin is active in the palliation of stage IIIB-IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins; Neoplasm Staging; Quality of Life; Remission Induction; Vinblastine | 1993 |
Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Prognosis; Vincristine | 1993 |
Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Interleukin-2; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 1993 |
Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Radiotherapy Dosage | 1993 |
Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin | 1993 |
Combined modality therapy for stage IIIA non-small cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis | 1993 |
No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Melphalan; Middle Aged; Platelet Aggregation; Prednisone; Survival Rate | 1993 |
Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1993 |
[Phase II study of a novel combination regimen composed of cisplatin, carboplatin and etoposide against unresectable non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 1993 |
A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Vincristine | 1993 |
Postoperative complications after combined neoadjuvant treatment of lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Feasibility Studies; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Complications; Radiotherapy Dosage | 1993 |
Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Small Cell; Chromogranin A; Chromogranins; Etoposide; Female; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Predictive Value of Tests; Prognosis; Recurrence | 1993 |
Phase II study of a 72-h concurrent continuous infusion of cisplatin and etoposide in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1993 |
Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects | 1993 |
Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage | 1993 |
A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusion Pumps; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life | 1993 |
Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Thorax | 1993 |
Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiotherapy; Survival Analysis; Thorax; Treatment Failure; Vincristine | 1993 |
Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Regression Analysis; Survival Analysis; Treatment Outcome | 1993 |
Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Count; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1993 |
Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1993 |
Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Ethylnitrosourea; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Rate; Thiotepa; Vincristine | 1993 |
Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Survival Rate; Vincristine | 1993 |
Combination chemotherapy for small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Malaysia; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life | 1993 |
A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Carcinoma, Small Cell; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Verapamil; Vincristine | 1993 |
Phase II trial of carboplatin and etoposide in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Etoposide; Female; Humans; Injections, Intravenous; Liver; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Survival Rate | 1993 |
Etoposide plus cisplatin followed by thoracic radiation for stage IIIB non-small cell lung cancer: MAOP study 2188.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1995 |
Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Recombinant Proteins; Remission Induction | 1995 |
Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Radiotherapy Dosage | 1995 |
Phase II study of infusional cisplatin in combination with etoposide in the treatment of small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1995 |
Dose intensification of carboplatin and etoposide as first-line combination chemotherapy in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Middle Aged; Pilot Projects | 1995 |
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cachexia; Carcinoma, Small Cell; Cisplatin; Double-Blind Method; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Megestrol; Megestrol Acetate; Pain Measurement; Quality of Life; Survival Analysis; Survival Rate; Thromboembolism | 1996 |
Predicting etoposide toxicity: relationship to organ function and protein binding.
Topics: Adult; Aged; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Creatinine; Etoposide; Female; Half-Life; Hematologic Diseases; Humans; Kidney Function Tests; Leukocyte Count; Liver Function Tests; Lung Neoplasms; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Protein Binding; Regression Analysis | 1996 |
Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Analysis | 1996 |
Prospective trial of combined hyperfractionated radiotherapy and bronchial arterial infusion of chemotherapy for locally advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Mitomycins; Neoplasm Staging; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis | 1996 |
Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Recombinant Proteins | 1995 |
Preoperative concurrent chemoradiotherapy for unresectable Stage III nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Adjuvant | 1996 |
[Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 1995 |
Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cisplatin; Disease Progression; Etoposide; Female; Humans; Hydrazines; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neuroendocrine Tumors; Prognosis; Staining and Labeling | 1996 |
Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 1996 |
Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine | 1996 |
Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cause of Death; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Lung; Lung Neoplasms; Neoplasm Staging; Radiation Pneumonitis; Remission Induction; Survival Rate; Thrombocytopenia | 1996 |
Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cause of Death; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Remission Induction; Vincristine | 1996 |
Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Analysis | 1996 |
Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thrombocytopenia | 1996 |
Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1996 |
Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Neutropenia; Prospective Studies; Remission Induction; Vindesine | 1995 |
Phase I study of a carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Outpatients; Paclitaxel; Survival Analysis | 1996 |
Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Small Cell; Codon; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Point Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA | 1996 |
Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Remission Induction | 1995 |
Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Analysis; Treatment Failure; Treatment Outcome | 1996 |
Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 1996 |
Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Analysis; Thymalfasin; Thymosin | 1995 |
Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carmustine; Cyclophosphamide; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Drug Monitoring; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Time Factors | 1996 |
A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Prognosis; Quality of Life; Vincristine | 1996 |
[Preoperative radio-chemotherapy of stage III unresectable non-small cell lung cancer: results of a pilot study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Pilot Projects; Pneumonectomy; Preoperative Care; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 1996 |
Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Retrospective Studies; Thrombocytopenia | 1996 |
Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Savings; Deoxycytidine; Direct Service Costs; Drug Costs; Etoposide; Female; Gemcitabine; Health Services Research; Hospital Costs; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Models, Economic; Monte Carlo Method; Oncology Service, Hospital; Sensitivity and Specificity; United States | 1996 |
[Clinical trial of oral etoposide in the treatment of malignancies].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Child; Etoposide; Female; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Ovarian Neoplasms; Prospective Studies | 1995 |
Randomised trial of vindesine and etoposide +/- dexverapamil in advanced non-small cell lung cancer: first results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Calcium Channel Blockers; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Verapamil; Vindesine | 1995 |
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Europe; Female; Humans; Ifosfamide; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Rate; Vindesine | 1996 |
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; United States | 1996 |
Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recurrence; Survival Rate; Time Factors; Treatment Failure | 1995 |
Intensified VICE regimen may improve SCLC survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Vincristine | 1996 |
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia | 1996 |
Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Lung Neoplasms; Male; Middle Aged | 1996 |
Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Interleukin-3; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Thrombocytopenia | 1996 |
Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Palliative Care; Survival Analysis; Treatment Failure | 1996 |
Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Etoposide; Female; Hematologic Diseases; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 1996 |
The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukocyte Count; Lung Neoplasms; Male; Neutropenia; Prospective Studies | 1996 |
r-metHuG-CSF support to ifosfamide, cisplatin, etoposide chemotherapy in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1996 |
A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged | 1996 |
Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Evaluation Studies as Topic; Humans; Lomustine; Lung Neoplasms; Mechlorethamine; Methotrexate; Palliative Care; Predictive Value of Tests; Prospective Studies; Specimen Handling; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Vincristine | 1996 |
[Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male | 1995 |
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Recombinant Proteins; Survival Rate | 1996 |
Phase I trial of intravenous carboplatin added to oral etoposide and oral cyclophosphamide for stage IV non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged | 1996 |
Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Vinblastine | 1996 |
Management of germ cell testicular cancer with pulmonary metastases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Germinoma; Humans; Lung Neoplasms; Male; Orchiectomy; Testicular Neoplasms | 1996 |
Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Survival Analysis; Treatment Outcome | 1996 |
Partial substitution of cisplatin with carboplatin in combination with etoposide in advanced non-small cell lung cancer (NSCLC): a multicentric randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Therapeutic Equivalency | 1996 |
Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Synergism; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction | 1996 |
A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Phase I/II study of combination chemotherapy with cisplatin, carboplatin and etoposide in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 1996 |
Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Multivariate Analysis; Survival Analysis; Vincristine | 1996 |
Failure to induce resistance to cytotoxic drugs in normal lymphocytes.
Topics: Antineoplastic Agents; Chlorambucil; Drug Resistance, Multiple; Etoposide; Humans; Immunity, Cellular; Lung Neoplasms; Lymphocytes | 1996 |
Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Mitomycin; Multivariate Analysis; Survival Rate; Treatment Outcome; Vindesine | 1996 |
Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Cause of Death; Dose-Response Relationship, Drug; Drug Tolerance; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sepsis; Thrombocytopenia | 1996 |
Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 1996 |
Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cause of Death; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Vinblastine; Vinorelbine | 1996 |
Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Etoposide; Head and Neck Neoplasms; Humans; Leucovorin; Lung Neoplasms; Middle Aged; Stomach Neoplasms; Tegafur; Uracil | 1997 |
[Administration of oral etoposide for one year as adjuvant chemotherapy for non-small cell lung cancer-side effect].
Topics: Administration, Oral; Aged; Anorexia; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Etoposide; Fever; Gastrointestinal Diseases; Humans; Lung Neoplasms; Pneumonia; Postoperative Care; Vomiting | 1996 |
High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Chi-Square Distribution; Confidence Intervals; Diarrhea; Disease-Free Survival; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Humans; Liver Neoplasms; Lung Neoplasms; Melphalan; Middle Aged; Neoplasm Staging; Survival Rate; Thiotepa; Treatment Outcome | 1996 |
Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies | 1996 |
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Drug Monitoring; Etoposide; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Prodrugs | 1996 |
Clinical studies with etoposide phosphate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Remission Induction | 1996 |
Combinations of paclitaxel and etoposide in the treatment of lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Tumor Cells, Cultured | 1996 |
Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Treatment Outcome | 1996 |
Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 1996 |
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vincristine | 1997 |
[Treatment of broncho-pulmonary cancer using carboplatin/etoposide: survival analysis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Analysis | 1996 |
Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Failure | 1996 |
Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Analysis | 1997 |
A phase II study of carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1997 |
Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Interferon Type I; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Rate; Vincristine | 1997 |
[Phase II study of combination chemotherapy with cisplatin, carboplatin and etoposide (CPVP) in unresectable non-small cell lung cancer: analysis of survival time and prognostic factors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 1997 |
A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Radiotherapy Dosage; Survival Analysis | 1997 |
Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Survival Analysis | 1997 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Small Cell; Cardiovascular Diseases; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Etoposide; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pneumonectomy; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 1997 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Lung Neoplasms; Male; Middle Aged; Palliative Care; Pneumonectomy; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 1997 |
Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Rate | 1997 |
A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage I to IIIA small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Pilot Projects | 1997 |
Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Survival Analysis; Treatment Outcome; Vincristine | 1997 |
A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1997 |
Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel | 1997 |
Optimization of chemotherapy administration for clinical 41.8 degrees C whole body hyperthermia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cross-Over Studies; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Hyperthermia, Induced; Ifosfamide; Lung Neoplasms; Male; Neutropenia; Platelet Count; Sarcoma | 1997 |
Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sepsis; Survival Analysis | 1997 |
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis | 1997 |
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia | 1997 |
Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins; Prospective Studies; Survival Rate; Vinblastine | 1997 |
Gemcitabine and etoposide in small cell lung cancer: phase I and II trials.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases | 1997 |
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Ribonucleotide Reductases; Treatment Outcome; Vomiting | 1997 |
[A study on treatment of lung cancer by combined therapy of traditional Chinese medicine and chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diagnosis, Differential; Drugs, Chinese Herbal; Etoposide; Female; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Mitomycin; Survival Rate; Vindesine | 1996 |
Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Vinblastine | 1997 |
A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Treatment Failure | 1997 |
A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1997 |
Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
Prognostic factors and prognostic staging system for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Regression Analysis; Survival Rate; Vincristine | 1997 |
Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1997 |
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1997 |
[Effect of daily administration of oral etoposide for non-small cell lung cancer treated with concurrent radiation therapy].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Pneumonitis; Survival Rate; Treatment Outcome | 1997 |
Results of surgery for bronchogenic carcinoma located in the aortic window.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness | 1997 |
Dose-intensive chemotherapy in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neutropenia; Treatment Outcome; Vincristine | 1997 |
[Prolonged oral etoposide therapy in advanced stage lung cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome | 1997 |
Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Count; Radiography; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Time Factors; Treatment Outcome; Vincristine | 1997 |
[Neoadjuvant combined therapy in stage IIIA if non-small-cell bronchial cancer].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dimethoate; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Vindesine | 1997 |
Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Epirubicin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outpatients; Survival Rate | 1997 |
Prolonged administration of oral etoposide alone or with intravenous carboplatin in stage IV non-small cell lung cancer: a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1997 |
Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclosporine; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1997 |
A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis | 1997 |
Chemoradiotherapy for poor-risk stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Radiotherapy Dosage; Survival Analysis | 1997 |
Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Diseases; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Radiotherapy; Radiotherapy Dosage | 1997 |
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Pilot Projects | 1997 |
A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage | 1997 |
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 1997 |
Paclitaxel, carboplatin, and oral etoposide: a phase II trial in limited-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
[Chemotherapy versus chemoradiotherapy in patients with limited small cell lung carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vincristine | 1997 |
Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Etoposide; Female; Humans; Injections, Intravenous; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Radiotherapy; Radiotherapy Dosage; Remission Induction; Sex Factors; Survival Rate; Treatment Outcome; Vinblastine; Weight Loss | 1997 |
Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cause of Death; Cisplatin; Clinical Trials, Phase II as Topic; Cochlea; Digestive System Neoplasms; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Etoposide; Evaluation Studies as Topic; Female; Humans; Kidney; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Remission Induction; Sepsis; Stomach Neoplasms; Thrombocytopenia; Vomiting | 1997 |
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Amsacrine; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Survival Analysis; Warfarin | 1997 |
A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Melatonin; Middle Aged; Prognosis; Remission Induction | 1997 |
Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Thrombocytopenia | 1997 |
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1997 |
A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients wit
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis; Teniposide; Treatment Outcome; Vincristine | 1997 |
Re: five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Palliative Care; Survival Analysis; Treatment Outcome | 1997 |
The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Recombinant Proteins; Time Factors | 1997 |
A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Echinomycin; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Intercalating Agents; Lung Neoplasms; Male; Middle Aged; Prognosis; Quality of Life; Remission Induction; Survival Rate; Trimetrexate | 1998 |
Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Granulocytes; Humans; Ifosfamide; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Survival Rate; Thrombocytopenia; Vomiting | 1998 |
Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Recombinant Proteins; Thrombocytopenia | 1998 |
Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etanidazole; Etoposide; Humans; Lung Neoplasms; Peripheral Nervous System Diseases; Radiation-Sensitizing Agents; Vincristine | 1998 |
Absence of thoracic radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for Stage III nonsmall-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Myelitis | 1998 |
Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Radiotherapy Dosage; Survival Rate | 1998 |
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Double-Blind Method; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Vincristine | 1998 |
Preliminary study of efficacy of intravenous cisplatin plus oral etoposide in small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1998 |
Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Double-Blind Method; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Megestrol Acetate; Middle Aged; Neoplasm Proteins; Vincristine | 1998 |
Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Radiotherapy Dosage; Survival Analysis | 1998 |
A phase II study of carboplatin and prolonged administration of oral etoposide in patients with small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Thrombocytopenia | 1997 |
A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 1998 |
The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 1998 |
Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1998 |
Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Extremities; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Osteosarcoma; Prognosis | 1998 |
Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Filgrastim; Germinoma; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins | 1998 |
Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vincristine | 1998 |
Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer. Fukuoka Lung Cancer Study Group.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting | 1998 |
Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Male; Megestrol Acetate; Middle Aged; Recombinant Proteins | 1998 |
Advanced non-small cell lung cancer chemotherapy: a randomized trial of two active regimens (MVP and PE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Treatment Outcome; Vindesine | 1997 |
High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Endothelial Growth Factors; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Lymphokines; Male; Middle Aged; Prognosis; Recombinant Proteins; Survival Analysis; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Prognosis; Survival Rate; Vincristine | 1998 |
Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cognition; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Emotions; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neuropsychological Tests; Trail Making Test; Warfarin | 1998 |
Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Thoracotomy | 1998 |
Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Hematologic Diseases; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Nausea; Remission Induction; Survival Analysis | 1998 |
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Recombinant Proteins; Recurrence; Survival Rate; Treatment Outcome; Vincristine | 1998 |
CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: a Hoosier Oncology Group phase II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vincristine | 1998 |
[Cytostatic treatment of patients with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vinblastine | 1998 |
Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male | 1998 |
A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long ter
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 1998 |
A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neutropenia; Recombinant Proteins | 1998 |
Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1998 |
Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Risk Factors; Survival Analysis | 1998 |
A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Tretinoin | 1998 |
The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Surface Area; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Esophageal Neoplasms; Etoposide; Female; Hematologic Tests; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Sex Factors; Thrombocytopenia | 1998 |
Radiotherapy with/without cisplatin following chemotherapy in limited small-cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms | 1998 |
Treatment of non-small-cell lung cancer with prolonged oral etoposide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1998 |
[Therapeutic effect of Chinese medicinal herbs combined with chemotherapy on advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Drugs, Chinese Herbal; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1997 |
Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.
Topics: Adolescent; Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Neoplasms; Capillary Leak Syndrome; Combined Modality Therapy; Cytokines; Drug Synergism; Etoposide; Feasibility Studies; Female; Femoral Neoplasms; Fever; Fibrosis; Gastrointestinal Diseases; Humans; Hypotension; Immunologic Factors; Interleukin-1; Lung Neoplasms; Male; Neutropenia; Osteosarcoma; Recombinant Proteins; Remission Induction; Respiration Disorders; Salvage Therapy; Treatment Outcome | 1997 |
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Regression Analysis; Time Factors | 1997 |
Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Nausea; Recombinant Proteins; Reproducibility of Results; Vomiting | 1997 |
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 1998 |
Modified ice study: a phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with better prognosis, small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Prognosis; Quality of Life | 1998 |
Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Treatment Outcome | 1998 |
Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cognition; Disease Progression; Emotions; Etoposide; Female; Hematologic Diseases; Humans; Interpersonal Relations; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Treatment Outcome | 1998 |
Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer--impact of total treatment time.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Retrospective Studies; Survival Rate; Treatment Outcome | 1998 |
A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds | 1998 |
Phase II study of hyperfractionated radiotherapy and concurrent weekly alternating chemotherapy in limited-stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Survival Analysis; Treatment Outcome | 1998 |
Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group.
Topics: Administration, Oral; Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Thrombocytopenia; Vomiting | 1998 |
Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Quality of Life; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 1998 |
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Radiotherapy Dosage; Survival Rate | 1999 |
Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiation-Sensitizing Agents; Survival Rate | 1999 |
[CBDCA, etoposide and epirubicin high-dose combination chemotherapy supported by peripheral blood stem cell transplantation (PBSCT) in metastatic breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local | 1999 |
Dipyridamole modulated Tc-99m sestamibi lung SPECT in small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cisplatin; Dipyridamole; Drug Resistance, Multiple; Etoposide; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 1999 |
Induction chemoradiotherapy for advanced stage III non-small cell lung cancer: long-term follow-up in 42 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction | 1998 |
Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cranial Irradiation; Drug Administration Schedule; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 1999 |
Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Analysis; Time Factors | 1999 |
Advanced non-small-cell lung cancer: adjunctive interferon gamma in induction and maintenance therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Etoposide; Female; Humans; Interferon-gamma; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite Stimulants; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Megestrol Acetate; Mesna; Middle Aged; Protective Agents; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1998 |
A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1998 |
Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
Topics: Adult; Aged; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 1999 |
[Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Topics: Aged; Alprostadil; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Middle Aged | 1999 |
Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Melanoma; Middle Aged; Prospective Studies; Survival Rate | 1999 |
Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Risk Assessment; Survival Analysis | 1999 |
Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiotherapy; Survival Analysis; Treatment Outcome; Vomiting, Anticipatory | 1999 |
Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cross-Over Studies; Cytoprotection; Double-Blind Method; Etoposide; Female; Hematologic Tests; Humans; Leukopoiesis; Lung Neoplasms; Male; Melatonin; Middle Aged; Protective Agents; Treatment Outcome | 1999 |
Induction of gamma-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Blotting, Northern; Camptothecin; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Glutamate-Cysteine Ligase; Humans; Irinotecan; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric; Tumor Cells, Cultured | 1999 |
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Morpholines; Retinoids | 1999 |
Short-term chemotherapy and palliative radiotherapy for elderly patients with stage IV non-small cell lung cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Survival Rate; Treatment Outcome | 1999 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary | 1999 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Survival Rate | 1999 |
Pharmacological analysis of etoposide in elderly patients with lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Etoposide; Humans; Lung Neoplasms; Treatment Outcome | 1999 |
High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Tamoxifen | 1999 |
A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Platinum Compounds; Salvage Therapy; Survival Rate | 1999 |
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Rate | 1999 |
Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Heparin; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 1999 |
Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Thorax; Treatment Outcome | 1999 |
Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): a randomized trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 1999 |
Modifying the ICE regimen for better prognosis small cell lung cancer--an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Pilot Projects; Prognosis; Survival Rate | 1999 |
A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pulmonary Fibrosis; Radiotherapy; Radiotherapy Dosage; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Vindesine | 1999 |
Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Multivariate Analysis; Survival Rate; Time Factors | 1999 |
Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Europe; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Ifosfamide; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins | 1999 |
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Prognosis; Regression Analysis | 1999 |
Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Radiotherapy; Survival Rate; Yugoslavia | 1999 |
Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1999 |
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis; United States; Vincristine | 1999 |
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Sensitivity and Specificity; Survival Analysis | 1999 |
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1999 |
Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clini
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Epirubicin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Nervous System Neoplasms; Neutropenia; Recurrence; Survival Rate; Thoracic Neoplasms; Thrombocytopenia; Treatment Outcome | 1999 |
Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1999 |
A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Time Factors | 1999 |
The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1999 |
[Combined alternating radiochemotherapy in stage III (TNM) (limited disease) small cell bronchial carcinoma: a phase II study with carboplatin/etoposide/vincristine and alternating radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vincristine | 1999 |
The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Humans; Karnofsky Performance Status; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prospective Studies; Quality-Adjusted Life Years; Survival Analysis | 1999 |
Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomize
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Thrombocytopenia | 2000 |
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Treatment Failure | 2000 |
A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infusions, Intravenous; Injections, Subcutaneous; Leukapheresis; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Recombinant Proteins; Transplantation, Autologous; Treatment Outcome | 2000 |
Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Postoperative Care; Treatment Outcome | 2000 |
Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Megestrol; Middle Aged; Neoplasm Staging; Phosphopyruvate Hydratase; Survival Rate; Time Factors | 2000 |
Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2000 |
Concurrent cisplatin/etoposide chemotherapy plus twice daily thoracic radiotherapy in limited stage small cell lung cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 2000 |
A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Survival Analysis; Time Factors | 2000 |
Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Etoposide; Female; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic | 2000 |
Cisplatin containing chemotherapy influences HLA-DR expression on monocytes from cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Etoposide; Fluorouracil; HLA-DR Antigens; Humans; Lung Neoplasms; Male; Middle Aged; Monocytes; Reference Values | 1999 |
A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Sex Factors; Survival Analysis | 1999 |
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2000 |
Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d'Oncologie Thoracique des Régions Alpines.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Radiotherapy Dosage; Survival Rate | 2000 |
A phase II study of combined chemoradiotherapy for limited disease-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Esophagitis; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Finland; Humans; Ifosfamide; Injections, Subcutaneous; Interferon-alpha; Isotretinoin; Lung Neoplasms; Male; Middle Aged | 2000 |
Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Necrosis; Neutropenia; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Stomatitis; Survival Analysis | 1999 |
Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2000 |
[Etoposide and cisplatin for non-small cell lung cancer: trial at the Soroka Medical Center 1986-1994].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Hospitals, University; Humans; Israel; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2000 |
[Peripheral blood stem cell harvest in patients with limited stage small-cell lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Male; Middle Aged | 2000 |
A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Survival Analysis | 2000 |
Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Treatment Outcome | 2000 |
[Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Survival Rate | 2000 |
[Combination of irinotecan hydrochloride and etoposide for treatment of refractory or relapsed small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2000 |
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Diarrhea; Disease Progression; Etoposide; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Survival Rate | 2000 |
Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neutrophils; Recombinant Proteins; Remission Induction; Survival Rate | 2000 |
Sample sizes for cancer trials where Health Related Quality of Life is the primary outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Methotrexate; Normal Distribution; Quality of Life; Randomized Controlled Trials as Topic; Sample Size; Statistics as Topic; Surveys and Questionnaires; Vincristine | 2000 |
Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cytarabine; Data Interpretation, Statistical; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Models, Statistical; Quality of Life; Randomized Controlled Trials as Topic; Time Factors | 2000 |
Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Small Cell; Doxorubicin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Middle Aged | 2000 |
Feasibility and preliminary results of intensive chemotherapy and extensive irradiation in selected patients with limited small-cell lung carcinoma--results of three consecutive phase II programs.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Survival Analysis; Treatment Outcome; Vindesine | 2000 |
Effect of chemotherapy on pulmonary epithelial permeability in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Gas Analysis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Membrane Permeability; Cisplatin; Doxorubicin; Etoposide; Forced Expiratory Volume; Humans; Ifosfamide; Lung; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Mitomycin; Mucociliary Clearance; Respiratory Mucosa; Technetium Tc 99m Pentetate; Vital Capacity | 2000 |
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk; Survival Analysis | 2000 |
[Evaluation of bronchial arterial infusion (BAI) for high risk lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2000 |
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia | 2001 |
Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2000 |
Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Platelet Count; Quality of Life | 2001 |
Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quality of Life; Risk; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2001 |
A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thorax | 2000 |
Combination of paclitaxel and etoposide in the treatment of advanced non-small cell lung cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2001 |
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Etoposide; Female; Humans; Hypoxanthine Phosphoribosyltransferase; Lung Neoplasms; Male; Middle Aged; Mutation; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2001 |
[Use of etoposide, ifosfamide and cisplatin (EIP) for treatment of inoperable non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction | 2000 |
Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Topotecan; Treatment Outcome | 2001 |
Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiotherapy; Survival Rate | 2001 |
Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endpoint Determination; Etoposide; Feasibility Studies; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Treatment Failure | 2001 |
A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
Combination chemotherapy for extensive small cell lung cancer -- experience from India.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Drug Costs; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; India; Lung Neoplasms; Male; Mesna; Middle Aged; Patient Compliance; Poverty; Survival Analysis; Survival Rate; Treatment Outcome; Vincristine | 2001 |
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
[Enhancement of efficacy of neoadjuvant polychemotherapy in combined treatment of lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Microwaves; Vincristine | 2000 |
Postoperative adjuvant therapy for stage IB non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies | 2001 |
[The effect of small cell lung cancer extension on secretion of interleukin-2 (IL-2) and interferon gamma (IFM gamma) in whole blood culture stimulated with mitogens].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Epirubicin; Etoposide; Female; Glucuronates; Humans; Ifosfamide; Interferon-gamma; Interleukin-2; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Adjuvant; Remission Induction | 2001 |
Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2001 |
Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2001 |
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Neutropenia; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2001 |
Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: a phase III randomized trial with quality-of-life evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis | 2001 |
Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Organophosphorus Compounds; Survival Analysis; Treatment Outcome | 2001 |
A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2001 |
Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2001 |
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Endpoint Determination; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vindesine | 2001 |
Population pharmacokinetics and pharmacodynamics of oral etoposide.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Breast Neoplasms; Creatinine; Cross-Over Studies; Etoposide; Female; Humans; Injections, Intravenous; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Models, Biological; Software; Stomach Neoplasms | 2001 |
Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Survival Rate; Treatment Outcome | 2002 |
Commentary on "carboplatin-etoposide association in small cell lung cancer patients older than 70 years: a phase II trial".
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Survival Rate; Treatment Outcome | 2002 |
Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Double-Blind Method; Doxorubicin; Etoposide; Female; Fever; Fluoroquinolones; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Infections; Infusions, Intravenous; Lung Neoplasms; Macrolides; Male; Middle Aged; Neutropenia; Placebos; Survival Analysis; Treatment Outcome | 2001 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2002 |
Long-term results of a phase I/II study of high-dose thoracic radiotherapy with concomitant cisplatin and etoposide in limited stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2001 |
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Random Allocation; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Rate; Time Factors | 2002 |
Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Competence; Cohort Studies; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Radiotherapy Dosage; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine | 2002 |
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Radiation Pneumonitis; Radiation-Protective Agents | 2002 |
Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Radiotherapy Dosage; Remission Induction; Survival Rate | 2002 |
Intensive chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small cell lung cancer: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chi-Square Distribution; Combined Modality Therapy; Disease Progression; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 2002 |
A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Survival Analysis; Vinblastine | 2002 |
[Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Survival Rate | 2002 |
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Gastrointestinal Diseases; Germinoma; Hematologic Diseases; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Peripheral Nervous System Diseases; Prognosis; Prospective Studies; Remission Induction; Seminoma; Survival Analysis; Survival Rate; Testicular Neoplasms; Treatment Outcome; Vincristine | 2002 |
VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
Topics: Adult; Aged; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Podophyllotoxin; Prognosis; Vincristine | 1976 |
Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Ifosfamide; Lomustine; Lung Neoplasms; Male; Methotrexate; Procarbazine; Thymosin; Thymus Hormones; Vincristine | 1979 |
Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Humans; Ifosfamide; Lomustine; Lung Neoplasms; Methotrexate; Procarbazine; Remission, Spontaneous; Vincristine | 1979 |
Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Topics: Alopecia; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Evaluation; Etoposide; Humans; Leukemia; Leukopenia; Lung Neoplasms; Lymphoma; Podophyllotoxin; Teniposide | 1979 |
VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
Topics: Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Middle Aged; Podophyllotoxin | 1978 |
A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1992 |
Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 1992 |
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vincristine | 1992 |
Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1992 |
Phase I trial of granulocyte-macrophage colony-stimulating factor with high-dose cisplatin and etoposide for treatment of small-cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged | 1992 |
A study of oral etoposide, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small-cell lung cancer. A Mid-Atlantic Oncology Program study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Evaluation; Etoposide; Female; Fluorouracil; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Analysis | 1992 |
Intensive chemotherapy for extensive-stage small-cell lung cancer (SCLC)
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Vincristine | 1992 |
Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Interactions; Drug Therapy, Combination; Etoposide; Glutathione; Half-Life; Humans; Lung Neoplasms; Mesothelioma; Platinum; Pleural Neoplasms; Time Factors | 1992 |
[A phase II trial of pirarubicin in untreated disseminated small cell lung cancer. A cooperative study of the French Pneumo-Cancerology Group].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Remission Induction; Survival Rate | 1992 |
Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Random Allocation; Time Factors; Vincristine | 1992 |
Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects | 1992 |
Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vincristine | 1992 |
Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; France; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging | 1992 |
Phase II study of combination therapy with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins; Survival Analysis | 1992 |
Randomized trial of neoadjuvant therapy for lung cancer: interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Survival Rate | 1992 |
Calculation of received dose intensity for combinations of drugs using small-cell lung carcinoma treatment regimens as examples.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Numerical Analysis, Computer-Assisted; Vincristine | 1992 |
Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Etoposide; Feasibility Studies; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1992 |
Carboplatin/etoposide/vincristine therapy in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Drug Evaluation; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recurrence; Thrombocytopenia; Time Factors; Vincristine | 1992 |
Platinum/etoposide therapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging | 1992 |
Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Leukocyte Count; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platelet Count | 1992 |
Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Count | 1992 |
Platinum/oral etoposide therapy in non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Female; Hemoglobins; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platelet Count | 1992 |
Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1992 |
Chronic oral etoposide in non-small cell lung carcinoma.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1992 |
Oral etoposide in oncology: an evolving role.
Topics: Administration, Oral; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms | 1992 |
Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Vincristine | 1992 |
Phase II and III studies with carboplatin in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vincristine | 1992 |
Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pilot Projects; Remission Induction; Survival Rate; Thrombocytopenia | 1992 |
Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Epirubicin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia | 1992 |
A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Survival Rate | 1992 |
Carboplatin and etoposide (CarE) combined with radiotherapy and vincristine, doxorubicin and cyclophosphamide (VAC) in limited small cell lung cancer. A phase II study.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Radiography; Time Factors; Treatment Outcome; Vincristine | 1992 |
A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1992 |
Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1992 |
Combination chemotherapy with oral etoposide.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1992 |
The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1992 |
Cyclophosphamide, epirubicin, etoposide, cis platinum (CEVP) in combination with radiotherapy: evaluation of a protocol adopted for 6 years in 148 cases of small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1992 |
Extensive small-cell lung cancer. A randomized comparison of two chemotherapy programs with early crossover in instances of failure. Association pour le Traitement des Tumeurs Intra-Thoraciques (ATTIT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Vincristine | 1992 |
Etoposide versus methotrexate in small cell bronchial carcinoma. A randomized study of two types of four-drug chemotherapy regimens.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prospective Studies; Vincristine | 1992 |
[Studies of the possibility of long-term survival of patients with small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate | 1992 |
[Comparison of 2 cisplatin and etoposide dosages in relapsing small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thrombocytopenia | 1992 |
CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Time Factors; Treatment Outcome; Vincristine | 1992 |
Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small-cell lung cancer.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Middle Aged; Multivariate Analysis; Palliative Care; Prognosis; Prospective Studies; Survival Analysis | 1992 |
Carboplatin in small cell lung cancer: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Mesothelioma; Middle Aged; Palliative Care; Pleural Neoplasms; Remission Induction; Survival Rate | 1992 |
Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Synergism; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitomycin; Skin Neoplasms; Time Factors | 1992 |
Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Remission Induction; Time Factors | 1991 |
A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Mitoguazone; Mitomycins; Peptichemio; Survival Rate; United States; Vinblastine; Vincristine | 1991 |
[Cisplatin etoposide versus cisplatin/etoposide/ifosfamide combination chemotherapy in small-cell lung cancer: a multicenter randomized controlled study. Hokkaido Study Group of Treatment for Small-Cell Lung Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Japan; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate | 1991 |
Sequential chemotherapy in good-prognosis patients with small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prognosis; Vincristine; Vindesine | 1991 |
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1991 |
A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins; Proportional Hazards Models; Survival Rate; Vindesine | 1991 |
Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate; Vincristine | 1991 |
Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlant
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prognosis; Proportional Hazards Models; Survival Rate; Vincristine | 1991 |
A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prognosis; Radiotherapy; Survival Rate | 1991 |
Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.
Topics: Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Prospective Studies; Teniposide | 1991 |
A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Vincristine | 1991 |
A Medical Research Council phase II trial of alternating chemotherapy and radiotherapy in small-cell lung cancer. The Medical Research Council Lung Cancer Working Party.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Remission Induction | 1991 |
5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Thrombocytopenia | 1991 |
Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prognosis; Vinblastine | 1991 |
Phase II trial of high-dose cisplatin plus etoposide plus vinblastine in non-small-cell lung cancer. A Hoosier Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Survival Rate; Vinblastine | 1991 |
A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Prognosis; Survival Rate; Vindesine | 1991 |
Determining carboplatin/etoposide dosage in extensive stage small-cell lung cancer (SCLC).
Topics: Aged; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1991 |
Excessive toxicity of mitoxantrone combined with etoposide in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Etoposide; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mitoxantrone | 1991 |
Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Combined Modality Therapy; Culture Techniques; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Tumor Cells, Cultured; Vincristine | 1991 |
Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1991 |
Treatment of small cell lung cancer: experience at Maharaj Nakhon Chiang Mai Hospital.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Thailand; Vincristine | 1991 |
A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1991 |
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Etoposide; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infection Control; Length of Stay; Lung Neoplasms; Neutropenia; Recombinant Proteins; Survival Rate | 1991 |
A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Confidence Intervals; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Remission Induction | 1991 |
Brief intensive chemotherapy for metastatic non-small-cell lung cancer: a phase II study of the weekly CODE regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prednisone; Remission Induction; Survival Rate; Vincristine | 1991 |
Daily oral etoposide in the treatment of cancer.
Topics: Administration, Oral; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Neoplasms; Neoplasms, Germ Cell and Embryonal | 1991 |
Carboplatin in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vincristine | 1991 |
Limited small cell lung cancer: prognostic significance of a complete response to the induction phase of chemotherapy followed by thoracic irradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiotherapy, High-Energy; Vincristine | 1991 |
Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Prognosis | 1991 |
Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Meta-Analysis as Topic; Podophyllotoxin; Vincristine | 1991 |
Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Vincristine | 1991 |
Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Vincristine | 1991 |
Adjuvant chemotherapy for T1-2NOMO small cell lung cancer: single-agent or combination chemotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Etoposide; Female; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Vomiting | 1991 |
Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Survival Rate | 1991 |
Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vincristine | 1991 |
Phase I study with combination therapy of pirarubicin, etoposide, and vincristine in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Vincristine | 1990 |
Pirarubicin phase II study in untreated metastatic small-cell lung carcinoma. A cooperative study of the Groupe Français de Pneumo-Cancérologie (GFPC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate | 1990 |
A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vindesine | 1990 |
A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged | 1991 |
Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: a Cancer and Leukemia Group B Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Remission Induction; Survival Rate; Time Factors | 1990 |
Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, High-Energy; Randomized Controlled Trials as Topic; Time Factors; Vincristine | 1990 |
Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncolo
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Vincristine | 1990 |
The response of cerebral metastases in small cell lung cancer to systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Vincristine | 1990 |
Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Thiotepa; Vincristine | 1990 |
A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Random Allocation; Remission Induction; Survival Rate; Vincristine | 1990 |
A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: a preliminary report. European Organization for the Research and Treatment of Cancer--Lung Cancer Working Party.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
The clinical effect of medroxyprogesterone (MPA) in elderly patients with lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medroxyprogesterone; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis | 1990 |
[Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Regression Analysis; Remission Induction; Sex Factors; Survival Rate; Vindesine | 1990 |
A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Organoplatinum Compounds; Prognosis; Prospective Studies; Remission Induction; Survival Analysis | 1990 |
Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Remission Induction; Survival Rate; United States; Vincristine | 1990 |
[Small cell lung carcinoma. Value of the evaluation of extension for the therapeutic strategy].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Prognosis; Prospective Studies; Spinal Cord Neoplasms | 1990 |
Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Randomized Controlled Trials as Topic; Remission Induction | 1990 |
Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 1990 |
[Progress and obstacles in chemotherapy and combined modality treatment of small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Procarbazine; Survival Rate; Vincristine | 1990 |
[Current results of chemotherapy in non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Prognosis; Survival Rate; Vindesine | 1990 |
[Cisplatin-Vepeside versus Endoxan-Vepeside in the treatment of small cell bronchial cancer. A randomized study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic | 1990 |
[Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Mitomycins; Prospective Studies; Randomized Controlled Trials as Topic; Vindesine | 1990 |
Induction chemo-radiotherapy and maintenance alternating chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Procarbazine; Vincristine | 1990 |
Vincristine, doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Vincristine | 1990 |
A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis | 1990 |
Phase II feasibility study of high dose epirubicin-based regimens for untreated patients with small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction | 1990 |
[Chemotherapy in non-small cell bronchial carcinoma. 12 years' experience in an international cooperative group: EORTC Lung Cancer Working Party].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Vindesine | 1990 |
Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cisplatin; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged | 1990 |
Alternating radiotherapy and chemotherapy in 173 consecutive patients with limited small cell lung carcinoma. GROP and the French Cancer Center's Lung Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; France; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Survival Rate | 1990 |
Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Radiotherapy Dosage; Survival Rate | 1990 |
[Clinical results of carboplatin in the treatment of malignant tumors. Clinical Cooperative Group of Carboplatin].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms | 1990 |
Five-day continuous infusion of cisplatin and etoposide in non-small cell lung cancer. A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life | 1990 |
Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Leukopenia; Lung Neoplasms; Middle Aged; Pilot Projects; Platelet Count; Recombinant Proteins; Time Factors; Vincristine | 1990 |
Carboplatin and etoposide in advanced lung cancer:--a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Creatinine; Drug Evaluation; Etoposide; Female; Glomerular Filtration Rate; Humans; Lung Neoplasms; Male; Middle Aged | 1990 |
Cancer of the testis: a new paradigm.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Cisplatin; Clinical Trials as Topic; Doxorubicin; Dysgerminoma; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Teratoma; Testicular Neoplasms; Vinblastine | 1986 |
The prognostic value of response to the first cycle of chemotherapy in small cell lung cancer. Results of a multicenter German trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lomustine; Lung Neoplasms; Male; Methotrexate; Nimustine; Nitrosourea Compounds; Peplomycin; Prognosis; Random Allocation; Vincristine; Vindesine | 1987 |
[A comparative randomized phase II study of CDDP, CDDP-carboquone (CQ) and CDDP-etoposide as second-line chemotherapy in small cell lung cancer (SCLC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Random Allocation; Remission Induction | 1989 |
Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; England; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Random Allocation; Vincristine | 1989 |
Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Germany, West; Humans; Ifosfamide; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Staging; Random Allocation; Remission Induction; Vincristine | 1989 |
Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1989 |
Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Random Allocation; Vincristine | 1989 |
Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Prognosis; Quality of Life; Random Allocation; Vincristine | 1989 |
[Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Nimustine; Procarbazine; Random Allocation; Remission Induction; Retrospective Studies; Vincristine | 1989 |
Primary chemotherapy of brain metastasis in small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Vincristine | 1989 |
Lack of relationship between in vitro tumor cell growth and prognosis in extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Prognosis; Prospective Studies; Random Allocation; Tumor Cells, Cultured | 1989 |
Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Random Allocation | 1989 |
A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Mitomycin; Mitomycins; Prognosis; Random Allocation; Remission Induction; Warfarin | 1989 |
Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lomustine; Lung Neoplasms; Methotrexate; Neoplasm Staging; Random Allocation; Remission Induction; Time Factors; Vincristine | 1989 |
Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Middle Aged; Prospective Studies; Random Allocation; Vindesine | 1989 |
A comparison of cis-platinum-vindesine and cis-platinum-etoposide combined with radiotherapy for previously untreated localized inoperable non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Vindesine | 1989 |
Chemotherapy plus adjuvant surgery for local small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Pneumonectomy; Preoperative Care; Remission Induction; Vincristine | 1989 |
A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Half-Life; Humans; Lung Neoplasms; Metabolic Clearance Rate; Random Allocation; Vincristine | 1989 |
Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Humans; Interferon Type I; Interferon-gamma; Lung Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic | 1989 |
Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Folic Acid Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Triazines | 1989 |
Phase II trial with alternating two drug schedules, CAP/MEC', for advanced (stage III Mo/M1) non-small-cell lung cancer.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasm Staging | 1989 |
[Sequential induction chemotherapy and radiation treatment of inoperable small cell bronchial cancer. Results of a prospective randomized study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Vincristine | 1989 |
Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: a dose escalation study of carboplatin. UCL Clinical Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Organoplatinum Compounds | 1989 |
Treatment of small cell lung cancer with induction chemotherapy followed by late intensification.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Remission Induction; Survival Rate; Vincristine | 1989 |
[Evaluation of the second line of treatment of patients with small cell carcinoma of the lung].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 1989 |
A phase III study on intermittent versus weekly cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1989 |
Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Random Allocation; Vincristine | 1987 |
A phase II trial of cyclophosphamide, etoposide, and cisplatin with combined chest and brain radiotherapy in limited small-cell lung cancer: a Cancer and Leukemia Group B Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thorax | 1987 |
Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Random Allocation; Vincristine | 1987 |
The importance of dose and dose intensity in lung cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Vincristine | 1987 |
[Global approach to the treatment of small cell bronchial cancers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Random Allocation | 1987 |
[Therapeutic results in the treatment of small cell bronchial cancer: experience of the EORTC Lung Cancer Working Party (Belgium)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Pilot Projects; Vincristine | 1987 |
The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deglutition Disorders; Dose-Response Relationship, Radiation; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation Dosage; Random Allocation; Vincristine | 1988 |
A randomized study evaluating radiotherapy versus chemotherapy in patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiotherapy, High-Energy; Random Allocation | 1988 |
[Clinical trial of high-dose etoposide].
Topics: Adult; Aged; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Hodgkin Disease; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1988 |
Cyclic alternating polychemotherapy with or without upper and lower half-body irradiation in small cell anaplastic lung cancer. A randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Random Allocation; Time Factors; Vincristine | 1987 |
Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1988 |
[Randomized comparative study of CE (CDDP plus etoposide) and CE-AVN (ACNU, VCR plus procarbazine) as combined anticancer chemotherapy in small cell cancer of the lung].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Nimustine; Nitrosourea Compounds; Procarbazine; Prognosis; Random Allocation; Vincristine | 1988 |
Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms | 1988 |
A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage | 1988 |
Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Hospitalization; Humans; Lung Neoplasms; Outpatient Clinics, Hospital; Prognosis; Random Allocation; Retrospective Studies; Vincristine | 1988 |
Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Procarbazine; Prognosis; Random Allocation | 1988 |
[Results of 2 multicenter therapy studies in inoperable non-small cell bronchial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Vindesine | 1988 |
Toxicity, physical function and everyday activity reported by patients with inoperable non-small cell lung cancer in a randomized trial (chemotherapy versus radiotherapy).
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Quality of Life; Radiotherapy, High-Energy; Random Allocation; Surveys and Questionnaires | 1988 |
Etoposide v etoposide and cisplatin in the treatment of advanced non-small cell lung cancer: a FONICAP randomized study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Random Allocation | 1988 |
Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Metastasis; Random Allocation | 1988 |
Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prospective Studies; Random Allocation | 1988 |
[Phase III therapy study in patients with small cell bronchial cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Random Allocation; Vindesine | 1988 |
Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for nonsmall-cell lung cancer. A randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Random Allocation; Vindesine | 1988 |
Complications of treatment of small cell carcinoma of the lung. Experience from a recent Canadian trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1988 |
Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cats; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Combinations; Etoposide; Female; Humans; Infection Control; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Random Allocation; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine; Vomiting | 1985 |
Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Random Allocation; Vinblastine; Vindesine | 1985 |
Etoposide (VP-16-213). Current status of an active anticancer drug.
Topics: Animals; Carcinoma, Small Cell; Clinical Trials as Topic; DNA; Drug Administration Schedule; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Podophyllotoxin; Testicular Neoplasms; Tissue Distribution | 1985 |
[Phase I clinical study of NK 171 (etoposide)].
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Liver Neoplasms; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Podophyllotoxin | 1985 |
Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. A study by the EORTC Lung Cancer Working Party (Belgium).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged | 1985 |
Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.
Topics: Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Random Allocation | 1986 |
Combination chemotherapy with c-DDP, cyclophosphamide, etoposide and prednisolone in small cell carcinoma of the lung.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prednisolone | 1985 |
The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Prospective Studies; Random Allocation; Remission Induction; Vincristine | 1986 |
Therapy with cisplatin and etoposide for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms | 1986 |
Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Random Allocation; Vincristine | 1986 |
Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Prognosis; Random Allocation; Remission Induction; Vincristine | 1986 |
Initial therapy with cisplatin plus VP-16 in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Prospective Studies; Random Allocation; Remission Induction; Vincristine | 1986 |
Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Prognosis; Remission Induction | 1986 |
Oral etoposide in small-cell lung cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms | 1986 |
A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Random Allocation | 1986 |
Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: a Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Random Allocation | 1986 |
Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Random Allocation; Vincristine | 1987 |
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Time Factors | 1987 |
Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lomustine; Lung Neoplasms; Male; Methotrexate; Prognosis; Vincristine; Vindesine | 1987 |
The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Random Allocation | 1987 |
Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwes
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Radiotherapy; Random Allocation; Vincristine | 1987 |
No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Humans; Lomustine; Lung Neoplasms; Random Allocation; Remission Induction; Vincristine | 1987 |
Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 1987 |
Small cell lung cancer trials in the EORTC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms | 1987 |
Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Random Allocation; Vincristine | 1987 |
[Restorative effect of muroctasin, MDP-Lys (L 18), on leukopenia caused by anticancer chemotherapy in lung cancer--comparative study by envelope method].
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Random Allocation; Vincristine; Vindesine | 1988 |
High-dose metoclopramide and chlorpromazine in the treatment of cisplatin-induced emesis.
Topics: Adult; Aged; Chlorpromazine; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Kinetics; Lung Neoplasms; Male; Metoclopramide; Middle Aged; Random Allocation; Vomiting | 1987 |
Neuropsychological evaluation of patients with inoperable non-small cell lung cancer treated with combination chemotherapy or radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neurologic Examination; Psychological Tests; Radiotherapy Dosage | 1988 |
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Mitomycin; Mitomycins; Neoplasm Metastasis; Procarbazine; Progesterone; Random Allocation; Vinblastine; Vindesine | 1986 |
High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Bronchogenic; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Transplantation, Autologous; Vincristine | 1986 |
Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin | 1985 |
1587 other study(ies) available for etoposide and Lung Neoplasms
| Article | Year |
|---|---|
N-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide. A novel, systemically active antitumor agent effective against 3LL Lewis lung carcinoma.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Doxorubicin; Guanidines; Lung Neoplasms; Mice; Molecular Structure; Thiazoles | 1991 |
Synthesis and antitumor activity of structural analogues of the epipodophyllotoxins.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Chemical Phenomena; Chemistry; Colonic Neoplasms; Etoposide; Humans; Indans; Leukemia P388; Lung Neoplasms; Mice; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship; Tumor Cells, Cultured | 1991 |
Synthesis and cytotoxicity of novel lignans.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Humans; Lignans; Lung Neoplasms; Tumor Cells, Cultured | 1995 |
Antitumor agents. 3. Synthesis and biological activity of 4 beta-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-O-demethyl-4-desoxypodophyllotoxin as antitumor agents.
Topics: Animals; Antineoplastic Agents; Etoposide; Humans; Leukemia L1210; Leukemia P388; Lung Neoplasms; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tubulin Modulators; Tumor Cells, Cultured | 1993 |
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
Topics: Acridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Microscopy, Fluorescence; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine | 2001 |
Cytotoxic oxoisoaporphine alkaloids from Menispermum dauricum.
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Drugs, Chinese Herbal; Enzyme Inhibitors; Female; Humans; Leukemia; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Molecular Structure; Plant Roots; Plants, Medicinal; Porphyrins; Tumor Cells, Cultured | 2001 |
Dicerandrols, new antibiotic and cytotoxic dimers produced by the fungus Phomopsis longicolla isolated from an endangered mint.
Topics: Antibiotics, Antineoplastic; Ascomycota; Bacillus subtilis; Colonic Neoplasms; Florida; Geotrichum; Humans; Lamiaceae; Lung Neoplasms; Magnetic Resonance Spectroscopy; Molecular Structure; Saccharomyces cerevisiae; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet; Staphylococcus aureus; Stereoisomerism; Tumor Cells, Cultured; Xanthenes; Xanthones | 2001 |
Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Catalysis; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Electrophoresis, Agar Gel; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Female; Glioma; Humans; Inhibitory Concentration 50; Lung Neoplasms; Methyl Green; Molecular Structure; Plants, Medicinal; Saccharomyces cerevisiae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Triterpenes; Tumor Cells, Cultured | 2001 |
Synthetic lanostane-type triterpenoids as inhibitors of DNA topoisomerase II.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Lanosterol; Lung Neoplasms; Molecular Structure; Pinus; Plant Bark; Structure-Activity Relationship; Topoisomerase II Inhibitors; Triterpenes; Tumor Cells, Cultured | 2005 |
Synthesis and structure-activity relationships of novel pyrimido[1,2-b]indazoles as potential anticancer agents against A-549 cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Quantitative Structure-Activity Relationship; Tubulin | 2007 |
Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Survival; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Lung Neoplasms; Naphthoquinones; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Plasmids; Pyrans; Quinones; Sesquiterpenes; Structure-Activity Relationship; Telomerase; Topoisomerase Inhibitors | 2011 |
Studies on quinones. Part 47. Synthesis of novel phenylaminophenanthridinequinones as potential antitumor agents.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Fibroblasts; Humans; Inhibitory Concentration 50; Lung Neoplasms; Molecular Structure; Phenanthridines; Quinones; Stomach Neoplasms; Structure-Activity Relationship; Urinary Bladder Neoplasms | 2011 |
Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Coordination Complexes; Copper; Crystallography, X-Ray; Dimerization; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Injections, Intravenous; Ketones; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oxidation-Reduction; Pyridines; Structure-Activity Relationship; Thiosemicarbazones; Transferrin; Transplantation, Heterologous | 2012 |
Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA; DNA Topoisomerases, Type II; Drug Design; Humans; Indoles; Lung Neoplasms; Mice; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2017 |
A Multipronged Approach Establishes Covalent Modification of β-Tubulin as the Mode of Action of Benzamide Anti-cancer Toxins.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Colchicine; Humans; Lung Neoplasms; Microtubules; Protein Conformation; Small Cell Lung Carcinoma; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2020 |
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy.
Topics: Adenosine Triphosphatases; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Etoposide; Fatty Acid Synthases; Fatty Acids; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Progression-Free Survival; Prospective Studies; Sequence Analysis, RNA; Small Cell Lung Carcinoma; Survival Analysis; Whole Genome Sequencing | 2021 |
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2022 |
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.]
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Italy; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum | 2022 |
Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.
Topics: Animals; Cyclic GMP-Dependent Protein Kinases; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplastic Cells, Circulating; Nitric Oxide; Nitric Oxide Synthase Type II; Receptors, Notch; Signal Transduction; Small Cell Lung Carcinoma; Soluble Guanylyl Cyclase | 2021 |
Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Progression-Free Survival; Retrospective Studies | 2021 |
FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
A 33-Year-Old Man With Chest Pain.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma; Etoposide; Fatal Outcome; Gene Rearrangement; Humans; Liver Failure; Liver Neoplasms; Lung Neoplasms; Lymphadenopathy; Male; Neoplasm Proteins; Nuclear Proteins; Positron-Emission Tomography; Tomography, X-Ray Computed; Transcription Factors; Tumor Lysis Syndrome | 2022 |
In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Etoposide; Humans; Lung Neoplasms; Mice; Oncolytic Virotherapy; Small Cell Lung Carcinoma | 2022 |
Trilaciclib (Cosela) for prevention of chemotherapy-related myelosuppression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Etoposide; Humans; Lung Neoplasms; Organoplatinum Compounds; Platinum Compounds; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management.
Topics: Adenocarcinoma; Adult; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Etoposide; Female; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Retrospective Studies | 2022 |
Yeast
Topics: A549 Cells; beta-Glucans; Cullin Proteins; Etoposide; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Saccharomyces cerevisiae | 2022 |
Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Carboplatin; Cell Line, Tumor; Cell Proliferation; Etoposide; Female; Humans; Immunoconjugates; Lung Neoplasms; Maytansine; Mice; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Small Cell Lung Carcinoma; Trastuzumab; Tubulin Modulators; Xenograft Model Antitumor Assays | 2022 |
Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Platinum Compounds; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
Topics: Brain Neoplasms; Etoposide; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Immunoconjugates; Lung Neoplasms; Peptides; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Small Cell Lung Carcinoma; Topoisomerase Inhibitors | 2022 |
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Autoimmune Encephalitis Associated with Anti-N-methyl-D-aspartate Receptor and Anti-Hu Antibodies Successfully Treated with Carboplatin and Etoposide for Small-cell Lung Cancer.
Topics: Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Autoantibodies; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Receptors, N-Methyl-D-Aspartate | 2023 |
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carboplatin; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Topics: Animals; Cell Death; Enzyme Inhibitors; Etoposide; Histone Demethylases; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lysine; Mice; Platinum; Small Cell Lung Carcinoma; Tumor Microenvironment | 2022 |
A 75-Year-Old Female Smoker with Advanced Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status 2 who Responded to Combination Immunochemotherapy with Atezolizumab, Etoposide, and Carboplatin.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Group Processes; Humans; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma; Smokers | 2022 |
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2022 |
Large cell neuroendocrine carcinoma of the lung controlled for 4 years by a single administration of pembrolizumab: A case report.
Topics: Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; ErbB Receptors; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local | 2022 |
Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Prospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2022 |
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.
Topics: Adenosine; Afatinib; Crizotinib; Dasatinib; Drug Resistance; Erlotinib Hydrochloride; Etoposide; Humans; Lapatinib; Lung Neoplasms; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2022 |
Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Veterans | 2022 |
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Etoposide; Gefitinib; Humans; Immunologic Factors; Immunotherapy; Lactic Acid; Lung Neoplasms; Prognosis; Reproducibility of Results; Tumor Microenvironment | 2022 |
Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Male; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Dual-Drug Nanosystem: Etoposide Prodrug and Cisplatin Coloaded Nanostructured Lipid Carriers for Lung Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Cisplatin; Drug Carriers; Etoposide; Humans; Lipids; Lung Neoplasms; Mice; Nanostructures; Particle Size; Prodrugs | 2022 |
Evaluation of Lung and Liver Tumor Dose Coverage Treated With the CyberKnife Synchrony System With Consideration of Measured Tracking Errors.
Topics: Etoposide; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Phantoms, Imaging; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Respiration | 2023 |
ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms.
Topics: Ataxia Telangiectasia Mutated Proteins; DNA Topoisomerases, Type II; Etoposide; Humans; Lung Neoplasms; Topoisomerase II Inhibitors | 2023 |
Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor performance status.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Iris; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Topics: Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
Thoracic Radiotherapy Effect on the Outcome in Extensive Stage Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Remission Induction; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Concomitant Chemoradiotherapy Using Carboplatin and Etoposide-induced Cutaneous Vasculitis in a Patient with Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Etoposide; Humans; Lung Neoplasms; Skin Diseases, Vascular; Small Cell Lung Carcinoma | 2022 |
Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
The novel role of etoposide in inhibiting the migration and proliferation of small cell lung cancer and breast cancer via targeting Daam1.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Etoposide; Lung Neoplasms; Mice; Mice, Nude; Microfilament Proteins; rho GTP-Binding Proteins; Small Cell Lung Carcinoma; Wnt Proteins | 2023 |
Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Propensity Score; Small Cell Lung Carcinoma | 2023 |
First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Topics: Etoposide; Humans; Lung Neoplasms; Phenotype; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Topics: Animals; Etoposide; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-myc; Small Cell Lung Carcinoma | 2023 |
PRMT5 promotes chemotherapy-induced neuroendocrine differentiation in NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cisplatin; Etoposide; Humans; Lung Neoplasms; Protein-Arginine N-Methyltransferases | 2023 |
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Early Detection of Cancer; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma | 2023 |
Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study.
Topics: Carcinoma, Non-Small-Cell Lung; Etoposide; Humans; Lung Neoplasms; Radiation Injuries; Radiosurgery; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated | 2023 |
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Relationship between immune-related adverse events and treatment effectiveness in extensive disease small cell lung cancer.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Etoposide; Humans; Lung Neoplasms; Nivolumab; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2023 |
Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Etoposide; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Radiosurgery; Radiotherapy Planning, Computer-Assisted; Retrospective Studies | 2023 |
Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
Topics: Aged; Etoposide; Humans; Lung Neoplasms; Middle Aged; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Benmelstobart Ups ES-SCLC Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment.
Topics: Animals; Cell Survival; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice | 2023 |
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Tailoring molecular recognition in predesigned multifunctional enzyme mimicking porphyrin imprinted interface for high affinity and differential selectivity; sensing etoposide in lung cancer patients.
Topics: Biosensing Techniques; Etoposide; Humans; Hydrogen Peroxide; Lung Neoplasms; Molecular Imprinting; Multifunctional Enzymes; Polymers | 2024 |
Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Topics: B7-H1 Antigen; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Mutation; ROC Curve; Small Cell Lung Carcinoma | 2019 |
Contactin 1 modulates pegylated arginase resistance in small cell lung cancer through induction of epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Arginase; Cell Line, Tumor; Cell Movement; Cisplatin; Contactin 1; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Gene Knockdown Techniques; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Small Cell Lung Carcinoma | 2019 |
The role of 18F-FDG PET/CT in management of paraneoplastic limbic encephalitis combined with small cell lung cancer: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Limbic Encephalitis; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Small Cell Lung Carcinoma; Treatment Outcome; Whole Body Imaging | 2019 |
Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Etoposide; Humans; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; RNA, Small Interfering; Spheroids, Cellular; Vascular Endothelial Growth Factor A | 2019 |
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Neoplasm Staging; NF-E2-Related Factor 2; Paclitaxel; Prognosis; Spheroids, Cellular; Survival Rate | 2020 |
Immunotherapy: a new era in small-cell lung cancer.
Topics: Antibodies, Monoclonal; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum | 2019 |
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; United Kingdom | 2019 |
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cell-Free Nucleic Acids; Deoxycytidine; Etoposide; Female; Gemcitabine; Genomics; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Prognosis; Survival Rate; Taxoids | 2020 |
Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Logistic Models; Lung; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Respiratory Function Tests; Retrospective Studies; Risk; ROC Curve; Sensitivity and Specificity; Severity of Illness Index | 2020 |
Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medicare; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; United States | 2020 |
Therapy-related acute myeloid leukemia secondary to histiocytic sarcoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasms, Second Primary; Polyethylene Glycols; Prednisone; Sarcoma; Vincristine | 2021 |
Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymphocytes; Male; Polyethylene Glycols; Prognosis; Prospective Studies; Receptors, Antigen, T-Cell; Recombinant Proteins; Small Cell Lung Carcinoma; Survival Rate | 2020 |
Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lipids; Lung Neoplasms; Nanoparticles; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polylactic Acid-Polyglycolic Acid Copolymer; Porphyrins | 2020 |
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Consolidation Chemotherapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Durable response to combination radiotherapy and immunotherapy in EP-resistant lung large-cell neuroendocrine carcinoma with
Topics: AMP-Activated Protein Kinase Kinases; beta 2-Microglobulin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemoradiotherapy; Drug Resistance, Neoplasm; Etoposide; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Ipilimumab; Lung Neoplasms; Male; Middle Aged; Mutation; Nivolumab; Protein Serine-Threonine Kinases; Radiosurgery; Treatment Outcome | 2020 |
Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Follow-Up Studies; Hospitalization; Humans; Lung Neoplasms; Male; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2020 |
Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Pemetrexed; Xenograft Model Antitumor Assays | 2020 |
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2020 |
The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
Topics: Animals; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Chickens; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Female; Histones; Humans; Indans; Isoquinolines; Lung Neoplasms; Lymphoma; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Poultry Diseases; Random Allocation; Recombinant Proteins; Substrate Specificity; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2020 |
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Apoptosis; Autophagy; Calreticulin; Carboplatin; Caspase 3; Cell Survival; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; HMGB1 Protein; Humans; Immunogenic Cell Death; Lung Neoplasms; Paclitaxel; Prognosis | 2020 |
Kinesin light chain 4 as a new target for lung cancer chemoresistance via targeted inhibition of checkpoint kinases in the DNA repair network.
Topics: Apoptosis; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cisplatin; Colorectal Neoplasms; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Kinesins; Lung Neoplasms; Microtubule-Associated Proteins; Molecular Targeted Therapy; Signal Transduction | 2020 |
IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Synergism; Etoposide; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Proteins; Organoplatinum Compounds; Progression-Free Survival; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis | 2020 |
Role of mTOR As an Essential Kinase in SCLC.
Topics: Cisplatin; Etoposide; Humans; Lung Neoplasms; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2020 |
Chemotherapy dosing and toxicity in a patient with muscular dystrophy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Muscular Dystrophies, Limb-Girdle; Myelopoiesis; Palliative Care | 2018 |
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2021 |
Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Quality of Life; Small Cell Lung Carcinoma; Treatment Outcome | 2021 |
Carboplatin plus etoposide or topotecan for small-cell lung cancer.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan | 2020 |
Etoposide and immunotherapy can improve the outcome of severe anti-GABAB R encephalitis presenting with delta brush: A case report.
Topics: Anti-Inflammatory Agents; Autoantibodies; Electroencephalography; Encephalitis; Etoposide; Hashimoto Disease; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Receptors, GABA-B; Small Cell Lung Carcinoma; Topoisomerase II Inhibitors | 2020 |
American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC.
Topics: Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Radium; Small Cell Lung Carcinoma; United States | 2021 |
[Evaluation of drug interactions in patients treated for a lung or digestive cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Contraindications, Drug; Digestive System Neoplasms; Drug Interactions; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Polypharmacy; Retrospective Studies; Young Adult | 2020 |
Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report.
Topics: Administration, Oral; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Quinolines; Renal Dialysis; Renal Insufficiency; Small Cell Lung Carcinoma; Topoisomerase II Inhibitors; Treatment Outcome | 2020 |
Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Lactates; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Mutagens; Snail Family Transcription Factors; Transcription Factor AP-1; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Up-Regulation | 2020 |
Trigonelline inhibits Nrf2 via EGFR signalling pathway and augments efficacy of Cisplatin and Etoposide in NSCLC cells.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; NF-E2-Related Factor 2; Signal Transduction | 2021 |
Chemotherapy-induced changes in bronchoalveolar lavage fluid CD4 + and CD8 + cells of the opposite lung to the cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoalveolar Lavage Fluid; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Prognosis; Prospective Studies; Vinorelbine | 2020 |
Pulmonary microinvasive small cell carcinoma with an extensive in-situ component identified after photodynamic therapy for 'squamous cell carcinoma in situ': a case report.
Topics: Aged; Antineoplastic Agents; Bronchoscopy; Carcinoma in Situ; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Male; Photochemotherapy; Small Cell Lung Carcinoma | 2021 |
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan | 2020 |
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer - Authors' reply.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan | 2020 |
ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Topics: Alternative Splicing; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Female; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Protein-Arginine N-Methyltransferases; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Smad7 Protein; Small Cell Lung Carcinoma; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2021 |
Placental site trophoblastic tumour: five challenges of patient clinical management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chorionic Gonadotropin; Cisplatin; Consolidation Chemotherapy; Dactinomycin; Etoposide; Female; Humans; Hysterectomy; Lung Neoplasms; Lymph Node Excision; Methotrexate; Paclitaxel; Pregnancy; Puerperal Disorders; Salpingectomy; Trophoblastic Tumor, Placental Site; Uterine Neoplasms | 2021 |
Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Lung Neoplasms; Mice; Nanoparticles | 2021 |
Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids.
Topics: Antineoplastic Agents; Cisplatin; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Organ Culture Techniques; Organoids; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2021 |
Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations.
Topics: A549 Cells; Adaptor Proteins, Vesicular Transport; Antineoplastic Agents; Biomarkers; Etoposide; Gene Expression Profiling; Gene Expression Regulation; Genome-Wide Association Study; Humans; Lung Neoplasms; Pharmacogenetics | 2021 |
Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Remission Induction | 2020 |
Combinatory Delivery of Etoposide and siCD47 in a Lipid Polymer Hybrid Delays Lung Tumor Growth in an Experimental Melanoma Lung Metastatic Model.
Topics: Animals; Cell Line, Tumor; Etoposide; Lipids; Lung; Lung Neoplasms; Melanoma, Experimental; Mice; Nanoparticles; Polymers; RNA, Small Interfering; Tissue Distribution | 2021 |
Combination treatment options for small-cell lung cancer - Authors' reply.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Etoposide; Humans; Lung Neoplasms; Platinum | 2021 |
Combination treatment options for small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Etoposide; Humans; Lung Neoplasms; Platinum | 2021 |
Case Report: Ectopic Adrenocortical Carcinoma in the Ovary.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Bevacizumab; Cisplatin; Cytoreduction Surgical Procedures; Etoposide; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Ovary | 2021 |
Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function.
Topics: Aged; Antineoplastic Agents; Disease Progression; Dyspnea; Etoposide; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Neoplasms; Male; Organoplatinum Compounds; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Immunosuppression Therapy; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2021 |
Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Small Cell Lung Carcinoma; Survival Analysis | 2021 |
Chemotherapy as cause of refractory severe headache in a case of small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Headache; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
Lysosome Fe
Topics: Cisplatin; Etoposide; Humans; Lung Neoplasms; Lysosomes; Small Cell Lung Carcinoma | 2021 |
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; China; Etoposide; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Paraneoplastic Syndromes, Nervous System; Small Cell Lung Carcinoma | 2022 |
Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Etoposide; Gene Knockdown Techniques; Gene Silencing; Humans; Iran; Lung Neoplasms; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein | 2021 |
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Topics: Aged; Antibodies, Monoclonal; Cost-Benefit Analysis; Etoposide; Humans; Lung Neoplasms; Medicare; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
Prognostic Factors and Treatment of Early-stage Small-cell Lung Cancer.
Topics: Aged; Carboplatin; Chemoradiotherapy; Cisplatin; Cranial Irradiation; Early Detection of Cancer; Etoposide; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thoracic Wall; Time Factors | 2017 |
Diagnosing lung cancer using etoposide microparticles labeled with
Topics: A549 Cells; Animals; Etoposide; Humans; Isotope Labeling; Lung Neoplasms; Male; Mice; Microspheres; Technetium; Tomography, Emission-Computed, Single-Photon | 2018 |
Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases.
Topics: Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Validated UHPLC-MS/MS assay for quantitative determination of etoposide, gemcitabine, vinorelbine and their metabolites in patients with lung cancer.
Topics: Aged; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cohort Studies; Deoxycytidine; Etoposide; Gemcitabine; Humans; Linear Models; Lung Neoplasms; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Vinblastine; Vinorelbine | 2017 |
The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Retrospective Studies; Risk Factors; Sex Characteristics | 2017 |
Characterization and antitumor efficacy of poly(L-lactid acid)-based etoposide-loaded implants.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Etoposide; Excipients; Humans; Lung Neoplasms; Polyethylene Glycols; Polymers | 2017 |
TRIM28 knockdown increases sensitivity to etoposide by upregulating E2F1 in non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lung Neoplasms; Mice; RNA, Small Interfering; Tripartite Motif-Containing Protein 28; Xenograft Model Antitumor Assays | 2017 |
Metastatic Neuroendocrine Carcinoma of Unknown Origin Arising in the Femoral Nerve Sheath.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Etoposide; Female; Femoral Nerve; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Unknown Primary; Nerve Sheath Neoplasms; Palliative Care; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |
Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Signal Transduction; Smad4 Protein; Topoisomerase I Inhibitors; Transforming Growth Factor beta | 2017 |
BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biphenyl Compounds; Cell Proliferation; Cell Survival; Chemoradiotherapy; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Molecular Mimicry; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; RNA Interference; Signal Transduction; Sulfonamides; Transfection; Up-Regulation | 2017 |
Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose Fractionation, Radiation; Esophagitis; Esophagus; Etoposide; Female; Heart; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Prospective Studies; Proton Therapy; Radiation Pneumonitis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Small Cell Lung Carcinoma; Spinal Cord; Treatment Outcome | 2017 |
Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Computational Biology; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Small Molecule Libraries | 2017 |
A multicomponent microemulsion using rational combination strategy improves lung cancer treatment through synergistic effects and deep tumor penetration.
Topics: A549 Cells; Animals; Apoptosis; Coix; Etoposide; Humans; Lung Neoplasms; Mice | 2017 |
TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neuroendocrine Tumors; Sirolimus; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 | 2017 |
Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2017 |
Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.
Topics: 3' Untranslated Regions; Antagomirs; Apoptosis; Base Sequence; Beclin-1; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Male; MicroRNAs; Middle Aged; RNA Interference; RNA, Small Interfering; Sequence Alignment; Small Cell Lung Carcinoma; Up-Regulation | 2017 |
Etoposide induced NMI promotes cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Etoposide; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Signal Transduction; Tumor Suppressor Protein p14ARF; Tumor Suppressor Protein p53 | 2018 |
Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Analysis | 2017 |
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Exons; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Receptor, Fibroblast Growth Factor, Type 3 | 2017 |
ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA Repair; Doxorubicin; Estrogen Receptor beta; Etoposide; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Transfection; Tumor Suppressor Protein p53; Up-Regulation | 2018 |
A rare complication of metastatic lung disease treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Etoposide; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Pericardium; Tomography, X-Ray Computed; Tongue Neoplasms | 2017 |
Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
Topics: Aminopyridines; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Daunorubicin; DNA Damage; DNA Glycosylases; DNA Repair; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Lung Neoplasms; Piperazines; Poly (ADP-Ribose) Polymerase-1; Promoter Regions, Genetic; Purines; Pyridines | 2018 |
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Endostatins; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Osteosarcoma; Pleural Effusion, Malignant; Recombinant Proteins | 2017 |
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Organs at Risk; Paclitaxel; Probability; Radiation Dosage; Retrospective Studies; ROC Curve; Small Cell Lung Carcinoma; Thoracic Vertebrae | 2018 |
[Non-Small Cell Lung Cancer - Development of Parallel Mechanisms of Resistance].
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Carriers; Drug Synergism; Etoposide; Female; Humans; Lung Neoplasms; Mice, Nude; Micelles; Polymers | 2018 |
MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Gene Expression Profiling; Humans; Immune Evasion; Lung Neoplasms; MicroRNAs; Neoplasm Invasiveness; Neoplasms, Squamous Cell | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
High-dose chemotherapy without whole lung radiation for refractory pulmonary metastases in an infant with stage IV favorable histology Wilms tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Etoposide; Humans; Infant; Kidney Neoplasms; Lung Neoplasms; Male; Melphalan; Wilms Tumor | 2018 |
High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Radiotherapy Dosage; Retrospective Studies | 2018 |
Surgery and Platinum/Etoposide-Based Chemotherapy for the Treatment of Epithelioid Trophoblastic Tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Lung Neoplasms; Organoplatinum Compounds; Pregnancy; Retrospective Studies | 2018 |
Autologous stem-cell transplant for metastatic renal medullary carcinoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Doxorubicin; Etoposide; Humans; Ifosfamide; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Sickle Cell Trait; Transplantation, Autologous | 2018 |
Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anthracyclines; Carboplatin; Etoposide; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2018 |
A Case of Refractory Subcutaneous Panniculitis-like T-cell Lymphoma with Bone Marrow and Lung Involvement Treated Successfully with Oral Etoposide.
Topics: Administration, Oral; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Biopsy; Bone Marrow Neoplasms; Etoposide; Humans; Immunohistochemistry; Lung Neoplasms; Lymphoma, T-Cell; Male; Panniculitis; Treatment Outcome | 2018 |
Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Humans; Immunohistochemistry; Lung Neoplasms; Male; Pleural Effusion, Malignant; Small Cell Lung Carcinoma | 2018 |
Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy.
Topics: A549 Cells; Administration, Inhalation; Animals; Antineoplastic Agents, Phytogenic; Berberine; Boronic Acids; Drug Carriers; Drug Delivery Systems; Drug Liberation; Etoposide; Humans; Lung Neoplasms; Male; Mice; N-Acetylneuraminic Acid; Nanocomposites; Serum Albumin, Human | 2018 |
TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage.
Topics: A549 Cells; Acetylation; Apoptosis; Camptothecin; Cell Proliferation; Chromatin Assembly and Disassembly; Deoxycytidine; DNA Damage; DNA-Binding Proteins; E1A-Associated p300 Protein; Etoposide; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Processing, Post-Translational; Sirtuin 1; Transcriptional Activation; Tumor Suppressor Protein p53 | 2019 |
Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Transformation, Neoplastic; Clone Cells; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Small Cell Lung Carcinoma | 2018 |
Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Immunotherapy; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 2018 |
Successful management of a patient with radiological presentation of choriocarcinoma syndrome before induction chemotherapy.
Topics: Blood Vessels; Choriocarcinoma; Chorionic Gonadotropin; Cisplatin; Etoposide; Hemorrhage; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Orchiectomy; Testicular Neoplasms; Vascular Surgical Procedures | 2018 |
Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Berberine; Cell Survival; Drug Carriers; Drug Liberation; Drug Synergism; Etoposide; Humans; Hydrophobic and Hydrophilic Interactions; Lectins; Lung Neoplasms; Mice; Molecular Targeted Therapy; Nanoparticles; Particle Size; Plant Extracts; Serum Albumin, Human; Vascular Endothelial Growth Factor A | 2018 |
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
Topics: Cell Line, Tumor; Cell Survival; Deoxycytidine; Etoposide; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Models, Biological; Neoplasm Staging; Pleural Neoplasms; Proportional Hazards Models; Transcriptome; Tumor Suppressor Protein p53; Wound Healing | 2018 |
Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Cisplatin; Etoposide; Female; Glucuronosyltransferase; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Retrospective Studies; Small Cell Lung Carcinoma; Thrombocytopenia | 2019 |
Large Cell Neuroendocrine Carcinoma of the Mediastinum Successfully Treated with Systemic Chemotherapy after Palliative Radiotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Mediastinum; Treatment Outcome | 2019 |
The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; DNA End-Joining Repair; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Radiation, Ionizing; Recombinational DNA Repair | 2018 |
Small-Cell Lung Cancer Comorbid with Pulmonary Mycobacterium avium Infection: A Case Report.
Topics: Aged; Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Bronchoscopy; Clarithromycin; Drug Therapy, Combination; Etoposide; Humans; Lung; Lung Neoplasms; Male; Mycobacterium avium; Peptide Fragments; Recombinant Proteins; Rifampin; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Tuberculosis, Avian | 2018 |
Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Needs Assessment; Neoplasm Grading; Practice Guidelines as Topic; Practice Patterns, Physicians' | 2019 |
Lambert-Eaton myasthenic syndrome developing post-diagnosis of small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carboplatin; Diagnosis, Differential; Disease Progression; Etoposide; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Neoplasm Staging; Neurologic Examination; Prognosis; Small Cell Lung Carcinoma; Terminal Care | 2018 |
Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Genotype; Glucuronosyltransferase; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Small Cell Lung Carcinoma | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
[RETROPERITONEAL LIPOSARCOMA WITH MULTIPLE RECURRENCE OF LUNG METASTASES TREATED BY MULTIMODAL THERAPY CENTERING ON THE OPERATION: A CASE REPORT].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Etoposide; Humans; Ifosfamide; Liposarcoma; Lung Neoplasms; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Pneumonectomy; Retroperitoneal Neoplasms; Surgical Procedures, Operative; Thoracoscopy; Time Factors; Treatment Outcome | 2018 |
[Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Interleukin Receptor Common gamma Subunit; Lung Neoplasms; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Small Cell Lung Carcinoma; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2019 |
Prognostic Significance of Mean Platelet Volume on Local Advanced Non-Small Cell Lung Cancer Managed with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Mean Platelet Volume; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Young Adult | 2019 |
[Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA-Directed DNA Polymerase; Etoposide; Genetic Variation; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; Regression Analysis; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Survival; Checkpoint Kinase 1; Cisplatin; CRISPR-Associated Protein 9; DNA Damage; Drug Synergism; Etoposide; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Small Cell Lung Carcinoma; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cohort Studies; Etoposide; Female; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Etoposide; Fluorouracil; HEK293 Cells; Humans; Lung Neoplasms; Membrane Proteins; Methotrexate; Mice; Molecular Targeted Therapy; Pemetrexed; Serine Endopeptidases | 2019 |
Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Pyrimidines; Small Cell Lung Carcinoma; Sulfoxides | 2019 |
A Common Purpuric Rash With Uncommon Association in a Woman With Pedal Edema.
Topics: Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Edema; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Purpura; Vasculitis, Leukocytoclastic, Cutaneous | 2019 |
Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017.
Topics: Aged; Bridged-Ring Compounds; Cardiovascular Diseases; Etoposide; Female; France; Humans; Liver Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum Compounds; Prognosis; Small Cell Lung Carcinoma; Survival Analysis; Taxoids | 2019 |
A Comprehensive Preclinical Evaluation of Intravenous Etoposide Lipid Emulsion.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Drug Evaluation, Preclinical; Drug Liberation; Drug Stability; Emulsions; Etoposide; Female; Humans; Injections, Intravenous; Lipids; Lung Neoplasms; Male; Oleic Acids; Rats, Wistar; Small Cell Lung Carcinoma | 2019 |
Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
The HtrA3 protease promotes drug-induced death of lung cancer cells by cleavage of the X-linked inhibitor of apoptosis protein (XIAP).
Topics: A549 Cells; Apoptosis; Binding Sites; Coenzymes; Etoposide; Humans; Lung Neoplasms; Protein Binding; Proteolysis; Serine Endopeptidases; Topoisomerase II Inhibitors; X-Linked Inhibitor of Apoptosis Protein | 2019 |
Outcome of treatment in patients with small cell lung cancer in poor performance status.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2019 |
The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Patients with Small Cell Lung Cancer Before First-Line Treatment with Etoposide and Progression-Free Survival.
Topics: Adult; Aged; Biomarkers, Tumor; Blood Platelets; Body Mass Index; Etoposide; Female; Hemoglobins; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Prognosis; Progression-Free Survival; Retrospective Studies; Serum Albumin, Human; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity.
Topics: Antineoplastic Agents; Cell Proliferation; Cisplatin; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Microfluidic Analytical Techniques; Organ Culture Techniques; Organoids; Particle Size; Surface Properties | 2019 |
Preparation, characterization and
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Drug Liberation; Etoposide; Humans; Liposomes; Lung Neoplasms; Nanoparticles; Particle Size; Polyethylene Glycols | 2019 |
Case report: Treatment of metastatic germ cell tumor in a newly diagnosed HIV infected man: use of BEP chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; HIV Infections; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Testicular Neoplasms; Treatment Outcome | 2011 |
Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2013 |
Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Propensity Score; Treatment Outcome | 2013 |
Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2015 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma | 2014 |
[Neuroendocrine tumors: analysis of 252 cases].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoid Tumor; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Cisplatin; Digestive System Neoplasms; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Retrospective Studies; Sex Factors; Survival Rate; Young Adult | 2013 |
Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Evidence-Based Medicine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Patient Selection; Platinum Compounds; Positron-Emission Tomography | 2013 |
Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Etoposide; Female; Humans; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Review Literature as Topic | 2013 |
[Up-regulation of DLL1 may promote the chemotherapeutic sensitivity in small cell lung cancer].
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Calcium-Binding Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Etoposide; Green Fluorescent Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Reverse Transcriptase Polymerase Chain Reaction; Small Cell Lung Carcinoma; Transcription Factor HES-1; Up-Regulation | 2013 |
Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Lymph Nodes; Male; Mediastinal Neoplasms; Middle Aged; Neuroectodermal Tumors, Primitive, Peripheral; Pleural Neoplasms; Retroperitoneal Neoplasms; Retrospective Studies; Teratoma; Testicular Neoplasms; Treatment Outcome; Vincristine; Young Adult | 2015 |
Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Survival; Chromones; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Vincristine | 2014 |
Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; DNA Damage; Drug Synergism; Etoposide; Female; Glutathione; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides; Reactive Oxygen Species; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2013 |
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
Topics: Adenosine Triphosphatases; Adult; Aged; Antigens, Neoplasm; BRCA1 Protein; Carrier Proteins; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Disease-Free Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Etoposide; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Neoplasm; Humans; Lung Neoplasms; Membrane Proteins; Middle Aged; Multivariate Analysis; Predictive Value of Tests; RNA, Messenger; Small Cell Lung Carcinoma; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Treatment Outcome | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
[Second-line chemotherapy and its survival analysis of 181 patients with extensive-stage small cell lung cancer in a single institute].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2013 |
[A case of a nonseminomatous germ cell tumor responding to MEA therapy].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Etoposide; Humans; Lung Neoplasms; Male; Methotrexate; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms | 2013 |
[Role of homeobox gene A5 in multidrug resistance of human small cell lung cancer cells].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Homeodomain Proteins; Humans; Immunoblotting; Lung Neoplasms; Plasmids; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Small Cell Lung Carcinoma; Transfection | 2013 |
Does routine clinical practice reproduce the outcome of large prospective trials? The analysis of institutional database on patients with limited-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials as Topic; Cranial Irradiation; Databases, Factual; Dose Fractionation, Radiation; Etoposide; Evidence-Based Medicine; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Practice Patterns, Physicians'; Proportional Hazards Models; Prospective Studies; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome | 2014 |
Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Etoposide; Gene Expression; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Piperidines; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Small Cell Lung Carcinoma; Snail Family Transcription Factors; Transcription Factors; Xenograft Model Antitumor Assays | 2014 |
Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aldehyde Dehydrogenase 1 Family; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calcium-Binding Proteins; CD24 Antigen; Cell Movement; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Female; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Isoenzymes; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Retinal Dehydrogenase; RNA Interference; RNA, Small Interfering; Spheroids, Cellular; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2014 |
Dosing of carboplatin in a patient with amputated legs: A case report.
Topics: Aged; Amputees; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma | 2014 |
Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiat
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proto-Oncogene Proteins c-bcl-2; Radiopharmaceuticals; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed | 2014 |
A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer.
Topics: Acetylation; Apoptosis; Carcinoma, Non-Small-Cell Lung; Drug Screening Assays, Antitumor; Etoposide; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Neoplasm Proteins; Sirtuin 2; Tumor Suppressor Protein p53 | 2014 |
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2013 |
Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Cisplatin; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Small Cell Lung Carcinoma; Survival Rate; Tumor Burden | 2014 |
Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Medicare; Neoplasm Staging; Prognosis; Retrospective Studies; SEER Program; Small Cell Lung Carcinoma; Survival Rate; United States | 2013 |
A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comparative Effectiveness Research; Etoposide; Female; Humans; Lung Neoplasms; Male; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; SEER Program; Treatment Outcome | 2014 |
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Feroniellin A-induced autophagy causes apoptosis in multidrug-resistant human A549 lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; Autophagy; Beclin-1; Cell Line, Tumor; Coumarins; Drug Resistance, Neoplasm; Etoposide; Furans; Glycosides; Humans; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Nitriles; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sirolimus; Sulfones; Transcription Factor RelA; Transcription, Genetic | 2014 |
Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Etoposide; Kaplan-Meier Estimate; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Solubility; Surface Properties; Survival Analysis; Tissue Distribution; Triglycerides | 2014 |
Rapamycin rescues ABT-737 efficacy in small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Drug Synergism; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Sirolimus; Small Cell Lung Carcinoma; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
The patient with ataxia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Ataxia; Carboplatin; Diagnosis, Differential; Etoposide; Humans; Lung; Lung Neoplasms; Male; Palliative Care; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Regulation of cell survival by the HIP-55 signaling network.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Etoposide; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Microfilament Proteins; Protein Array Analysis; Signal Transduction; src Homology Domains; Tissue Array Analysis | 2014 |
MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Etoposide; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neutropenia; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-mdm2; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Etoposide; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Models, Biological; Phosphopyruvate Hydratase; Population; Predictive Value of Tests | 2014 |
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chest Pain; Cohort Studies; Cough; Dyspnea; Esophagitis; Etoposide; Female; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Pemetrexed; Radiation Injuries; Radiation Pneumonitis; Retrospective Studies; Treatment Outcome | 2015 |
[Modified BEP regimen leads to abatement of choriocarcinoma syndrome in a patient with extra gonadal germ cell tumor : a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma, Non-gestational; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Respiratory Distress Syndrome; Syndrome | 2014 |
[A case of lung abscess during chemotherapy for testicular tumor].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Lung Abscess; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms | 2014 |
A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Etoposide; Female; Heterografts; Humans; Immunoglobulin G; Lung Neoplasms; Melanoma, Experimental; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction; Small Cell Lung Carcinoma | 2014 |
Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2014 |
Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; NF-kappa B; Receptors, Tumor Necrosis Factor; Signal Transduction; Small Cell Lung Carcinoma; TWEAK Receptor | 2014 |
Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cross-Sectional Studies; Desensitization, Immunologic; Docetaxel; Drug Eruptions; Etoposide; Female; Humans; Hypersensitivity, Delayed; Hypersensitivity, Immediate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Skin Tests; Taxoids | 2015 |
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Random Allocation; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2014 |
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Cell Line, Tumor; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Receptors, Somatostatin; Small Cell Lung Carcinoma; Translational Research, Biomedical | 2015 |
Tumor lysis syndrome in a nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Fatal Outcome; Female; Humans; Liver Neoplasms; Lung Neoplasms; Tumor Lysis Syndrome | 2014 |
Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child; Child, Preschool; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Sarcoma, Ewing; Survival Rate; Young Adult | 2015 |
Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Chromogranins; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lung; Lung Neoplasms; Organic Anion Transporters; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Synaptophysin; Topotecan; Tumor Cells, Cultured | 2015 |
Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiation Dose Hypofractionation; Radiotherapy, Intensity-Modulated; Response Evaluation Criteria in Solid Tumors; Survival Rate; Tomography, X-Ray Computed | 2017 |
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Cisplatin; ErbB Receptors; Etoposide; Female; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Retinoblastoma Protein; Sequence Analysis, DNA; Smad4 Protein; Small Cell Lung Carcinoma; Smoking; Tumor Suppressor Protein p53; Young Adult | 2015 |
Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brucea; Cantharidin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Patient Safety; Phytotherapy; Plant Extracts; Prognosis; Quality of Life; Retrospective Studies; Risk Assessment; Survival Analysis | 2014 |
Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude of Health Personnel; Carboplatin; Child; Child, Preschool; Curriculum; Databases, Factual; Education, Medical; Enzyme Inhibitors; Etoposide; Europe; Female; General Surgery; Germany; Hospitals, University; Humans; Ifosfamide; Lung Neoplasms; Male; Medical History Taking; Mesothelioma; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Neurons; Muscular Atrophy; Neoplasms; Neuroprotective Agents; Phospholipase A2 Inhibitors; Phospholipases A2, Cytosolic; Physical Examination; Quality Improvement; Spinal Cord Injuries; Topotecan; Universities; World Health Organization; Young Adult | 2014 |
Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Phosphorylation; Repressor Proteins; RNA Interference; RNA, Small Interfering; STAT1 Transcription Factor; Transcription, Genetic | 2015 |
Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Choriocarcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Hysterectomy; Liver Neoplasms; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasm Staging; Pregnancy; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Uterine Neoplasms; Vaginal Neoplasms; Vincristine; Young Adult | 2015 |
Association of GWAS-identified lung cancer susceptibility loci with survival length in patients with small-cell lung cancer treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 5; Etoposide; Female; Genetic Loci; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2014 |
Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; United States; United States Department of Veterans Affairs | 2015 |
Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A.
Topics: Apoptosis; Autophagy; Autophagy-Related Proteins; Blotting, Western; Cell Line, Tumor; Cell Survival; Cisplatin; Cysteine Endopeptidases; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Small Cell Lung Carcinoma; Transfection | 2015 |
Metastasectomy as optimal treatment for late relapsing solitary brain metastasis from testicular germ cell tumor: a case report.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Metastasectomy; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Recurrence; Remission Induction; Testicular Neoplasms; Treatment Outcome; Young Adult | 2014 |
[Role of SALL4 in regulating multi-drug resistance of small cell lung cancer and its clinical significance].
Topics: Antineoplastic Agents; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Small Cell Lung Carcinoma; Transcription Factors | 2014 |
Deubiquitinase OTUD5 mediates the sequential activation of PDCD5 and p53 in response to genotoxic stress.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Endopeptidases; Etoposide; Gene Knockdown Techniques; HCT116 Cells; Humans; Lung Neoplasms; Mice; Neoplasm Proteins; Signal Transduction; Stress, Physiological; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53; Ubiquitination | 2015 |
Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Quality of Life | 2014 |
Extraskeletal myxoid chondrosarcoma of the thigh in a child: a case report.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Chondrosarcoma; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Neoplasms, Connective and Soft Tissue; Soft Tissue Neoplasms; Thigh | 2014 |
[Influence of interference of WIG-1 on the multi-drug resistance in small cell lung cancer].
Topics: Antineoplastic Agents; Apoptosis; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Nuclear Proteins; RNA-Binding Proteins; RNA, Small Interfering; Small Cell Lung Carcinoma | 2014 |
Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Prognosis; Salvage Therapy; Seminoma; Survival Analysis; Testicular Neoplasms | 2015 |
[Severe hyponatremia during chemotherapy for small cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Coma; Etoposide; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lung Neoplasms; Male; Recurrence; Tomography, X-Ray Computed | 2015 |
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
Topics: Anaphase; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; DNA Helicases; Enhancer of Zeste Homolog 2 Protein; Etoposide; Genes, erbB-1; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Nuclear Proteins; Polycomb Repressive Complex 2; Topoisomerase II Inhibitors; Transcription Factors; Xenograft Model Antitumor Assays | 2015 |
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Radiography; Small Cell Lung Carcinoma | 2015 |
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids | 2015 |
Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2015 |
Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Remission Induction; Small Cell Lung Carcinoma | 2015 |
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients.
Topics: Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Nomograms; Probability; Radiotherapy Dosage; Regression Analysis; Severity of Illness Index; Sex Factors; Vinblastine; Vinorelbine | 2015 |
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Transfusion; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Hematinics; Hemoglobins; Humans; Incidence; Iron; Lung Neoplasms; Male; Middle Aged; Observational Studies as Topic; Prevalence; Retrospective Studies; Small Cell Lung Carcinoma; Spain; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2015 |
Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proto-Oncogene Proteins c-akt; Resveratrol; RNA Interference; Signal Transduction; Stilbenes; Time Factors; Transfection; X-ray Repair Cross Complementing Protein 1 | 2015 |
Prognosis of small cell lung cancer patients with diabetes treated with metformin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Diabetes Mellitus, Type 2; Etoposide; Female; Humans; Hypoglycemic Agents; Irinotecan; Lung Neoplasms; Male; Metformin; Middle Aged; Multivariate Analysis; Platinum Compounds; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Etoposide; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Hemoglobins; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Severity of Illness Index; Survival Rate; Taxoids; Thrombocytopenia | 2017 |
Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Immunoassay; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Small Cell Lung Carcinoma | 2016 |
Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2015 |
Peripherally Inserted Central Catheter-Related Vein Thrombosis in Patients With Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catheterization, Central Venous; Cohort Studies; Etoposide; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; Venous Thrombosis | 2017 |
Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Testicular Neoplasms; Treatment Outcome | 2015 |
Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Polycomb Repressive Complex 1; RNA, Messenger | 2015 |
The Role of Computed Tomography Scanning of the Thorax in the Initial Assessment of Gestational Trophoblastic Neoplasia.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin; Dactinomycin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Lung Neoplasms; Methotrexate; Neoplasm Staging; Pregnancy; Radiography, Thoracic; Risk Assessment; Salvage Therapy; Tomography, X-Ray Computed | 2015 |
Inclusion of functional information from perfusion SPECT improves predictive value of dose-volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: A prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Radiation; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiation Pneumonitis; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2015 |
Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Etoposide; Febrile Neutropenia; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Diseases; Treatment Outcome | 2015 |
Effects of Definitive Chemoradiotherapy on Respiratory Function Tests and Quality of Life Scores During Treatment of Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Forced Expiratory Volume; Humans; Lung; Lung Neoplasms; Middle Aged; Quality of Life; Retrospective Studies; Small Cell Lung Carcinoma; Vital Capacity | 2015 |
[Role and clinical significance of RLIP76 in regulation of multi-drug resistance of small cell lung cancer].
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Cisplatin; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; GTPase-Activating Proteins; Humans; Lung Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Small Cell Lung Carcinoma; Transfection; Up-Regulation | 2015 |
Secondary Hemophagocytic Lymphohistiocytosis in a Patient With Favorable Histology Wilms Tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Combined Modality Therapy; Dactinomycin; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Immunoglobulins, Intravenous; Kidney Neoplasms; Lung Neoplasms; Lymphohistiocytosis, Hemophagocytic; Neoadjuvant Therapy; Nephrectomy; Remission Induction; Vincristine; Wilms Tumor | 2015 |
pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Delayed-Action Preparations; Etoposide; Female; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nanoparticles; Xenograft Model Antitumor Assays | 2016 |
Theranostic etoposide phosphate/indium nanoparticles for cancer therapy and imaging.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Drug Carriers; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Indium; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Nanoparticles; Organophosphorus Compounds; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2015 |
Key contribution of eIF4H-mediated translational control in tumor promotion.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Etoposide; Eukaryotic Initiation Factors; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; NIH 3T3 Cells; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNAi Therapeutics; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Unresectable Middle Mediastinal Biphasic Pulmonary Blastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Mediastinal Neoplasms; Neoplasm Staging; Neoplasms, Multiple Primary; Prognosis; Pulmonary Blastoma; Testicular Neoplasms | 2015 |
A simple dried blood spot method for clinical pharmacological analyses of etoposide in cancer patients using liquid chromatography and fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Etoposide; Fluorescence; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2016 |
Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Chemotherapy, Adjuvant; E2F1 Transcription Factor; Etoposide; Feasibility Studies; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; HEK293 Cells; Homeostasis; Host-Pathogen Interactions; Humans; Lung Neoplasms; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Oncolytic Virotherapy; Oncolytic Viruses; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Time Factors; Transcription, Genetic; Transfection; Virus Replication; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2015 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.
Topics: Animals; Antigens, Neoplasm; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; HEK293 Cells; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 6; Nuclear Proteins; Phosphoric Diester Hydrolases; Phosphorylation; Poly-ADP-Ribose Binding Proteins; Protein Processing, Post-Translational; Sf9 Cells; Topoisomerase II Inhibitors; Transcription Factors; Transfection | 2016 |
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2016 |
[A Case of Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy with Carboplatin plus Etoposide in a Hemodialysis Patient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Dialysis; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2016 |
Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Comorbidity; Decision Support Techniques; Dose Fractionation, Radiation; Dyspnea; Etoposide; Female; Health Status; Health Status Indicators; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Risk Factors; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome | 2016 |
Global proteomic profiling identifies etoposide chemoresistance markers in non-small cell lung carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; Gene Expression Profiling; Humans; Lung Neoplasms; Neoplasm Proteins; Proteomics | 2016 |
Prognostic significance of standardised uptake value (SUV
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Retrospective Studies; Serum Albumin; Small Cell Lung Carcinoma | 2017 |
A Child with Rapid-onset Respiratory Distress after Chemotherapy, Lung Irriadiation, General Anaesthesia, and Blood Transfusion.
Topics: Abdominal Neoplasms; Acute Lung Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Etoposide; Fluoroscopy; Humans; Ifosfamide; Kidney Neoplasms; Lung Neoplasms; Male; Postoperative Complications; Prosthesis Implantation; Radiography, Thoracic; Radiotherapy; Respiratory Distress Syndrome; Transfusion Reaction; Vascular Access Devices | 2015 |
NUT midline carcinoma of the lung, a rare form of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chromosomes, Human, Pair 15; Cisplatin; Etoposide; Fatal Outcome; Humans; Lung Neoplasms; Male; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins; Palliative Care; Pneumonectomy; Positron-Emission Tomography; Proteins; Tomography, X-Ray Computed; Translocation, Genetic; Young Adult | 2016 |
Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in Non-Small Cell Lung Cancer Stage IIIB/IV.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quality of Life | 2016 |
Chemotherapy in non-small cell lung cancer: opportunities for advancement.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic | 2016 |
[Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Humans; Hypokinesia; Leukopenia; Lung Neoplasms; Nausea; Neutropenia; Remission Induction; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia; Vomiting | 2016 |
Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medicare; Small Cell Lung Carcinoma; Treatment Outcome; United States | 2016 |
Narcissus, the beam and lung cancer: What is the message?
Topics: Etoposide; Humans; Lung Neoplasms; Narcissus | 2016 |
α-Lipoic acid sensitizes lung cancer cells to chemotherapeutic agents and anoikis via integrin β1/β3 downregulation.
Topics: Anoikis; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Synergism; Drug Therapy; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Integrin beta1; Integrin beta3; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Reactive Oxygen Species; Thioctic Acid | 2016 |
Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.
Topics: Aged; Antineoplastic Agents; Carboplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Karnofsky Performance Score, Radiation Dose and Nodal Status Predict Survival of Elderly Patients Irradiated for Limited-disease Small-cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Proliferation; Cell Survival; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Etoposide; Humans; Lung Neoplasms; Mice; Mutation; Precision Medicine; Proto-Oncogene Proteins p21(ras); Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2016 |
[Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients].
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Etoposide; Genetic Variation; Genotype; Haplotypes; Humans; Lung Neoplasms; Odds Ratio; Polymorphism, Single Nucleotide; Proportional Hazards Models; Rad52 DNA Repair and Recombination Protein; Regression Analysis; Risk; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Prognosis; Risk Assessment; Survival Analysis; Testicular Neoplasms; Treatment Outcome; Young Adult | 2017 |
Small cell carcinoma of the pyriform sinus successfully treated with concurrent chemo-radiotherapy: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Etoposide; Humans; Hypopharyngeal Neoplasms; Lung Neoplasms; Male; Neoplasms, Second Primary; Pyriform Sinus; Small Cell Lung Carcinoma | 2016 |
Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Child; Cisplatin; Etoposide; Humans; Ifosfamide; Indiana; Lung Neoplasms; Male; Mediastinal Neoplasms; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Neoplasms, Germ Cell and Embryonal; Pneumonectomy; Postoperative Complications; Retrospective Studies; Risk Factors; Testicular Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2016 |
A Case of Mixed Germ Cell Tumor in the Intramedullary Spinal-cord.
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Guillain-Barre Syndrome; Humans; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Paraplegia; Spinal Cord Neoplasms; Tomography, X-Ray Computed | 2016 |
Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell; Choriocarcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pelvic Neoplasms; Remission Induction; Ureteral Neoplasms | 2017 |
Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
CXCR4 antagonists suppress small cell lung cancer progression.
Topics: Animals; Benzylamines; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cisplatin; Cyclams; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Heterocyclic Compounds; Humans; Lung Neoplasms; Mice; Mice, Knockout; Neoplasm Metastasis; Nuclear Proteins; Peptides; Receptors, CXCR4; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2016 |
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Nitro Compounds; Treatment Outcome | 2016 |
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2017 |
Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Biocompatible Materials; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Drug Carriers; Drug Synergism; Electrophoresis; Erythrocytes; Etoposide; Flow Cytometry; Hemolysis; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kinetics; Lung Neoplasms; Microscopy, Electron, Scanning; Nanotubes, Carbon; Nucleic Acids; Oligonucleotides; Oligonucleotides, Antisense; Polyethylene Glycols; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Small Cell Lung Carcinoma | 2017 |
Gestational choriocarcinoma with renal and pulmonary metastases lacking a primary uterine origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Etoposide; Female; Hematuria; Humans; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Methotrexate; Neoplasms, Unknown Primary; Pregnancy; Vincristine | 2016 |
Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Etoposide; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Patient Selection; Platinum Compounds; Retrospective Studies; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Young Adult | 2017 |
Nonfunctioning Adrenocortical Carcinoma in Pediatric Acute Lymphoblastic Leukemia: A Case Report of a Rare Multiple Primaries Combination.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Fatal Outcome; Humans; Language Development Disorders; Lung Neoplasms; Mercaptopurine; Methotrexate; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Nephrectomy; Pneumonectomy; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2017 |
Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calibration; Cisplatin; Disease Progression; Drug Dosage Calculations; Etoposide; Humans; Lung Neoplasms; Models, Theoretical; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome; Tumor Burden | 2017 |
[Recurrent Gastric Carcinoma(Endocrine Cell Type)Successfully Treated with Multidisciplinary Therapy - A Case Report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Etoposide; Female; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Recurrence; Stomach Neoplasms | 2016 |
Elusive Target of Angiogenesis in Small-Cell Lung Cancer.
Topics: Bevacizumab; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neovascularization, Pathologic; Small Cell Lung Carcinoma | 2017 |
[Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Genetic Variation; Genotype; Glutathione Synthase; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Platinum Compounds; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Risk; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma, Non-gestational; Cisplatin; Compassionate Use Trials; Endodermal Sinus Tumor; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Nivolumab; Platinum Compounds; Programmed Cell Death 1 Receptor; Retrospective Studies; Seminoma; Stem Cell Transplantation; Teratoma; Testicular Neoplasms; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome | 2017 |
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; Etoposide; Feasibility Studies; Female; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Respiratory Insufficiency; Retrospective Studies; Tegafur | 2017 |
Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Placental site trophoblastic tumor with multiple metastases and complete response to salvage BEP regimen: a case report and review of the literature.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Chorionic Gonadotropin; Cisplatin; Cyclophosphamide; Dactinomycin; Digestive System Neoplasms; Endocrine Gland Neoplasms; Etoposide; Female; Humans; Hysterectomy; Kidney Neoplasms; Lung Neoplasms; Lymph Node Excision; Methotrexate; Pelvis; Pregnancy; Trophoblastic Tumor, Placental Site; Uterine Hemorrhage; Uterine Neoplasms; Vincristine; Young Adult | 2009 |
Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Repair; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Etoposide; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Italy; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate | 2008 |
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Improved systemic chemotherapy for metastatic testicular choriocarcinoma can result in excellent prognosis for life and vision.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Choroid Neoplasms; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Male; Orchiectomy; Prognosis; Testicular Neoplasms; Ultrasonography; Visual Acuity; Vitreous Detachment; Vitreous Hemorrhage | 2008 |
Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Carcinogens; Caspase 9; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mitochondria; Nicotine; Nicotinic Agonists; Protein Transport; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Smoking | 2009 |
Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; ROC Curve; Small Cell Lung Carcinoma; Tumor Burden; Vinblastine; Vinorelbine | 2009 |
Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Diabetic Nephropathies; Disease-Free Survival; Etoposide; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Renal Dialysis; Small Cell Lung Carcinoma | 2008 |
Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer.
Topics: Annexin A5; Antineoplastic Agents; Benzamides; Cell Survival; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Small Cell Lung Carcinoma | 2008 |
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2008 |
COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Child; Cisplatin; Combined Modality Therapy; Cyclooxygenase 2; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Osteosarcoma; Pneumonectomy; Prognosis; Retrospective Studies; Salvage Therapy; Survival Analysis | 2008 |
Skeletal muscle metastasis in a case of bronchogenic carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Bronchogenic; Cisplatin; Doxorubicin; Etoposide; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Muscle Neoplasms; Muscle, Skeletal | 2008 |
[Case of cancer-associated retinopathy in which immediate treatment succeeded].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Fatal Outcome; Humans; Lung Neoplasms; Male; Methylprednisolone; Paraneoplastic Syndromes; Prednisolone; Pulse Therapy, Drug; Retinal Diseases; Treatment Outcome | 2008 |
Lymphomatoid granulomatosis with involvement of the hard palate: a case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Interferon-alpha; Lung Neoplasms; Lymphomatoid Granulomatosis; Palatal Neoplasms; Palate, Hard; Prednisone; Rituximab; Vincristine | 2008 |
[Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Follow-Up Studies; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiation Pneumonitis; Radiotherapy, High-Energy; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Formation of a bronchoesophageal fistula following concurrent radiation and chemotherapy for lung cancer in the setting of Behçet's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Behcet Syndrome; Bronchial Fistula; Cisplatin; Combined Modality Therapy; Esophageal Fistula; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged | 2008 |
[Clinical analysis of stage I pediatric testicular yolk sac tumors: a report of ten cases].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Child, Preschool; Cisplatin; Endodermal Sinus Tumor; Etoposide; Follow-Up Studies; Humans; Infant; Lung Neoplasms; Male; Neoplasm Staging; Orchiectomy; Remission Induction; Retroperitoneal Neoplasms; Testicular Neoplasms; Ultrasonography | 2008 |
Treatment experiences of testicular cancer in Hispanic patients with Down's syndrome at the National Cancer Institute of Mexico.
Topics: Abnormalities, Multiple; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Cryptorchidism; Down Syndrome; Etoposide; Fatal Outcome; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mexico; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Remission Induction; Retroperitoneal Neoplasms; Seminoma; Testicular Neoplasms; Treatment Outcome; Young Adult | 2008 |
Synchronous small-cell lung cancer and gastrointestinal stromal tumor: a case report.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Doxorubicin; Etoposide; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Palliative Care; Piperazines; Pyrimidines; Small Cell Lung Carcinoma; Stomach Neoplasms | 2009 |
F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Topics: Animals; Binding, Competitive; Biogenic Polyamines; Breast Neoplasms; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Delivery Systems; Etoposide; Female; Humans; Leukemia L1210; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Podophyllotoxin; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2008 |
Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Flow Cytometry; Humans; Interferon-gamma; Interleukin-10; Killer Cells, Natural; Lung Neoplasms; Male; Middle Aged; T-Lymphocytes; Transforming Growth Factor beta1; ZAP-70 Protein-Tyrosine Kinase | 2009 |
Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
Down-regulation of GRP78 is associated with the sensitivity of chemotherapy to VP-16 in small cell lung cancer NCI-H446 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Calcimycin; Cell Cycle; Cell Line, Tumor; Down-Regulation; Egtazic Acid; Endoplasmic Reticulum Chaperone BiP; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Heat-Shock Proteins; Humans; Lung Neoplasms; Molecular Chaperones; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma | 2008 |
[Efficacy of surgical management combined with chemotherapy in the treatment of drug-resistant gestational trophoblastic neoplasm].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Human; Combined Modality Therapy; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Fluorouracil; Gestational Trophoblastic Disease; Humans; Hysterectomy; Lung Neoplasms; Middle Aged; Neoplasm Staging; Pregnancy; Retrospective Studies; Treatment Outcome; Uterine Neoplasms; Young Adult | 2008 |
Cutaneous metastasis of gastric adenocarcinoma: an exuberant and unusual clinical presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cachexia; Carcinoma, Signet Ring Cell; Etoposide; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Skin Neoplasms; Spinal Neoplasms; Stomach Neoplasms; Treatment Failure | 2008 |
Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Tomography, X-Ray Computed | 2009 |
RYBP stabilizes p53 by modulating MDM2.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; DNA Damage; Down-Regulation; Etoposide; Feedback, Physiological; Genes, Tumor Suppressor; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Lung Neoplasms; Neoplasm Proteins; Protein Binding; Protein Interaction Mapping; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-mdm2; Recombinant Fusion Proteins; Repressor Proteins; RNA Interference; Tumor Suppressor Protein p53; Two-Hybrid System Techniques; Ubiquitination | 2009 |
Re: 'A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small-cell lung cancer: a randomized trial'.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Research Design; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
[Pulmonary resection in the management of gestational trophoblastic neoplasia: a clinical study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Human; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Gestational Trophoblastic Disease; Humans; Lung Neoplasms; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Pregnancy; Prognosis; Retrospective Studies | 2008 |
HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2009 |
Balloon tamponade of hemorrhage after uterine curettage for gestational trophoblastic disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Balloon Occlusion; Catheterization; Dactinomycin; Dilatation and Curettage; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Pregnancy; Uterine Hemorrhage | 2009 |
Application of microfluidic gradient chip in the analysis of lung cancer chemotherapy resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Calcimycin; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Etoposide; Fluorescent Antibody Technique; Fluorescent Dyes; Heat-Shock Proteins; Humans; Image Processing, Computer-Assisted; Indoles; Ionophores; Lung Neoplasms; Microfluidic Analytical Techniques; Reproducibility of Results | 2009 |
Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Radiography; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Spinal Neoplasms | 2009 |
Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells.
Topics: Antineoplastic Agents; Caspases; Cell Line, Tumor; Complex Mixtures; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Ganoderma; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2009 |
[A case of small cell lung cancer with dermatomyositis that deteriorated with leukocytopenia due to chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dermatomyositis; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Small Cell Lung Carcinoma | 2008 |
Upregulation of GRP78 and GRP94 and its function in chemotherapy resistance to VP-16 in human lung cancer cell line SK-MES-1.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Calcimycin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Etoposide; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Lung Neoplasms; Membrane Glycoproteins; Molecular Chaperones; Neoplastic Stem Cells; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Stem Cell Assay; Up-Regulation | 2009 |
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Topics: Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Etoposide; Everolimus; Humans; Lung Neoplasms; Mice; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sirolimus; Stem Cell Factor; TOR Serine-Threonine Kinases | 2009 |
Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Hypoxia; Cell Line, Tumor; Culture Media; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Lysophospholipids; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; RNA, Small Interfering; Sphingosine; Transfection | 2009 |
Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Tolerance; Etoposide; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Gastrointestinal hemorrhage as the first manifestation of metastatic extragonadal choriocarcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Choriocarcinoma; Chorionic Gonadotropin; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Combined Modality Therapy; Etoposide; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Ifosfamide; Lung Neoplasms; Male; Occipital Lobe; Remission Induction; Retroperitoneal Neoplasms; Stomach Neoplasms; Supratentorial Neoplasms; Thoracic Surgery, Video-Assisted | 2009 |
Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity.
Topics: Aneuploidy; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Chromosomal Instability; Cytogenetic Analysis; Drug Synergism; Etoposide; Female; Flow Cytometry; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Mutagens; Oncogene Proteins; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Translocation, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
Desmoplastic small round cell tumor in children: a new therapeutic approach.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Neoadjuvant Therapy; Oncogene Proteins, Fusion; Pelvic Neoplasms; Radiotherapy, Adjuvant; Sarcoma, Small Cell; Splenic Neoplasms; Translocation, Genetic; Transplantation, Autologous; Vincristine | 2009 |
Results of surgical treatment for patients with small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Preoperative Care; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Vincristine | 2009 |
The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1.
Topics: Base Sequence; Binding Sites; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; E2F1 Transcription Factor; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Liver Neoplasms; Lung Neoplasms; Molecular Sequence Data; Promoter Regions, Genetic; RNA, Messenger; Sequence Alignment; Transcription, Genetic; Up-Regulation | 2009 |
Surgical resection in the management of pulmonary metastatic disease of gestational trophoblastic neoplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Fluorouracil; Gestational Trophoblastic Disease; Humans; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasm Staging; Pregnancy; Vincristine; Young Adult | 2009 |
The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Disease Progression; Etoposide; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Neoplasm Staging; Plasma; Prognosis; Retrospective Studies; Sex Factors; Small Cell Lung Carcinoma; Sodium; Survival Analysis | 2010 |
[Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Topotecan | 2009 |
Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis | 2009 |
A newly developed lung nodule during chemotherapy for small cell lung cancer. Chronic necrotising pulmonary aspergillosis.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronic Disease; Etoposide; Humans; Lung Neoplasms; Male; Pulmonary Aspergillosis; Pyrimidines; Small Cell Lung Carcinoma; Triazoles; Voriconazole | 2009 |
The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Pulmonary Diffusing Capacity; Radiotherapy Dosage; Retrospective Studies | 2009 |
[Gastric metastasis from small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pneumonia; Stomach Neoplasms; Vincristine | 2009 |
Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Radiotherapy, Adjuvant; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vincristine | 2009 |
A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Irradiation; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy; Drug Therapy, Combination; Enzyme Inhibitors; Ethnicity; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2009 |
Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo.
Topics: Animals; Cell Line, Tumor; Decanoic Acids; Dicarboxylic Acids; Disease Models, Animal; Drug Delivery Systems; Etoposide; Female; Humans; Kaplan-Meier Estimate; Kinetics; Lung Neoplasms; Mice; Microscopy, Electron, Scanning; Polyethylene Glycols; Small Cell Lung Carcinoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Caffeine-potentiated chemotherapy for metastatic osteosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Child; Cisplatin; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Osteosarcoma; Young Adult | 2009 |
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Platinum; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2009 |
Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Humans; Ifosfamide; Lung Neoplasms; Mice; Mice, Nude; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis | 2010 |
Small-cell lung cancer arising after chemotherapy for a patient with lymphoma of pulmonary mucosa-associated lymphoid tissue-a case report.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Cladribine; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Mucous Membrane; Neoplasms, Second Primary; Rituximab; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2009 |
Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Etoposide; Humans; Incidence; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Thalidomide; Thromboembolism | 2009 |
Pneumonectomy after neoadjuvant chemotherapy and radiation for advanced-stage lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Prospective Studies; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
[Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
Mechanism of action of an imidopiperidine inhibitor of human polynucleotide kinase/phosphatase.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Binding Sites; Camptothecin; Cell Survival; Circular Dichroism; DNA Ligase ATP; DNA Ligases; DNA Polymerase beta; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fluorescence Resonance Energy Transfer; Humans; Lung Neoplasms; Mutagenesis, Site-Directed; Phosphotransferases (Alcohol Group Acceptor); Photoelectron Spectroscopy; Piperidines; Poly-ADP-Ribose Binding Proteins; Protein Conformation; Pyrroles; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenopus Proteins | 2010 |
[Successful response of reccurent adult wilms' tumor to multiagent chemotherapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Vincristine; Wilms Tumor; Young Adult | 2009 |
The combination of Young's syndrome and small cell lung cancer-A spiky connection?
Topics: Antineoplastic Agents; Azoospermia; Carboplatin; Etoposide; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Radiography; Sinusitis; Small Cell Lung Carcinoma; Syndrome | 2010 |
[Successful treatment of small cell lung cancer with secondary immune thrombocytopenic purpura].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Purpura, Thrombocytopenic; Small Cell Lung Carcinoma | 2009 |
Iatrogenic tracheoesophageal fistula.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Fatal Outcome; Female; Humans; Iatrogenic Disease; Lung Neoplasms; Middle Aged; Radiotherapy; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Tracheoesophageal Fistula | 2009 |
[Small cell lung cancer with Sézary syndrome].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Sezary Syndrome; Small Cell Lung Carcinoma | 2009 |
Chemotherapy resistance research of lung cancer based on micro-fluidic chip system with flow medium.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Survival; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Physical Phenomena; Research | 2010 |
Methylation induced gene silencing of HtrA3 in smoking-related lung cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Cells, Cultured; Cisplatin; DNA Methylation; Drug Resistance, Neoplasm; Etoposide; Gene Silencing; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nitrosamines; Serine Endopeptidases; Smoking | 2010 |
Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Pulmonary Blastoma; Radiotherapy Dosage; Tomography, Emission-Computed; Tomography, X-Ray Computed; Young Adult | 2010 |
High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines.
Topics: Cell Death; Cell Line, Tumor; Cisplatin; Etoposide; Humans; Lung Neoplasms; Mitochondria; Mutagenesis, Site-Directed; Protein Structure, Tertiary; Recombinant Proteins; RNA, Small Interfering; Sequence Deletion; Serine Endopeptidases; Stress, Physiological | 2010 |
[Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Etoposide; Female; Granulocyte Precursor Cells; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2010 |
Effects of 17beta-estradiol on the cytotoxicity of etoposide in a lung carcinoma cell line and its bioavailability in ovariectomized Sprague-Dawley rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Line, Tumor; Estradiol; Etoposide; Female; Humans; Lung Neoplasms; Ovariectomy; Rats; Rats, Sprague-Dawley | 2010 |
Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Etoposide; Female; Glutathione; Humans; Kaplan-Meier Estimate; Lipid Peroxidation; Lung Neoplasms; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Superoxide Dismutase; Survival Rate; Treatment Outcome | 2010 |
Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Topics: Antineoplastic Agents; Cell Cycle; Cisplatin; DNA, Complementary; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Profiling; Humans; Lung Neoplasms; Microarray Analysis; MicroRNAs; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Small Cell Lung Carcinoma; Transfection; Tumor Cells, Cultured | 2010 |
[Case report: simultaneous bilateral testicular tumors with different cell types].
Topics: Adult; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Diagnostic Imaging; Etoposide; Hormone Replacement Therapy; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasms, Multiple Primary; Seminoma; Teratoma; Testicular Neoplasms; Treatment Outcome | 2010 |
Sequential fluctuating paraneoplastic ocular flutter-opsoclonus-myoclonus syndrome and Lambert-Eaton myasthenic syndrome in small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Opsoclonus-Myoclonus Syndrome; Small Cell Lung Carcinoma | 2011 |
[Treatment and prognosis of extrapulmonary small cell carcinoma of 243 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Etoposide; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Radiotherapy, High-Energy; Survival Rate; Urogenital Neoplasms; Young Adult | 2010 |
Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Caspase 8; Cell Line, Tumor; Doxorubicin; Enzyme Activation; Etoposide; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Small Cell Lung Carcinoma; TNF-Related Apoptosis-Inducing Ligand | 2010 |
[Malignant pilomatrixoma of head and neck. A case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Facial Neoplasms; Fatal Outcome; Humans; Lung Neoplasms; Male; Pilomatrixoma; Skin Neoplasms; Vinblastine; Vinorelbine | 2010 |
Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Etoposide; Female; Gene Expression; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Mice, SCID; Microarray Analysis; Neoplasm Transplantation; Small Cell Lung Carcinoma; Transplantation, Heterologous; Valproic Acid | 2010 |
Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer.
Topics: Carboplatin; Cisplatin; Etoposide; Female; Genes; Genome; Humans; Inuit; Lung Neoplasms; Male; Middle Aged; Nerve Tissue Proteins; Platinum; Polymorphism, Single Nucleotide; R-SNARE Proteins; Small Cell Lung Carcinoma | 2010 |
Solitary brain metastasis of an occult and stable small-cell lung cancer in a schizophrenic patient: a 3-year control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Brain Neoplasms; Carboplatin; Clozapine; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Radiotherapy; Schizophrenia; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2010 |
A case of metastatic testicular cancer complicated by pulmonary hemorrhage due to choriocarcinoma syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Choriocarcinoma; Cisplatin; Endodermal Sinus Tumor; Etoposide; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Male; Prognosis; Syndrome; Testicular Neoplasms | 2010 |
Successful chemotherapy for small-cell lung cancer in an elderly patient undergoing continuous ambulatory peritoneal dialysis.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Male; Peritoneal Dialysis, Continuous Ambulatory; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Moyamoya in a child treated with interferon for recurrent osteosarcoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Carotid Artery Diseases; Cerebral Arterial Diseases; Cerebral Infarction; Chemotherapy, Adjuvant; Child; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Interferon-alpha; Lung Neoplasms; Magnetic Resonance Angiography; Methotrexate; Moyamoya Disease; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Osteosarcoma; Thyroiditis, Autoimmune | 2010 |
[Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2010 |
Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Comorbidity; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2011 |
Protection of p53 wild type cells from taxol by genistein in the combined treatment of lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Genistein; Humans; Lung Neoplasms; Paclitaxel; Tumor Suppressor Protein p53 | 2010 |
Neutropenic enterocolitis during first-line chemotherapy with carboplatin and etoposide in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Enterocolitis, Neutropenic; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Radiography; Small Cell Lung Carcinoma | 2011 |
Salvage chemotherapy with methotrexate, etoposide and actinomycin D in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin; Choroid Neoplasms; Dactinomycin; Etoposide; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasms, Germ Cell and Embryonal; Salvage Therapy; Testicular Neoplasms; Treatment Outcome | 2010 |
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Hsp72 mediates TAp73α anti-apoptotic effects in small cell lung carcinoma cells.
Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; DNA-Binding Proteins; Etoposide; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; HEK293 Cells; HSP72 Heat-Shock Proteins; Humans; Immunoblotting; Lung Neoplasms; Membrane Potential, Mitochondrial; Microscopy, Confocal; Nuclear Proteins; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; Small Cell Lung Carcinoma; Tumor Protein p73; Tumor Suppressor Proteins | 2011 |
Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lipid Peroxidation; Lung Neoplasms; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Superoxide Dismutase; Survival Rate; Treatment Outcome | 2010 |
INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cullin Proteins; Cytoskeletal Proteins; DNA Fragmentation; Etoposide; Gamma Rays; Humans; Hydroquinones; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Lysine; Mice; Phosphorylation; Phosphoserine; Protein Binding; Protein Processing, Post-Translational; Protein Stability; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Ubiquitination; Ultraviolet Rays; Up-Regulation | 2011 |
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Etoposide; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Genome-Wide Association Study; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Phosphoproteins; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Transcription Factors; YAP-Signaling Proteins | 2010 |
Orbital metastatic angiosarcoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Etoposide; Fatal Outcome; Hemangiosarcoma; Humans; Lung Neoplasms; Male; Middle Aged; Orbital Neoplasms; Tomography, X-Ray Computed | 2010 |
Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Epithelial Cells; Etoposide; Humans; Immunohistochemistry; Lung Neoplasms; Male; Microscopy, Electron, Transmission; Muscle, Skeletal; Myofibroblasts; Neoplasm Staging; Neurosecretory Systems; Pneumonectomy; Small Cell Lung Carcinoma; Smoking | 2011 |
[Clinical analysis of patients with relapsed and chemo-resistant gestational trophoblastic neoplasia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pregnancy; Prognosis; Retrospective Studies; Time Factors; Treatment Outcome; Vincristine; Young Adult | 2010 |
[Case of a testicular germ cell tumor presenting with multiple metastasized pulmonary nodules and masses].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Diagnosis, Differential; Etoposide; Gynecomastia; Humans; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Testicular Neoplasms; Tomography, X-Ray Computed | 2010 |
Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Floxuridine; Follow-Up Studies; Gestational Trophoblastic Disease; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine; Young Adult | 2011 |
Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; DNA Damage; Drug Synergism; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Lung Neoplasms; Micronucleus Tests; Naphthoquinones; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2011 |
The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Idiopathic Interstitial Pneumonias; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2011 |
Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Bone Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Remission Induction | 2011 |
Reversible posterior leukoencephalopathy induced by carboplatin and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Posterior Leukoencephalopathy Syndrome; Prognosis; Small Cell Lung Carcinoma | 2012 |
Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vault Ribonucleoprotein Particles; Vincristine | 2011 |
[Pneumocystis and Staphylococcus aureus pulmonary co-infection after chemotherapy for lung cancer].
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Ceftriaxone; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Lung Neoplasms; Opportunistic Infections; Pneumonia, Pneumocystis; Pneumonia, Staphylococcal; Staphylococcus aureus; Trimethoprim, Sulfamethoxazole Drug Combination | 2011 |
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Chemical Analysis; Calibration; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials, Phase I as Topic; Drug Synergism; Etoposide; Humans; Indoles; Lung Neoplasms; Prognosis; Pyrroles; Small Cell Lung Carcinoma | 2011 |
The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; NAD(P)H Dehydrogenase (Quinone); Neoplasm Staging; Polymorphism, Single Nucleotide; Proportional Hazards Models; Radiotherapy; Randomized Controlled Trials as Topic | 2011 |
Overcoming multidrug resistance in human lung cancer with novel benzo[a]quinolizin-4-ones.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Cell Line, Tumor; Cell Shape; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lung Neoplasms; Quinolizines | 2011 |
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2011 |
[Thoracic radiation therapy improves the prognosis for patients with extensive stage small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2011 |
Sequential or concomitant chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
Two novel determinants of etoposide resistance in small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DNA Polymerase beta; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Lung Neoplasms; Nuclear Proteins; Small Cell Lung Carcinoma; Transcription Factors; Zebrafish Proteins | 2011 |
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
[Successful treatment of a case of advanced adult Wilms' tumor with pre-surgical chemotherapy, irradiation and radical nephrectomy].
Topics: Adult; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Treatment Outcome; Wilms Tumor | 2011 |
Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center.
Topics: Age Factors; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Heparin; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2011 |
Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiation Pneumonitis; Radiotherapy Dosage; Time Factors; Tomography, X-Ray Computed | 2011 |
Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Staging; Pneumonia; Radiation Injuries; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine | 2011 |
MicroRNA expression and clinical outcome of small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Screening Assays, Antitumor; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2011 |
[Bilateral conjunctival oedema as a symptom of adrenal adenocarcinoma].
Topics: Adenocarcinoma; Adrenal Cortex Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Conjunctival Diseases; Cushing Syndrome; Cyclophosphamide; Diabetes Mellitus, Type 2; Doxorubicin; Edema; Etoposide; Fatal Outcome; Female; Humans; Hydrocortisone; Ketoconazole; Lung Neoplasms; Neoplasm Recurrence, Local; Paraneoplastic Syndromes; Respiratory Insufficiency; Vincristine | 2011 |
Dyspnoea and a lung mass in a young female 2 weeks after Caesarean delivery.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cesarean Section; Cyclophosphamide; Doxorubicin; Dyspnea; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Paresis; Pulmonary Blastoma; Radiography, Thoracic; Smoking; Treatment Outcome; Vincristine | 2011 |
Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell lines.
Topics: Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cisplatin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Glutathione S-Transferase pi; Humans; Inhibitory Concentration 50; Lung Neoplasms; Multidrug Resistance-Associated Proteins; RNA, Messenger; Vault Ribonucleoprotein Particles | 2011 |
QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells.
Topics: Adenocarcinoma; Antigens, Neoplasm; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Caspase 3; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Flow Cytometry; Humans; Lung Neoplasms; Piperidines; Podophyllotoxin; Poly(ADP-ribose) Polymerases; RNA, Small Interfering; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2012 |
Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cinnamomum zeylanicum; Doxorubicin; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Etoposide; Humans; Lung Neoplasms; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Proanthocyanidins | 2011 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
Laminin receptor-targeted etoposide loaded polymeric micelles: a novel approach for the effective treatment of tumor metastasis.
Topics: Animals; Drug Delivery Systems; Etoposide; Female; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Micelles; Polymers; Random Allocation; Receptors, Laminin; Treatment Outcome | 2012 |
Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cushing Syndrome; Doxorubicin; Etoposide; Fatal Outcome; Humans; Hyperaldosteronism; Lung Neoplasms; Male; Mitotane; Pneumonia; Tomography, X-Ray Computed | 2011 |
Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.
Topics: Antineoplastic Agents, Phytogenic; Benzoquinones; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Synergism; Endonucleases; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lactams, Macrocyclic; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Time Factors | 2012 |
Development of a double-layer microfluidic chip with flow medium for chemotherapy resistance analysis of lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Equipment Design; Etoposide; Humans; Lung Neoplasms; Microfluidic Analytical Techniques; Microscopy, Fluorescence; Multidrug Resistance-Associated Proteins; Propionates; Quinolines; Rhodamine 123 | 2011 |
Histiocytic sarcoma of the thyroid.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Glutamates; Guanine; Histiocytic Sarcoma; Humans; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Palliative Care; Pemetrexed; Positron-Emission Tomography; Receptors, Cell Surface; Thyroid Neoplasms; Tomography, X-Ray Computed | 2012 |
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
Topics: Animals; Antineoplastic Agents; Cathepsins; Cell Line, Tumor; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Etoposide; Female; Lung Neoplasms; Macrophages; Mammary Neoplasms, Animal; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neoplasm Invasiveness; Paclitaxel | 2011 |
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Clinical Trials, Phase III as Topic; Collagen Type XVIII; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Etoposide; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Methylenetetrahydrofolate Reductase (NADPH2); Pemetrexed; Peptide Synthases; Phosphoribosylglycinamide Formyltransferase; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Reduced Folate Carrier Protein; Small Cell Lung Carcinoma; Thymidylate Synthase | 2012 |
Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines.
Topics: Annexin A5; beta-Galactosidase; Cell Death; Cell Line, Tumor; Chemistry, Pharmaceutical; Coumarins; Deoxyribonucleases; Docetaxel; Electrophoresis, Agar Gel; Electrophoretic Mobility Shift Assay; Etoposide; Flow Cytometry; Fluorescein-5-isothiocyanate; Freeze Drying; Humans; Intracellular Space; Liposomes; Lung Neoplasms; Microscopy, Electron, Transmission; Particle Size; Static Electricity; Taxoids; Transfection; Tumor Suppressor Protein p53 | 2012 |
Chemotherapy-induced infertility in patients with testicular cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Counseling; Etoposide; Female; Humans; Infertility, Male; Lung Neoplasms; Male; Oncology Nursing; Semen Preservation; Sperm Banks; Testicular Neoplasms | 2012 |
[Acquired ichthyosis and haematological malignancies: five cases].
Topics: Adult; Aged; Allopurinol; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematologic Neoplasms; Hodgkin Disease; Humans; Ichthyosis; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Lung Neoplasms; Lymphoma, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Parotid Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prednisone; Procarbazine; Pyrimidines; Retrospective Studies; Rituximab; Schizophrenia; Stomach Neoplasms; Vincristine | 2012 |
Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Vaginal cancer following etoposide-containing chemotherapy for metastatic gestational trophoblastic tumour.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Etoposide; Female; Humans; Hydatidiform Mole; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Pregnancy; Uterine Neoplasms; Vaginal Neoplasms | 2012 |
ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Disease-Free Survival; DNA Topoisomerases, Type I; DNA-Binding Proteins; Doxorubicin; Endonucleases; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Transcription, Genetic; Vincristine | 2012 |
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Etoposide; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neovascularization, Pathologic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Choriocarcinoma of the lung masquerading as a persisting pregnancy of unknown location (PUL).
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma, Non-gestational; Chorionic Gonadotropin; Cyclophosphamide; Dactinomycin; Diagnostic Errors; Etoposide; False Positive Reactions; Female; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Pregnancy; Radiography; Treatment Outcome; Vincristine; Vitamin B Complex | 2012 |
Small cell neuroendocrine carcinoma of the cervix: analysis of the prognosis and role of radiation therapy for 43 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Neuroendocrine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Hysterectomy; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors; Uterine Cervical Neoplasms | 2012 |
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Etoposide; Female; Fluid Therapy; Gemcitabine; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Synergism; Etoposide; Humans; Immunoblotting; Lung Neoplasms; Paclitaxel; Protein Kinase C; Signal Transduction; Staurosporine; Time Factors | 2012 |
Mutant p53 cooperates with ETS2 to promote etoposide resistance.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Mutation; Nuclear Proteins; Phosphoric Diester Hydrolases; Proto-Oncogene Protein c-ets-2; Transcription Factors; Tumor Suppressor Protein p53 | 2012 |
Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Etoposide; Female; Gene Frequency; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Small Cell Lung Carcinoma; Vincristine | 2012 |
Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation.
Topics: Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Screening Assays, Antitumor; Etoposide; Free Radical Scavengers; Humans; Hydroxyl Radical; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondrial Membranes; Permeability; Reactive Oxygen Species | 2012 |
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Lymph Nodes; Male; Methotrexate; Middle Aged; Neoplasm Staging; Perioperative Care; Platinum; Pneumonectomy; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hemorrhage; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Pulmonary Embolism; Retrospective Studies; Risk Factors; Survival Rate | 2012 |
Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Topics: Antineoplastic Agents; Antioxidant Response Elements; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation; Gene Knockdown Techniques; Glutamate-Cysteine Ligase; Heme Oxygenase-1; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Models, Biological; NAD(P)H Dehydrogenase (Quinone); Neoplastic Stem Cells; NF-E2-Related Factor 2; Oxides; PPAR gamma; Proto-Oncogene Mas; RNA Interference; Rosiglitazone; Thiazolidinediones | 2012 |
Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide.
Topics: ACTH Syndrome, Ectopic; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Metyrapone; Middle Aged; Small Cell Lung Carcinoma | 2011 |
Clinical characteristics of the patients with Hodgkin's lymphoma involving extranodal sites.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Procarbazine; Remission Induction; Retrospective Studies; Survival Rate; Vinblastine; Vincristine; Young Adult | 2012 |
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Melphalan; Myeloablative Agonists; Neoplasm Metastasis; Prognosis; Sarcoma, Ewing; Stem Cell Transplantation; Vincristine; Young Adult | 2012 |
[Organ-preserving interventions in combined therapy of children and adolescents with osteosarcoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Transplantation; Chemotherapy, Cancer, Regional Perfusion; Child; Cisplatin; Cohort Studies; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Neoadjuvant Therapy; Orthopedic Procedures; Osteosarcoma; Transplantation, Autologous; Treatment Outcome | 2012 |
[Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myelopoiesis; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Epirubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pilot Projects; Prognosis; Retrospective Studies; Single-Blind Method; Slovenia; Topotecan; Treatment Outcome; Vincristine | 2012 |
An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary?
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Time Factors | 2012 |
Benefit of a second opinion for lung cancer: no recurrent disease, but infection.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Ciprofloxacin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Postoperative Care; Prognosis; Referral and Consultation | 2012 |
Is diabetes mellitus a prognostic factor for survival in patients with small cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diabetes Complications; Etoposide; Female; Hemoglobins; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Serum Albumin; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed | 2012 |
sVEGF R1 and Tie-2 levels during chemotherapy of lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pulmonary Disease, Chronic Obstructive; Receptor, TIE-2; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage | 2012 |
[Biphasic pulmonary blastoma with germ cell differentiation: a challenge in diagnosis and treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Cisplatin; Etoposide; Humans; Ifosfamide; Lung; Lung Neoplasms; Male; Taxoids; Tomography, X-Ray Computed | 2011 |
Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cisplatin; Comet Assay; DNA Damage; Doxorubicin; Etoposide; Female; Histone Deacetylase 6; Histone Deacetylases; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Tetrazolium Salts; Thiazoles | 2012 |
Recurrent endobronchial diffuse large B-cell lymphoma. Diagnosed by cryoprobe.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bronchi; Cisplatin; Combined Modality Therapy; Cryosurgery; Cyclophosphamide; Cytarabine; Diagnosis, Differential; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Prednisone; Recurrence; Remission Induction; Rituximab; Spleen; Splenectomy; Splenomegaly; Vincristine | 2013 |
Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Array Analysis; Proteomics; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Support Vector Machine; Treatment Outcome | 2012 |
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Etoposide; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Pemetrexed; Prognosis; Proportional Hazards Models; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Small Cell Lung Carcinoma | 2012 |
Trimodality therapy for superior sulcus tumours: evolution and evaluation of a treatment protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Reoperation; Retrospective Studies; Risk Factors; Thoracotomy; Tracheostomy; Treatment Failure; Treatment Outcome | 2013 |
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Anthracyclines; Antigens, CD; Biomarkers, Tumor; Camptothecin; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glycoproteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Peptides; Receptors, Urokinase Plasminogen Activator; Retinal Dehydrogenase; RNA, Messenger; Small Cell Lung Carcinoma | 2013 |
A bilateral primary yolk sac tumor of the lung associated with chromosome 3 polysomy: understanding the Oct 3/4 and Sox 2 interaction.
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 3; Cisplatin; Drug Resistance, Neoplasm; Endodermal Sinus Tumor; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Octamer Transcription Factor-3; Radiography; SOXB1 Transcription Factors | 2013 |
Treatment update in small-cell lung cancer: from limited to extensive disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan | 2012 |
Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Vinblastine | 2012 |
Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Irradiation; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Radionuclide Imaging; Radiotherapy Dosage; Severity of Illness Index; Small Cell Lung Carcinoma; Tumor Burden | 2013 |
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Paclitaxel; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2013 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Small Cell; Caspases; Cell Survival; DNA, Antisense; DNA, Complementary; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Gene Expression Regulation, Enzymologic; Humans; Isoenzymes; Lung Neoplasms; Mitochondria; Phenotype; Protein Kinase C; Protein Kinase C-epsilon; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
A rare presentation of biphasic pulmonary blastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Pulmonary Blastoma; Radiography, Thoracic | 2002 |
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Patient Acceptance of Health Care; Patient Selection; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Refusal | 2002 |
Successful salvage of relapsed adults Wilms' tumour with high dose chemotherapy and autologous peripheral blood stem cell rescue.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Wilms Tumor | 2002 |
Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide.
Topics: Angiography; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Pain; Thrombosis; Tissue Plasminogen Activator | 2002 |
Tirapazamine: a hypoxia-activated topoisomerase II poison.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Hypoxia; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; HeLa Cells; Humans; Lung Neoplasms; Tirapazamine; Topoisomerase II Inhibitors; Triazines | 2002 |
Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Fractionation; Etoposide; Gamma Rays; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Proteins; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2002 |
Unusual intrathoracic location of a primary germ cell tumour.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Embryonal; Chemotherapy, Adjuvant; Choriocarcinoma; Cisplatin; Endodermal Sinus Tumor; Etoposide; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Tomography, X-Ray Computed | 2002 |
Small-cell lung cancer, high growth rate, high response rate to chemotherapy: ideal for high-dose chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Survival Analysis | 2002 |
[Outpatient chemotherapy for small cell lung cancer in our hospital].
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2002 |
Superior vena cava syndrome caused by chemotherapy-induced fibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fibrosis; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Superior Vena Cava Syndrome; Vena Cava, Superior | 2002 |
Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Female; Heart Transplantation; Humans; Immunosuppression Therapy; Kidney Transplantation; Lung Neoplasms; Lymphoma, AIDS-Related; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Methotrexate; Postoperative Complications; Prednisone; Remission Induction; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Vincristine | 2002 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
Coexisting true hermaphroditism and partial hydatidiform mole developing metastatic gestational trophoblastic tumors. A case report.
Topics: Abortion, Therapeutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Disorders of Sex Development; Etoposide; Female; Fetus; Humans; Hydatidiform Mole; Lung Neoplasms; Magnetic Resonance Imaging; Male; Methotrexate; Mosaicism; Neoplasms, Multiple Primary; Pregnancy; Pregnancy Complications, Neoplastic; Radiography; Trophoblastic Neoplasms; Uterine Neoplasms | 2002 |
High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Germany; Hematologic Diseases; Humans; Ifosfamide; Infant; Kidney Diseases; Kidney Neoplasms; Life Tables; Lung Neoplasms; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Prognosis; Stomatitis; Survival Analysis; Thiotepa; Transplantation, Autologous; Wilms Tumor | 2002 |
The effect of cisplatin, etoposide and quercetin on Hsp72 expression.
Topics: Antineoplastic Agents; Blotting, Western; Cisplatin; Etoposide; Fibroblasts; Heat-Shock Proteins; HeLa Cells; Hot Temperature; HSP72 Heat-Shock Proteins; Humans; Laryngeal Neoplasms; Lung Neoplasms; Quercetin; Skin; Tumor Cells, Cultured | 2002 |
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Topics: Alleles; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Small Cell; Cell Death; Cell Division; Cell Survival; Chromones; Doxycycline; Enzyme Inhibitors; Etoposide; Genes, Dominant; Genetic Vectors; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Insulin-Like Growth Factor I; Lung Neoplasms; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Stem Cell Factor; Time Factors; Tumor Cells, Cultured | 2002 |
"The guard dies, it does not surrender!" progress in the management of small-cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Humans; Lung Neoplasms; Vincristine | 2002 |
[Neuron-specific enolase (NSE) serum level as a prognostic factor in non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Poland; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Vindesine | 2002 |
[Early irradiation with radiochemotherapy for limited-stage small cell lung cancer is superior to late irradiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic; Survival Rate | 2002 |
[New data presented at ASCO 2002 concerning small cell bronchial cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Quinolones; Smoking; Smoking Prevention; Survival Analysis; Treatment Outcome | 2002 |
[Radio-chemotherapy combination in locally advanced, inoperable, non-small cell bronchial cancers].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Mitomycin; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2002 |
High-dose chemotherapy and autologous peripheral blood stem cell rescue in a patient with pleuropulmonary blastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Melphalan; Pulmonary Blastoma; Radiography; Transplantation, Autologous; Treatment Outcome | 2003 |
Preoperative chemotherapy is essential for conservative surgery of Askin tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Pneumonectomy; Postoperative Care; Preoperative Care; Prognosis; Radiotherapy, Adjuvant; Sarcoma, Small Cell; Thoracic Neoplasms; Treatment Outcome; Vincristine | 2003 |
GL331 inhibits HIF-1alpha expression in a lung cancer model.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Electrophoretic Mobility Shift Assay; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Models, Biological; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured | 2003 |
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Dacarbazine; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Temozolomide; Treatment Outcome | 2003 |
[Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids; Tumor Cells, Cultured | 2003 |
In regard to hyperfractionation for non-small-cell lung cancer: fire, ready, aim!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic | 2003 |
Chemotherapy for elderly SCLC patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Treatment Outcome | 2003 |
The relationship between local dose and loss of function for irradiated lung.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Male; Middle Aged; Pulmonary Diffusing Capacity; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Respiratory Function Tests; Retrospective Studies; Tomography, X-Ray Computed | 2003 |
Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Forced Expiratory Volume; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Pulmonary Diffusing Capacity; Radioisotope Teletherapy; Respiratory Function Tests; Retrospective Studies; Total Lung Capacity; Vinblastine | 2003 |
Shorter is not better.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Survival Analysis; Treatment Outcome | 2003 |
Metallothionein is a potential negative regulator of apoptosis.
Topics: Apoptosis; Cadmium; Carcinoma, Hepatocellular; Caspase 3; Caspases; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Combinations; Etoposide; Hepatocytes; Humans; Liver Neoplasms; Lung Neoplasms; Metallothionein; Zinc | 2003 |
S29 ribosomal protein induces apoptosis in H520 cells and sensitizes them to chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Calcium Signaling; Carcinoma, Non-Small-Cell Lung; Caspases; Cisplatin; Etoposide; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Mitochondria; Neoplasm Proteins; NF-kappa B; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Ribosomal Proteins; Survivin; Telomerase; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells.
Topics: Anthracenes; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase 9; Caspases; Cell Survival; DNA Damage; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Etoposide; Genes, Dominant; Genes, p53; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Glycoproteins; Mesothelioma; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Recombinant Proteins; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; Ultraviolet Rays | 2003 |
A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carbazoles; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Macromolecular Substances; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Protein Binding; Pyrimidines; Stomach Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; DNA-Activated Protein Kinase; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Endodeoxyribonucleases; Etoposide; Exodeoxyribonucleases; Humans; Lung Neoplasms; Nuclear Proteins; Protein Serine-Threonine Kinases; Rad51 Recombinase; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer.
Topics: Carcinoma, Small Cell; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Nuclear Proteins; Protein Serine-Threonine Kinases; Rad51 Recombinase; Tumor Cells, Cultured | 2003 |
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Ethylenediamines; Etoposide; Female; Glycine; Half-Life; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Razoxane | 2003 |
P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Genistein; Humans; Lung Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Serine; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2003 |
AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression.
Topics: AMP-Activated Protein Kinases; Apoptosis; Base Sequence; Blotting, Western; Cold Temperature; Electrophoretic Mobility Shift Assay; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Sequence Data; Multienzyme Complexes; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Kinases; Protein Serine-Threonine Kinases; Protein Subunits; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2003 |
Multiple relapses of mature teratoma, germinal and non-germ cell cancer in a patient treated with chemotherapy for testicular non-seminomatous germ cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Peritoneal Neoplasms; Teratoma; Testicular Neoplasms | 2003 |
Modified Ifosphamide/CarboPlatin/Etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging; Patient Selection; Prognosis; Randomized Controlled Trials as Topic | 2003 |
Radiation therapy for esthesioneuroblastoma: rationale for elective neck irradiation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blindness; Bone Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Cytarabine; Epirubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Nasal Cavity; Necrosis; Neoplasm Recurrence, Local; Nose Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Salvage Therapy; Spinal Cord Neoplasms; Survival Analysis | 2003 |
[The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells].
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Drug Interactions; Esophageal Neoplasms; Etoposide; Fluorouracil; Humans; Insulin; Lung Neoplasms; Tumor Cells, Cultured | 2003 |
Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Calpain; Caspase 3; Caspase 9; Caspases; Cathepsins; Cell Membrane; Cytochrome c Group; Ecdysterone; Endopeptidases; Etoposide; Gene Expression; HL-60 Cells; Humans; Interleukin-3; K562 Cells; Kidney; Lung Neoplasms; Mice; Mitochondria; Mutagenesis; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; U937 Cells | 2003 |
[Marked improvement of Lambert-Eaton myasthenic syndrome resulting from treatment for small cell lung carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Inappropriate ADH Syndrome; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male | 2003 |
[Remission rate of mediastinal lymph nodes after multimodal therapy of lung cancer--is it a prognostic factor?].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Etoposide; Feasibility Studies; Female; Gemcitabine; Hospital Mortality; Humans; Lung; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Prognosis; Radiotherapy Dosage; Survival Analysis | 2003 |
Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Immunoenzyme Techniques; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Treatment Outcome | 2003 |
Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glutathione; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2003 |
[Evaluation of surgical resection of pulmonary metastasis of trophoblastic tumour].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Hydatidiform Mole, Invasive; Lung Neoplasms; Male; Methotrexate; Middle Aged; Pneumonectomy; Pregnancy; Prognosis; Retrospective Studies; Trophoblastic Neoplasms; Uterine Neoplasms; Vincristine | 2003 |
[Maintenance chemotherapy for small-cell lung cancer. A new publication].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2003 |
Using technetium-99m methoxyisobutylisonitrile lung single-photon-emission computed tomography to predict response to chemotherapy and compare with P-glycoprotein expression in patients with untreated small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Retrospective Studies; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 2003 |
Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Retrospective Studies; Survival Rate; Vincristine | 2003 |
Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Flutamide; Humans; Leuprolide; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Orchiectomy; Postoperative Complications; Prostatic Neoplasms; Radiography; Testicular Neoplasms | 2003 |
Kit expression in small cell carcinomas of the lung: effects of chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Survival Rate | 2003 |
Topotecan as first-line therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan | 2003 |
Options for first- and second-line therapy in small cell lung cancer--a workshop discussion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local | 2003 |
Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Blotting, Western; Body Weight; Bombesin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cell Division; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; Humans; Immunotherapy; Interferon-gamma; Lung Neoplasms; Mice; Mice, SCID; Models, Chemical; Monocytes; Neoplasm Transplantation; Paclitaxel; Protein Binding; Receptors, Bombesin; Thymidine | 2003 |
Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Small Cell; Cell Division; Diphosphonates; Drug Combinations; Etoposide; Humans; Imidazoles; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoclasts; Parathyroid Hormone-Related Protein; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2003 |
Sterically stabilized etoposide liposomes: evaluation of antimetastatic activity and its potentiation by combination with sterically stabilized pentoxifylline liposomes in mice.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Etoposide; Female; Liposomes; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Pentoxifylline | 2003 |
Cytomegalovirus colitis--a severe complication after standard chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Colitis; Cytomegalovirus Infections; Etoposide; Humans; Lung Neoplasms; Male | 2002 |
Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Renal Dialysis | 2004 |
[Alternating electric heart axis in a patient with small cell lung cancer].
Topics: Abdominal Pain; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Echocardiography; Electrocardiography; Etoposide; Heart Conduction System; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pericardial Effusion; Pericardiocentesis | 2004 |
[Tumor staging with PET/CT. Detection of a second tumor].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biopsy; Bronchoscopy; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Hypopharyngeal Neoplasms; Hypopharynx; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Radiography, Thoracic; Radiotherapy, Adjuvant; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
[Lambert-Eaton myasthenic syndrome with acute respiratory failure associated with small cell lung cancer].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bronchoscopy; Carcinoma, Small Cell; Cisplatin; Diagnosis, Differential; Electromyography; Etoposide; Fatal Outcome; Female; Humans; Immunization, Passive; Inappropriate ADH Syndrome; Lambert-Eaton Myasthenic Syndrome; Lung; Lung Neoplasms; Middle Aged; Neurologic Examination; Palliative Care; Respiratory Insufficiency; Tomography, X-Ray Computed | 2004 |
Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Emulsions; Etoposide; Lethal Dose 50; Lung Neoplasms; Mice; Mice, Inbred C57BL; Receptors, LDL; Structure-Activity Relationship; Tumor Cells, Cultured | 2003 |
Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer patients treated with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Radiation Injuries; Retrospective Studies; Risk Factors; Spirometry; Survival Analysis; Treatment Outcome; Vincristine | 2004 |
RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspases; Cell Line, Tumor; Enzyme Activation; Etoposide; Humans; Lung Neoplasms; ras GTPase-Activating Proteins | 2004 |
[Pleuropulmonary blastoma: possible interest of neoadjuvant chemotherapy. A case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child, Preschool; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Neoadjuvant Therapy; Pleural Neoplasms; Pulmonary Blastoma; Radiotherapy, Adjuvant; Treatment Outcome | 2003 |
[A difficult case of advanced testicular choriocarcinoma effectively treated by chemotherapy and resection of lung metastasis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Choriocarcinoma; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Peripheral Blood Stem Cell Transplantation; Pneumonectomy; Testicular Neoplasms | 2004 |
Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Tumor Cells, Cultured | 2004 |
Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells.
Topics: Acetophenones; Antineoplastic Agents, Phytogenic; Apoptosis; Benzopyrans; Blotting, Western; Carcinoma, Small Cell; Caspase 3; Caspase 9; Caspases; Cell Death; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Immunoblotting; Lung Neoplasms; Membrane Potentials; Mitochondria; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2004 |
Mantle cell lymphoma in lymph nodes with metastatic small cell carcinoma of lung: a diagnostic and treatment dilemma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Carcinoma, Small Cell; CD3 Complex; Cisplatin; Etoposide; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Lymphoma, Mantle-Cell; Middle Aged; Remission Induction; Rituximab | 2004 |
[Cellular changes in non-small cell lung cancer after neoadjuvant therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Diagnosis, Differential; Etoposide; Humans; Ifosfamide; Lung Neoplasms | 2004 |
Population-based outcomes for SCLC.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Outcome Assessment, Health Care | 2004 |
[Chemotherapy for small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2004 |
[Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Vincristine | 2004 |
Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carrier Proteins; Caspases; Cell Line, Tumor; Cell Membrane; Cytochromes c; DNA Fragmentation; Down-Regulation; Etoposide; HeLa Cells; High-Temperature Requirement A Serine Peptidase 2; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Potentials; Mitochondria; Mitochondrial Proteins; Peptides; Protein Transport; Proteins; RNA, Small Interfering; Serine Endopeptidases | 2004 |
Resection of pulmonary metastases following chemotherapy for high stage testicular tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease-Free Survival; Etoposide; Follow-Up Studies; Germinoma; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Retrospective Studies; Testicular Neoplasms; Treatment Outcome | 2004 |
Stage III non-small-cell lung cancer treated with high-dose hyperfractionated radiation therapy and concurrent low-dose daily chemotherapy with or without weekend chemotherapy: retrospective analysis of 301 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Downregulation of peroxiredoxin V stimulates formation of etoposide-induced double-strand DNA breaks.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Nucleus; Clone Cells; Cloning, Molecular; DNA Damage; DNA Polymerase II; DNA Primers; Etoposide; Flow Cytometry; Gene Expression Regulation; HeLa Cells; Histones; Humans; Lung Neoplasms; Neoplasms; Peroxidases; Peroxiredoxins; Phospholipases A; Phosphorylation | 2004 |
Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caveolin 1; Caveolins; Cell Membrane; Cholesterol; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2004 |
Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent.
Topics: Abdominal Pain; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Dexamethasone; Etoposide; Female; Fetus; Humans; Ifosfamide; Infant, Newborn; Kidney Neoplasms; Lumbar Vertebrae; Lung Neoplasms; Neoplasm Recurrence, Local; Patient Dropouts; Polyradiculopathy; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Spinal Cord Compression; Vincristine; Wilms Tumor | 2004 |
Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Apoptosis; Drug Synergism; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2004 |
[A case of cT0N2M0 small cell lung cancer with Lambert-Eaton myasthenic syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Calcium Channels; Carboplatin; Carcinoma, Small Cell; Electromyography; Etoposide; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male | 2004 |
Tumor excision and reconstruction of the upper cervical spine: a multidisciplinary approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axis, Cervical Vertebra; Bone Transplantation; Cervical Atlas; Chemotherapy, Adjuvant; Chondrosarcoma; Chordoma; Combined Modality Therapy; Cranial Fossa, Posterior; Etoposide; Fatal Outcome; Female; Femoral Neoplasms; Humans; Ifosfamide; Interdisciplinary Communication; Internal Fixators; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Osteosarcoma; Palliative Care; Patient Care Team; Proton Therapy; Remission Induction; Skull Base Neoplasms; Spinal Fusion; Spinal Neoplasms; Surgical Flaps | 2004 |
Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Quinazolines; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure; Treatment Outcome | 2005 |
[Paclitaxel and cisplatin combined with etoposide chemotherapy in non-small cell lung cancer with brain metastases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2004 |
[Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Critical Pathways; Etoposide; Evidence-Based Medicine; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 2004 |
Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy: final results in 536 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Survival Analysis | 2004 |
Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Lumbar Vertebrae; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Thoracic Vertebrae; Time Factors; Tomography, X-Ray Computed | 2005 |
Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Middle Aged; Salvage Therapy | 2005 |
Double-platinum chemotherapy combined with etoposide in metastatic brain tumor from small cell lung carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Adjuvant; Treatment Outcome | 2005 |
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Etoposide; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Insulin-Like Growth Factor I; Lung Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA, Messenger; Vascular Endothelial Growth Factor A | 2005 |
CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
Topics: Apoptosis; Carcinoma, Small Cell; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Chemokines, CXC; Collagen; Drug Resistance, Neoplasm; Etoposide; Fibronectins; Humans; Integrins; Lung Neoplasms; Peptides; Phosphotyrosine; Receptors, CXCR4; rho GTP-Binding Proteins; Signal Transduction | 2005 |
[Study on the indication of surgical resection of pulmonary metastasis of malignant trophoblastic tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin, beta Subunit, Human; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Administration Schedule; Etoposide; Female; Humans; Hydatidiform Mole, Invasive; Lung; Lung Neoplasms; Methotrexate; Pneumonectomy; Pregnancy; Radiography; Trophoblastic Neoplasms; Uterine Neoplasms | 2005 |
Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Retrospective Studies; Time Factors | 2005 |
Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Etoposide; Fibroblasts; Fibrosarcoma; Lung Neoplasms; Male; Mice; Plasminogen Activator Inhibitor 1 | 2005 |
Cytogenetic damage in lymphocytes of patients undergoing therapy for small cell lung cancer and ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Kinetics; Leukocyte Count; Lung Neoplasms; Lymphocytes; Male; Micronuclei, Chromosome-Defective; Micronucleus Tests; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2005 |
Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Differentiation; Cell Division; Cell Line, Tumor; Cisplatin; Coloring Agents; Down-Regulation; ErbB Receptors; Etoposide; Humans; Interleukin-6; Lung Neoplasms; Neurosecretory Systems; Phosphopyruvate Hydratase; Receptors, Interleukin-6; Recombinant Proteins; Signal Transduction; Tetrazolium Salts; Thiazoles | 2005 |
Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Etoposide; Genes, p53; Humans; Lung Neoplasms; Phenotype | 2005 |
Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 7; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Coumarins; DNA Fragmentation; Etoposide; Genes, p53; Humans; Lung Neoplasms; Oligopeptides; Poly(ADP-ribose) Polymerases; Tumor Suppressor Protein p53; Up-Regulation | 2005 |
[Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diterpenes; Drug Administration Schedule; Etoposide; Germinoma; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Observer Variation; Retroperitoneal Neoplasms; Seminoma; Testicular Neoplasms | 2005 |
Efficacy of two different platinum- or anthracycline-containing chemotherapy regimens for the treatment of small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chi-Square Distribution; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Probability; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids | 2005 |
[Chemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies | 2005 |
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Creatinine; Cyclophosphamide; Decision Making; Etoposide; Female; Humans; Lung Neoplasms; Male; Medical Records; Middle Aged; Multiple Organ Failure; Neoplasm Staging; Paclitaxel; Platelet Count; Survival Rate; Treatment Outcome | 2005 |
Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Treatment Outcome; Vindesine | 2005 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Modification of thermosensitivity by amrubicin or amrubicinol in human lung adenocarcinoma A549 cells and the kinetics of apoptosis and necrosis induction.
Topics: Adenocarcinoma; Anthracyclines; Apoptosis; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Synergism; Etoposide; Hot Temperature; Humans; Lung Neoplasms; Necrosis; Time Factors | 2005 |
Prophylactic cranial irradiation in limited-stage small-cell lung cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Hospitals, Community; Humans; Lung Neoplasms; Male; Middle Aged; North Dakota; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Treatment Refusal | 2004 |
Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Carcinoma, Small Cell; Cell Proliferation; Etoposide; Extracellular Signal-Regulated MAP Kinases; Growth Substances; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Membrane Microdomains; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; ras Proteins; Signal Transduction; Simvastatin; Tumor Cells, Cultured; Up-Regulation | 2006 |
[Combined radiochemotherapy in localised small-cell lung cancer. Concurrent treatment protocols?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Esophagitis; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Radiation Pneumonitis; Radiotherapy; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
[Small cell carcinoma of the bladder: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Urinary Bladder Neoplasms; Urinary Diversion | 2005 |
Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Binding Sites; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Silencing; HCT116 Cells; Humans; Introns; Lung Neoplasms; Membrane Glycoproteins; Promoter Regions, Genetic; Protein Binding; Receptors, Tumor Necrosis Factor; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Transcriptional Activation; Transfection; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2005 |
[Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Period; Survival Rate | 2005 |
Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Male; Nerve Sheath Neoplasms; Neurofibromatosis 1; Peripheral Nervous System Neoplasms; Retroperitoneal Neoplasms | 2005 |
Is radiotherapy optimally combined with chemotherapy in elderly patients with limited-stage small-cell lung cancer?
Topics: Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Middle Aged; Treatment Outcome | 2005 |
Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cytoplasm; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Gene Expression Profiling; Humans; Lung Neoplasms; Tumor Cells, Cultured | 2005 |
[Yolk sac tumor of the anterior mediastinum and pulmonary metastases; report of a case].
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Endodermal Sinus Tumor; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Ifosfamide; Lung Neoplasms; Mediastinal Neoplasms; Positron-Emission Tomography; Superior Vena Cava Syndrome | 2005 |
[Thymic cancer effectively treated by combination chemotherapy of carboplatin and etoposide with concurrent radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Thymectomy; Thymus Neoplasms | 2005 |
Term delivery choriocarcinoma patient with brain and lung metastases successfully treated by etoposide, methotrexate, actomycin D, cyclophosphamide and vincristine (EMA-CO) chemotherapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lung Neoplasms; Methotrexate; Pregnancy; Uterine Neoplasms; Vincristine | 2005 |
Treatment of unresectable nonsmall-cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Treatment Outcome; Vincristine | 1989 |
Choriocarcinoma with markedly elevated serum hCG levels and negative urine hCG levels.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin, beta Subunit, Human; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lung Neoplasms; Methotrexate; Pregnancy; Treatment Outcome; Uterine Neoplasms; Vincristine | 2006 |
ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Small Cell; Cell Adhesion; Cell Cycle; Cell Line, Tumor; DNA Damage; Etoposide; Extracellular Matrix; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Integrin beta1; Laminin; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Vanadates | 2006 |
The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysi
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Enzyme Inhibitors; Etoposide; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Hypoxia; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ultraviolet Rays | 2006 |
MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Forecasting; Genes, MDR; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic | 2006 |
[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
Massive hemoptysis as a rare presentation of metastatic choriocarcinoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchoalveolar Lavage Fluid; Bronchoscopy; Choriocarcinoma; Chorionic Gonadotropin; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hemoptysis; Humans; Liver Neoplasms; Lung Neoplasms; Radiography, Thoracic; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Uterine Neoplasms | 2006 |
Third-line chemotherapy for small cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors | 2006 |
Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Chromones; Enzyme Inhibitors; Etoposide; Flavonoids; Flow Cytometry; Humans; Indoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mitosis; Morpholines; Nocodazole; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine; Wortmannin | 2006 |
Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Curcumin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione Transferase; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Rhodamines; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Verapamil; Vinblastine | 2006 |
Metastatic choriocarcinoma successfully treated with paclitaxel and carboplatin after interstitial lung disease induced by EMA-CO.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Methotrexate; Paclitaxel; Uterine Neoplasms; Vincristine | 2006 |
[Intrapericardial infusion of etoposide and cisplatin in treating malignant pericardial effusion of non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Pericardial Effusion; Pericardiocentesis; Survival Rate | 2006 |
Prognostic factors in pleuro-pulmonary blastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dactinomycin; Disease Progression; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Pleural Neoplasms; Pneumonectomy; Prognosis; Pulmonary Blastoma; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Second-Look Surgery; Treatment Outcome; Vincristine | 2007 |
Reponses to topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Enzyme Inhibitors; Etoposide; Humans; Lung Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2006 |
Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Cloning, Molecular; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lung Neoplasms; Male; Neoplasm Proteins; RNA, Messenger; RNA, Small Interfering; Transfection | 2006 |
Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cost-Benefit Analysis; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Middle Aged; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; State Medicine; Survival Analysis | 2006 |
Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2006 |
[Current data concerning neoadjuvant chemotherapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Ifosfamide; Lung; Lung Neoplasms; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk; Time Factors | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
[Collision cancer of squamous cell carcinoma and small cell carcinoma of the lung; report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Pneumonectomy | 2006 |
[A case of primary choriocarcinoma of the mediastinum in a Japanese woman].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Cisplatin; Etoposide; Female; Humans; Japan; Lung Neoplasms; Mediastinal Neoplasms | 2006 |
Treatment and prognosis of post term choriocarcinoma in The Netherlands.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cohort Studies; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Hydatidiform Mole; Liver Neoplasms; Lung Neoplasms; Methotrexate; Netherlands; Pregnancy; Prognosis; Retrospective Studies; Uterine Neoplasms; Vincristine | 2006 |
Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Pleural Diseases; Pneumonectomy; Pneumonia; Pneumonia, Aspiration; Postoperative Complications; Pulmonary Embolism; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Tract Fistula; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells.
Topics: Apoptosis; CDC2 Protein Kinase; Cyclin A; Cyclin A1; Cyclin A2; DNA, Neoplasm; Etoposide; Female; G2 Phase; Gene Expression Profiling; Humans; Kidney Neoplasms; Lung Neoplasms; Mitosis; Mutation; Ovarian Neoplasms; Polyploidy; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2006 |
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Small Cell; Cell Line; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase C-epsilon; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein | 2006 |
Small-cell lung cancer with lymphadenopathy in an 18-year-old female nonsmoker.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Diagnosis, Differential; Etoposide; Female; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Diseases; Lymphatic Metastasis; Mediastinal Neoplasms; Neoplasm Staging; Pneumonectomy; Radiotherapy, Adjuvant; Smoking | 2006 |
Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane.
Topics: Adrenal Cortex Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Mitotane; Tomography, X-Ray Computed | 2006 |
Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Fatal Outcome; Humans; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Male; Middle Aged | 2006 |
Lung cell fiber evanescent wave spectroscopic biosensing of inhalation health hazards.
Topics: Air Pollutants; Alkylating Agents; Biosensing Techniques; Cell Line, Tumor; Cells, Immobilized; Epithelial Cells; Etoposide; Fiber Optic Technology; Gliotoxin; Humans; Inhalation Exposure; Lung Neoplasms; Methyl Methanesulfonate; Mycotoxins; Nucleic Acid Synthesis Inhibitors; Optical Fibers; Spectroscopy, Fourier Transform Infrared | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Thoracic radiation therapy in limited stage small-cell lung cancer: timing is everything...isn't it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Etoposide; Humans; London; Lung Neoplasms; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Staging; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Treatment Outcome; Vincristine | 2006 |
[Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome; Turkey | 2006 |
Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Vault Ribonucleoprotein Particles | 2006 |
A case of metastatic testicular cancer complicated by tumour lysis syndrome and choriocarcinoma syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Cisplatin; Drug Administration Schedule; Etoposide; Hemorrhage; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Radiography, Abdominal; Seminoma; Taxoids; Testicular Neoplasms; Tomography, X-Ray Computed; Tumor Lysis Syndrome | 2006 |
The anti-apoptotic livin gene is an important determinant for the apoptotic resistance of non-small cell lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Etoposide; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Neoplasm Proteins; RNA Interference; RNA, Small Interfering; Transfection; Tumor Stem Cell Assay; Ultraviolet Rays | 2006 |
[A non-seminomatous extra-gonadal germ cell tumor responding to intensive treatment: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Retroperitoneal Neoplasms | 2006 |
[Chemotherapy treatment for anti-Hu paraneoplastic syndrome without active malignancy].
Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Encephalitis; Etoposide; Humans; Infant; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Cerebellar Degeneration; Treatment Outcome | 2006 |
The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Fever; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Treatment Outcome | 2006 |
Invited commentary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Lung Neoplasms; Pneumonectomy; Survival Analysis | 2006 |
[Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Particle Accelerators; Radioisotope Teletherapy; Radiotherapy, Conformal; Radiotherapy, High-Energy; Retrospective Studies; Survival Analysis | 2006 |
[A case of non-small cell lung cancer in which complete response was achieved with chemotherapy including cisplatin, vinorelbine, mitomycin C, followed by additional cisplatin, etoposide and concurrent radiotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Mitomycin; Neoplasm Staging; Pneumonectomy; Remission Induction; Vinblastine; Vinorelbine | 2006 |
[Complete resection of Pancoast tumor while receiving preoperative concurrent chemoradiotherapy (CCRT) as an induction therapy--report of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Pancoast Syndrome; Pneumonectomy; Preoperative Care; Remission Induction | 2006 |
[Choriocarcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Postpartum Period; Pregnancy; Radiography, Thoracic; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Uterine Neoplasms | 2006 |
The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Vault Ribonucleoprotein Particles | 2006 |
Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Survival Rate | 2007 |
[Pulmonary and pleural manifestations of multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Humans; Immunoglobulin G; Immunoglobulin lambda-Chains; Lung; Lung Neoplasms; Male; Multiple Myeloma; Plasma Cells; Pleura; Pleural Effusion, Malignant; Pleural Neoplasms; Prednisone; Vincristine | 2006 |
[Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Etoposide; Female; France; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2006 |
[Role of radiotherapy of lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
Data acquisition for the histoculture drug response assay in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Probability; Retrospective Studies; Sensitivity and Specificity; Tumor Cells, Cultured | 2007 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biphenyl Compounds; Carboplatin; Carcinoma, Small Cell; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Nitrophenols; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Sulfonamides; Transfection; Up-Regulation | 2007 |
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carboplatin; Carcinoma, Large Cell; Chromatography, Gel; Etoposide; Female; Human Growth Hormone; Humans; Hypoglycemia; Immunohistochemistry; In Situ Hybridization; Insulin; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paraneoplastic Endocrine Syndromes; Reverse Transcriptase Polymerase Chain Reaction; RNA | 2007 |
Mid-course thoracic radiotherapy with cisplatin-etoposide chemotherapy in limited-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Retrospective Studies; Survival Analysis; Survival Rate | 2006 |
[A case of recurrent Helicobacter cinaedi-associated bacteremia in a small cell lung cancer patient during chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Helicobacter Infections; Humans; Immunocompromised Host; Lung Neoplasms; Male; Middle Aged; Recurrence | 2007 |
Identification of uPAR-positive chemoresistant cells in small cell lung cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Fluorouracil; Humans; Hyaluronan Receptors; Lung Neoplasms; Neoplasm Proteins; Neoplastic Stem Cells; Phenotype; Receptors, Urokinase Plasminogen Activator; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urokinase-Type Plasminogen Activator | 2007 |
Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan | 2007 |
Association between anemia arising during therapy and outcomes of chemoradiation for limited small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Ontario; Prevalence; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Prospective Studies; Survival Analysis | 2007 |
Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Neoadjuvant Therapy; Neuroectodermal Tumors, Primitive; Pelvic Bones; Peripheral Blood Stem Cell Transplantation; Remission Induction; Risk; Sarcoma, Ewing; Scapula; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2007 |
Syndrome of inappropriate antidiuretic hormone secretion and ectopic ACTH production in small cell lung carcinoma.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Immunohistochemistry; Inappropriate ADH Syndrome; Lung Neoplasms; Middle Aged; Radiography; Remission Induction | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Small Cell; Central Nervous System Neoplasms; Combined Modality Therapy; Dementia; Etoposide; Female; Humans; Lung Neoplasms; Memory Disorders; Radiotherapy | 2007 |
Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Netherlands; Neuroectodermal Tumors, Primitive, Peripheral; Retrospective Studies; Sarcoma, Ewing; Survival Analysis; Treatment Outcome; Vincristine | 2007 |
[Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Pneumonectomy; Prognosis; Remission Induction | 2007 |
Isolated metastasis of lung cancer to the thyroid gland.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Small Cell; CD56 Antigen; Chemotherapy, Adjuvant; Chromogranin A; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Thyroid Neoplasms | 2007 |
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan | 2008 |
Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Preoperative Care; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 2007 |
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Biphenyl Compounds; Butylated Hydroxytoluene; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis; Etoposide; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Nitrophenols; Paclitaxel; Permeability; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides | 2007 |
[Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Pyridostigmine Bromide; Treatment Outcome | 2007 |
Case report: clozapine given in the context of chemotherapy for lung cancer.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Carcinoma, Small Cell; Cisplatin; Clozapine; Comorbidity; Cooperative Behavior; Drug Interactions; Etoposide; Humans; Leukocyte Count; Lung Neoplasms; Neoplasm Staging; Palliative Care; Patient Care Team; Quality of Life; Referral and Consultation; Remission Induction; Schizophrenia, Paranoid | 2008 |
Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cause of Death; Combined Modality Therapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Analysis; Sweden; Treatment Outcome | 2007 |
Oral etoposide-induced leucocytoclastic vasculitis in a patient with lung carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Synergism; Etoposide; Female; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Pyrimidines; Transplantation, Heterologous | 2007 |
Transurethral drainage for prostatic abscess in a patient with metastatic testicular cancer undergoing systemic chemotherapy.
Topics: Abscess; Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Ceftazidime; Cisplatin; Drainage; Etoposide; Humans; Immunocompromised Host; Lung Neoplasms; Male; Meropenem; Orchiectomy; Prostatic Diseases; Pseudomonas Infections; Testicular Neoplasms; Thienamycins; Transurethral Resection of Prostate | 2007 |
Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Caspases; Drug Evaluation, Preclinical; Etoposide; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Models, Biological; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2008 |
[Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Poland; Quality of Life; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine | 2007 |
Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Hypoxia; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Lung Neoplasms; Neoplasm Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Transcription, Genetic; Tumor Suppressor Protein p53 | 2007 |
Gestational choriocarcinoma: morphological features in a liquid-based endometrial cytological sample.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Dactinomycin; Doxorubicin; Endometrium; Etoposide; Female; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Pregnancy; Uterine Neoplasms; Vincristine | 2008 |
Successful treatment of small cell lung cancer during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Pregnancy; Pregnancy Complications | 2008 |
[A case of long-term survival of postoperative brain metastasis of small cell lung cancer effectively treated with chemotherapy, whole brain radiotherapy and stereotactic radiosurgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Radiosurgery; Time Factors; Tomography, X-Ray Computed | 2008 |
[A patient with small cell lung cancer who developed a drug eruption due to concomitant therapy with carboplatin and etoposide].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Eruptions; Etoposide; Humans; Lung Neoplasms; Male | 2008 |
Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Treatment Outcome | 2008 |
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Carcinoma, Small Cell; Caspase 3; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Etoposide; Humans; Lung Neoplasms; Mice; Mice, Nude; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Xenograft Model Antitumor Assays | 2008 |
Caecal metastasis from a primary small-cell lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Stem Neoplasms; Carboplatin; Carcinoma, Small Cell; Cecal Neoplasms; Cecum; Colonoscopy; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged | 2008 |
Diseases desperate grown.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Randomized Controlled Trials as Topic; Research Design; Sample Size; Treatment Outcome | 2008 |
[Erythropoietic protein supportive treatment in small cell lung cancer].
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Erythropoietin; Etoposide; Female; Hematinics; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2008 |
Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Etoposide; Genes, p53; Genotype; Humans; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Predictive Value of Tests; Prospective Studies; Radiotherapy, Adjuvant; Treatment Outcome | 2008 |
Full-length cytokeratin 8 is released and circulates in patients with non-small cell lung cancer.
Topics: Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Etoposide; Humans; Keratin-8; Lung Neoplasms | 2008 |
Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Transplantation, Autologous | 1984 |
Pulmonary blastoma: remission with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pneumonectomy; Vincristine | 1984 |
[3 multicenter phase II studies of the treatment of small cell bronchogenic carcinoma (incl. AIO studies BI + BII)].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Vinblastine; Vincristine; Vindesine | 1984 |
[A combination chemotherapy consisting of vincristine, etoposide and cyclophosphamide (VEC) for small cell carcinoma of the lung].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1984 |
Remission of brain metastases from small-cell lung cancer after high-dose chemotherapy.
Topics: Brain Neoplasms; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1984 |
Pilot studies of superfractionated radiotherapy and combination chemotherapy in limited oat cell carcinoma of the bronchus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Procarbazine; Radiotherapy Dosage; Vincristine | 1984 |
Phase II trial of etoposide in previously treated small cell carcinoma of the lung.
Topics: Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Podophyllotoxin | 1984 |
Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Podophyllotoxin | 1984 |
Adriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1984 |
Cisplatin and etoposide combination in the treatment of bronchogenic carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Middle Aged | 1984 |
Etoposide: a new anti-cancer agent.
Topics: Animals; Drug Evaluation; Etoposide; Female; Humans; Kinetics; Lung Neoplasms; Male; Mitosis; Neoplasms; Podophyllotoxin; Testicular Neoplasms | 1981 |
Further advances in the management of malignant teratomas of the testis and other sites.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin; Cyclophosphamide; Cytarabine; Dactinomycin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Methotrexate; Neoplasm Staging; Prognosis; Retroperitoneal Neoplasms; Teratoma; Testicular Neoplasms; Vincristine | 1983 |
Prospective study of follow up alone in stage I teratoma of the testis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Castration; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Prednisolone; Prospective Studies; Teratoma; Testicular Neoplasms; Vinblastine; Vindesine | 1983 |
Recurrent testis cancer: seeding from retroperitoneal nodes after complete remissions by chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Seeding; Neoplasms, Germ Cell and Embryonal; Retroperitoneal Space; Testicular Neoplasms; Vinblastine | 1983 |
Potential therapeutic and diagnostic applications of the growth of testicular cancer in soft agar.
Topics: Agar; alpha-Fetoproteins; Chorionic Gonadotropin; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Retroperitoneal Neoplasms; Testicular Neoplasms; Vinblastine | 1983 |
Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Prognosis; Vinblastine; Vindesine | 1984 |
Progress in chemotherapy of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dianhydrogalactitol; Doxorubicin; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Prognosis; Random Allocation; Vinblastine; Vindesine | 1984 |
Smoking abstinence and small cell lung cancer survival. An association.
Topics: Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Prognosis; Smoking; Thymosin; Vincristine | 1980 |
Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung.
Topics: Aged; Agranulocytosis; Alopecia; Antineoplastic Agents; BCG Vaccine; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Prognosis; Prospective Studies; Vomiting | 1980 |
Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1981 |
VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy.
Topics: Adult; Aged; Carcinoma, Small Cell; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1981 |
Treatment of small cell carcinoma of lung with combined high dose mediastinal irradiation, whole brain prophylaxis and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Radiotherapy, High-Energy; Vincristine | 1981 |
Possible enhancement of vincristine neuropathy by VP-16.
Topics: Aged; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Electrophysiology; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Muscles; Nervous System Diseases; Peripheral Nerves; Podophyllotoxin; Vincristine | 1982 |
Tumor size, response rate, and prognosis in small cell carcinoma of the bronchus treated by combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Inappropriate ADH Syndrome; Leucovorin; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged | 1982 |
Alternating non-cross-resistant combination chemotherapy for small cell anaplastic carcinoma of the lung.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Methotrexate; Vincristine | 1982 |
Non-cross-resistant chemotherapy and consolidation radiotherapy for small cell carcinoma of the lung.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prognosis; Vincristine | 1982 |
Treatment of small cell lung cancer with a combination of VP16-213 and cyclophosphamide with cisplatin or radiotherapy.
Topics: Adult; Aged; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Time Factors | 1982 |
Vincristine, Adriamycin, cyclophosphamide, and etoposide (VP16-213) in small-cell anaplastic carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1982 |
VP16-213 combined with cis-platinum (CDDP) in the treatment of small cell carcinoma of the lung (SCLC).
Topics: Adult; Aged; Carcinoma, Small Cell; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1982 |
Chemotherapy combination with cyclophosphamide (CTX) adriamycin (ADM), vincristine (VCR), and VP16-213 in small cell carcinoma of the lung (SCCL).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1982 |
[Prevention of recurrence of small-cell lung cancer by adjuvant polychemotherapy (author's transl)].
Topics: Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lomustine; Lung Neoplasms; Methotrexate; Neoplasm Recurrence, Local; Vincristine | 1982 |
Enhanced radiation reaction following combination chemotherapy for small cell carcinoma of the lung, possibly secondary to VP16-213.
Topics: Aged; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Radiotherapy; Vincristine | 1982 |
VP16-213 in combined modality treatment of small cell carcinoma of the lung.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Methotrexate; Nausea; Neoplasm Staging; Podophyllotoxin | 1982 |
Small-cell bronchogenic carcinoma--primary and relapse therapy with etoposide (VP-16), methotrexate and CCNU.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Drug Therapy, Combination; Etoposide; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin | 1982 |
Etoposide after ACO treatment for small-cell bronchogenic carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Podophyllotoxin; Vincristine | 1982 |
Etoposide as single agent and in combination chemotherapy of bronchogenic carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1982 |
Combination cis-platinum and etoposide in small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Small Cell; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1982 |
Combination chemotherapy of small-cell bronchogenic carcinoma with etoposide (VP-16), ifosfamide and vindesine (VPIV), and with adriamycin, cis-platinum and vincristine (APO).
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Podophyllotoxin; Vinblastine; Vincristine; Vindesine | 1982 |
Small cell lung cancer. Serial bronchofiberscopy and photographic documentation--the bridge sign.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bronchoscopy; Carcinoma, Small Cell; Cicatrix; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Fiber Optic Technology; Humans; Ifosfamide; Lomustine; Lung Neoplasms; Methotrexate; Prospective Studies; Vincristine | 1983 |
VP-16 plus cyclophosphamide in the treatment of advanced lung cancer.
Topics: Adult; Aged; Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Probability | 1983 |
[Late intensive chemotherapy with bone marrow autograft. Pilot study in small cell bronchial cancer].
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects | 1983 |
High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Bone Marrow Transplantation; Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1983 |
Etoposide in small cell lung cancer resistant to prior chemotherapy.
Topics: Carcinoma, Small Cell; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1983 |
High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung.
Topics: Adult; Aged; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1983 |
VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Thrombocytopenia; Time Factors | 1984 |
Chemotherapy of refractory germ cell cancer with Etoposide.
Topics: Adolescent; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Choriocarcinoma; Cisplatin; Dysgerminoma; Etoposide; Humans; Lung Neoplasms; Male; Mesonephroma; Nausea; Neoplasms, Germ Cell and Embryonal; Podophyllotoxin; Retroperitoneal Neoplasms; Testicular Neoplasms | 1983 |
Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.
Topics: Adult; Aged; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Humans; Injections, Intravenous; Lung Neoplasms; Middle Aged; Podophyllotoxin; Tomography, X-Ray Computed | 1984 |
Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Environment, Controlled; Etoposide; Female; Humans; Ifosfamide; Leukocyte Count; Lung Neoplasms; Male; Mediastinal Neoplasms; Methotrexate; Middle Aged; Procarbazine; Vincristine | 1984 |
[Multidisciplinary treatment for small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Nimustine; Nitrosourea Compounds; Vincristine | 1984 |
Cyclic alternating combination chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Time Factors; Vincristine | 1984 |
Etoposide (VP 16-213; VePesid).
Topics: Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Male; Podophyllotoxin; Testicular Neoplasms | 1984 |
[Effects of oral etoposide in small cell carcinoma of the lung].
Topics: Administration, Oral; Adult; Aged; Capsules; Carcinoma, Small Cell; Etoposide; Humans; Leukopenia; Lung Neoplasms; Male; Nausea; Podophyllotoxin; Thrombocytopenia | 1984 |
Etoposide infusions for treatment of metastatic lung cancer.
Topics: Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Etoposide; Follow-Up Studies; Humans; Infusions, Parenteral; Kinetics; Lung Neoplasms; Neoplasm Metastasis; Podophyllotoxin | 1984 |
[Treatment of bronchopulmonary small cell carcinoma with a combination of cyclophosphamide and VP-16].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1984 |
VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fever; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms, Germ Cell and Embryonal | 1984 |
[Results of drug therapy of inoperable non-small cell lung carcinoma with VP 16-213 (Etoposide) and cis-platin. A phase II study].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1983 |
Pharmacokinetic studies in lung cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Naphthacenes; Organoplatinum Compounds | 1984 |
[Effect of etoposide for pulmonary metastases from urogenital tract cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Carcinoma, Transitional Cell; Etoposide; Humans; Infusions, Parenteral; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Prostatic Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 1984 |
Etoposide by oral route in the treatment of unresectable non-small cell lung cancer.
Topics: Administration, Oral; Aged; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1984 |
Trial of vindesine, etoposide, and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cisplatin; Dogs; Drug Administration Schedule; Drug Evaluation; Etoposide; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Time Factors; Vinblastine; Vindesine | 1984 |
cis-Platinum (DDP) and VP 16-213 (etoposide) combination chemotherapy for advanced non-small cell lung cancer. A phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Atelectasis; Time Factors | 1984 |
Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Thrombocytopenia | 1984 |
Warfarin, etoposide, and vindesine interactions.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interactions; Etoposide; Humans; Lung Neoplasms; Male; Prothrombin Time; Vinblastine; Vindesine; Warfarin | 1984 |
[Phase I study of an oral administration of VP 16-213].
Topics: Administration, Oral; Adult; Aged; Capsules; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Podophyllotoxin | 1983 |
Stevens-Johnson syndrome associated with etoposide therapy.
Topics: Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Stevens-Johnson Syndrome | 1983 |
cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1983 |
Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship.
Topics: Adenocarcinoma; Cell Line; Cell Survival; DNA; DNA Repair; Etoposide; Humans; Kinetics; Lung Neoplasms; Podophyllotoxin; Structure-Activity Relationship; Teniposide | 1984 |
Chemotherapy-induced interstitial pneumonitis during treatment of small cell anaplastic lung cancer.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Cyclophosphamide; Etoposide; Female; Humans; Hypoxia; Lung Neoplasms; Male; Methotrexate; Middle Aged; Pulmonary Fibrosis; Serologic Tests | 1984 |
[Etoposide effect on cell cycle kinetics of a human lung cancer cell line].
Topics: Cell Count; Cell Cycle; Cell Division; Cell Line; Cell Survival; DNA, Neoplasm; Etoposide; Flow Cytometry; Humans; Lung Neoplasms; Podophyllotoxin | 1984 |
Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma.
Topics: Animals; Cell Cycle; Cell Line; DNA, Neoplasm; Etoposide; Flow Cytometry; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Podophyllotoxin | 1983 |
In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma.
Topics: Animals; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Etoposide; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms, Experimental; Podophyllotoxin; Thymidine | 1982 |
A review of etoposide in patients with non-small-cell lung cancer (NSCLC).
Topics: Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin | 1982 |
Etoposide alone and in combination with cyclophosphamide, adriamycin and cis-platinum in patients with Mo and Mi non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Podophyllotoxin | 1982 |
Etoposide and cis-platinum in non-small-cell bronchogenic carcinoma.
Topics: Carcinoma, Bronchogenic; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin | 1982 |
Treatment of inoperable non-small-cell bronchogenic carcinoma with etoposide and cis-platinum.
Topics: Carcinoma, Bronchogenic; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1982 |
Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Middle Aged; Podophyllotoxin | 1982 |
Phase II trial of VP-16-213 in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Squamous Cell; Digestive System; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1982 |
Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.
Topics: Animals; Etoposide; Kinetics; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Podophyllotoxin; Tissue Distribution | 1982 |
Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1982 |
VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Podophyllotoxin | 1982 |
Etoposide--an effective single drug for treating bronchogenic carcinoma.
Topics: Bone Marrow; Carcinoma, Bronchogenic; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1982 |
[Etoposide: VP-16].
Topics: Etoposide; Humans; Lung Neoplasms; Lymphoma; Neoplasms; Podophyllotoxin | 1982 |
Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.
Topics: Brain Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Dianhydrogalactitol; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Pilot Projects; Podophyllotoxin; Sugar Alcohols | 1981 |
[Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Topics: Adenocarcinoma; Body Weight; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Leukocyte Count; Lung Neoplasms; Podophyllotoxin; Vomiting | 1981 |
Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.
Topics: Bone Marrow Diseases; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Methotrexate; Podophyllotoxin; Vincristine | 1981 |
Oral VP-16-213 in advanced bronchogenic carcinoma.
Topics: Bone Marrow Diseases; Carcinoma, Bronchogenic; Drug Combinations; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Vincristine | 1981 |
Patient with extensive small cell lung cancer given moderately dose-intensified chemotherapy and peripheral blood stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Vincristine | 1995 |
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cladribine; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; In Vitro Techniques; Leukemia; Lung Neoplasms; Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured; Urogenital Neoplasms | 1995 |
[Lhermitte's sign and cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Head; Humans; Lung Neoplasms; Male; Movement; Radiotherapy, Adjuvant | 1995 |
[A case of stage IIIB2 infantile yolk sac tumor of testis achieved complete remission by "COMPE" chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Endodermal Sinus Tumor; Etoposide; Humans; Infant; Lung Neoplasms; Male; Methotrexate; Peplomycin; Remission Induction; Testicular Neoplasms; Vincristine | 1993 |
[Lung residuals following chemotherapy in patients with stage III nonseminomatous testicular cancer. Report of 4 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Germinoma; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Peplomycin; Testicular Neoplasms; Thoracotomy; Vincristine | 1994 |
[A case of testicular cancer in which complete response was achieved with chemotherapy including cisplatin, etoposide and bleomycin, and salvage surgery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Embryonal; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Orchiectomy; Remission Induction; Salvage Therapy; Testicular Neoplasms | 1994 |
Metastatic adamantinoma of bone to lung. A case report of the natural history and the use of chemotherapy and radiation therapy.
Topics: Ameloblastoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Postoperative Care; Radiotherapy Dosage; Tibia | 1994 |
Cardiac arrhythmia and ischaemic events after combination chemotherapy for testicular cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Bleomycin; Cisplatin; Electrocardiography; Electrocardiography, Ambulatory; Etoposide; Germinoma; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Myocardial Ischemia; Testicular Neoplasms; Vinblastine | 1994 |
Osteosarcoma following radiation treatment for meningioma: report of a case and effective treatment with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Dactinomycin; Etoposide; Female; Gonadotropin-Releasing Hormone; Humans; Ifosfamide; Lung Neoplasms; Meningeal Neoplasms; Meningioma; Methotrexate; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Osteosarcoma; Tamoxifen; Tomography, X-Ray Computed; Vincristine | 1994 |
The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Palliative Care; Thrombocytopenia | 1995 |
A complicated case of metastatic teratoma. Growing teratoma syndrome and cerebral metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Occipital Lobe; Orchiectomy; Remission Induction; Teratocarcinoma; Testicular Neoplasms; Thoracotomy; Vincristine | 1995 |
[Spontaneous pneumothorax in response to chemotherapy of metastatic germinal tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Mediastinal Neoplasms; Methotrexate; Pneumothorax; Testicular Neoplasms; Vincristine | 1995 |
Dosing of oral etoposide normalized for body surface area.
Topics: Administration, Oral; Adult; Aged; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
A marrow harvest procedure under local anesthesia.
Topics: Anesthesia, Local; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carmustine; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Mitoxantrone; Outpatients; Pain Measurement; Thiotepa; Tissue Preservation; Transplantation, Autologous | 1995 |
Early alternating chemotherapy and radiotherapy schedule in limited disease stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 1995 |
Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent.
Topics: Abdominal Muscles; Abdominal Neoplasms; Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Combined Modality Therapy; Drug Screening Assays, Antitumor; Etoposide; Female; Fibrinolysin; Glycoproteins; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; Specific Pathogen-Free Organisms; Trypsin Inhibitors | 1995 |
Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Endothelium, Vascular; Etoposide; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mitoxantrone; Neoplasm Transplantation; Neovascularization, Pathologic; Rats | 1995 |
Fatal pulmonary toxicity following oral etoposide therapy.
Topics: Administration, Oral; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis | 1995 |
Ifosfamide, carboplatin and etoposide for good prognosis small cell lung cancer: are four courses inadequate? West of Scotland Lung Cancer Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 1995 |
Influence of systemic chemotherapy on anti-P-glycoprotein antibody-dependent cell-mediated cytotoxicity in patients with small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Humans; Interleukin-2; Lung Neoplasms; Macrophage Colony-Stimulating Factor; Tumor Cells, Cultured | 1995 |
An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Drug Resistance; Drug Resistance, Multiple; Etoposide; Gene Expression; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Multidrug Resistance-Associated Proteins; Phenotype; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Gestational choriocarcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lung Neoplasms; Methotrexate; Postpartum Period; Pregnancy; Prognosis; Spinal Neoplasms; Uterine Neoplasms; Vincristine | 1995 |
Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Pneumonectomy; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Thoracotomy | 1995 |
[Benign enlargement of the thymus after chemotherapy of metastasizing testicular cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms; Thymus Hyperplasia; Tomography, X-Ray Computed | 1993 |
[Chemotherapy for older cancer patients].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Floxuridine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Neoplasms, Multiple Primary; Palliative Care; Quality of Life | 1993 |
A limited sampling method for estimation of the etoposide area under the curve.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Models, Biological; Regression Analysis | 1993 |
Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Adjuvant; Thrombocytopenia | 1995 |
Dose intensity of the CAVE regimen in small cell lung cancer correlates to response rate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Analysis; Vincristine | 1994 |
[A case of small cell lung cancer with renal insufficiency effectively treated with oral etoposide administration].
Topics: Administration, Oral; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Heart Failure; Humans; Lung Neoplasms; Remission Induction; Renal Insufficiency | 1995 |
Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance.
Topics: ATP-Binding Cassette Transporters; Base Sequence; Biological Transport; Carcinoma, Small Cell; Cell Division; Cell Line; Cell Membrane; Daunorubicin; DNA Primers; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Multiple; Etoposide; Gene Expression; Humans; Lung Neoplasms; Membrane Proteins; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Phosphorylation; Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vincristine | 1995 |
[Carboplatin-VP16 combination in non small cell lung cancers in the aged patient. A study of the French group in pneumology (GFPC)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; France; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1995 |
Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Nucleus; Cricetinae; Cricetulus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Drug Resistance; Etoposide; Fibrosarcoma; Lung Neoplasms; Neoplasm Proteins; Suramin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Surgical treatment of small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Vincristine | 1995 |
Severe, disabling neurologic toxicity following cisplatin retreatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Cerebrovascular Disorders; Cisplatin; Cognition Disorders; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms | 1995 |
The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function.
Topics: Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Regression Analysis; Vindesine | 1995 |
Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16.
Topics: Aclarubicin; Animals; Carcinoma, Small Cell; DNA Damage; DNA, Neoplasm; Etoposide; Humans; Lung Neoplasms; Mice; Time Factors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Etoposide; Feasibility Studies; Follow-Up Studies; Humans; Linear Models; Lung Neoplasms; Programming Languages; Research Design; Sensitivity and Specificity; Software; Survival Rate; Topotecan | 1995 |
Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Regression Analysis | 1995 |
[Response rate of small cell lung cancer treated with CE-CAP alternating chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1994 |
Uterine myxoid leiomyosarcoma and CYVADIC-etoposide therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Epirubicin; Etoposide; Fatal Outcome; Female; Humans; Hysterectomy; Immunohistochemistry; Leiomyosarcoma; Lung Neoplasms; Mitotic Index; Treatment Outcome; Uterine Neoplasms; Vincristine | 1994 |
Reversible myocardial ischaemia following vincristine containing chemotherapy.
Topics: Carcinoma, Small Cell; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Middle Aged; Myocardial Ischemia; Vincristine | 1994 |
Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.
Topics: Amsacrine; Antineoplastic Agents; Carcinoma, Small Cell; Cell Fractionation; Cell Line; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Exons; Genes, myc; Humans; Lung Neoplasms; Restriction Mapping; Saline Solution, Hypertonic; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
Topics: Amsacrine; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Etoposide; Humans; Lung Neoplasms; Methylation; RNA, Messenger; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
[Small cell bronchial cancer in a 17-year-old young man].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Metastasis; Pneumonectomy | 1994 |
Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Small Cell; Cell Line; Drug Resistance, Multiple; Etoposide; Gene Expression; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Polymerase Chain Reaction; Proteins; Tumor Cells, Cultured | 1995 |
Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vincristine | 1994 |
[A pilot study of combination chemotherapy with cyclophosphamide, adriamycin, chronic daily dosing of oral etoposide for patients with SCLC ineligible for intensive chemotherapy].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects | 1995 |
The price of success.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Etoposide; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasms, Second Primary | 1995 |
[Therapeutic effect of carboplatin and etoposide combinative therapy on 123 lung cancer cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Humans; Leukopenia; Lung Neoplasms; Middle Aged; T-Lymphocyte Subsets | 1994 |
Prognostic factors in locoregional non-small cell lung cancer treated with radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Vinblastine | 1995 |
Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Carrier Proteins; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Flow Cytometry; Humans; Lung Neoplasms; Male; Membrane Glycoproteins; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Time Factors; Verapamil | 1993 |
Enhanced therapeutic effects of anti-tumour agents against growth and metastasis of colon carcinoma 26 when given in combination with interferon and interleukin-2.
Topics: Animals; Carcinoma; Cisplatin; Colonic Neoplasms; Drug Therapy, Combination; Etoposide; Interferon-beta; Interleukin-2; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis | 1994 |
Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
Topics: Bromodeoxyuridine; Carcinoma, Small Cell; Cell Cycle; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Flow Cytometry; G1 Phase; Genes, p53; Humans; Kinetics; Lung Neoplasms; Mutation; S Phase; Tumor Cells, Cultured | 1994 |
Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide?
Topics: Administration, Oral; Aged; Base Sequence; Carcinoma, Small Cell; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Drug Administration Schedule; Etoposide; Genes; Humans; Leukemia, Myelomonocytic, Acute; Lung Neoplasms; Male; Molecular Sequence Data; Neoplasms, Second Primary; Polymerase Chain Reaction; Translocation, Genetic | 1994 |
In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured | 1994 |
Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.
Topics: Blotting, Northern; Carcinoma, Small Cell; DNA Probes; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Lung Neoplasms; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1994 |
[Immunohistochemical study and treatment result of small cell lung carcinoma using combination chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chromogranin A; Chromogranins; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Phosphopyruvate Hydratase; Prednisone; Prognosis; Remission Induction; Vincristine | 1994 |
Multifocal osteonecrosis following chemotherapy and short-term corticosteroid therapy in a patient with small-cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Dexamethasone; Etoposide; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Osteonecrosis; Radionuclide Imaging | 1994 |
[Successful treatment of refractory extensive small cell lung cancer by oral etoposide].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1994 |
Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP Binding Cassette Transporter, Subfamily B, Member 3; ATP-Binding Cassette Transporters; Base Sequence; Breast Neoplasms; Carcinoma, Small Cell; Carrier Proteins; Cytotoxicity, Immunologic; DNA Primers; Drug Resistance; Etoposide; Female; Gene Expression; HLA Antigens; Humans; Interferon-gamma; Killer Cells, Lymphokine-Activated; Lung Neoplasms; Molecular Sequence Data; Ovarian Neoplasms; Recombinant Proteins; Tumor Cells, Cultured | 1994 |
Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody.
Topics: Action Potentials; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channels; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Humans; Immunoglobulin G; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Muscles; Plasmapheresis | 1994 |
Structural changes of duodenum brush border in lung cancer patients treated with cisplatin plus etoposide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Duodenum; Etoposide; Female; Humans; Lung Neoplasms; Male; Microvilli; Middle Aged | 1993 |
Rapid polymerase chain reaction assay to detect variation in the extent of gene-specific damage between cisplatin- or VP-16-resistant and sensitive lung cancer cell lines.
Topics: Base Sequence; Cisplatin; DNA Damage; Drug Resistance; Etoposide; Humans; Hypoxanthine Phosphoribosyltransferase; Lung Neoplasms; Molecular Sequence Data; Polymerase Chain Reaction; Tumor Cells, Cultured | 1994 |
Consolidative thoracic radiotherapy and prophylactic cranial irradiation in limited disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Lomustine; Lung Neoplasms; Methotrexate; Remission Induction; Survival Analysis; Thorax; Treatment Outcome; Vincristine | 1993 |
Teniposide for meningeal carcinomatosis of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Immunologic Factors; Injections, Spinal; Interferon-gamma; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Morphine; Teniposide; Vincristine | 1993 |
The prognostic significance of bone marrow metastases in small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Survival Analysis | 1993 |
A Bayesian analysis of institutional effects in a multicenter cancer clinical trial.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biometry; Carcinoma, Small Cell; Cyclophosphamide; Data Interpretation, Statistical; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Methotrexate; Multicenter Studies as Topic; Probability; Proportional Hazards Models; Randomized Controlled Trials as Topic; Vincristine | 1994 |
Considerations on radiotherapy dose intensity for limited small cell lung cancer.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Platinum; Radiotherapy Dosage; Time Factors | 1994 |
Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Daunorubicin; DNA Topoisomerases, Type II; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Membrane Glycoproteins; Tumor Cells, Cultured | 1993 |
Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DNA, Neoplasm; Doxorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Female; Flow Cytometry; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1993 |
Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carcinoma, Small Cell; Carrier Proteins; Cell Line; Chromosome Banding; DNA Topoisomerases, Type II; Drug Resistance; Electrophoresis, Polyacrylamide Gel; Etoposide; Gene Deletion; Genetic Markers; Humans; Isoenzymes; Karyotyping; Lung Neoplasms; Membrane Glycoproteins; RNA, Messenger; Tumor Cells, Cultured | 1993 |
Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells.
Topics: Alkaloids; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carrier Proteins; Daunorubicin; Doxorubicin; Drug Resistance; Etoposide; Genistein; Humans; Hydrogen-Ion Concentration; Isoflavones; Lung Neoplasms; Membrane Glycoproteins; Neoplasms; Protein-Tyrosine Kinases; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1993 |
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Topics: Adenocarcinoma; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Colonic Neoplasms; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Flow Cytometry; Humans; Leukemia L1210; Lung Neoplasms; Membrane Glycoproteins; Mice; Novobiocin; Tumor Cells, Cultured | 1993 |
[Leiomyosarcoma of the prostate: response to treatment with cisplatin, etoposide and methotrexate chemotherapy: a case report].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Leiomyosarcoma; Lung Neoplasms; Male; Methotrexate; Prostatic Neoplasms | 1994 |
High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Hemorrhage; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Methotrexate; Middle Aged; Neutropenia; Remission Induction; Survival Rate; Thrombocytopenia | 1994 |
Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate | 1994 |
Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice.
Topics: Animals; Apoptosis; Bone Marrow; Cyclophosphamide; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Lung Neoplasms; Melatonin; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Stem Cells; T-Lymphocytes | 1994 |
Predictive performance of a pharmacodynamic model for oral etoposide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Leukocyte Count; Leukopenia; Lung Neoplasms; Male; Middle Aged; Models, Biological; Prospective Studies | 1994 |
Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Topics: Amsacrine; Animals; Carcinoma, Small Cell; Chloroquine; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydrogen-Ion Concentration; Leukemia L1210; Lung Neoplasms; Mice; Tumor Cells, Cultured | 1994 |
Etoposide-related acral erythema.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Erythema; Etoposide; Hand; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence | 1994 |
Chemotherapy combined with surgery in the treatment of gestational trophoblastic disease (GTD).
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Hydatidiform Mole; Hydroxyurea; Hysterectomy; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Pregnancy; Salvage Therapy; Thoracotomy; Treatment Outcome; Trophoblastic Neoplasms; Uterine Hemorrhage; Uterine Neoplasms; Vincristine | 1993 |
VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1994 |
Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Doxorubicin; Drug Resistance; Etoposide; Humans; Lung Neoplasms; Organoplatinum Compounds; Tumor Cells, Cultured | 1993 |
[Correlations between clinical pharmacodynamics and pharmacokinetics of cisplatin and etoposide].
Topics: Carcinoma, Bronchogenic; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms | 1993 |
[Neoadjuvant chemotherapy effective for small cell lung cancer in a nephrectomized patient].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Renal Cell; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Male; Neoplasms, Second Primary; Nephrectomy | 1993 |
Clinical significance of DNA measurements in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bronchi; Carcinoma, Small Cell; Cisplatin; DNA, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Ploidies; Probability; Prognosis; Remission Induction; Sensitivity and Specificity | 1993 |
Cisplatin, etoposide, and vincristine combination chemotherapy in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1993 |
Clinical trials referral resource. Small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Tamoxifen | 1993 |
[Combination chemotherapy with carboplatin and etoposide against lung adenocarcinoma in a patient undergoing hemodialysis: a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Renal Dialysis | 1993 |
A simulated sequential analysis based on data from two MRC trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Data Interpretation, Statistical; Etoposide; Humans; Lung Neoplasms; Methotrexate; Proportional Hazards Models; Radiotherapy, High-Energy; Randomized Controlled Trials as Topic; Regression Analysis; Research Design; Survival Analysis; Survival Rate; Vincristine | 1993 |
Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Drug Resistance; Etoposide; Harringtonines; Homoharringtonine; Humans; Lung Neoplasms; Tumor Cells, Cultured | 1993 |
Treatment of small cell lung cancer in the elderly.
Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Comorbidity; Cyclophosphamide; Doxorubicin; Effect Modifier, Epidemiologic; Etoposide; Female; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Selection Bias; Survival Rate; Treatment Outcome; Vincristine | 1994 |
[Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 1994 |
Apoptosis induced by etoposide in small-cell lung cancer cell lines.
Topics: Apoptosis; Carcinoma, Small Cell; DNA, Neoplasm; Endonucleases; Etoposide; Humans; Lung Neoplasms; Tumor Cells, Cultured | 1994 |
Acute myeloid leukemia presenting as granulocytic sarcoma of the lung.
Topics: Acute Disease; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Humans; Leukemia, Myeloid; Lung Neoplasms; Male | 1993 |
[Intensive chemotherapy for alveolar soft part sarcoma with lung metastasis in a child].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Sarcoma; Soft Tissue Neoplasms; Vincristine | 1993 |
[A case of drug induced pneumonitis caused by oral etoposide].
Topics: Administration, Oral; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis | 1993 |
[A case of metastatic cancer of the stomach from small cell carcinoma of the lung].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Male; Stomach Neoplasms; Vincristine | 1993 |
Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer.
Topics: Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance | 1993 |
Influence of platelet-derived microparticles on coagulation in a lung cancer patient receiving chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Blood Platelets; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Male; Vincristine | 1993 |
[A new cell line derived from a nude mouse resembling human large cell lung cancer].
Topics: Adult; Animals; Carcinoma, Non-Small-Cell Lung; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Genes, myc; Genes, ras; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Subrenal Capsule Assay; Tumor Cells, Cultured | 1993 |
[In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Division; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Teniposide; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1993 |
Management of small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging; Paraneoplastic Syndromes; Survival Rate | 1993 |
High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Feasibility Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Time Factors | 1993 |
[Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
Topics: Carcinoma, Small Cell; Doxorubicin; Drug Resistance; Etoposide; Humans; Lung Neoplasms; Polymerase Chain Reaction; RNA, Messenger; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 1993 |
Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Vincristine | 1993 |
Unusual presentation and course of Cushing's syndrome due to ectopic ACTH secretion by a bronchial carcinoma.
Topics: ACTH Syndrome, Ectopic; Adult; Carcinoma, Small Cell; Cisplatin; Cushing Syndrome; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms | 1993 |
Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1993 |
[Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
Topics: Antibiotics, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lactones; Lung Neoplasms; Macrolides; Tumor Cells, Cultured | 1993 |
[A combination chemotherapy of carboplatin and etoposide for malignant fibrous histiocytoma with marked effect on the metastatic lung region].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Etoposide; Female; Histiocytoma, Benign Fibrous; Humans; Lung Neoplasms; Soft Tissue Neoplasms | 1993 |
Cisplatin-resistant metastatic hepatoblastoma: complete response to carboplatin, etoposide, and liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Drug Resistance; Etoposide; Female; Humans; Infant; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Remission Induction | 1993 |
Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Interferon Type I; Interferon-gamma; Lung Neoplasms; Recombinant Proteins; Tumor Cells, Cultured | 1993 |
[Antigen phenotype of lung cancer and its relation to chemo-radiosensitivity].
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Small Cell; Cell Survival; Etoposide; Humans; Immunohistochemistry; Immunophenotyping; Lung Neoplasms; Radiotherapy Dosage; Tumor Cells, Cultured | 1993 |
Prolonged oral etoposide in small cell lung cancer.
Topics: Administration, Oral; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms | 1993 |
Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results.
Topics: Administration, Oral; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia | 1993 |
Etoposide and secondary haematological malignancies: coincidence or causality?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Chromosome Aberrations; Chromosome Disorders; Etoposide; Female; Hematologic Diseases; Hodgkin Disease; Humans; Karyotyping; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary | 1993 |
Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis; Tomography, X-Ray | 1993 |
[Antiemetic efficacy of granisetron in patients receiving 5-day continuous infusion of cisplatin].
Topics: Adenocarcinoma; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granisetron; Humans; Indazoles; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Nausea; Vindesine; Vomiting | 1993 |
[Pathology and clinical aspects of peripheral neuroectodermal tumors].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Fatal Outcome; Humans; Ifosfamide; Lung Neoplasms; Male; Neuroectodermal Tumors, Primitive, Peripheral; Neurofilament Proteins; Pancoast Syndrome; Vincristine | 1993 |
[Experimental study on the combined treatment of UFT with etoposide against mouse Lewis lung carcinoma].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; DNA, Neoplasm; Etoposide; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Tegafur; Tumor Cells, Cultured; Uracil | 1993 |
Respiratory failure due to pulmonary lymphangitis carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Male; Middle Aged; Respiratory Insufficiency | 1993 |
[Disease-free survival in a patient with squamous cell lung carcinoma following complete response with the combination chemotherapy of cisplatin and etoposide].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Prognosis; Remission Induction; Tegafur; Uracil | 1993 |
Surgical treatment of small cell carcinoma of the lung: advantage of preoperative chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisone; Preoperative Care; Prognosis; Retrospective Studies; Vincristine | 1995 |
Antitumor activity of treosulfan in human lung carcinomas.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Time Factors | 1996 |
Patient experiences adverse drug reaction to etoposide for adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Etoposide; Humans; Lung Neoplasms; Male | 1995 |
[A case of mycosis fungoides with pulmonary involvement: effect of etoposide and prednisolone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Male; Mycosis Fungoides; Neoplasm Invasiveness; Prednisolone; Skin Neoplasms | 1995 |
[Pulmonary malignant fibrous histiocytoma treated with cisplatin plus etoposide followed by surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Female; Histiocytoma, Benign Fibrous; Humans; Lung Neoplasms; Middle Aged | 1995 |
Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Verapamil | 1995 |
[Leukoencephalopathy in a patient being treated for small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Cranial Irradiation; Etoposide; Humans; Leukoencephalopathy, Progressive Multifocal; Lung Neoplasms; Male; Middle Aged; Radiotherapy | 1995 |
Case report: pulmonary blastoma in children--response to chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphatic Metastasis; Pulmonary Blastoma; Vincristine | 1996 |
[A case of superior vena cava syndrome treated with combination radiation and CRE (CBDCA and VP-16) therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Male; Radiotherapy Dosage; Superior Vena Cava Syndrome | 1996 |
Chemotherapy given for lung cancer causes incidental and long-term cure of fungal skin infection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Dermatomycoses; Etoposide; Humans; Lung Neoplasms; Male | 1995 |
Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotid Arteries; Cisplatin; Etoposide; Glioma; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Lung Neoplasms; Meningeal Neoplasms | 1996 |
Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients.
Topics: Administration, Oral; Aged; Biological Availability; Capsules; Drug Administration Schedule; Etoposide; Half-Life; Humans; Japan; Lung Neoplasms; Middle Aged | 1996 |
Modification of chemo-radiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Doxorubicin; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured | 1996 |
Serum cytokine level fluctuations in chemotherapy-induced myelosuppression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-1; Interleukin-3; Interleukin-6; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Stem Cell Factor | 1996 |
Long-term survival of a patient with primary sellar choriocarcinoma with pulmonary metastases: a case report.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Child; Choriocarcinoma; Cisplatin; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Male; Prognosis | 1996 |
A case of extragonadal germ cell tumor with elevated postchemotherapy HCG successfully treated by resection of a solitary metastasis and chronic oral etoposide.
Topics: Administration, Oral; Adult; Chorionic Gonadotropin; Combined Modality Therapy; Etoposide; Germinoma; Humans; Lung Neoplasms; Male; Remission Induction; Salvage Therapy; Solitary Pulmonary Nodule | 1996 |
Is there a circadian variation in plasma concentrations of etoposide given by prolonged continuous infusion?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Circadian Rhythm; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 1996 |
Influence of age on the treatment of limited-stage small-cell lung cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Vincristine | 1996 |
Extensive stage small cell lung cancer: determining suitability for outpatient management of febrile neutropenia.
Topics: Adrenal Gland Neoplasms; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Decision Making; Etoposide; Female; Fever; Hospitalization; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia | 1996 |
Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Humans; Lung Neoplasms | 1995 |
Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Frontal Lobe; Humans; Liver Neoplasms; Lung Neoplasms; Methotrexate; Middle Aged; Paclitaxel; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms; Vincristine | 1996 |
Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Receptor, ErbB-2; Regression Analysis; Tumor Cells, Cultured | 1996 |
Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Meta-Analysis as Topic; Odds Ratio; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Treatment Outcome; Vinca Alkaloids | 1996 |
Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Emodin; Enzyme Inhibitors; Etoposide; Gene Expression; Genes, erbB-2; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Receptor, ErbB-2; Recombinant Proteins; Transfection; Tumor Cells, Cultured | 1996 |
Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cadmium; Cadmium Chloride; Carcinoma, Small Cell; Cell Line; Chlorides; Cisplatin; Cross Reactions; DNA; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Humans; Lung Neoplasms; Metallothionein; Platinum Compounds; Podophyllotoxin; Teniposide; Tumor Cells, Cultured; Vinca Alkaloids | 1996 |
MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; DNA, Complementary; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluoresceins; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Tumor Cells, Cultured | 1996 |
Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Topics: Aclarubicin; Blotting, Western; Diterpenes; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Razoxane; Tumor Cells, Cultured | 1996 |
Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Neoplasms, Experimental; Specific Pathogen-Free Organisms; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
[A case report of small cell carcinoma of the esophagus with remarkable response to neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged | 1996 |
[Correlation between an enzyme (glutathione S-transferase-pi) and effects of chemotherapy (cisplatin + etoposide)].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Glutathione Transferase; Humans; Lung Neoplasms; Male; Middle Aged; Staining and Labeling | 1996 |
Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines. Correlation to topoisomerase II alpha content and topoisomerase II catalytic activity.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blotting, Western; Bronchoalveolar Lavage Fluid; Catalysis; Coloring Agents; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Kinetoplast; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Humans; Immunohistochemistry; Isoenzymes; Lung Neoplasms; Tumor Cells, Cultured | 1996 |
[Effect of calmodulin antagonist on chemosensitivity of primary cultured lung cancer cells].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Calmodulin; Carcinoma, Squamous Cell; Doxorubicin; Drug Synergism; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Trifluoperazine; Tumor Cells, Cultured; Vincristine | 1995 |
Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Etoposide; Gemcitabine; Germany; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging | 1995 |
[Results of radiotherapy combined with CDDP (BAI) plus VP-16 in the treatment of inoperable non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Artery; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Survival Rate | 1996 |
Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer.
Topics: Aged; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Coronary Vasospasm; Etoposide; Humans; Lung Neoplasms; Male | 1996 |
[Introduction and prospect of peripheral blood stem cell transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
Oral etoposide and palliative treatment for small-cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Palliative Care; Survival Rate | 1996 |
Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Membrane; Cell Survival; Dibenzocycloheptenes; Drug Resistance, Multiple; Etoposide; Humans; Kinetics; Leukemia P388; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Protein Binding; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine | 1996 |
Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer.
Topics: Administration, Oral; Drug Monitoring; Etoposide; Humans; Leukopenia; Lung Neoplasms | 1996 |
[Surgery for bone metastasis of testicular tumor: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Humans; Lumbar Vertebrae; Lung Neoplasms; Male; Orchiectomy; Peplomycin; Spinal Neoplasms; Teratocarcinoma; Testicular Neoplasms | 1996 |
Prolonged infusion of etoposide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Infusion Pumps; Lung Neoplasms; Male; Middle Aged | 1996 |
Higher in vivo protein binding of etoposide in children compared with adult cancer patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Child; Child, Preschool; Etoposide; Female; Histiocytic Sarcoma; Humans; Infant; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Male; Middle Aged; Multiple Myeloma; Oligodendroglioma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Reference Values; Serum Albumin | 1996 |
Hyperfractionated radiotherapy combined with simultaneous chemotherapy in inoperable non-small cell lung cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Prognosis; Radioisotope Teletherapy; Radiotherapy Dosage; Time Factors | 1995 |
Resolution of superior vena cava obstruction in small cell lung cancer patients treated with chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Remission Induction; Survival Rate; Time Factors; Vena Cava, Superior; Vincristine | 1995 |
Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Cell Survival; Cisplatin; Drug Resistance; Etoposide; Genes, ras; Humans; Lung Neoplasms; Metallothionein; Phenotype; RNA, Messenger; RNA, Transfer; Sulfhydryl Compounds; Transfection; Tumor Cells, Cultured | 1995 |
[Chemohyperthermic peritoneal perfusion and high-dose chemotherapy followed by peripheral blood stem cell transplantation in advanced colon cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Colonic Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hyperthermia, Induced; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mitomycin; Perfusion; Peritoneum | 1996 |
[A case of lung metastasis from breast cancer successfully treated by FLEP (5-FU leucovorin, etoposide CDDP) combined arterial infusion chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Leucovorin; Lung Neoplasms | 1996 |
mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Carcinoma, Squamous Cell; Codon; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Exons; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Phenotype; Plasmids; Polymerase Chain Reaction; RNA, Antisense; RNA, Catalytic; RNA, Messenger; RNA, Neoplasm; Substrate Specificity; Transfection; Tumor Cells, Cultured; Vincristine | 1996 |
Absence of correlation between chemo- and radioresistance in a range of human tumour cell lines.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Clone Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; HeLa Cells; Humans; Laryngeal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation Tolerance; Selection, Genetic; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vincristine | 1996 |
Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vinblastine | 1996 |
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Topotecan | 1996 |
[Burned-out tumor and carcinoma-in-situ of the testis mimicking an extragonadal germ cell tumor: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Etoposide; Germinoma; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Neoplasms, Multiple Primary; Orchiectomy; Retroperitoneal Neoplasms; Testicular Neoplasms | 1996 |
Treatment of small cell lung cancer: a single institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Survival Rate; Vincristine | 1996 |
Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Induction; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Piperazines; Selection, Genetic; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vincristine | 1996 |
Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Topics: Antineoplastic Agents; Bleomycin; Bryostatins; Carcinoma; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Female; Head and Neck Neoplasms; Herpes Simplex Virus Protein Vmw65; Humans; Lactones; Lung Neoplasms; Macrolides; Ovarian Neoplasms; Paclitaxel; Phorbol 12,13-Dibutyrate; Protein Kinase C; Signal Transduction; Tumor Cells, Cultured | 1996 |
Comparison of carboplatin/etoposide/vincristine with cisplatin/etoposide as combination chemotherapy for small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1995 |
[A patient with lung metastasis of medulloblastoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Male; Medulloblastoma; Spinal Cord Neoplasms | 1996 |
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Survival Analysis | 1997 |
Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Vincristine | 1997 |
Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Isoenzymes; Lung Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Costs and Cost Analysis; Economics, Pharmaceutical; Etoposide; Humans; Lung Neoplasms; Models, Economic; Organophosphorus Compounds | 1996 |
Combination of chemotherapy and recombinant interferon-alpha in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1997 |
Superiority of cyclosporin A over PSC-833 in enhancement of VP-16 efficacy in murine tumors in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cyclosporine; Cyclosporins; Drug Synergism; Etoposide; Female; Immunosuppressive Agents; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Survival Rate; Time Factors | 1997 |
Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region.
Topics: Acetyltransferases; Adenovirus E1A Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; DNA, Neoplasm; Doxorubicin; Enzyme Inhibitors; Etoposide; Histone Acetyltransferases; Humans; Lung Neoplasms; p300-CBP Transcription Factors; Retinoblastoma; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
[A case of small cell lung carcinoma associated with pneumoconiosis who responded well to the over twenty chemotherapy treatments, resulting in prolonged survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Pneumoconiosis; Survivors; Vincristine | 1997 |
[Etoposide-induced pneumonitis].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Etoposide; Humans; Lung Neoplasms; Male; Pneumonia | 1997 |
Prolonged oral etoposide for advanced uterine leiomyosarcoma with pulmonary metastases: case report.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Uterine Neoplasms | 1997 |
Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Cisplatin; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Models, Theoretical; Probability; Tumor Cells, Cultured | 1997 |
Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chi-Square Distribution; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis | 1996 |
Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
Topics: Amino Acid Sequence; Base Composition; Base Sequence; Blotting, Northern; Carcinoma, Small Cell; Cloning, Molecular; Cytoplasm; DNA Topoisomerases, Type II; Etoposide; Gene Deletion; Humans; Lung Neoplasms; Molecular Sequence Data; Molecular Weight; Polymerase Chain Reaction; Restriction Mapping; RNA-Directed DNA Polymerase; RNA, Messenger; Sequence Analysis, DNA; Tumor Cells, Cultured | 1997 |
Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Breast Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Lung Neoplasms; Lymphoma; Neoplasm Proteins; Polymerase Chain Reaction; Prednisone; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Verapamil; Vincristine | 1997 |
[Early results of chemotherapy in patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Treatment Outcome | 1996 |
Indomethacin enhances the cytotoxicity of VCR and ADR in human pulmonary adenocarcinoma cells.
Topics: Adenocarcinoma; Adjuvants, Pharmaceutic; Coloring Agents; Doxorubicin; Drug Combinations; Drug Screening Assays, Antitumor; Etoposide; Humans; Indomethacin; Lung Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Vincristine | 1997 |
[Investigation of chemotherapy combined with peripheral blood stem cell transplantation (PBSCT) both in elderly and in recurred patients with small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Count; Recombinant Proteins | 1997 |
Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Colony-Forming Units Assay; Cytarabine; Cytotoxicity, Immunologic; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cells; HL-60 Cells; Humans; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukemia; Lung Neoplasms; Lymphocyte Activation; Tissue Donors; Transplantation, Autologous; Transplantation, Homologous; Tumor Cells, Cultured | 1997 |
[Case of ectopic ACTH-producing small cell carcinoma of the lung: a reduction in tumor size after chemotherapy in spite of a marked rise in the plasma ACTH level].
Topics: Adrenocorticotropic Hormone; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Hormones, Ectopic; Humans; Lung Neoplasms | 1997 |
Ifosfamide-based chemotherapy for recurrent or metastatic hemangiopericytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Forearm; Hemangiopericytoma; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Neoplasm Recurrence, Local; Salvage Therapy; Thoracic Neoplasms | 1997 |
Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pilot Projects | 1997 |
[Small cell lung cancer with acute monocytic leukemia after combined chemotherapy including etoposide].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary | 1997 |
[Comparison of induction chemotherapy before radiotherapy and radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Time Factors | 1997 |
Multidrug-resistant gene expression in small-cell lung cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Northern; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Survival Analysis; Survival Rate; Transcription, Genetic; Treatment Failure; Tumor Cells, Cultured; Vincristine | 1997 |
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carmustine; Cisplatin; Cyclin-Dependent Kinases; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Flavonoids; Fluorouracil; Humans; Lung Neoplasms; Paclitaxel; Piperidines; Tumor Stem Cell Assay | 1997 |
[A case with lung metastasis of malignant thymoma who showed complete response to VP-16 and achieved long-term survival].
Topics: Aged; Antineoplastic Agents, Phytogenic; Etoposide; Humans; Lung Neoplasms; Male; Remission Induction; Survivors; Thymoma; Thymus Neoplasms | 1988 |
Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzophenanthridines; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cisplatin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Membrane Glycoproteins; Mice; Mice, SCID; Phenanthridines; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Cycle; Cell Survival; DNA Topoisomerases, Type II; Doxorubicin; Drug Interactions; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lung Neoplasms; Paclitaxel; Polymerase Chain Reaction; Rhodamines; Stomach Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vincristine | 1997 |
New drugs for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vincristine | 1997 |
Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Small Cell; Clone Cells; DNA Damage; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Humans; Hypoxanthine Phosphoribosyltransferase; Lung Neoplasms; Male; Mutagenesis; Point Mutation; Polymerase Chain Reaction; T-Lymphocytes; Topoisomerase II Inhibitors | 1997 |
Limited-stage small cell lung cancer: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Male; Neoplasm Staging; Radiotherapy, Adjuvant | 1997 |
Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Differentiation; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Phosphopyruvate Hydratase; Predictive Value of Tests; Treatment Outcome; Vincristine | 1997 |
Experience with ifosfamide and etoposide combination chemotherapy in extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 1997 |
Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Small Cell; Cell Nucleus; Consensus Sequence; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Isoenzymes; Lung Neoplasms; Lysine; Molecular Sequence Data; Molecular Weight; Multidrug Resistance-Associated Proteins; Peptide Fragments; Point Mutation; Polymerase Chain Reaction; RNA, Messenger; Sequence Deletion; Serine; Tumor Cells, Cultured | 1997 |
Concurrent 5-fluorouracil, leucovorin, etoposide, cisplatin and radiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Radiotherapy | 1997 |
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Indenes; Indoles; Irinotecan; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
[A case report of coronary artery bypass graft surgery and subsequent chemotherapy for the patient with unstable angina and small cell lung cancer].
Topics: Aged; Angina, Unstable; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Coronary Artery Bypass; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Vincristine | 1994 |
Technetium-99m-MIBI uptake in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Case-Control Studies; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 1998 |
[Myocardial infarction during a treatment combining etoposide and cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Myocardial Infarction | 1997 |
Metastatic placental site trophoblastic tumor: long-term remission in a patient treated with EMA/CO chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lung Neoplasms; Methotrexate; Pregnancy; Radiography; Remission Induction; Trophoblastic Tumor, Placental Site; Uterine Neoplasms; Vaginal Neoplasms; Vincristine | 1998 |
[Augmented antitumor activity in combination chemotherapy of nedaplatin with etoposide].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Synergism; Etoposide; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Weight Loss | 1998 |
Double high-dose chemotherapy with autologous peripheral stem cell rescue in relapsed Wilms' tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Kidney Neoplasms; Lung Neoplasms; Salvage Therapy; Vincristine; Wilms Tumor | 1997 |
[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Child; Drug Administration Schedule; Etoposide; Female; Fever; Humans; Ifosfamide; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neutropenia; Osteosarcoma; Pilot Projects; Thrombocytopenia | 1998 |
Brain metastasis from germinal tumors of the testis. Case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cerebellar Neoplasms; Cisplatin; Combined Modality Therapy; Etoposide; Germinoma; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Radiography, Thoracic; Reoperation; Testicular Neoplasms | 1998 |
Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Survival; Cisplatin; Cyclophosphamide; Cyclosporine; Doxorubicin; Drug Resistance, Multiple; Etoposide; Humans; Kinetics; Lung Neoplasms; Methotrexate; Neuroblastoma; Rhabdomyosarcoma; Time Factors; Tumor Cells, Cultured; Verapamil; Vincristine | 1998 |
Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1998 |
Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomography.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Ouabain; Prognosis; Radiography; Sodium-Potassium-Exchanging ATPase; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tumor Cells, Cultured | 1998 |
Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bacterial Proteins; Carcinoma, Small Cell; Chlorambucil; Cisplatin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Paclitaxel; RNA, Messenger; Serine Endopeptidases; Tumor Cells, Cultured; Vinblastine | 1998 |
Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Erythropoietin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Retrospective Studies | 1997 |
[Evaluation of polychemotherapy of small cell lung carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Retrospective Studies; Vincristine | 1995 |
Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Topics: Antibody Formation; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Enzyme-Linked Immunosorbent Assay; Etoposide; Genes, p53; Humans; Lung Neoplasms; Monitoring, Immunologic; Neoplasm Staging; Prognosis; Radiotherapy; Survival Rate; Tumor Suppressor Protein p53 | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment | 1998 |
[A guide for the timing of peripheral blood stem cell harvest in patients with lung cancer].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Cisplatin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Platelet Count; Time Factors | 1998 |
[Endoscopic findings of esophagitis in concurrent chemo-radiotherapy for lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophagitis; Esophagoscopy; Etoposide; Humans; Lung Neoplasms; Middle Aged; Mitomycin; Radiation Injuries; Radiotherapy; Vindesine | 1998 |
[A case of binocular blindness in small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blindness; Carcinoma, Small Cell; Cyclophosphamide; Epirubicin; Etoposide; Fatal Outcome; Humans; Lung Neoplasms; Male; Paraneoplastic Syndromes | 1998 |
Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.
Topics: Analysis of Variance; Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Etoposide; Humans; Keratin-19; Keratins; L-Lactate Dehydrogenase; Lung Neoplasms; Phosphopyruvate Hydratase; Prognosis; Regression Analysis; Tissue Polypeptide Antigen | 1998 |
Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Monitoring; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies | 1998 |
Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Vault Ribonucleoprotein Particles | 1998 |
Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Mesna; Prospective Studies; Recombinant Proteins; Vincristine | 1998 |
Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; RNA, Messenger; Transplantation, Heterologous | 1998 |
[Clinical efficacy of concurrent carboplatin, etoposide, and definitive radiotherapy for stage III non-small-cell lung cancer: consideration as to therapeutic outcomes and morbidity].
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Morbidity; Retrospective Studies; Survival Rate; Treatment Outcome | 1998 |
Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Refusal; Vincristine | 1998 |
Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 1998 |
Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1998 |
Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Creatinine; Drug Administration Schedule; Etoposide; Humans; Leukocytosis; Lung; Lung Neoplasms; Male; Retrospective Studies; Seminoma; Testicular Neoplasms; Vinblastine | 1998 |
Pulmonary multinodular relapse of non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Etoposide; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Radiography; Recurrence; Remission Induction; Tuberculosis, Pulmonary | 1998 |
A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pilot Projects; Radiotherapy Dosage; Survival Analysis; Thrombocytopenia; Treatment Failure | 1998 |
Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Phytogenic; Biological Availability; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia | 1995 |
Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Platinum Compounds; Predictive Value of Tests; Survival Analysis; Treatment Outcome | 1998 |
Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Small Cell; Cell Survival; Culture Media; Cystine; Etoposide; Gene Expression; Genes, bcl-2; Humans; Lung Neoplasms; Methionine; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1998 |
Long term results of surgery and chemotherapy in small cell lung cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Postoperative Complications; Prospective Studies; Radiotherapy, Adjuvant; Survival Rate; Vincristine | 1998 |
Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; New Zealand; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Drug Evaluation; Drug Monitoring; Etoposide; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Middle Aged | 1999 |
Effect of Tween-80 on cell killing by etoposide in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Polysorbates; Surface-Active Agents; Tumor Cells, Cultured | 1999 |
Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Fenretinide; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1999 |
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Separation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Genes, p53; Humans; Lung Neoplasms; Mutation | 1999 |
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Deoxycytosine Nucleotides; DNA Damage; Drug Synergism; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured | 1999 |
[A case of small cell carcinoma of the stomach with multiple liver and lung metastases successfully treated by combined chemotherapy with cisplatin and etoposide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Gastrectomy; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Splenectomy; Stomach Neoplasms | 1999 |
The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Patient Compliance; Radiation Pneumonitis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Retrospective Studies; Vincristine | 1999 |
[Successful management for chemorefractory testicular cancer with brain and lung metastases. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinoma, Embryonal; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Salvage Therapy; Testicular Neoplasms | 1998 |
Monocyte chemoattractant protein-1 gene modification of multidrug-resistant human lung cancer enhances antimetastatic effect of therapy with anti-P-glycoprotein antibody in SCID mice.
Topics: Animals; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Chemokine CCL2; Clone Cells; Drug Resistance, Multiple; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Metastasis; Organ Specificity; Recombinant Proteins; Transfection; Tumor Cells, Cultured | 1999 |
Hepatic artery administration of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cimetidine; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Etoposide; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication | 1999 |
Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Injections, Intravenous; Lung Neoplasms; Male; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nitrosourea Compounds; Paclitaxel; Vinblastine | 1998 |
Cost comparison between PAV and ICE treatment with peripheral blood progenitor cells (PBPC) reinfusion in small-cell lung cancer (SCLC)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Health Care Costs; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Middle Aged | 1999 |
[Nedaplatin and etoposide combination chemotherapy in a patient with small cell carcinoma undergoing hemodialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Remission Induction; Renal Dialysis | 1999 |
Gestational trophoblastic disease: does central nervous system chemoprophylaxis have a role?
Topics: Adolescent; Adult; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dactinomycin; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Middle Aged; Patient Compliance; Pregnancy; Prognosis; Retrospective Studies; Risk Assessment; Trophoblastic Neoplasms; Uterine Neoplasms | 1999 |
In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Models, Biological; Models, Statistical; Purine Nucleosides; Tumor Cells, Cultured | 1999 |
Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer.
Topics: Administration, Oral; Carcinoma, Small Cell; Cisplatin; Cost Savings; Cost-Benefit Analysis; Etoposide; Health Care Costs; Humans; Infusions, Intravenous; Lung Neoplasms | 1992 |
Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Epirubicin; Etoposide; Humans; Keratin-19; Keratins; Lung Neoplasms; Markov Chains; Prognosis; Proportional Hazards Models; Prospective Studies; Tissue Polypeptide Antigen | 1999 |
Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Coloring Agents; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Pyrazines; Quinolines; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Enhanced sensitivity of small cell lung cancer cell lines to cisplatin and etoposide after infection with adeno-associated virus type 2.
Topics: Adenovirus Infections, Human; Animals; Antineoplastic Agents; Blotting, Southern; Carcinoma, Small Cell; Cell Division; Cisplatin; Dependovirus; Etoposide; Female; HeLa Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Tumor Cells, Cultured | 1999 |
[A case report: modified PMUE therapy might be effective for advanced gastric carcinoma with pulmonary carcinomatous lymphangitis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Stomach Neoplasms | 1999 |
CombiTool--a new computer program for analyzing combination experiments with biologically active agents.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma; Cisplatin; Computer Graphics; Computer Simulation; Dose-Response Relationship, Drug; Drug Antagonism; Drug Combinations; Drug Interactions; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Models, Biological; Models, Chemical; Software; Tumor Cells, Cultured | 1999 |
Etoposide phosphate: new preparation. Makes outpatient therapy easier.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; France; Humans; Lung Neoplasms; Organophosphorus Compounds | 1998 |
Evaluation of apoptosis and necrosis induction in cultured cells of lung carcinomas under effect of cytostatic drugs in vitro.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; Etoposide; Humans; Lung Neoplasms; Methotrexate; Necrosis; Tumor Cells, Cultured; Vinblastine; Vincristine | 1999 |
Evaluation of individual sensitivity to cytostatic drugs of in vitro cultured lung tumor cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Epirubicin; Etoposide; Fluorouracil; Lung Neoplasms; Methotrexate; Tumor Cells, Cultured; Vinblastine; Vincristine | 1999 |
Pharmacokinetics of etoposide after intrathoracic instillation to lung cancer patients with pleural effusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant | 1999 |
Severe muscle weakness due to hypokalemia as a manifestation of small-cell carcinoma.
Topics: ACTH Syndrome, Ectopic; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Etoposide; Humans; Hypokalemia; Lung Neoplasms; Male; Middle Aged; Muscle Weakness | 1999 |
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Bradykinin; Carcinoma, Small Cell; Caspase 3; Caspase Inhibitors; Caspases; Cell Adhesion; Cell Division; Collagen; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Extracellular Matrix Proteins; Fibronectins; Galanin; Humans; Integrin beta1; Laminin; Lung Neoplasms; Protein-Tyrosine Kinases; Tenascin; Tumor Cells, Cultured; Tyrphostins | 1999 |
[Accelerated hyperfractionated compared with conventional radiotherapy in limited small-cell lung carcinoma, with concurrent chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Radiotherapy; Radiotherapy Dosage | 1999 |
Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer.
Topics: Adenocarcinoma; Aged; Angina Pectoris, Variant; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Electrocardiography; Etoposide; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Ischemia; Neoplasm Staging; Radiation Injuries; Radiotherapy; Vindesine | 1999 |
Neuron-specific enolase, thymidine kinase, and tissue polypeptide-specific antigen in diagnosis and response to chemotherapy of small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Immunoradiometric Assay; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Prospective Studies; Thymidine Kinase; Tissue Polypeptide Antigen; Treatment Outcome | 1999 |
[A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diphosphonates; Etoposide; Humans; Hypercalcemia; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Protein Biosynthesis; Renal Insufficiency | 1999 |
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Amino Acid Substitution; Amsacrine; Animals; Antineoplastic Agents; Binding Sites; Carcinoma, Small Cell; Catalysis; CHO Cells; Consensus Sequence; Cricetinae; Cricetulus; DNA Damage; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Lung Neoplasms; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Protein Isoforms; Razoxane; Recombinant Fusion Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Thiobarbiturates; Topoisomerase II Inhibitors; Tumor Stem Cell Assay | 1999 |
Cancer-associated retinopathy during treatment for small-cell lung carcinoma.
Topics: Adrenal Cortex Hormones; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Calcium-Binding Proteins; Carboplatin; Carcinoma, Small Cell; Etoposide; Eye Proteins; Female; Hippocalcin; Humans; Immunosuppressive Agents; Lipoproteins; Lung Neoplasms; Nerve Tissue Proteins; Paraneoplastic Syndromes; Recoverin; Retinal Diseases; Vision, Low; Visual Acuity | 1999 |
Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Potassium; Sodium | 1999 |
[Two-step ultra high-dose chemotherapy with peripheral blood stem cell autotransplantation for refractory testicular cancer: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Embryonal; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Male; Remission Induction; Testicular Neoplasms; Transplantation, Autologous | 1999 |
Marked increase in plasma ACTH with tumor reduction after chemotherapy in ectopic ACTH syndrome.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Pyridines; Radiography; Suicide | 1999 |
Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma. A prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Melanoma; Prospective Studies; Skin Neoplasms; Survival Analysis | 1999 |
Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Albumins; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Endothelial Growth Factors; Epidermal Growth Factor; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphokines; Male; Middle Aged; Neoplasm Proteins; Neovascularization, Pathologic; Oxidative Stress; Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vindesine | 1999 |
[Atypical paraneoplastic myasthenic syndrome: Lambert-Eaton syndrome or myasthenia?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Combined Modality Therapy; Diagnosis, Differential; Etoposide; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Lung; Lung Neoplasms; Middle Aged; Myasthenia Gravis; Paraneoplastic Syndromes; Radiotherapy Dosage; Tomography, X-Ray Computed | 1999 |
The effects of two different cisplatin-based chemotherapy regimens on advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Mitomycin; Retrospective Studies; Survival Rate | 1999 |
Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Time Factors; Tumor Cells, Cultured | 1999 |
Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Division; Dipyridamole; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Phosphodiesterase Inhibitors; Tumor Cells, Cultured | 1999 |
[A case of metastatic nephroblastoma in an adult with favorable outcome under cisplatyl, etoposide].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Tomography, X-Ray Computed; Treatment Outcome; Wilms Tumor | 1999 |
Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Etoposide; Female; Humans; Lung Neoplasms; Male; Mitomycin; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 1999 |
Etoposide-induced pulmonary toxicity.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Diagnosis, Differential; Dyspnea; Etoposide; Female; Humans; Lung Neoplasms; Male; Pulmonary Fibrosis | 1999 |
[Chemically-induced paraneoplastic hyperleukocytic lung].
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Etoposide; Humans; Leukemoid Reaction; Leukocyte Count; Leukostasis; Lung; Lung Diseases; Lung Neoplasms; Male; Paraneoplastic Syndromes; Radiography, Thoracic; Respiratory Insufficiency | 1999 |
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.
Topics: Animals; Antidotes; Auditory Threshold; Carboplatin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Ear, Middle; Etoposide; Female; Guinea Pigs; Humans; Lung Neoplasms; Male; Rats; Rats, Long-Evans; Rats, Nude; Thiosulfates; Tumor Cells, Cultured | 2000 |
[Evidence based chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Evidence-Based Medicine; Humans; Lung Neoplasms; Survival Analysis | 2000 |
[A long-term survivor of extensive-stage small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Remission Induction; Survivors; Vindesine | 2000 |
Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Clinical Protocols; Decision Making; Diagnostic Imaging; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Paclitaxel; Practice Patterns, Physicians'; Radiation Oncology; Radiotherapy, Adjuvant; United States | 2000 |
[Long-term results of small cell lung cancer treated by surgery combined with postoperative chemotherapy: a report of 65 patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Postoperative Period; Survival Rate; Vincristine | 1997 |
Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Survival Analysis; Vinblastine | 1999 |
A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.
Topics: Animals; Antineoplastic Agents; Cytokines; Disease Models, Animal; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Osteosarcoma; Vinblastine | 1999 |
[VP-16 and VM-26 plus platinum drugs combined with radiotherapy in the treatment of small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Teniposide | 1998 |
Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Time Factors; Transplantation, Heterologous; Treatment Outcome | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Tumor Cells, Cultured | 2000 |
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Oligonucleotides, Antisense; Phosphatidylethanolamines; Polymerase Chain Reaction; Proteins; RNA, Messenger; Survivin; Transfection; Tumor Cells, Cultured | 2000 |
Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes.
Topics: 5' Untranslated Regions; Antigens, CD; Chloramphenicol O-Acetyltransferase; Dose-Response Relationship, Drug; Etoposide; Gene Expression; Genes, Reporter; Humans; Kangai-1 Protein; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Regulatory Sequences, Nucleic Acid; Transcription Factor AP-1; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Division; Cell Survival; Cisplatin; Etoposide; Glioblastoma; Head and Neck Neoplasms; Humans; Isoxazoles; Leflunomide; Lung Neoplasms; Mice; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
[Relapse of small cell carcinoma of the lung with metastasis to iris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Iris Neoplasms; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Adjuvant; Treatment Outcome | 2000 |
[An successful case of combined daily oral administration of UFT and low-dose etoposide for multiple metastases of lung cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Tegafur; Uracil | 2000 |
[Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (antagonist G) induces AP-1 transcription and sensitizes cells to chemotherapy.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Small Cell; Cell Division; CHO Cells; Cricetinae; Drug Synergism; Etoposide; Free Radical Scavengers; Glutathione; Growth Inhibitors; JNK Mitogen-Activated Protein Kinases; Lipid Peroxidation; Lung Neoplasms; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Oligopeptides; Oxidation-Reduction; Reactive Oxygen Species; Stimulation, Chemical; Transcription Factor AP-1; Transcription, Genetic; Tumor Cells, Cultured | 2000 |
Expression of PCNA in non-small cell lung cancer before and after treatment with cisplatin and vepeside.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Proliferating Cell Nuclear Antigen; Treatment Outcome | 2000 |
Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Immunohistochemistry; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Time Factors | 2000 |
A case of metastatic ovarian non-gestational choriocarcinoma: successful treatment with conservative type surgery and myeloablative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Child; Choriocarcinoma; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Treatment Outcome | 2000 |
Postpartum choriocarcinoma complicated by brain and lung metastases treated successfully with EMA/CO regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebral Hemorrhage; Choriocarcinoma; Cyclophosphamide; Etoposide; Female; Humans; Infant; Lung Neoplasms; Magnetic Resonance Imaging; Methotrexate; Pregnancy; Tomography, X-Ray Computed; Uterine Neoplasms; Vincristine | 2000 |
Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Fibroblasts; Gene Expression Regulation; Humans; Lung; Lung Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Vinblastine | 2000 |
Acute tumor lysis syndrome with choriocarcinoma.
Topics: Acidosis; Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Cisplatin; Etoposide; Fatal Outcome; Heart Arrest; Humans; Hyperkalemia; Hypocalcemia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Phosphates; Respiratory Insufficiency; Testicular Neoplasms; Tumor Lysis Syndrome; Uric Acid | 2000 |
[Combined chemotherapy after prolonged oral etoposide maintenance therapy in patients with small-cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 2000 |
DNA damage after chemotherapy correlates with tumor response and survival in small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carboplatin; Carcinoma, Small Cell; DNA Damage; DNA Primers; DNA, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Pseudogenes | 2000 |
Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Radiography; Reproducibility of Results; Retrospective Studies; Survival Analysis; Time Factors | 2000 |
Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Etoposide; Lung; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Phospholipids; Quinidine; Tissue Distribution | 2000 |
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Topics: Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peptide Hydrolases; Proteasome Endopeptidase Complex; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Follow-Up Studies; Humans; Interleukin-2; Life Tables; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Remission Induction; Survival Analysis; Th1 Cells; Treatment Outcome | 2000 |
Identification of chromosomal loci associated with non-P-glycoprotein-mediated multidrug resistance to topoisomerase II inhibitor in lung adenocarcinoma cell line by comparative genomic hybridization.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Southern; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Genetic Markers; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lung Neoplasms; Nucleic Acid Hybridization; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Cross-Over Studies; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Statistics, Nonparametric | 2000 |
Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Life Tables; Lung Neoplasms; Male; Radiation Pneumonitis; Radiotherapy; Remission Induction; Retrospective Studies; Sarcoma, Ewing; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
[Postoperative complications after radiochemotherapy or chemotherapy for bronchial cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carcinoma, Bronchogenic; Cause of Death; Cisplatin; Etoposide; Female; Fluorouracil; Hospital Mortality; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pneumonectomy; Pneumonia; Radiotherapy, Adjuvant; Reoperation; Retrospective Studies; Risk Factors; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2000 |
Ectopic expression of MyD118/Gadd45/CR6 (Gadd45beta/alpha/gamma) sensitizes neoplastic cells to genotoxic stress-induced apoptosis.
Topics: Antigens, Differentiation; Apoptosis; Blotting, Northern; Blotting, Western; Carrier Proteins; Cell Cycle; DNA Damage; DNA Repair; Etoposide; Flow Cytometry; GADD45 Proteins; Gene Expression Regulation; Genetic Vectors; Humans; Intracellular Signaling Peptides and Proteins; Isopropyl Thiogalactoside; Leukemia, Myeloid, Acute; Lung Neoplasms; Mitogen-Activated Protein Kinases; Nucleic Acid Synthesis Inhibitors; Oxidative Stress; Protein Biosynthesis; Proteins; Transfection; Tumor Cells, Cultured | 2001 |
Quality of life in cancer patients treated by chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Colorectal Neoplasms; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires | 2000 |
Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; DNA Fragmentation; Etoposide; G1 Phase; Genes, p53; Humans; Lung Neoplasms; S Phase; Tumor Cells, Cultured | 2001 |
Metastatic placental site trophoblastic tumor. Report of a case with complete response to chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lung Neoplasms; Methotrexate; Pregnancy; Remission Induction; Trophoblastic Tumor, Placental Site; Uterine Neoplasms; Vincristine | 2001 |
Preoperative chemotherapy for lung cancer does not increase surgical morbidity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Pneumonectomy; Postoperative Care; Premedication; Reference Values; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Small cell lung cancer as a cause of acute renal failure secondary to bilateral renal infiltration.
Topics: Acute Kidney Injury; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cytarabine; Etoposide; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2000 |
[Determination of etoposide (VP16) in human serum by high performance liquid chromatography].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Etoposide; Female; Humans; Lung Neoplasms; Male | 1998 |
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Topics: Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Isoenzymes; Ki-67 Antigen; Life Tables; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Mutation, Missense; Neoplasm Proteins; Paclitaxel; Point Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Teniposide; Topotecan; Treatment Outcome; Vault Ribonucleoprotein Particles | 2001 |
Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Topics: Aminoquinolines; Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Indenes; Inhibitory Concentration 50; Injections, Intraperitoneal; Injections, Intravenous; Isoenzymes; Lung Neoplasms; Mice; Mice, Nude; Phenazines; Remission Induction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Thymidine incorporation is highly predictive of colony formation and can be used for high-throughput screening.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Chickens; CHO Cells; Colonic Neoplasms; Colony-Forming Units Assay; Cricetinae; Drug Screening Assays, Antitumor; Etoposide; Humans; Hydroxyurea; Kidney Neoplasms; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Thymidine; Tritium; Tumor Cells, Cultured | 2001 |
[A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Pneumonectomy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2001 |
[Does chemotherapy improve the results of postoperative radiotherapy in completely resected stage II and IIIA non-small-cell bronchial cancer?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Radiation Injuries; Radiotherapy; Randomized Controlled Trials as Topic; Time Factors | 2001 |
Defective caspase-3 relocalization in non-small cell lung carcinoma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Nucleus; Cytochrome c Group; Cytosol; Enzyme Precursors; Etoposide; Fas Ligand Protein; Gamma Rays; Lung Neoplasms; Membrane Glycoproteins; Nucleic Acid Synthesis Inhibitors; Poly(ADP-ribose) Polymerases; Protein Transport; Proteins; Signal Transduction; Tumor Cells, Cultured | 2001 |
Metastatic placental site trophoblastic tumors: clinical aspects of two unique cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin; Cyclophosphamide; Dactinomycin; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Methotrexate; Pregnancy; Trophoblastic Tumor, Placental Site; Uterine Neoplasms; Vincristine | 2001 |
A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Doxorubicin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Neoplasm Metastasis; Quinolines; Vincristine; Xenograft Model Antitumor Assays | 2001 |
Paclitaxel and lung cancer: new preparation. No therapeutic progress.
Topics: Antineoplastic Agents, Phytogenic; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Teniposide; Treatment Outcome | 2000 |
[Typical forms of choriocarcinoma in clinical practice--diagnosis and therapeutic course in four patients].
Topics: Abortion, Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Methotrexate; Neoplasm Metastasis; Pregnancy; Radiography; Uterine Neoplasms | 2001 |
In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
Three conventional-drug combination (ifosfamide, carboplatin, etoposide--ICE regimen) in advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2001 |
[Neoadjuvant chemoradiotherapy and peroperative radiotherapy for non-small-cell lung cancer of the apex. A study of 5 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Feasibility Studies; Female; Humans; Intraoperative Care; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pain; Pancoast Syndrome; Patient Selection; Pneumonectomy; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2001 |
Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Female; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Preoperative Care; Prospective Studies; Radiation Injuries; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Survival Analysis; Survival Rate; Treatment Outcome | 2001 |
[Outpatient chemotherapy for advanced lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
Etoposide induction of tumor immunity in Lewis lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Cell Membrane; Enzyme-Linked Immunosorbent Assay; Etoposide; Graft Rejection; Humans; Immunity, Cellular; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Inbred C57BL; Spleen; Transplantation, Heterologous | 2001 |
Twelve-year follow-up of trimodality therapy for stage IIIA non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2001 |
Primary gastric choriocarcinoma: a case report and review of the literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Diagnosis, Differential; Etoposide; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Salvage Therapy; Stomach Neoplasms; Tomography, X-Ray Computed | 2001 |
Improvement of anti-Hu-associated paraneoplastic sensory neuropathy after chemoradiotherapy in a small cell lung cancer patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Carboplatin; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Male; Paraneoplastic Polyneuropathy; Treatment Outcome | 2001 |
Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Ciprofloxacin; Cyclophosphamide; Doxorubicin; Endpoint Determination; Etoposide; Fever; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Neutropenia; Palliative Care; Randomized Controlled Trials as Topic; Research Design; Roxithromycin | 2001 |
Experience in treatment of metastatic pulmonary carcinoid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Cisplatin; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Somatostatin; Streptozocin; Survival Analysis | 2001 |
Lung cancer--time to move on from chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Smoking; Survival Rate | 2002 |
The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Clone Cells; Colchicine; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Daunorubicin; DNA Damage; DNA, Neoplasm; Etoposide; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Lung Neoplasms; Models, Biological; Proline; Promoter Regions, Genetic; Protein Structure, Tertiary; Recombinant Fusion Proteins; Structure-Activity Relationship; Tetracycline; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Carcinoma, Squamous Cell; Cloning, Molecular; DNA Fingerprinting; DNA-Binding Proteins; Dose-Response Relationship, Drug; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Proteins; Kinetics; Lung Neoplasms; Membrane Glycoproteins; NF-kappa B; NF-KappaB Inhibitor alpha; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Small Cell; Caspases; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fas Ligand Protein; fas Receptor; Humans; Lung Neoplasms; Membrane Glycoproteins; Mitochondria; Neoplasms, Experimental; Oligonucleotides, Antisense; Phenotype; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured; Up-Regulation | 2002 |
[Modulation of human small cell lung cancer cell line GLC4/ADR multidrug resistance in the inhibition of multidrug resistance-associated protein and its antisense].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Small Cell; Cell Cycle; Cell Division; Cloning, Molecular; Disease Models, Animal; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Genes, MDR; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mice, Nude; RNA, Antisense; Tumor Cells, Cultured | 2001 |
Expression of p21 and bcl-2 proteins and p53 mRNA in surgically resected preparations of non-small cell lung cancer (stage IIIA) after etoposide and cisplatin chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Etoposide; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Suppressor Protein p53 | 2001 |
Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Prognosis; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 2001 |
[Neoadjuvant chemotherapy and chemoradiotherapy in surgically treated non-small-cell stage III bronchial carcinoma].
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Reoperation; Survival Rate | 2001 |
Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferon-gamma; Interleukin-12; Interleukins; Lung Neoplasms; Lymphoma; Male; Middle Aged; Prednisone; Regression Analysis; T-Lymphocytes; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Time Factors; Tissue and Organ Harvesting; Transplantation, Autologous; Tumor Necrosis Factor-alpha; Vincristine | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
[Chemotherapy for small-cell lung cancer (SCLC) patients with renal failure].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Polyneuropathy; Renal Dialysis; Renal Insufficiency | 2002 |
Choriocarcinoma and epithelial trophoblastic tumor: successful treatment of relapse with hysterectomy and high-dose chemotherapy with peripheral stem cell support: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hysterectomy; Lung Neoplasms; Methotrexate; Pregnancy; Trophoblastic Neoplasms; Uterine Neoplasms; Vincristine | 2002 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; DNA Mutational Analysis; DNA, Complementary; DNA, Neoplasm; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Genes, p53; Humans; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Prognosis; Tumor Cells, Cultured | 2002 |
Reply to the article "Editorial comments on 'reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'", by P.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Ciprofloxacin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Etoposide; Fever; Humans; Lung Neoplasms; Neutropenia; Palliative Care; Randomized Controlled Trials as Topic; Roxithromycin | 2002 |
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bradykinin; Bradykinin Receptor Antagonists; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cisplatin; Dimerization; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Gefitinib; Humans; Infusion Pumps; Injections, Intralesional; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Quinazolines; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2002 |
Severe gustatory disorder caused by cisplatin and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Taste Disorders; Taste Threshold | 2002 |
[Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Prostatic Neoplasms; Remission, Spontaneous | 1975 |
Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside).
Topics: Administration, Oral; Aged; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Remission, Spontaneous; Solutions | 1977 |
Chemotherapy of small cell carcinoma of the lung with V.P. 16-213.
Topics: Bone Marrow; Carcinoma, Small Cell; Disability Evaluation; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Podophyllotoxin; Recurrence; Remission, Spontaneous; Time Factors | 1978 |
Radiation recall associated with VP-16-213 therapy.
Topics: Carcinoma, Small Cell; Erythema; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Podophyllotoxin; Radiation Injuries; Radiation-Sensitizing Agents; Time Factors | 1979 |
Intensive induction therapy for small cell carcinoma of the lung.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Procarbazine; Remission, Spontaneous; Vincristine | 1979 |
VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Remission, Spontaneous; Time Factors; Vomiting | 1979 |
VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Time Factors | 1978 |
VP 16-213 (VP 16) and cyclophosphamide in the treatment of primitive lung cancer in phase M 1.
Topics: Adult; Aged; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Prednisone; Remission, Spontaneous; Vincristine | 1979 |
[VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Topics: Adenocarcinoma; Anaplasia; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Methotrexate; Neoplasm Metastasis; Podophyllotoxin; Remission, Spontaneous; Vincristine | 1977 |
Effect of hemostasis modifiers of the activity of VP 16 213 on Lewis lung carcinoma.
Topics: Animals; Aspirin; Etoposide; Hemostasis; Heparin; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Podophyllotoxin; Transplantation, Homologous | 1977 |
Antimetastasis effect of two derivatives of epiposophyllotoxin in mice.
Topics: Animals; Etoposide; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Podophyllotoxin; Solvents; Teniposide; Time Factors | 1976 |
[Successful management of choriocarcinoma of the testis with brain metastasis: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Chemotherapy, Adjuvant; Choriocarcinoma; Cisplatin; Etoposide; Humans; Lung Neoplasms; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Orchiectomy; Peplomycin; Remission Induction; Retroperitoneal Neoplasms; Teratoma; Testicular Neoplasms | 1992 |
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Cell Membrane Permeability; Daunorubicin; Drug Resistance; Energy Metabolism; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Nigericin; Phenotype; RNA, Messenger; Tumor Cells, Cultured; Vincristine | 1992 |
[Etoposide and cisplatin combination chemotherapy in a patient with small cell lung carcinoma under artificial hemodialysis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Lung Neoplasms; Male; Renal Dialysis | 1992 |
Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Screening Assays, Antitumor; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Middle Aged; Prognosis | 1992 |
Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Humans; Lung Neoplasms; Tumor Cells, Cultured | 1992 |
Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data.
Topics: Adult; Carcinoma, Small Cell; Etoposide; Feasibility Studies; Humans; Injections, Spinal; Lung Neoplasms; Male; Meningitis; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1992 |
[Advances in the treatment of small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms | 1992 |
A pilot study of intensive weekly chemotherapy for extensive disease small-cell lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Neoplasm Metastasis; Pilot Projects; Recurrence; Treatment Outcome; Vincristine | 1992 |
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line; Cell Survival; Cisplatin; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Phenotype; Restriction Mapping; RNA, Neoplasm; Teniposide | 1992 |
[Clinical study of etoposide (NK 171s, miniaturized capsule) in advanced small cell lung cancer].
Topics: Administration, Oral; Aged; Capsules; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1992 |
[High dose chemotherapy with autologous bone marrow rescue for small cell lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Transplantation, Autologous; Vincristine | 1992 |
Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile.
Topics: Aged; Attitude to Health; Carcinoma, Small Cell; Etoposide; Follow-Up Studies; Humans; Longitudinal Studies; Lung Neoplasms; Neoplasm Staging; Probability; Quality of Life; Surveys and Questionnaires; Teniposide | 1992 |
Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Topics: Amsacrine; Animals; Base Sequence; Binding Sites; Carcinoma, Small Cell; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Genes, myc; Humans; Leukemia L1210; Lung Neoplasms; Mice; Molecular Sequence Data; Promoter Regions, Genetic; Restriction Mapping; Substrate Specificity; Teniposide | 1992 |
[Pilot phase II trial of high-dose etoposide combined with cisplatin in the treatment of refractory lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Sarcoma | 1992 |
Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Tomography, X-Ray Computed | 1992 |
Antitumor activity of magainin analogues against human lung cancer cell lines.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Etoposide; Fibroblasts; Humans; Lung Neoplasms; Peptides; Tumor Cells, Cultured | 1992 |
Clinical trials referral resource. Non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Vinblastine | 1992 |
[The effect of combination chemotherapy with cisplatin, vincristine, doxorubicin and etoposide (Tokushima-CODE: T-CODE) against lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Middle Aged; Pilot Projects; Vincristine | 1992 |
[A case with delayed-onset radiation pneumonitis suspected to be induced by oral etoposide].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonia; Radiation Injuries; Radiotherapy, High-Energy | 1992 |
Analysis of the four combination chemotherapies in non-small cell lung cancer treated at Maharaj Nakorn Chiang Mai Hospital.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Mitomycin; Survival Rate; Vinblastine | 1992 |
Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Buthionine Sulfoximine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Doxorubicin; Drug Synergism; Etoposide; Female; Glutathione; Humans; Lung Neoplasms; Methionine Sulfoximine; Ovarian Neoplasms; Tumor Cells, Cultured; Verapamil | 1992 |
Metastatic choriocarcinoma with coexistent term pregnancy following four recurrent consecutive moles.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Hydatidiform Mole; Lung Neoplasms; Methotrexate; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms | 1992 |
Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Protocols; Clinical Trials, Phase II as Topic; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Remission Induction; Survival Rate | 1992 |
Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Remission Induction; Survival Rate; Vomiting | 1992 |
Carboplatin-containing regimens for small cell lung cancer: implications for management in the elderly.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Protocols; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Remission Induction; Survival Rate; Vincristine | 1992 |
Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Mesna; Middle Aged; Phosphopyruvate Hydratase; Probability; Prospective Studies; Remission Induction; Survival Rate | 1992 |
Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy with carboplatin, etoposide and epirubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Epirubicin; Etoposide; Humans; Lung Neoplasms | 1992 |
[Pharmacokinetic study and side effects of chronic daily administration of oral etoposide].
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Hemoglobins; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Platelet Count | 1992 |
Multidrug resistance in a small cell lung cancer line: rapid selection with etoposide and differential chemosensitization with cyclosporin A.
Topics: Alkalies; Biological Transport; Carcinoma, Small Cell; Cell Division; Cell Nucleus; Cyclosporine; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Lung Neoplasms; Organelles; Phenotype; Ribonucleases; Tumor Cells, Cultured | 1992 |
Relationships between various uses of antineoplastic drug-interaction terms.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Synergism; Etoposide; Humans; Leukemia P388; Lung Neoplasms; Terminology as Topic; Tumor Cells, Cultured | 1992 |
Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Hematologic Diseases; Humans; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Models, Statistical | 1992 |
[Chemotherapy with cisplatin, adriamycin, etoposide and ifosfamide in microcytic lung carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 1992 |
An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Indazoles; Lung Neoplasms; Tumor Cells, Cultured | 1992 |
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Treatment Outcome | 1992 |
[The treatment of small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prednisone; Procarbazine; Prospective Studies; Survival Rate; Vincristine | 1992 |
Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Glutathione; Humans; Lung Neoplasms; Membrane Glycoproteins; RNA, Messenger; Tumor Cells, Cultured | 1992 |
Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Carmustine; Cell Division; Cisplatin; Cytarabine; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Membrane Glycoproteins; Tumor Cells, Cultured | 1992 |
Primary treatment of pelvic osteosarcoma. Report of five cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Fluid Therapy; Follow-Up Studies; Humans; Ifosfamide; Injections, Intra-Arterial; Lung Neoplasms; Osteosarcoma; Pelvic Bones; Radiotherapy Dosage; Survival Rate | 1992 |
Weekly dose-intensive chemotherapy in patients with small-cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Remission Induction; Survival Analysis; Vincristine | 1992 |
Obstructing endobronchial bands complicating radiation therapy for lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchi; Bronchoscopy; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Fibrosis; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prednisone; Radiotherapy; Radiotherapy Dosage; Vincristine | 1992 |
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Topics: Adenocarcinoma; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Leukemia; Lung Neoplasms; Novobiocin; RNA; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
[A case of adenocarcinoma of lung cancer with multiple brain metastasis and lymphangitis carcinomatosa responding well to chemotherapy with carboplatin, etoposide and ifosfamide].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Lymphangitis; Male; Radiotherapy Dosage | 1992 |
Case report: cisplatin-induced hemolytic uremic syndrome.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carcinoma, Small Cell; Cisplatin; Etoposide; Hemolytic-Uremic Syndrome; Humans; Lung Neoplasms; Male; Middle Aged; Spinal Neoplasms | 1991 |
In vitro and in vivo modulation of multi-drug resistance with amiodarone.
Topics: Adult; Amiodarone; Biological Transport; Carcinoma, Small Cell; Cell Line; Cell Survival; Colonic Neoplasms; DNA Damage; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Tumor Stem Cell Assay; Vincristine | 1991 |
[Surgical treatment of esophago-pleural fistula caused by chemotherapy for lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Esophageal Fistula; Esophagoplasty; Etoposide; Female; Fistula; Humans; Lung Neoplasms; Pleural Diseases | 1991 |
A phase II study of vindesine plus etoposide in metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Middle Aged; Vindesine | 1991 |
Limited small cell lung cancer: the effect of radiotherapy on local control following response to chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Survival Analysis; Survival Rate; Vincristine | 1991 |
A retrospective analysis of patients receiving surgery after chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nimustine; Pneumonectomy; Prognosis; Retrospective Studies; Survival Rate; Vincristine | 1991 |
Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Rate; Vincristine | 1991 |
Intercalated radio-chemotherapy in small cell lung cancer: toxicity and implications for future regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis; Radiation Injuries; Radiotherapy Dosage | 1991 |
[Phase II study of lung cancer--evaluation of new drug in small cell lung cancer (SCLC) and phase II testing of analogues].
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Drug Resistance; Etoposide; Humans; Lung Neoplasms | 1991 |
Vindesine and etoposide chemotherapy in the management of patients with small cell lung cancer and poor prognosis.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Serum Albumin; Survival Rate; Vincristine; Vindesine | 1991 |
Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Survival Rate; Vincristine | 1991 |
Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitomycin; Neoplasm Staging; Remission Induction; Time Factors; Vindesine | 1991 |
[Successful treatment of a pretreated elderly case of small-cell lung carcinoma with continuous five-day intravenous infusion of cisplatin plus etoposide].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphatic Metastasis; Male | 1991 |
Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
Topics: Alkenes; Antibiotics, Antineoplastic; Carcinoma, Small Cell; Cell Line; Cell Nucleus; DNA Topoisomerases, Type II; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Methotrexate; Polyenes; Pyrones; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1991 |
Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIb).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Vincristine | 1991 |
[Remarkable effect of the combination therapy of etoposide, epiadriamycin, and CDDP (EAP) in the treatment of metachronous lung metastases of breast cancer--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Mastectomy, Radical; Remission Induction | 1991 |
[A pilot study of etoposide, split-dose cisplatin and THP in small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Pilot Projects; Survival Rate | 1991 |
[The evaluation of the cardiotoxicity of 4'-epidoxorubicin at high doses].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Echocardiography; Epirubicin; Etoposide; Female; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Myocardium | 1991 |
Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1991 |
[Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lomustine; Lung Neoplasms; Methotrexate; Procarbazine; Remission Induction; Time Factors; Vincristine | 1991 |
Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Leukopenia; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Remission Induction; Salvage Therapy; Vincristine | 1991 |
Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Regression Analysis | 1991 |
Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Carcinoma, Small Cell; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Gene Expression; Humans; In Vitro Techniques; Lung Neoplasms; Membrane Glycoproteins; Molecular Sequence Data; Oligonucleotides; Tumor Cells, Cultured | 1991 |
Adult Wilms' tumor. Cisplatin and etoposide for relapse after adjuvant chemotherapy.
Topics: Adult; Cisplatin; Dactinomycin; Etoposide; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Prognosis; Vincristine; Wilms Tumor | 1990 |
Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Colony-Stimulating Factors; Drug Evaluation; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Remission Induction; Survival Rate | 1990 |
[Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Vincristine | 1990 |
Respiratory failure due to choriocarcinoma: a study of 103 dyspneic patients.
Topics: Adult; Anemia; Blood Gas Analysis; Choriocarcinoma; Cyanosis; Dactinomycin; Drug Therapy, Combination; Dyspnea; Etoposide; Extracorporeal Membrane Oxygenation; Female; Humans; Hypertension, Pulmonary; Lung; Lung Neoplasms; Methotrexate; Pregnancy; Radiography; Respiratory Insufficiency; Risk Factors; Tachycardia; Uterine Neoplasms | 1990 |
Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II.
Topics: Acridines; Amsacrine; Animals; Antineoplastic Agents; Benzimidazoles; Bisbenzimidazole; Colonic Neoplasms; Doxorubicin; Drug Synergism; Etoposide; Fluorescent Dyes; Leukemia L1210; Lung Neoplasms; Melanoma; Mice; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
Pneumothorax following cytotoxic chemotherapy in malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Humans; Lung; Lung Neoplasms; Lymphoma; Male; Methotrexate; Middle Aged; Pneumothorax; Prednisone; Procarbazine; Radiography; Vinblastine; Vincristine | 1990 |
Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Differentiation; Cyclophosphamide; Cytoplasmic Granules; Desmosomes; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Immunohistochemistry; Keratins; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Weight; Neoplasm Staging; Phenotype; Phosphopyruvate Hydratase; Survival Rate | 1991 |
Cytoreductive surgery in disseminated non-seminomatous germ cell tumours of testis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Teratoma; Testicular Neoplasms; Vincristine | 1991 |
Low dose bleomycin with etoposide and cisplatin for metastatic testicular teratoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Prognosis; Teratoma; Testicular Neoplasms | 1991 |
Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Cell Line; Colonic Neoplasms; DNA; DNA Damage; DNA Probes; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Humans; Immunoblotting; Lung Neoplasms; Membrane Glycoproteins; Molecular Sequence Data; Neoplasm Proteins; Porfiromycin; RNA; Teniposide | 1991 |
Enhancement of etoposide and methotrexate sensitivity by indomethacin in vitro.
Topics: Animals; Bleomycin; Drug Synergism; Etoposide; Humans; Indomethacin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipoxygenase Inhibitors; Lung Neoplasms; Lymphoma; Methotrexate; Neoplasms, Experimental; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostaglandins; Protein Kinase Inhibitors; Tumor Cells, Cultured | 1991 |
[BEP (bleomycin, etoposide, cisplatinum) chemotherapy as an induction therapy of advanced extragonadal germ cell tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Remission Induction; Retroperitoneal Neoplasms | 1991 |
Acute gastroduodenal mucosal injury after cisplatin plus etoposide chemotherapy. Clinical and endoscopic study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endoscopy; Etoposide; Famotidine; Female; Gastric Mucosa; Gastritis; Humans; Intestinal Mucosa; Lung Neoplasms; Male; Middle Aged; Ulcer | 1991 |
Normal pregnancy after curative multiagent chemotherapy for choriocarcinoma with brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Cisplatin; Dactinomycin; Etoposide; Female; Humans; Lung Neoplasms; Methotrexate; Pregnancy; Pregnancy Complications, Neoplastic; Primary Ovarian Insufficiency; Uterine Neoplasms | 1991 |
Infusion of floxuridine plus etoposide plus cisplatin in human malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Diarrhea; Drug Evaluation; Etoposide; Female; Floxuridine; Gastrointestinal Neoplasms; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Risk Factors; Stomatitis; Thrombocytopenia | 1991 |
[An elderly case of small cell lung cancer showing a good partial response by chronic daily administration of oral etoposide].
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Remission Induction; Time Factors | 1991 |
Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1991 |
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Regression Analysis; Survival Analysis | 1991 |
[A case of remission of multiple retroperitoneal lymph node relapse in small cell lung cancer treated with oral etoposide].
Topics: Administration, Oral; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Retroperitoneal Neoplasms | 1991 |
Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vincristine | 1991 |
[Adriamycin, cisplatin and etoposide combination chemotherapy in non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Vomiting | 1991 |
[A case of small cell carcinoma of the lung responding well to oral etoposide therapy].
Topics: Administration, Oral; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Peritoneal Neoplasms | 1991 |
Detection of multidrug resistance and quantification of responses of human tumour cells to cytotoxic agents using flow cytometric spectral shift analysis of Hoechst 33,342-DNA fluorescence.
Topics: Benzimidazoles; Carcinoma, Small Cell; Cell Line, Transformed; Cell Nucleus; Cell Survival; DNA, Neoplasm; Drug Resistance; Etoposide; Flow Cytometry; Fluorescent Dyes; Humans; Lung Neoplasms; Lymphocytes; Tumor Cells, Cultured | 1991 |
A feasibility study of testing new drugs for small-cell lung cancer in patients with a poor performance status.
Topics: Adult; Aged; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Feasibility Studies; Humans; Lung Neoplasms; Middle Aged | 1991 |
Small-cell lung cancer in elderly patients: the case for chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prednisone; Retrospective Studies; Survival Rate; Vincristine | 1991 |
Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mitomycins; Remission Induction; Survival Rate; Time Factors | 1991 |
[The efficacy and side effects of chemotherapy for primary lung cancer with cisplatin and etoposide].
Topics: Adenocarcinoma; Administration, Oral; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Humans; Infusions, Intravenous; Kidney; Leukopenia; Lung Neoplasms | 1991 |
[Small-cell lung carcinoma. Inappropriate antidiuretic hormone secretion revealed by chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Inappropriate ADH Syndrome; Lung Neoplasms | 1991 |
Correlation of in vitro drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival.
Topics: Carcinoma, Small Cell; Cell Line; Cisplatin; Drug Screening Assays, Antitumor; Etoposide; Humans; In Vitro Techniques; Lung Neoplasms; Time Factors; Tumor Cells, Cultured | 1990 |
[Cisplatin and vinca alkaloid combination chemotherapy of advanced non-small-cell lung cancer in the aged].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Vindesine | 1990 |
A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Remission Induction | 1990 |
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Cycle; Cell Division; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Humans; Lung Neoplasms; Membrane Glycoproteins; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Verapamil | 1990 |
Characterization of an etoposide-resistant human small-cell lung cancer cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Lung Neoplasms; Membrane Glycoproteins; Phenotype; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1990 |
Spontaneous pneumothorax in metastatic choriocarcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Pneumothorax; Thoracostomy; Uterine Neoplasms | 1991 |
[Catheter-in-catheter replacement technique for bronchial arterial continuous infusion therapy for pulmonary malignancies].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Catheters, Indwelling; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged | 1991 |
[Antitumor activity by long-term administration of low-dose etoposide].
Topics: Adenocarcinoma; Administration, Oral; Animals; Colonic Neoplasms; Etoposide; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL | 1991 |
[Combination effect of pentoxifylline and etoposide on a human lung cancer cell line].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Pentoxifylline; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1991 |
Role of chemotherapy in pediatric pulmonary blastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Thoracic Neoplasms; Vincristine | 1990 |
[An elderly case of small cell lung cancer showing complete response by oral administration of etoposide].
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms | 1990 |
Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
Topics: Carcinoma, Small Cell; DNA; DNA Damage; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1990 |
Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Organoplatinum Compounds; Survival Rate | 1990 |
Phase II studies with carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Remission Induction; Survival Rate | 1990 |
Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
Topics: Administration, Oral; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Remission Induction; Survival Rate | 1990 |
Single-agent oral etoposide for elderly small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Remission Induction | 1990 |
Chronic daily administration of oral etoposide.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasms; Neoplasms, Germ Cell and Embryonal | 1990 |
Chemotherapy for metastatic non-small-cell lung cancer. A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1990 |
Clinical pharmacodynamics of continuous-infusion etoposide.
Topics: Adult; Aged; Blood Cell Count; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Drug Resistance; Etoposide; Humans; Infusions, Intravenous; Kidney Function Tests; Leukocyte Count; Liver Function Tests; Lung Neoplasms; Middle Aged; Neoplasms | 1990 |
Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Vincristine | 1990 |
[A combination phase II study of adriamycin, CDDP and etoposide in small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea | 1990 |
[Acute myocardial infarction induced by lung cancer chemotherapy with cisplatin and etoposide].
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Cisplatin; Electrocardiography; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction | 1990 |
Phase I trial of high-dose etoposide, high-dose cisplatin, and reinfusion of autologous bone marrow for lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Middle Aged | 1990 |
Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Risk Factors | 1990 |
Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Pilot Projects; Remission Induction; Survival Rate; Thrombocytopenia | 1990 |
A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prognosis | 1990 |
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Topics: Aclarubicin; Amsacrine; Carcinoma, Small Cell; Cell Survival; DNA Damage; DNA, Neoplasm; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1990 |
Combination cyclophosphamide and etoposide in treatment of small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1990 |
Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bone Marrow Transplantation; Carcinoma, Non-Small-Cell Lung; Catheterization, Central Venous; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Middle Aged; Neoplasms | 1990 |
Acute nonlymphocytic leukemia following chemotherapy with cisplatin and etoposide for non-small-cell carcinoma of the lung: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Middle Aged; Time Factors | 1990 |
[Nerve conduction velocity following high-dose vincristine in the treatment of small cell bronchial cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Reaction Time; Synaptic Transmission; Vincristine | 1990 |
[Chemotherapy of small cell bronchial cancer with a combination of carboplatin, vincristine and etoposide].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Vincristine | 1990 |
[Carboplatin-Vepeside in the treatment of non-small cell bronchial cancers. A phase II study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Organoplatinum Compounds | 1990 |
Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Tamoxifen; Time Factors; Verapamil; Vincristine | 1990 |
Small cell bronchogenic carcinoma: a cyclical alternating combination of epirubicin plus cisplatin and cyclophosphamide plus etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1990 |
Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Radioligand Assay; Receptors, Cell Surface; Receptors, Tumor Necrosis Factor; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1990 |
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Leukopenia; Lung Neoplasms; Male; Mesna; Middle Aged; Nausea; Ovarian Neoplasms; Sarcoma, Ewing; Testicular Neoplasms; Vomiting | 1990 |
Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prognosis | 1990 |
Clinical trials referral resource. Small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Colony-Stimulating Factors; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Interferon Type I; Lung Neoplasms | 1990 |
Serum neuron-specific enolase as a marker of small-cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Skin Neoplasms; Vincristine | 1990 |
Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Remission Induction; Thrombocytopenia | 1990 |
Low-dose oral etoposide: a new role for an old drug?
Topics: Administration, Oral; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Remission Induction | 1990 |
Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Thrombocytopenia | 1990 |
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Remission Induction | 1990 |
Interaction of recombinant human tumor necrosis factor and etoposide in human lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cell Line; Cell Survival; Combined Modality Therapy; Doxorubicin; Drug Interactions; Etoposide; Humans; Lung Neoplasms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1990 |
Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Pilot Projects; Thrombocytopenia | 1990 |
Combined modality therapy for locally advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Complications; Radiation Injuries; Radiotherapy Dosage; Survival Rate; Tomography, X-Ray Computed | 1990 |
Large cell carcinoma of the lung secreting human chorionic gonadotropin which responded to combination chemotherapy: case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chorionic Gonadotropin; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Male; Methotrexate | 1990 |
Accelerated radiation therapy in small cell lung cancer: rationale and limitation in its utility.
Topics: Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Radiotherapy Dosage | 1990 |
Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate | 1990 |
Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Platinum; Regression Analysis; Remission Induction | 1990 |
Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
Topics: Aged; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Podophyllotoxin; Teniposide | 1990 |
Antitumor effects of antibody enzyme conjugates in combination with prodrugs.
Topics: Alkaline Phosphatase; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cattle; Colonic Neoplasms; Combined Modality Therapy; Etoposide; Humans; Immunotoxins; Lung Neoplasms; Mice; Mitomycins; Organophosphorus Compounds; Prodrugs; Tumor Cells, Cultured | 1990 |
Subrenal capsule assay as a test to predict the effectiveness of chemotherapy in choriocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Lung Neoplasms; Methotrexate; Mice; Mice, Nude; Subrenal Capsule Assay; Vincristine | 1990 |
Etoposide and mesothelioma.
Topics: Etoposide; Humans; Lung Neoplasms; Mesothelioma; Middle Aged; Remission Induction | 1990 |
[Chemotherapy of cerebral metastasis of lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1990 |
Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Screening Assays, Antitumor; Etoposide; Humans; Leukemia L1210; Leukemia P388; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Neoplasm Transplantation; Organophosphorus Compounds; Tumor Cells, Cultured | 1990 |
[A case of complete remission in brain metastasis from lung adenocarcinoma with EAP (etoposide, adriamycin, cisplatin)].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Postoperative Period; Remission Induction | 1990 |
[Current perspectives in the management of non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug Evaluation; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Mitomycin; Mitomycins; Vinblastine; Vincristine; Vindesine | 1985 |
Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.
Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms | 1985 |
Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Time Factors | 1985 |
[Complete remission obtained in advanced testicular cancer treated by etoposide (NK-171)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Lymph Node Excision; Male; Peplomycin; Podophyllotoxin; Teratoma; Testicular Neoplasms; Vincristine | 1986 |
Successful management of metastatic and primary germ cell tumors in the brain.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Child; Cisplatin; Cyclophosphamide; Cytarabine; Dactinomycin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms; Tomography, X-Ray Computed; Vincristine | 1986 |
Hemorrhagic cystitis after i.v. bleomycin, vinblastine, cisplatin, and etoposide for testicular cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cystitis; Dose-Response Relationship, Drug; Etoposide; Hemorrhage; Humans; Lung Neoplasms; Male; Radiography; Teratoma; Testicular Neoplasms; Vinblastine | 1986 |
[Advanced non-seminoma germinal tumors of the testicle. Therapeutic strategy and method of action of chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms; Vinblastine | 1986 |
Combined chemotherapy and radiation therapy for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Pilot Projects | 1986 |
[The relationship between morphological manifestations and cell kinetic changes of human lung cancer cells after exposure to chemotherapeutic agents].
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Cycle; Cell Line; Cisplatin; DNA, Neoplasm; Etoposide; Flow Cytometry; Humans; Lung Neoplasms; Peplomycin | 1986 |
Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Topics: Animals; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Line; Colchicine; Daunorubicin; Doxorubicin; Drug Resistance; Enzyme-Linked Immunosorbent Assay; Epirubicin; Etoposide; Glycoproteins; Gramicidin; Humans; Immunosorbent Techniques; Isoxazoles; Lung Neoplasms; Menogaril; Mice; Mice, Inbred BALB C; Mitoxantrone; Nogalamycin; Phenotype; Vinblastine; Vincristine | 1987 |
Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Dysgerminoma; Etoposide; Humans; Lung Neoplasms; Lymph Node Excision; Male; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Retroperitoneal Neoplasms; Testicular Neoplasms; Vinblastine; Vincristine | 1987 |
Toxicity of FED chemotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care | 1987 |
Raynaud's phenomenon following cytotoxic chemotherapy successfully managed by dorsal sympathectomy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Ganglionectomy; Humans; Lung Neoplasms; Male; Raynaud Disease | 1989 |
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Colony-Stimulating Factors; Doxorubicin; Drug Evaluation; Etoposide; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Ifosfamide; Leukocyte Count; Lung Neoplasms; Mesna; Neutrophils; Platelet Count; Recombinant Proteins | 1988 |
A phase II study of oral etoposide in elderly patients with small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Palliative Care | 1989 |
Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 1989 |
Oral etoposide for a 95-year-old patient with small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Male | 1989 |
High dose etoposide for brain metastases of small cell lung cancer. A phase II study. The EORTC Lung Cancer Cooperative Group.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1989 |
High-dose etoposide for meningeal carcinomatosis in patients with small cell lung cancer.
Topics: Aged; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged | 1989 |
European experience with ifosfamide in non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Europe; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Remission Induction; Vindesine | 1989 |
A phase I-II study of sequential infusion VP-16 and cisplatin therapy in advanced lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Safety | 1989 |
[High-frequency atrial arrhythmia induced by a cisplatin-etoposide combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Small Cell; Cisplatin; Electrocardiography; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged | 1989 |
Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pneumonia; Radiation Injuries; Remission Induction; Thrombocytopenia; Vincristine | 1989 |
[Pilot phase II study of hybrid chemotherapy of CAV-PVP in small cell lung cancer (SCLC)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Pilot Projects; Remission Induction; Thrombocytopenia; Vincristine | 1989 |
[Adriamycin, cisplatin, and etoposide combination chemotherapy for small cell lung cancer].
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Pilot Projects; Remission Induction; Thrombocytopenia | 1989 |
[Peripheral neuropathy caused by cisplatin in patients with lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neural Conduction; Peripheral Nervous System Diseases | 1989 |
Patients at risk of chemotherapy-associated toxicity in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Risk Factors; Vincristine | 1989 |
Acute phase reaction during chemotherapy in small cell lung cancer.
Topics: Acute-Phase Reaction; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Inflammation; Lung Neoplasms; Vincristine | 1989 |
Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Preoperative Care; Radiotherapy, High-Energy; Vindesine | 1989 |
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Procarbazine | 1989 |
Rapidly expanding exophthalmos: an unusual presentation of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Exophthalmos; Humans; Lung Neoplasms; Male; Middle Aged; Orbital Neoplasms; Remission Induction | 1989 |
Systemic therapy for small-cell lung cancer: old themes replayed, new ones awaited.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lomustine; Lung Neoplasms; Methotrexate; Mitomycin; Mitomycins | 1989 |
Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Melphalan; Organoplatinum Compounds; Prognosis; Radiotherapy Dosage; Remission Induction; Vincristine | 1989 |
A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 1989 |
Limited small cell lung cancer: possible prognostic impact of initial chemotherapy doses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Prognosis; Radiotherapy Dosage | 1989 |
High-dose etoposide and autologous bone marrow transplantation as intensification treatment in small cell lung cancer: a pilot study.
Topics: Adult; Bone Marrow Transplantation; Carcinoma, Small Cell; Cell Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Time Factors; Transplantation, Autologous | 1989 |
Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 1989 |
The effectiveness of combination chemotherapy with cisplatinum and etoposide in the treatment of advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1989 |
[Circulating hematopoietic stem cells in patients with small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinoma, Small Cell; Cisplatin; Etoposide; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Male; Middle Aged | 1989 |
Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Vincristine | 1989 |
[A case of intra-arterial infusion chemotherapy in small cell lung cancer with liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Hepatic Artery; Humans; Infusions, Intra-Arterial; Iodized Oil; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Remission Induction; Suspensions | 1989 |
Serial measurement of sister chromatid exchanges in the peripheral lymphocytes of patients with lung cancer receiving chemotherapy in relation to bone marrow toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Lymphocytes; Mitomycin; Mitomycins; Sister Chromatid Exchange; Vincristine; Vindesine | 1989 |
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Hematopoiesis; Humans; Kidney; Lung Neoplasms; Organoplatinum Compounds; Platelet Count | 1989 |
Treatment of small cell lung cancer by eight weeks chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Middle Aged; Time Factors; Vincristine | 1989 |
Resolution of small cell lung cancer intracranial metastases with standard dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1989 |
Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro.
Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Cell Survival; Cells, Cultured; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Melanoma; Neoplastic Stem Cells; Sarcoma; Stem Cells | 1985 |
[Partial remission of pulmonary metastasis of malignant gonadal stromal tumor by salvage chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Male; Orchiectomy; Remission Induction; Testicular Neoplasms | 1989 |
[Cisplatin combination chemotherapy in advanced lung cancer in the aged].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Etoposide; Female; Humans; Kidney; Lung Neoplasms; Male; Middle Aged; Remission Induction; Vindesine | 1989 |
Resolution of malignant small bowel obstruction after intraperitoneal etoposide therapy.
Topics: Abdominal Neoplasms; Adenocarcinoma; Etoposide; Humans; Infusions, Parenteral; Intestinal Obstruction; Intestine, Small; Lung Neoplasms; Male; Middle Aged | 1989 |
Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.
Topics: Adenocarcinoma; Alkaline Phosphatase; Animals; Antibodies, Monoclonal; Biotransformation; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitomycins; Neoplasm Transplantation; Organophosphorus Compounds; Transplantation, Heterologous; Tumor Cells, Cultured | 1989 |
Treatment strategies in relation to drug action.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Etoposide; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Podophyllotoxin; Teniposide | 1987 |
Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Vincristine | 1987 |
Vincristine and etoposide: an effective chemotherapy regimen with reduced toxicity in extensive small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Time Factors; Vincristine | 1987 |
Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged | 1987 |
Subrenal capsule assay for fresh human tumors in immunocompetent mice; an inappropriate technique for non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Hydrocortisone; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Subrenal Capsule Assay | 1987 |
Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds | 1987 |
Surgery after initial chemotherapy for localized small-cell carcinoma of the lung.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Necrosis; Neoplasm Staging; Prospective Studies | 1987 |
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Karyotyping; Leukemia; Lung Neoplasms; Male; Middle Aged | 1987 |
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Evaluation Studies as Topic; Female; Humans; Ifosfamide; Lorazepam; Lung Neoplasms; Male; Mesna; Metoclopramide; Middle Aged | 1987 |
Phase II study of oral VP-16-213 in small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1987 |
[COMVp regimen in the treatment of small cell lung cancer--report of 106 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Vincristine | 1987 |
Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Middle Aged; Recurrence; Remission Induction | 1987 |
Phase II pilot study with cisplatin, etoposide, and continuous-infusion 5-fluorouracil in metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Electrocardiography; Etoposide; Female; Fluorouracil; Heart; Humans; Lung Neoplasms; Male; Neoplasm Metastasis | 1987 |
[High-doses chemotherapy followed by bone marrow autograft in the treatment of small cell bronchial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Melphalan; Procarbazine | 1987 |
Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Middle Aged | 1987 |
Reinduction chemotherapy in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacterial Outer Membrane Proteins; Bacterial Proteins; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Membrane Glycoproteins; Peptidyl-Dipeptidase A; Vincristine | 1987 |
Cutaneous pathology following etoposide therapy.
Topics: Adult; Aged; Biopsy; Carcinoma, Small Cell; Drug Eruptions; Etoposide; Female; Humans; Leukemia, Lymphoid; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged | 1987 |
Continuous infusion of etoposide, bolus administration of cisplatin, and simultaneous radiation therapy in previously treated patients with small cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1988 |
Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Evaluation; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Radiotherapy Dosage | 1988 |
The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Vincristine | 1988 |
[Clinical evaluation of serum NSE (neuron specific enolase) levels in cases of small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Radiography, Thoracic | 1988 |
Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Trimetrexate | 1988 |
Results of a combined chemo-radiotherapeutic program in 61 patients affected by small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Procarbazine; Radiography; Vincristine; Vomiting | 1988 |
Summary of recent clinical experience in whole-body hyperthermia combined with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Evaluation Studies as Topic; Female; Humans; Hyperthermia, Induced; Lung Neoplasms; Male; Melanoma; Vincristine; Vindesine | 1988 |
Phase II study of an intensive combination chemotherapy with cisplatin, adriamycin, etoposide and cyclophosphamide (CAVE) in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prognosis; Time Factors | 1988 |
[The role of surgical treatment in the combination therapy of small cell lung cancer (SCLC)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1988 |
Cyclophosphamide, vindesine and oral VP-16 in the treatment of non-small cell lung cancer (NSCLC): an outpatient regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Vindesine | 1988 |
Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged | 1988 |
Pilot study of a continuous five-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Histiocytoma, Benign Fibrous; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Stomach Neoplasms; Tongue Neoplasms | 1988 |
Multimodality treatment of non-small cell lung cancer: response to cisplatin, VP-16, and 5-FU chemotherapy and to surgery and radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged | 1988 |
[A combination chemotherapy of cisplatin and etoposide in small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1988 |
Carboplatin (JM8), etoposide (VP16) and thoracic irradiation for small cell lung cancer (S.C.L.C.): an evaluation of lung toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pneumonia; Pulmonary Fibrosis; Radiation Injuries | 1988 |
Phase I-II study of cisplatin, VP-16, MGBG, mitomycin, and vinblastine with radiation therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitoguazone; Mitomycins; Vinblastine | 1988 |
Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cytarabine; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 1988 |
The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.
Topics: Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Half-Life; Humans; Infusions, Intravenous; Lung Neoplasms; Teratoma | 1988 |
Etoposide and split-dose cisplatin in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1988 |
Oral etoposide preceding cisplatin in advanced non small cell lung cancer (NSCLC). A phase II study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prognosis | 1988 |
Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small cell lung cancer.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1988 |
[Combination chemotherapy of CDDP and etoposide in advanced non-small cell carcinoma of the lung].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1988 |
VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds | 1988 |
In vitro chemical eradication of small cell lung cancer: application in autologous bone marrow transplantation.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Carbazoles; Carcinoma, Small Cell; Cell Line; Cell Survival; Cisplatin; Cyclophosphamide; Doxorubicin; Ellipticines; Etoposide; Humans; Intercalating Agents; Lung Neoplasms; Transplantation, Autologous; Tumor Cells, Cultured | 1988 |
[Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Vindesine | 1988 |
Podophyllotoxins for brain metastases of small cell lung cancer.
Topics: Brain Neoplasms; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Teniposide | 1988 |
Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer.
Topics: Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Middle Aged | 1988 |
[Hepatotoxicity with etoposide-ifosfamide combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemical and Drug Induced Liver Injury; Etoposide; Female; Humans; Ifosfamide; Liver Function Tests; Lung Neoplasms; Male; Middle Aged | 1988 |
Concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for the treatment of limited small cell lung cancer: a preliminary report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Time Factors | 1988 |
Role of small doses of radiotherapy combined with chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Radiotherapy Dosage | 1988 |
Reduced short-term neuropsychological performance in patients with nonsmall-cell lung cancer treated with cisplatin and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Memory; Middle Aged; Perception; Psychomotor Performance; Verbal Learning | 1988 |
Etoposide effective against small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Humans; Lung Neoplasms | 1988 |
Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Digestive System; Doxorubicin; Etoposide; Female; Humans; Kidney; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Vincristine | 1985 |
Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
Topics: Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Multi-Institutional Systems; Nausea; Podophyllotoxin; Vomiting | 1985 |
Pharmacokinetics of etoposide in gestochoriocarcinoma.
Topics: Choriocarcinoma; Etoposide; Female; Half-Life; Humans; Kinetics; Lung; Lung Neoplasms; Myometrium; Podophyllotoxin; Pregnancy; Trophoblastic Neoplasms; Uterine Neoplasms | 1985 |
Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Podophyllotoxin; Thrombocytopenia; Vincristine | 1985 |
Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation.
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carcinoma, Small Cell; Cyclophosphamide; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Podophyllotoxin | 1985 |
Intensive alternating chemotherapy regimen in small cell carcinoma of the lung.
Topics: Actuarial Analysis; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gastrointestinal Hemorrhage; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Thrombocytopenia; Vincristine | 1985 |
Probable cure of small cell carcinoma of the lung by etoposide.
Topics: Carcinoma, Small Cell; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Radiography; Smoking | 1985 |
The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group.
Topics: Carcinoma, Small Cell; Cyclophosphamide; Drug Resistance; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Verapamil | 1985 |
High-dose etoposide (VP-16) in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Middle Aged; Podophyllotoxin | 1985 |
Single-dose etoposide in combination with vincristine and doxorubicin in the treatment of small-cell lung cancer (SCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Podophyllotoxin; Vincristine | 1985 |
Alternating combination chemotherapy regimens in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Models, Biological; Vincristine | 1985 |
[Treatment of non-small-cell bronchial carcinoma with cisplatin, ifosfamide, vindesine and VP 16].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vindesine | 1985 |
Relationship between myelosuppression and chemotherapeutic response in small cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Vincristine | 1985 |
Bone marrow morphologic changes after combination chemotherapy including VP-16.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Erythrocytes; Etoposide; Female; Hematopoiesis; Humans; Lung Neoplasms; Male; Mitosis; Podophyllotoxin; Vincristine | 1985 |
Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male | 1985 |
Drug monitoring of etoposide (VP16-213). I. A combined method of liquid chromatography and mass spectrometry.
Topics: Californium; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Computers; Etoposide; Half-Life; Humans; Kinetics; Lung Neoplasms; Mass Spectrometry; Podophyllotoxin | 1985 |
Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Methotrexate; Middle Aged | 1985 |
Evaluation of drug efficacy in vitro using human small cell carcinoma of the lung spheroids.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cell Line; Cisplatin; Cytarabine; Doxorubicin; Drug Evaluation, Preclinical; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Mechlorethamine; Mice; Mice, Inbred Strains; Peritoneum; Tumor Stem Cell Assay | 1985 |
Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide, methotrexate, and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Methotrexate; Middle Aged; Platelet Count | 1985 |
Combination cyclophosphamide, Adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation Injuries; Vincristine | 1985 |
[A phase II study of oral VP-16 in primary lung cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Capsules; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1985 |
Three months treatment with chemotherapy and radiotherapy for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged | 1985 |
The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Small Cell; Drug Interactions; Etoposide; Food; Humans; Kinetics; Lung Neoplasms; Podophyllotoxin | 1985 |
[A phase II study of NK171 (etoposide)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Anorexia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1985 |
High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Podophyllotoxin | 1985 |
Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung.
Topics: Acute Disease; Carcinoma, Small Cell; Chromosome Aberrations; Chromosome Disorders; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Lomustine; Lung Neoplasms; Male; Methotrexate; Preleukemia; Risk; Vincristine | 1985 |
[A phase II study of etoposide (NK 171) in small cell lung cancer--comparison of results between intravenous administration and oral administration].
Topics: Administration, Oral; Adult; Aged; Alopecia; Anorexia; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Fatigue; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1985 |
Variable bioavailability following repeated oral doses of etoposide.
Topics: Adult; Biological Availability; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Kinetics; Lung Neoplasms; Mesothelioma; Podophyllotoxin; Time Factors | 1985 |
Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Hormones, Ectopic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Vincristine | 1985 |
[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Anorexia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Injections; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1986 |
Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Organoplatinum Compounds | 1985 |
Cyclic alternating chemotherapy for small cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Mitomycins; Nausea; Prospective Studies; Vincristine; Vomiting | 1985 |
Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Kidney Failure, Chronic; Kinetics; Lung Neoplasms; Male; Mathematics; Middle Aged; Podophyllotoxin; Renal Dialysis | 1985 |
High-dose cyclophosphamide and high-dose VP 16-213 for recurrent or refractory small cell lung cancer. A phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 1985 |
Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Procarbazine; Vincristine | 1986 |
[A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
Topics: Adult; Aged; Alopecia; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1986 |
[Phase II study of etoposide in patients with lung cancer, with special reference to small cell carcinoma].
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1986 |
[Phase II study of VP-16 in patients with primary bronchogenic carcinoma, with special reference to small cell carcinoma--a multi-institutional cooperative study].
Topics: Administration, Oral; Aged; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1986 |
Primary oral etoposide therapy in gestational trophoblastic disease. An update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin; Etoposide; Female; Humans; Hydatidiform Mole; Hysterectomy; Lung Neoplasms; Neoplasm Recurrence, Local; Podophyllotoxin; Pregnancy; Risk; Trophoblastic Neoplasms; Uterine Neoplasms; Vaginal Neoplasms | 1986 |
Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Tumor Stem Cell Assay | 1986 |
[Combination chemotherapy with etoposide, mitomycin C, and cyclophosphamide in advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Mitomycins | 1986 |
Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Middle Aged; Mitomycins; Pilot Projects | 1986 |
DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Topics: Adenocarcinoma; Adenosine Triphosphate; Carcinoma, Small Cell; Cell Division; Cell Nucleus; Cells, Cultured; DNA; DNA, Single-Stranded; Drug Resistance; Etoposide; Humans; Intercalating Agents; Lung Neoplasms; Podophyllotoxin; Teniposide; Topoisomerase II Inhibitors | 1986 |
No response improvement after sequential chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Prednisone; Time Factors; Vincristine | 1986 |
High-dose etoposide with autologous bone marrow transplantation as initial treatment of small cell lung cancer--a negative report.
Topics: Bone Marrow Diseases; Bone Marrow Transplantation; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Middle Aged; Mouth Mucosa; Podophyllotoxin; Stomatitis; Transplantation, Autologous | 1986 |
Etoposide, cisplatin and doxorubicin in patients with small cell lung cancer: tumor response and long term survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia | 1986 |
Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
Topics: Administration, Oral; Biological Availability; Carcinoma; Carcinoma, Small Cell; Etoposide; Female; Hodgkin Disease; Humans; Injections, Intravenous; Kinetics; Lung Neoplasms; Lymphoma; Male; Neoplasms; Podophyllotoxin | 1986 |
First-line therapy with VP-16 and cisplatin for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Remission Induction | 1986 |
Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited-stage small-cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Prognosis; Radiotherapy; Vincristine | 1986 |
Concurrent chemotherapy and radiotherapy for limited small-cell carcinoma of the lung: a Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Pilot Projects; Prognosis; Radiotherapy; Remission Induction | 1986 |
High-dose pilot studies in extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Pilot Projects; Remission Induction | 1986 |
A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Prognosis; Remission Induction | 1986 |
[A combination chemotherapy of cisplatin and etoposide in small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1986 |
Phase II studies on weekly cisplatinum plus epirubicin or etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1986 |
Infections in patients with non-small-cell lung cancer treated with intensive induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Candidiasis; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Opportunistic Infections; Risk | 1986 |
Short duration combination chemotherapy in the treatment of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Vincristine | 1986 |
Five-year survival in treated stage I and II small cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lomustine; Lung Neoplasms; Neoplasm Staging; Pneumonectomy; Postoperative Care; Vincristine | 1986 |
[Treatment of microcytic carcinoma of the lung with vincristine, adriamycin, cyclophosphamide and VP-16].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lung Neoplasms; Male; Vincristine | 1986 |
Long-term effects of intravenous hyperalimentation administered during intensive chemotherapy for small cell bronchogenic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Hypersensitivity, Delayed; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Middle Aged; Parenteral Nutrition, Total; Procarbazine; Prognosis; Vincristine | 1987 |
Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1986 |
Small cell carcinoma of the lung: influence of age on treatment outcome.
Topics: Actuarial Analysis; Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged | 1987 |
Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 1986 |
Cytogenetic effects of multiagent chemotherapy on the peripheral lymphocytes of patients with small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chromosome Aberrations; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Sister Chromatid Exchange; Vincristine | 1986 |
Cyclophosphamide, etoposide, and infusion cisplatin in refractory small cell lung cancer. A preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Vincristine | 1987 |
High-dose etoposide therapy for extensive small cell lung cancer: a Cancer and Leukemia Group B Study.
Topics: Aged; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1987 |
The role of surgery in the management of selected patients with small-cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Evaluation Studies as Topic; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged | 1987 |
High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Fever; Humans; Infections; Leukopenia; Lung Neoplasms; Middle Aged; Thrombocytopenia | 1987 |
[A cisplatin and etoposide combination in small cell anaplastic carcinoma of the lung].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms | 1987 |
High-dose etoposide for central nervous system metastases of small cell lung cancer. Preliminary results.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Middle Aged | 1987 |
Etoposide for small cell lung cancer.
Topics: Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms | 1987 |
Intensive chemotherapy in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms | 1986 |
Improved local control of thoracic disease in small cell lung cancer with higher dose thoracic irradiation and cyclic chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Radiotherapy Dosage | 1987 |
[Treatment of non-small cell cancer of the lung with a combination of cisplatin-VP-16 and mitomycin C].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins | 1987 |
Treatment of small cell lung cancer by pneumonectomy and single course high dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Male; Pneumonectomy | 1987 |
Etoposide combination therapy for small cell carcinoma of the lung.
Topics: Adult; Aged; Carcinoma, Small Cell; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1987 |
Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Neutropenia; Organoplatinum Compounds; Pancytopenia; Thrombocytopenia | 1988 |
Antitumor effect of two-drug simultaneous or sequential use of cisplatin, vindesine or etoposide on human pulmonary adenocarcinoma cell lines in tumor clonogenic assay.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cisplatin; Colony-Forming Units Assay; Etoposide; Humans; Lung Neoplasms; Tumor Stem Cell Assay; Vindesine | 1986 |
Etoposide and split-dose cisplatin in bronchogenic carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cisplatin; Etoposide; Humans; Lung Neoplasms; Middle Aged | 1988 |
Death from chemotherapy in gestational trophoblastic disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Methotrexate; Necrosis; Pregnancy; Pulmonary Embolism; Uterine Neoplasms | 1988 |
Brain metastases of lung cancer: excessive toxicity of high dose VP 16 213.
Topics: Aged; Brain Neoplasms; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1988 |
Respiratory tract fistulae in recurrent aerodigestive cancers after chemotherapy.
Topics: Bronchial Fistula; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Radiography | 1988 |
Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213). Cooperative study from the Groupe Franais Pneumo-Cancérologie.
Topics: Adenocarcinoma; Aged; Brain; Brain Neoplasms; Carcinoma; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Tomography, X-Ray Computed | 1988 |
Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation.
Topics: Adult; Aged; Bone Marrow Transplantation; Drug Evaluation; Etoposide; Humans; Infusions, Parenteral; Leukemia; Lung Neoplasms; Middle Aged; Podophyllotoxin | 1986 |
In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.
Topics: Carcinoma, Bronchogenic; Cell Line; Cell Survival; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Lymphoma; Regression Analysis; Tumor Stem Cell Assay | 1987 |
Pharmacokinetics of high dose etoposide (VP 16-213).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; Etoposide; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Saliva; Testicular Neoplasms | 1986 |
Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.
Topics: Animals; Body Weight; Cell Count; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Etoposide; Kinetics; Leukocyte Count; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Podophyllotoxin; Teniposide | 1986 |
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Mitomycin; Mitomycins; Neoplasm Metastasis; Procarbazine; Progesterone; Prognosis; Serum Albumin; Vinblastine | 1986 |
Phase II trial of chemotherapy with cisplatin and etoposide in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1986 |
Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1986 |
Paroxysmal supraventricular tachycardia during treatment with cisplatin and etoposide combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Electrocardiography; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Tachycardia, Paroxysmal | 1986 |
Vitamin A: failure to demonstrate in mice an anti-tumour effect, whether combined with cytotoxic drugs or not.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Female; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Teniposide; Vitamin A | 1986 |
[Combination of etoposide with cisplatin or cyclophosphamide in the treatment of mouse Lewis lung carcinoma].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Drug Synergism; Etoposide; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Podophyllotoxin | 1986 |
Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non-small-cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Radiotherapy | 1986 |
Sudden dyspnea occurring 24 hours after mitomycin plus etoposide combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dyspnea; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins | 1987 |
The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.
Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Lung Neoplasms; Podophyllotoxin; Teniposide | 1987 |
Etoposide prior to cis-diamminedichloroplatinum in combination chemotherapy: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Lung Neoplasms; Mice; Mice, Inbred C57BL; Podophyllotoxin | 1985 |
Chemotherapy of advanced non-small cell lung cancer with the use of cis-platinum and VP 16-213.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1985 |
Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
Topics: Adenocarcinoma; Aminoacridines; Amsacrine; Cells, Cultured; DNA; DNA Repair; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Teniposide | 1985 |
When is autologous bone marrow transplantation safe after high-dose treatment with etoposide?
Topics: Adult; Aged; Bone Marrow; Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Neutrophils; Podophyllotoxin; Reticulocytes; Time Factors; Transplantation, Autologous | 1985 |
Suppression of natural killer activity in patients treated with cisplatin and methylprednisolone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytotoxicity Tests, Immunologic; Doxorubicin; Etoposide; Female; Humans; Immune Tolerance; In Vitro Techniques; Killer Cells, Natural; Lung Neoplasms; Male; Mediastinal Neoplasms; Methylprednisolone; Middle Aged; Mitomycin; Mitomycins; Nimustine; Nitrosourea Compounds; Vinblastine; Vindesine | 1985 |
Protochemotherapy in non-small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vindesine | 1986 |
Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Vindesine | 1986 |
MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Podophyllotoxin; Time Factors | 1986 |
VP-16 and cisplatin in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Vinblastine; Vindesine | 1985 |
[Cisplatin drug therapy. Antiemetic treatment. Experiences with the use of high-dose metoclopramide combined with chlopromazine and prochlorperazine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Metoclopramide; Middle Aged; Nausea; Prochlorperazine; Vomiting | 1985 |
Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Kidney; Lung Neoplasms; Male; Middle Aged | 1985 |
Complete remissions in non small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Lung Diseases, Obstructive; Lung Neoplasms; Retrospective Studies; Smoking; Vindesine | 1985 |
[The antitumor activity of intraperitoneally- or orally-administered etoposide in animals and its administration-schedule dependency].
Topics: Adenocarcinoma; Administration, Oral; Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Female; Leukemia, Experimental; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Podophyllotoxin | 1985 |
Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Vincristine | 1985 |